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Tuberculosis (TB) is a life-threatening infectious disease caused by 
Mycobacterium tuberculosis (Mtb). Globally, TB is a major public health 
burden with an estimated 10.4 million new cases and 1.8 million deaths 
reported in 2015. Although TB is curable, the treatment options currently 
available are beset by numerous shortcomings such as lengthy and complex 
treatment regimens, drug-drug interactions, drug toxicities, as well as 
emergence of widespread multi-drug resistance. Therefore, there is an 
urgent and compelling need to develop new, more effective, safer drugs with 
novel mechanisms of action, and which are capable of shortening treatment 
duration.  
This study focused on hit-to-lead optimization of two new classes of 
compounds with potential anti-TB properties: 2-aminoquinazolinones (AQZs) 
and benzoxazole-based oximes (BZOs). A hit compound for each of these 
classes with low micromolar antimycobacterial activity had previously been 
identified through phenotypic whole-cell in vitro screening.  
With respect to the 2-aminoquinazolinones, the hit compound 2 (Figure 1) 
was structurally modified at two 
points (SAR 1 and SAR 2), while 
keeping the 2-aminoquinazolinone 
core constant, in an effort to explore 
the structure-activity relationships 
(SAR) associated with this class of compounds. In this regard, 43 analogues 
were synthesized, fully characterized, and evaluated in vitro for their 
antimycobacterial activity against the drug-susceptible Mtb H37Rv strain 
cultured in GAST-Fe and 7H9/ADC media. Of these, 17 compounds 
exhibited potent antimycobacterial activity (MIC99 ≤ 10 μM) and clear SAR 
trends. Furthermore, selected active compounds manifested low cytotoxicity 
(IC50 > 25 μM) when tested in vitro against the Chinese Hamster Ovarian 
(CHO) cells and the human hepatic cells, HepG2.  Besides, potent 
compounds displayed high microsomal metabolic stability in mouse liver 
microsomes (MLM). At this juncture, the frontrunner compound 3 [the 
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sulfoxide variant of 2] was subjected to in vivo pharmacokinetics studies in 
mice where it was found to be extensively metabolised to the equally active 
sulfone-based 2. Both the parent compound and its active metabolite 
exhibited good plasma exposure, favorable half-life, moderate volume of 
distribution, low rate of clearance, and were well tolerated in mice at the 
maximum administered oral dose of 300 mg/kg. However, when compound 
3 was evaluated for in vivo efficacy in an acute TB infection mouse model 
(BALB/c) at 100 and 200 mg/kg oral doses, it lacked activity. Further 
studies revealed that the 2-aminoquinazolinones killed Mtb in vitro via a 
glycerol-dependent mechanism of action, hence lacking in vivo efficacy in 
mice. These findings correlated well with the results of the studies on 
generation of spontaneous resistant mutants, wherein the strains resistant 
to 3 manifested mutations mapping to the glycerol metabolism genes that 
encode for glycerol kinase (glpK; Rv3696c) and glycerol-3-phosphate 
dehydrogenase (glpD2; Rv3302c). 
Benzoxazole-based oxime analogues were designed from the hit compound 
46 (Figure 2) by making 
structural modifications at 
three points of diversity 
(SAR 1, SAR 2, and SAR 
3). As a result, 38 
structural variants were synthesized and evaluated in vitro for their 
antimycobacterial activity against the drug-susceptible Mtb H37Rv strain. 
Unlike the 2-aminoquinazolinones, benzoxazole-based oximes exhibited a 
tight SAR, with only SAR 2 modifications being tolerated. As such, all 
attempts to introduce changes at the SAR 1 and SAR 3 positions yielded 
inactive compounds (MIC99 > 125 μM). Moreover, even though SAR 2 
analogues were active, they exhibited flat SAR, which was informed by the 
display of similar antimycobacterial activities for analogues with different 
substituents at varying positions on the phenyl ring. Subsequently, most of 
the active compounds exhibited low in vitro cytotoxicity against the CHO 
cells. To this end, low microsomal metabolic stability [7.3% remaining after 
30 minutes in MLM for 46] posed a major hurdle to the advancement of 
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benzoxazole-based oximes to other studies as planned. The low metabolic 
stability was most likely due to the metabolically labile dimethyl carbamate 
moiety; however, all attempts to remove it by forming free oximes as well as 
oxime ethers resulted in complete loss of antimycobacterial activity. 
All target compounds were subjected to physicochemical profiling and 
aqueous solubility studies, wherein the turbidimetric method was applied. 
The solubility values obtained were then correlated with melting points, 
HPLC retention times (tR), TLC retardation factors (Rf), and cLogP, in order to 
establish structure-property relationships (SPR) across the two compound 
sets. Accordingly, correlations were deduced, and tR [R2 = 0.49 for AQZs and 
0.65 for BZOs] and Rf [R2 = 0.64 for AQZs and 0.57 for BZOs] were found to 
be the most strongly correlated factors, albeit moderate. 
Further, compound 3 was selected for supramolecular derivatization studies 
in an effort to enhance its aqueous solubility, which involved formation of 
cocrystals, salts, and cyclodextrin inclusion complexes. The crystal 
structure of 3 was elucidated. This revealed the molecular geometry and the 
main intermolecular interactions in 3, which facilitated the selection of 
potential co-formers for co-crystallization. However, all attempts to 
synthesize cocrystals were unsuccessful, as salts were formed instead. All 
the new solid states of 3 were characterized by X-ray diffraction, thermal 
analysis, NMR spectroscopy, and thereafter subjected to solubility 
assessment by HPLC. In effect, only a moderate increase in solubility was 
observed in the salts of 3, whereby 3 mesylate exhibited the most improved 
solubility in the range of 2-fold increase (38 μM). 
Largely, this thesis work identifies the opportunities and challenges 
associated with the two classes of compounds from the drug discovery 
perspective, as potential novel antituberculosis agents. Indeed, the 
importance of utilizing in vitro antimycobacterial phenotypic screening 
conditions in the early stages of drug discovery, which are reflective of the in 
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CHAPTER 1  
INTRODUCTION AND LITERATURE REVIEW 
1.1 Chapter Overview 
In this chapter, a brief overview of tuberculosis (TB) and its treatment is 
provided. TB is highlighted with respect to etiology, epidemiology and 
pathogenesis; prevention, control and treatment; challenges in treating TB 
and their mitigation; as well as advances made in anti-TB drug discovery 
and development. In addition, attrition of drug candidates and the 
importance of optimizing physicochemical properties of compounds in the 
early stages of drug discovery are examined. Importantly, aqueous solubility 
of drug candidates is emphasized, and therefore its importance and 
strategies to improving the same are brought to the fore. Also, 
benzoheterocyclic structural motifs that form the basis of this thesis work as 
potential scaffolds for new anti-TB agents are reviewed and discussed. To 
sum up the chapter, a research program is examined, whereby study 
justifications, hypothesis, along with study objectives are briefly mentioned. 
1.2 Etiology of TB 
TB, a contagious airborne disease, is caused by the bacterium 
Mycobacterium tuberculosis (Mtb). Mtb is an oblong, rod-shaped, bacillus-
type, non-motile, non-sporulating, acid-fast, slow-growing, and aerobic 
bacterium that measures about 1–4 μm in length and 0.3–0.6 μm wide 
(Figure 1.1).1,2  
 
Figure 1.1: Scanning electron micrograph of Mycobacterium tuberculosis.2 
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On March 24, 1882, a German scientist, Robert Koch, announced the 
discovery of Mtb as the causative agent of TB.3,4 Mtb is a member of the 
Mycobacterium tuberculosis complex (MTC), which is characterized by 
extensive conservation of the 16S ribosomal deoxyribonucleic acid (rDNA) 
sequence, 99.9% similarity at the nucleotide level, as well as high DNA-DNA 
relatedness across the member species.5 Other members of the MTC include 
Mycobacterium africanum and Mycobacterium canettii, which are also human 
pathogens; Mycobacterium microti, a rodent pathogen; and Mycobacterium 
bovis, which is a pathogen with a wide spectrum of hosts.6 For a long time, 
Mtb was believed to have evolved from the present-day M. bovis; however, 
genomic studies have provided compelling evidence against this hypothesis. 
Indeed, it has been shown that the two species could have independently 
evolved from an Mtb-like common ancestral species, more than 15 000 years 
ago.6–8 Furthermore, the availability of complete Mtb genome sequence, as 
well as the technological advances in the field of genomics, have provided 
invaluable insights into the evolution and biology of Mtb.9 M. bovis causes 
zoonotic TB in humans mainly through consumption of unpasteurized dairy 
products. Consequently, in 2015, there were an estimated 149 000 cases of 
zoonotic TB globally.10 Also, there are no known animal or environmental 
reservoirs for Mtb, making it an obligate human pathogen.11  
Mtb is characterized by vast virulence factors that are incorporated in 
proteins and cell wall components. The Mtb cell wall is a distinctive, highly 
evolved, lipid-, protein-, and carbohydrate-based structure essential for its 
survival. It is composed of peptidoglycans linked to mycolic acids via 
covalent attachments to linear galactofurans and several strands of highly 
branched arabinofuran.12 In addition, arabinogalactan and lipoarabinomannan 
are abundantly present in the Mtb cell wall. Indeed, their presence has been 
reported by Lee and colleagues in a study involving high-resolution magic-
angle spinning (HR-MAS) nuclear magnetic resonance (NMR) on live 
mycobacterial cells.13 The waxy nature of the cell wall is due to mycolic 
acids, which are critical in Mtb survival by conferring properties such as 
acid-fastness, hydrophobicity, resistance to changes in pH, and 
 
 
Chapter 1: Introduction and Literature Review 
Paul M. Njaria – PhD Thesis 2017 3 
immunostimulatory attributes.12,14 
1.3 Epidemiology of TB 
Although curable, TB continues to be a weighty public health scourge of 
epidemic proportions with high morbidity and mortality globally, particularly 
in low- and middle-income countries. Even in recent times, TB has failed to 
relinquish its grip on mankind, and it can still be considered a “Captain 
Among these Men of Death”, an epithet it earned in the early 19th century.4 
It is a social disease roughly estimated to have infected a third of the world’s 
population, with majority having latent TB infection (LTBI). In the absence of 
treatment, approximately 50% of individuals who develop active TB disease 
will succumb to it.15 One of the goals of the United Nations’ Sustainable 
Development Goals (SDGs) for 2030 is to end the global TB epidemic. As a 
result, the World Health Organization (WHO) End TB Strategy (2016–2035) 
targets reducing TB deaths and incidence by 90% and 80%, respectively, by 
the year 2030, compared to 2015.16 For these goals to be achieved, a 4–5% 
annual worldwide decline in TB incidence is targeted by the year 2020. This 
comprehensive approach is anchored on three pillars: patient-centered TB 
care and prevention; bold policies and supportive systems; and intensified 
research and innovation.16  
The WHO global TB report, 2016, provides figures that demonstrate the 
global burden of TB in terms of incidence, prevalence, and mortality. The 
data is derived from comprehensive reports received from 202 countries and 
territories that account for > 99% of the world’s population and TB cases. In 
2015, the incidence of TB was estimated to be 10.4 million cases worldwide, 
signifying a 1.5% decline from that reported for 2014.10 Of these cases, 60% 
occurred in six countries: India, Indonesia, China, Nigeria, Pakistan, and 
South Africa, listed in the order of decreasing incidence (Figure 1.2). 
Overall, adults contributed to 90% of new cases while 10% were children, 
and the male:female (M:F) ratio was 1.6:1. In addition, an estimated 11% of 
incident TB cases in 2015 were Human Immunodeficiency Virus (HIV)-
linked, a proportion that was highest in Africa, and exceeded 50% in some 
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parts of southern Africa. It is also estimated that there were 1.4 million TB 
deaths in 2015 (Figure 1.3), and an additional 0.4 million deaths resulting 
from TB disease among HIV/AIDS (Acquired Immune Deficiency Syndrome) 
patients.10 These sobering statistics suggest that in 2015, about three 
human lives were exterminated every minute by TB. 
 
Figure 1.2: Estimated global TB incidence rates in 2015.10 
 
Figure 1.3: Estimated TB mortality rates in HIV-negative people in 2015.10 
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Globally, HIV is a major risk factor for TB infection, mainly due to a 
compromised body immunity. HIV not only increases the risk of reactivating 
LTBI, but also readily accelerates progression to active disease soon after 
primary infection or reinfection with Mtb.17,18 Equally important, as a co-
epidemic, TB is a major cause of mortality and morbidity among HIV-
positive patients, and therefore poses a risk throughout the course of 
HIV/AIDS.19 Indeed, the estimated TB deaths in 2015 were 0.20 million 
among HIV-positive men, 0.14 million among HIV-positive women, and 0.04 
million among HIV-positive children.10 75% of these deaths occurred in 
Africa, with a M:F ratio close to 1. Globally, 15% of TB patients with a HIV 
test result were HIV-positive. Overall, the percentage of TB patients testing 
HIV-positive has been falling globally since 2008.10  
Considering the fact that HIV-infected people make up only 0.5% of the 
world’s population, then other endogenous and exogenous risk factors for 
TB infection come into play.20 These include other diseases, socioeconomic 
factors, as well as behavioral determinants. For instance, diabetes 
mellitus,21 malnutrition, excessive alcohol use,22 tobacco smoking,23 air 
pollution, and use of immunosuppressive drugs. Moreover, increased 
household crowding, poor nutrition, and homelessness brought about by 
poverty, greatly accentuate the incidence and transmission of TB.20 
Worldwide, drug-resistant TB (DR-TB) is a major drawback in the treatment 
of TB. In 2015, there were an estimated 480 000 new cases of multidrug-
resistant TB (MDR-TB) and an additional 100 000 people with rifampicin-
resistant TB (RR-TB), globally. India, China, and the Russian Federation 
accounted for 45% of these cases. Of the estimated 580 000 people newly 
eligible for MDR-TB treatment, only 125 000 (20%) were enrolled. The 
average proportion of MDR-TB cases with extensively drug-resistant TB 
(XDR-TB) was 9.5%. Globally, the latest treatment outcome data show a 
treatment success rate of 83% for TB (2014), 52% for MDR-TB (2013) and 
28% for XDR-TB (2013). There were about 250 000 deaths from MDR/RR-
TB in 2015.10 
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1.4 Transmission, Pathogenesis and Clinical Presentation of TB 
TB most commonly affects the respiratory system, a condition referred to as 
pulmonary or lung TB. Pulmonary TB is acquired through inhalation of 
airborne, aerosolized Mtb-containing droplet nuclei, which are expectorated 
from an infected individual with active pulmonary or laryngeal TB through 
coughing, spitting, or sneezing.24 Mtb in aerosols are airborne and viable for 
several hours in the atmosphere, and the infectious dose is estimated to be 
a single bacterium.7,25 Additionally, there are cases of extrapulmonary TB 
that can cause disease in other body organs, for instance the central 
nervous system (CNS), genitourinary tract, bones, joints, as well as 
disseminated or miliary TB that affects many organs.26,27 
Pulmonary TB exists in a dynamic spectrum: an active, symptomatic 
disease; or an asymptomatic, non-transmissible LTBI, in which Mtb are 
contained by persistent immune responses.28,29 After inhalation, a cascade 
of events follows in a bid to clear Mtb from the host’s airways. In this regard, 
the mucociliary system in the upper respiratory tract offers the initial 
physical defense, whereby the Mtb bacilli are trapped by mucus, which is 
then driven up the airways by cilia.26 The pathogens that survive this barrier 
translocate down the airways to the alveoli. Afterwards, a local infection 
might set up, followed by propagation to draining lymphatics, as well as 
hematogenous spread throughout the body. Biochemical products of Mtb 
such as the mannosylated lipoarabinomannan, trehalose dimycolate, and N-
glycolylmuramyl dipeptide, facilitate recognition of Mtb by the alveolar 
macrophages – the main phagocytic cells infected by Mtb.30 Consequently, 
Mtb are engulfed by the alveolar macrophages via receptor-mediated 
phagocytosis, triggering a sequence of innate host-pathogen immune 
responses. This has been studied using small mammals, such as mice, 
guinea pigs and rabbits, as well as non-human primates that have 
substantially helped to experimentally identify the momentousness of the 
early immunopathological phenomena during TB infection.31 
The host’s immune response serves to limit multiplication and spread of the 
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tubercle bacilli, as well as to provide an opportunity for the body to destroy 
the invading mycobacteria and prevent infection. Nonetheless, to ensure its 
survival, Mtb employs diverse evasion strategies including blocking the 
fusion of phagosome with lysosome, delaying phagosome maturation, 
detoxifying reactive oxygen and nitrogen radicals, and releasing potent 
bioactive cell wall contents.32,33 The innate immune responses lead to 
elimination or persistence of the pathogen. 
Phagocytosis by the alveolar macrophages induce a localized 
proinflammatory response, leading to recruitment of immune cells such as 
neutrophils, natural killer (NK) T cells, CD4+ T cells, and CD8+ T cells. This 
process is influenced by the inflammatory cytokines and chemokines 
produced by the infected macrophages. Tumour necrosis factor (TNF)-α is 
the dominant cytokine, while chemokines include CCL2, CXCL10, CCL3, 4, 
5, and CXCL9. In addition, the inflammatory process is regulated and 
quietened by gamma interferon (IFN-γ). At this stage, the 
immunopathogenesis culminates in the formation of a structure consisting 
of infected macrophages, foamy macrophages, mononuclear phagocytes, 
lymphocytes, and a fibrous cuff of collagen (Figure 1.4).1,7,26,31,34 This mass 
of cellular debris is known as the granuloma, the hallmark of TB, which 
leads to remodeling of the infection site and containment of Mtb in a 
quiescent and latent state. Granuloma formation is valuable to both the 
host, for control of infection, and the bacilli, as a place to hide.35  
Primary infection is uncommon, but may occur in neonates. Globally, 
reactivation and disease progression causes majority of TB infections, with 
5–10% of individuals with LTBI developing symptomatic, clinical TB 
infection in their lifetime.36 Conditions such as old age, malnutrition, stress, 
or co-infection with HIV, which reduce the number and impair the function 
of CD4+ T cells, disrupt the containment of Mtb in LTBI.  Such a change in 
immune status causes necrosis and caseation of the granulomas, followed 
by their rupture and spillage of thousands of infectious bacilli into the 
airways, and a productive cough ensues. The cough facilitates the spread 
and transmission of Mtb via aerosolized droplet nuclei. A summary of the 
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Mtb transmission and immunopathogenetic continuum of pulmonary TB is 
depicted in Figure 1.4 below.  
 
Figure 1.4: Diagrammatic representation of the transmission and immunopathogenetic 
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Individuals with active TB present with symptoms such as fever, night 
sweats, chills, weight loss, persistent cough, and hemoptysis. However, 
some patients with active, culture-positive TB may be asymptomatic, and 
are principally reported as having subclinical TB.29 People who have LTBI 
neither feel sick, nor have any symptoms, and cannot spread TB to others. 
Symptoms of extrapulmonary TB vary considerably depending on the site of 
infection.27  
Diagnosis of active pulmonary TB can be culture-based or molecular-based. 
Accurate diagnosis of latent and active TB, as well as detection of drug 
resistance are highly important in the effective management and prevention 
of TB. Diagnosis involves clinical assessment, sputum smear microscopy, 
TB cultures, and chest X-ray radiography. Additionally, the Tuberculin Skin 
Test (TST) is the gold standard for diagnosis of LTBI. However, these 
diagnostic techniques have limited capabilities, and hence technological 
advances in newer diagnostic methods have been ongoing. For instance, 
Nucleic Acid Amplification (NAA) for diagnosis of active TB, and T-Cell-based 
in vitro assays that detect IFN-γ for diagnosis of LTBI, have been developed.37 
1.5 Prevention, Control and Treatment of TB 
1.5.1 Prevention of TB 
Prevention of TB entails pivotal strategies aimed at stopping the spread of 
Mtb. For example identifying and treating the infected;38 preventing 
reactivation of LTBI by early diagnosis and chemoprophylaxis, particularly 
in individuals at high risk of disease progression; reducing the spread of DR-
TB;39 tracing of contacts for screening, treatment and monitoring;40,41 
isolating and treating patients with active TB until such a time they become 
noninfectious;42 efficient management of outbreaks; as well as educating the 
general public on TB in efforts to reduce stigma and improve treatment 
compliance.43 Furthermore, control, management, and minimization of risk 
factors for TB infection such as HIV, are essential in the overall TB 
prevention strategy.44–46 It is also advisable for health care workers to use 
personal protective equipment.47,48 Also, pasteurization of milk and proper 
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cooking of beef are important in preventing zoonotic TB in humans.49,50 
Vaccination plays a key role in protecting infants and children below 16 
years against TB infection.51 The only TB vaccine currently available is the 
Bacillus Calmette-Guérin (BCG). In 2015, 163 countries reported providing 
BCG vaccination as a standard part of childhood immunization 
programmes.10 This vaccine is critical in preventing fatal meningitis TB in 
infants and schoolchildren. However, its efficacy against pulmonary TB in 
children is estimated to be about 50%.52,53 Nonetheless, at least 13 vaccine 
candidates are currently in clinical development. A tremendous effort is 
being made to design new vaccines in such a way that they are effective in 
adolescents and adults, because pulmonary TB is mostly spread by these 
age groups.33,54 
1.5.2 TB Chemotherapy  
1.5.2.1 Treatment of Drug-Susceptible TB (DS-TB) 
It is estimated that 80% of all patients diagnosed with active TB disease are 
infected with fully drug-susceptible (DS) Mtb strains while the remaining 
20% are infected with drug-resistant strains.55 According to the TB 
treatment guidelines published by the WHO, drugs for treatment of DS-TB 
are classified as first-line, based on their efficacy, experience of use, safety 
and pharmacological class. They were previously categorized as Group 1 
category in the old 5-group system. However, this classification has been 
reviewed, and it classifies only the second-line drugs used in the treatment 
of DR-TB.56,57 First-line oral anti-TB agents include isoniazid (INH), 
rifampicin (RIF), ethambutol (EMB), pyrazinamide (PZA), rifabutin (RFB), 
and rifapentine (RPT). Figure 1.5 shows the chemical structures of the 
above-mentioned drugs.  
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Figure 1.5: Chemical structures of the first-line anti-TB drugs. 
Streptomycin (STM) is administered parenterally, and is considered a first-
line agent due to high rates (> 50% in some countries) of streptomycin 
resistance in strains of MDR-TB.56 Although the first-line drugs have been 
shown to be the most potent and well tolerated, it is strongly recommended 
that their clinical use be based on laboratory and clinical evidence of their 
effectiveness, especially through drug-sensitivity tests (DST).58   
Optimal treatment of DS-TB and prevention of drug resistance involve the 
use of anti-TB drugs in combinations, which are based on regimen 
guidelines provided by the WHO. For example, new patients with active 
pulmonary TB are treated with a standard therapy containing rifampicin for 
a minimum of 6 months: 2 months intensive phase with INH, RIF, PZA, and 
EMB, followed by a 4 months continuation phase of INH and RIF. The 
treatment guidelines also prescribe the dosages and frequency of 
administration, preferably through the directly observed therapy-short 
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course (DOTS) – a strategy endorsed by the WHO to  promote optimal 
adherence and treatment success.59,60 In addition, it is recommended that 
the drugs be formulated as fixed dose combinations (FDCs) to reduce the pill 
burden and therefore promote compliance.61–64 Also, a significant proportion 
of patients have been reported to develop toxicity to these drugs, ranging 
from mild to severe adverse events. Thus, it is important to monitor patients 
for adverse events such as severe hepatitis, immune thrombocytopaenia, 
agranulocytosis, haemolysis, renal failure, optic neuritis, and ototoxicity, 
which may cause severe morbidity and compromise TB therapy.65–68 Equally 
important, as a follow-up support, repeat sputum smears, cultures and 
chest X‑rays are recommended and used as indicators of treatment efficacy 
and progress. Where possible and cost notwithstanding, therapeutic drug 
monitoring (TDM) should be conducted to provide information that may 
facilitate dosing decisions.69  
Isoniazid was first synthesized in 1912 and later introduced as an anti-TB 
drug in 1952.70 It is a prodrug with a complex mode of action that is 
believed to proceed via production of various highly reactive compounds 
targeting multiple Mtb enzymes. Indeed, several studies have revealed that 
mutations in about 117 Mtb enzymes, which influence metabolic pathways 
and cell wall biosynthesis, could be associated with INH resistance.71 INH is 
activated by the catalase-peroxidase (KatG) and MnCl2 to form an 
isonicotinoyl radical or anion, which then reacts with nicotinamide-adenine 
dinucleotide (NAD+) and nicotinamide-adenine dinucleotide phosphate 
(NADP+), to generate INH-NAD(P) adducts. The INH-NAD complex inhibits 
the enoyl-acyl carrier protein (ACP)-reductase enzyme (inhA), while INH-
NADP is an inhibitor of dihydrofolate reductase (dfrA) and 3-oxoacyl-ACP 
reductase.72–77 INH mainly kills the actively replicating Mtb. Strains of Mtb 
resistant to INH have been reported, and the genes responsible for their 
resistance identified. Most INH-resistant strains have mutations in katG and 
inhA genes. In this regard, S315T is a specific katG variant found in 94% of 
INH-resistant clinical isolates.78 Moreover, there are many other genes 
associated with INH resistance. For instance, in a study conducted by 
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Shekar et al., 60 genes responsible for INH resistance were identified, 
including katG, inhA, ahpC, kasA, and NDH. Equally important, their 
functions were pinpointed to functions in the Mtb’s cell wall, metabolism, 
and respiration.79 
Rifampicin is a rifamycin derivative that was introduced for TB treatment in 
1972.80 It strongly binds and selectively inhibits bacterial DNA-dependent 
ribonucleic acid (RNA) polymerase, thus interfering with DNA 
transcription.81 Mtb resistance to RIF is mainly mediated by mutations in 
the rpoB gene, which lead to changes in the structure of the RNA 
polymerase β-subunit.82–84 Rifabutin and rifapentine are rifamycins with 
similar chemistry and microbiological profiles as rifampicin. Rifabutin is 
routinely used in the treatment of active TB in HIV-positive patients 
receiving protease inhibitors, whereas rifapentine is a long-acting rifamycin 
used in some countries for treatment of LTBI and active TB.56 There have 
been reports of Mtb cross-resistance across rifamycins.85  
Pyrazinamide was introduced in the early 1950’s as an important sterilizing 
prodrug, which contributes to TB treatment shortening due to its high 
efficacy on the persister Mtb bacilli.86 The exact mechanism of action for PZA 
remains unknown. It has previously been reported that PZA requires acidic 
conditions for its activation, whereby nicotinamidase/pyrazinamidase 
converts pyrazinamide into its active form, pyrazinoic acid (POA), which 
disrupts membrane energetics leading to inhibition of membrane 
transport.86 Also, it has been reported that POA binds to the ribosomal 
protein S1 (RpsA) leading to inhibition of protein translation, as well as the 
ribosome-sparing process of trans-translation, a mechanism that could 
explain the sterilizing action of PZA.87 However, both mechanisms of action 
have since been debunked, further complicating the understanding of the 
PZA mode of action.88–89 Pyrazinamide-resistant Mtb strains lose 
pyrazinamidase activity due to mutations in the pncA gene.90–91  
Ethambutol was introduced for treatment of TB in 1966. Its site of action is 
on the cell wall where it inhibits the biosynthesis and polymerization of 
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arabinan by targeting the arabinosyltransferase enzyme. This leads to 
accumulation of mycolic acids with eventual Mtb cell death.92–94 Resistance 
of Mtb to EMB is mainly attributed to mutations in the embB gene.95  
Streptomycin is a natural product discovered in 1944, and was the first 
antibiotic to be used successfully to treat TB.96 It is an aminoglycoside that 
inhibits protein synthesis by binding the ribosomal 30S subunit at the 
ribosomal protein S12 and the 16S rRNA.97 Resistance to streptomycin 
occurs due to mutations on this target as well as by enzymatic inactivation 
of the drug. Indeed, 60–70% of streptomycin-resistant Mtb strains have 
mutations in the rpsL and rrs genes, which encode for the S12 and 16S 
rRNA, respectively.98  
The regimen of the first-line drugs used to treat DS pulmonary TB is also 
applicable for treating majority of the extrapulmonary TB cases, except TB of 
the central nervous system, bone, and joint, where longer therapy regimens  
are recommended.59,99 For example, the treatment of TB meningitis lasts 9–
12 months due to the high risk of disability, while treating TB of the bones 
takes a minimum of 9 months due to difficulties in monitoring treatment 
success. 
The WHO recommends that all HIV-positive individuals with active TB 
disease, irrespective of their CD4+ T cell count, should start antiretroviral 
therapy (ART) within the first 2 months of TB treatment. Nonetheless, there 
are two main challenges experienced when initiating ART during TB 
treatment: drug-drug interactions and immune reconstitution inflammatory 
syndrome (IRIS). Consequently, the scientific debate has been about when is 
the best time to start ART: early or delayed initiation? There is strong 
evidence from various studies, systematic reviews, and meta-analyses that 
ART initiation ought to be based on CD4+ T cell count. The general 
recommendation is to delay ART in HIV-positive patients who have CD4+ T 
cell counts > 220 per μL until after 6 months of TB treatment. Conversely, it 
has been found beneficial to initiate ART early enough during TB treatment 
of HIV-positive patients with CD4+ T cell counts < 50 per μL.100–104  
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1.5.2.2 Treatment of Latent Tuberculosis Infection (LTBI) 
LTBI is defined as an asymptomatic state of persistent cellular immune 
responses, particularly mycobacteria-specific T-cell responses to stimulation 
by the Mtb antigens without clinical evidence of active TB.105 Individuals 
with LTBI are at a significant risk of developing active TB, and therefore, 
treatment should be initiated in high risk individuals to prevent its 
reactivation and progression. In 2015, the WHO published guidelines for 
testing and treating LTBI, with an emphasis on evidence-based practices. It 
is highly recommended to initiate testing and treatment of LTBI in high risk 
individuals such as HIV-positive patients, contacts of pulmonary TB cases, 
patients initiating anti-TNF treatment, patients on dialysis, patients 
preparing for transplantation, and patients with silicosis. Additionally, 
prisoners, health care workers, immigrants from high TB burden countries, 
homeless persons, and illicit drug users, may be considered for LTBI testing 
and treatment.106  
The WHO prescribes either the interferon-gamma release assays (IGRA) or 
the Mantoux TST for LTBI testing. Although the IGRA test can distinguish 
between BCG-induced and Mtb infection-induced positive TST results,107 the 
WHO recommends that IGRA should not replace TST in low-income 
countries. Both tests are hampered by the lack of ability to accurately 
distinguish between either LTBI and active TB, or new infections and 
re‑infections; low predictive values for disease progression; as well as low 
sensitivity, especially in immunocompromised populations.108  
The regimen options recommended for the treatment of LTBI are: 6–9 
months of isoniazid, or 3 months of weekly rifapentine plus isoniazid, or 3–4 
months of isoniazid plus rifampicin, or 3–4 months of rifampicin alone.106,109 
Although the 9 months INH therapy has > 90% efficacy, it is unfortunately 
seriously hampered by adverse events, including hepatotoxicity.110 
Consequently, it is important that patients are regularly monitored, and the 
risks and benefits of treatment carefully balanced for each individual.111  
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1.5.2.3 Treatment of Drug-Resistant TB (DR-TB) 
First-line drugs have been instrumental in the successful treatment and 
prevention of TB over the years they have been in existence. However, this 
success has been under far-reaching threat by the emergence of DR-TB. 
Cases of DR-TB can be classified into categories that are not mutually 
exclusive: 1. Mono-resistant TB is resistant to one first-line anti-TB drug 
only; 2. Poly-resistant TB is resistant to more than one first-line anti-TB 
drug, other than both isoniazid and rifampicin; 3. MDR-TB is resistant to at 
least both isoniazid and rifampicin; 4. XDR-TB causes more severe disease 
manifestation and is defined as MDR-TB with additional resistance to any 
fluoroquinolone, and at least one of the three second-line injectable drugs 
(capreomycin, kanamycin, and amikacin); 4. Rifampicin resistant TB (RR-
TB) is resistant to rifampicin, with or without resistance to other anti-TB 
drugs;56 5. Totally drug-resistant TB (TDR-TB) or extremely drug resistant 
TB is resistant to all first- and second-line anti-TB drugs.112  For example, in 
a recent study conducted by Dheda and colleagues at the University of Cape 
Town regarding the programmatically incurable TB patients, 56% of isolates 
from patients with treatment failure were resistant to eight or more drugs.113 
Phenotypic, culture- and molecular-based methods are available for 
detection of DR-TB. Importantly, increased rollout and use of Xpert® 
MTB/RIF in many settings as a diagnostic tool for active TB has led to an 
upsurge in detection of MDR‑TB, as well as improving the universal drug-
susceptibility testing.114–116 This nucleic acid amplification-based tool 
produces results in less than 2 hours leading to greatly enhanced efficiency 
in initiation of treatment.117,118 Other diagnostic methods recommended by 
the WHO include loop-mediated isothermal amplification (TB-LAMP) and 
molecular line probe assays for rapid screening of patients at risk of 
MDR‑TB.119,120 Moreover, several new diagnostic tools are in the 
development pipeline, with priority being to develop a rapid, low-cost, non-
sputum-based test for use at the primary health care level.121 
Because developing new anti-TB drugs is a lengthy, expensive, and an 
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uncertain process, treatment of DR-TB is achieved by applying strategies 
such as the use of existing anti-TB drugs that were previously not widely 
prescribed; repurposing of existing drugs; as well as the use of current anti-
TB drugs in high doses. Consequently, the WHO in its 2016 update on the 
DR-TB treatment guidelines, approved a hierarchical classification of 
second-line anti-TB drugs into four groups as shown in Table 1.1. The role 
of this classification is to guide clinicians when deciding and designing 
treatment regimens for MDR-TB and XDR-TB. Compared to the first-line 
anti-TB drugs, these agents are usually less effective, more expensive, and 
more often associated with toxicity risks, therefore calling for close 
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Table 1.1: Classification of medicines recommended for the treatment of DR-TB.33,57,122 






Inhibition of DNA gyrase  QT interval prolongation (Cardiotoxicity)  







Inhibition of protein synthesis  Nephrotoxicity  
 Ototoxicity  
 Electrolyte derangement 










 Inhibition of cell wall synthesis 
(Eto & Pto) 
 Inhibition of protein synthesis (All 
others) 
 Nausea and vomiting (all) 
 Hypothyroidism (all) 
 CNS effects, including psychosis, 
confusion and depression (terizidone 
and cycloserine) 
 Peripheral neuropathy (linezolid) 
 Myelosuppression (linezolid) 
 Ocular toxicity (linezolid) 
 QT interval prolongation (clofazimine) 
 Skin and conjunctival pigmentation 
(clofazimine) 
Group D1  
(Add-on agents 







 Disruption of plasma membranes 
(PZA) 
 Inhibition of cell wall synthesis 
(EMB) 
 Inhibition of mycolic acid 
synthesis (INH) 
 Hepatotoxicity (PZA) 
 Gout (PZA) 
 Ocular toxicity (EMB) 
 Hepatotoxicity (INH) 
 Peripheral neuropathy (INH) 
 CNS toxicity (INH) 
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Table 1.1: Classification of medicines recommended for the treatment of DR-TB.33,57,122 
Group Drugs Mechanism of Action Key Adverse Events 
 




 Inhibition of mitochondrial ATP 
synthase (Bdq) 
 Inhibition of mycolic acid 
synthesis (Dlm) 
Bdq 








 QT interval prolongation 
Group D3  
 




 Meropenem (Mpm) 
 Amoxicillin-clavulanate 
(Amx-Clv) 
 Thioacetazone (T)b 
 Inhibition of DNA precursor 
Synthesis (PAS) 
 Inhibition of peptidoglycan 
synthesis (Ipm, Mpm, or Amx-Clv) 




 Gastrointestinal toxicity 
Ipm, Mpm, or Amx-Clv 
 Seizures 
T 
 Severe skin reactions (for example, 
Stevens–Johnson syndrome and toxic 
epidermal necrolysis), especially in HIV-
positive patients 
aStreptomycin can be used when the isolate is susceptible and none of the other injectable drugs are available. 
bThioacetazone should not be used in HIV-positive patients due to severe skin reactions. 
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Treatment regimens for DR-TB are less well defined than those of DS-TB. 
Nevertheless, in patients with MDR-TB, at least five effective medicines are 
recommended during the intensive phase of therapy whereby pyrazinamide 
and four core second-line drugs, one chosen from Group A, one from Group 
B, and at least two from Group C, are used. Alternatively, an agent from 
Group D2 and other agents from Group D3 may be added to bring the total 
to five. This regimen can further be strengthened with high-dose isoniazid 
and/or ethambutol.57 The treatment duration is usually at least 20 months, 
but a 9–12 month regimen may be adequate in selected patients after careful 
consideration of previous treatment and resistance profiles.57  
Fluoroquinolones were introduced into clinical practice in the 1980s and are 
widely used for treating diverse bacterial infections such as those of the 
respiratory, gastrointestinal, and urinary tracts.123 Only later-generation 
fluoroquinolones such as levofloxacin, moxifloxacin, and gatifloxacin are 
indicated for use in the treatment of MDR-TB. Indeed, it is recommended 
that ofloxacin and ciprofloxacin be phased out from the MDR-TB regimens.57 
Fluoroquinolones are administered orally, can penetrate macrophages, have 
a bactericidal effect,124 and act by antagonizing the bacterial DNA gyrase 
thereby disrupting DNA replication.125 Generally, they have favourable safety 
profiles but carry the risk of cardiotoxicity due to QT interval [beginning of 
the Q wave to the end of the T wave in the heart's electrical cycle] 
prolongation,126 which is a concern especially when used in combination 
with drugs with a similar risk such as bedaquiline, delamanid, and 
clofazimine. 
Members of Group B are injectable drugs namely kanamycin (Km), amikacin 
(Am), and capreomycin (Cm). Although they are usually intramuscularly 
injected, the drugs may also be administered by slow intravenous injection. 
Kanamycin and amikacin are aminoglycosides, which inhibit protein 
synthesis by altering the 16S rRNA.97 On the other hand, capreomycin is a 
cyclic peptide antibiotic that inhibits protein synthesis by binding to the 23S 
rRNA.127 Close monitoring of patients taking these drugs is recommended 
because they are associated with severe adverse events such as hearing loss 
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and nephrotoxicity.57  Chemical structures of group A, B, and C drugs are 
shown below in Figure 1.6. 
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Other core second-line drugs include pharmacologically diverse agents that 
are classified as Group C. Two or more of these agents are to be included in 
an MDR-TB treatment regimen to bring the total number of effective second-
line TB drugs to at least four in the intensive phase: ethionamide (or 
prothionamide), cycloserine (or terizidone), linezolid, and clofazimine. 
Linezolid is a repurposed drug belonging to the oxazolidinone class of 
antibiotics, which exert their effects by inhibiting bacterial protein synthesis 
through binding to the 23S rRNA.128,129  
Clofazimine is a riminophenazine dye that is applied worldwide for the 
treatment of leprosy. It is believed to serve a sterilizing function in MDR-TB 
regimens where pyrazinamide is ineffective. Although several studies have 
reported favorable outcomes on MDR-TB patients put on clofazimine-
containing regimens, majority of them suffer from skin discoloration and 
ichthyosis that may cause distress in some patients, which could result in 
treatment noncompliance.130,131 
Group D1 consists of first-line anti-TB drugs namely pyrazinamide, 
ethambutol, and high-dose isoniazid. They are usually added to the core 
second-line drugs, unless confirmed resistance, pill burden, intolerance, or 
drug–drug interactions outweigh their potential benefits. 
Group D2 drugs are bedaquiline and delamanid. Bedaquiline (TMC-207) was 
the first new anti-TB drug to be approved after more than 40 years with no 
new discoveries.132 It is a diarylquinoline that received conditional regulatory 
approval due to limited evidence on its safety and efficacy by the Food and 
Drug Administration (FDA) in late 2012 and by the European Commission in 
2014, for the treatment of pulmonary MDR-TB in adults.133 It is strongly 
bactericidal and exerts a sterilizing effect. On the other hand, delamanid is a 
dihydro-nitroimidazole prodrug, which received accelerated conditional 
approval by the European Medicines Agency (EMA) in November 2013.134,135 
Both drugs are orally administered and exert their effects through novel 
mechanisms whereby bedaquiline inhibits adenosine-5’-triphosphate (ATP) 
synthase,136,137 while delamanid inhibits the synthesis of the mycobacterial 
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cell wall components such as methoxy mycolic acid and ketomycolic acid. In 
addition, both drugs have not exhibited cross-resistance to the other anti-TB 
drugs; have good sterilizing properties, which may result in shorter 
treatment regimens; and their addition to treatment regimens, particularly 
bedaquiline, has resulted in low health care costs.138–140  
Group D3 drugs include p-aminosalicylic acid (PAS), carbapenems 
(imipenem–cilastatin and meropenem), clavulanate (available as amoxicillin-
clavulanate), and thioacetazone. They are the lowest ranked in terms of 
safety and efficacy, and therefore they should only be used when a regimen 
with at least five effective drugs in the intensive phase cannot otherwise be 
composed. It is recommended that in order to reduce their metabolism, 
carbapenems should be combined with amoxicillin-clavulanate, whenever 
used in a regimen.57 Figure 1.7 shows the chemical structures of group D2 
and D3 drugs. 
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1.5.3 Unmet medical needs in TB and challenges associated with the 
current TB chemotherapy 
Unmet medical needs in TB along with various shortcomings faced by the 
current therapeutic regimens, lead to unfavorable treatment outcomes. For 
instance, treatment protocols for both LTBI and active TB disease are 
lengthy and complex mainly due to the physiological heterogeneity of TB. As 
a consequence, clinicians experience prescribing challenges and patients 
suffer from adverse events, which may lead to noncompliance. This more 
often leads to treatment failures, relapses, deaths, as well as emergence of 
drug-resistance. Furthermore, DR-TB requires an even longer duration of 
treatment with drugs that are often of low availability especially in low-
income countries, less efficacious, more toxic, and much more expensive 
than the first-line drugs.141  
Also, drug-drug interactions are a stumbling block in the optimal treatment 
of TB patients suffering from other co-infections, particularly the treatment 
of HIV and TB co-infected individuals. In this regard, cytochrome P450 (CYP) 
3A4 interactions with rifampicin and antiretrovirals (ARVs) such as non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors 
(PIs) are a significant impediment in the management of TB patients co-
infected with HIV. For instance, rifampicin induces CYP 3A4 leading to 
increased metabolism of PIs, and hence reducing their blood concentration 
and effectiveness.142–145 Equally important, both ARVs and isoniazid can 
cause shared toxicities such as peripheral neuropathy and hepatitis, hence 
exacerbating the adverse events during co-treatment.146 Besides drug-drug 
interactions, co-infections and other underlying non-communicable co-
morbidities like diabetes mellitus pose other obstacles such as pill burden, 
toxicities, and acceleration of the TB disease, further complicating TB 
treatment.147 
Even after successful treatment completion and cure, some patients still 
suffer from permanent lung injury and functional impairment, which is 
characterized by chronic cough and breathlessness. Treatments for 
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prevention of lung injury are still not available and therefore presenting 
another unmet medical need in the management of TB.148  
Also, there is a pressing need for improved biomarkers to guide and monitor 
treatment as well as to speed up the process of drug development.148 
The constraints experienced with the current anti-TB drugs, as well as the 
enormous global burden of TB, have stimulated renewed interest by the 
pharmaceutical industry and research institutions in recent decades to 
develop new anti-TB medicines, albeit with low market incentives.  The 
major goals driving research into new and improved TB therapy include: 
shortening and simplifying treatment of DS-TB; improving and shortening 
treatment of DR-TB, particularly by use of new, affordable, better-tolerated, 
and more effective agents with novel mechanisms of action; simultaneous 
treatment of TB and HIV/AIDS by developing new anti-TB drugs that can be 
co-administered with ARVs; shortening the duration of treating LTBI to 
replace the currently recommended protocol of 9 months of isoniazid.149 
Consequently, various new anti-TB agents, repurposed drugs, and new 
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1.5.4 Development pipeline for new anti-TB drugs and regimens 
Worldwide, there are a total of about eighteen new anti-TB agents and 
regimens currently undergoing clinical development and ten new 
compounds in preclinical evaluation. This is according to the data on new 
anti-TB drugs development pipeline compiled and updated by the STOP TB 
Partnership Working Group on New TB Drugs as shown in Figure 1.8. 
Figure 1.8: Current global drug pipeline for new anti-TB agents and regimens in preclinical 
and clinical development (Updated: July 2017).150 
Bedaquiline and delamanid are currently in the confirmatory phase III 
clinical studies,151 having previously been granted accelerated approval for 
the management of pulmonary MDR-TB in adults. During a multicenter 
phase II clinical study (TMC207-C208), addition of bedaquiline to a five-drug 
regimen resulted in faster and higher rate of sputum-culture conversion at 
24 weeks. However, the study did not conclusively assess whether 
bedaquiline simplifies and/or shortens TB treatment. In addition, there were 
more deaths observed in the bedaquiline group compared to those on 
placebo (10 vs 2, p = 0.02).152 Although the exact causes of deaths were 
unclear, bedaquiline is beset by long term safety concerns particularly 
because it causes QT interval prolongation and distributes considerably in 
peripheral tissues. These concerns, as well as assessment of treatment 
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shortening are expected to be addressed to a greater extent when the 
current phase III clinical studies publish their reports sometime in 2019 and 
2021.153 Examples of the current clinical studies include the New 
Investigational Drugs for XDR-TB (NiX-TB) regimen (clinical trial: 
NCT02333799) comprised of 6 months of bedaquiline-pretomanid-linezolid 
(6Bdq-Pa-Lzd). The assessment is being conducted in South Africa to 
evaluate Bdq-Pa-Lzd as a salvage therapy for XDR-TB and is expected to 
conclude in 2021. Other bedaquiline studies include the NExT trials 
(NCT02454205), also in South Africa, involving 6–9 months of bedaquiline-
levofloxacin-linezolid-ethionamide-pyrazinamide/isoniazid/terizidone; Evaluation 
of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients 
with MDR-TB (STREAM) Stage 2 trials (NCT024092290) being carried out in 
Vietnam to investigate 9 months of bedaquiline-levofloxacin-clofazimine-
pyrazinamide-high dose isoniazid-prothionamide regimen, and in South 
Africa to assess a 6 months regimen of bedaquiline-kanamycin-levofloxacin-
clofazimine-pyrazinamide.150,151,153  
A definitive phase III, multicentered, randomized, double-blinded, placebo-
controlled, parallel group clinical trial is currently underway to evaluate the 
safety and efficacy of delamanid. The trial seeks to assess delamanid when 
administered orally at a dose of 100 mg twice daily for 2 months followed by 
200 mg once daily for 4 months in combination with an optimized 
background regimen (OBR) versus a placebo. Due to its impressive non-
interaction with ARVs, delamanid is also being studied in a select number of 
HIV-positive individuals who are on ARVs to give a clear perspective on 
drug-drug interactions.150 In addition, some studies have demonstrated 
delamanid’s promising potential for use in children, and for this reason two 
clinical trials are currently planned or underway to evaluate its safety, 
efficacy, and optimal dosing in pediatric populations.154 
Pretomanid (PA-824), like delamanid, is a nitroimidazole that is currently in 
phase III clinical trials. Pretomanid is bactericidal and active against both 
replicating and hypoxic, non-replicating Mtb. It is a prodrug that undergoes 
intracellular metabolic activation by a deazaflavin (cofactor F420)-dependent 
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nitroreductase (Ddn or Rv3547). The active metabolites kill Mtb by a dual 
mechanism: aerobic disruption of formation of mycolic acid, as well as by 
releasing nitric oxide to create a toxic environment that leads to respiratory 
poisoning of Mtb in anaerobic conditions.155–157 In an open-label, partly 
randomized phase IIb clinical trial, a combination of pretomanid, 
moxifloxacin, and pyrazinamide was found to be safe, well tolerated, and 
with superior bactericidal activity during the 8 weeks of treatment.158 This 
regimen is currently in phase III Shortening Treatments by Advancing New 
Drugs (STAND) trial (NCT02342886) to assess its treatment-shortening and 
simplifying capabilities.151 
Sutezolid (PNU-100480), like linezolid, belongs to oxazolidinone class of 
antibiotics. It exerts its anti-TB actions by binding to the 23S ribosomal 
subunit, thereby disrupting protein synthesis. At a daily dose of 1200 mg, 
sutezolid is reported to be better tolerated and more efficacious than 
linezolid. Furthermore, it is neither associated with inhibition nor induction 
of CYP enzymes, thus expected to exhibit low risk of drug-drug interactions. 
It is currently undergoing phase II clinical assessment.159 
Another drug in phase II clinical trials is SQ109, an adamantane-based 1,2-
ethylenediamine (ethambutol analogue) with a novel mechanism of action 
that is different from that of ethambutol. Indeed, it has been reported to be 
active against ethambutol-resistant strains of Mtb.160 It works by inhibiting 
MmpL3, a transmembrane trehalose monomycolate transporter that is 
essential for incorporation of mycolic acid into the Mtb cell wall, and 
therefore hinders cell wall assembly.160–162 It has also been shown to act via 
depleting the transmembrane electrochemical proton gradient.163 
Two new agents are currently in phase I clinical trials: Q203 and PBTZ169. 
The compound Q203 belongs to the imidazopyridine amide class and is 
reported to affect energy metabolism in Mtb by targeting cytochrome b 
subunit (QcrB) of the respiratory cytochrome bc1 complex electron transport 
chain, and accordingly inhibits the synthesis of ATP.164,165 Benzothiazinones 
PBTZ169 and BTZ043 (in advanced preclinical development) kill Mtb by 
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binding to the essential flavo-enzyme, decaprenylphosphoryl-β-D-ribose-2-
epimerase (DprE1), leading to its inhibition and irreversible inactivation. 
DprE1 catalyzes epimerization of decaprenylphosporyl ribose to 
decaprenylphosporyl arabinose during the synthesis of arabinans, which are 
essential parts of the Mtb cell wall.166 Studies in zebrafish and mouse 
models of TB suggest that PBTZ169 is a more efficacious and safer 
compound compared to BTZ043.167  
There are several compounds in the stage of preclinical development.150,168 
BTZ043 and TBA7371 (1,4-azaindole)169,170 are DprE1 inhibitors while GSK-
070 is a Leucyl-tRNA synthetase inhibitor.150 TBI-166 is a riminophenazine 
analogue that is less lipophilic than clofazimine, therefore less accumulated 
in tissues and poses a lower risk of skin discoloration.171,172 CPZEN-45, a 
caprazamycin derivative, inhibits Mtb’s decaprenyl-phosphate-GlcNAc-1-
phosphate transferase (WecA), which is responsible for initiation of cell wall 
biosynthesis.173 Spectinamide 1810 is a structurally modified spectinomycin 
to improve target affinity and prevent efflux. It disrupts protein synthesis by 
binding to the 16S bacterial ribosomal subunit, thereby blocking ribosome 
translocation.174 SATB-082, a cyclopeptide derivative (cyclohexylgriselimycin), 
prevents DNA replication by binding to DNA β-sliding clamp, coded by DnaN 
gene, hence inhibiting DNA polymerase III.175 The chemical structures of the 
above-mentioned anti-TB drug candidates are shown in Figure 1.9 below.     
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Figure 1.9: Chemical structures of preclinical and clinical anti-TB drug candidates. 
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To summarize and further illustrate the intensified research in the recent 
past towards delivering novel anti-TB medicines, Figure 1.10 shows a 
pipeline of currently ongoing projects in multifarious early stages of drug 
discovery. Some projects involve discovery of new agents for novel targets, 
whereas others are based on the already established targets as well as 
phenotypic whole-cell screening approaches. 
 
Figure 1.10: Global TB drug discovery pipeline (Updated: July 2017).150 
1.6 Attrition of Drug Candidates  
From the foregoing discussion, it is observable that there are more projects 
in the early drug discovery phase compared to those in the preclinical and 
clinical development. This is most likely ascribable to not only attrition of 
drug candidates along the development pipeline, but also a reflection of a 
period of about five decades of near inactivity in developing new anti-TB 
drugs.70 For instance, the development of AZD5847, an oxazolidinone, by 
AstraZeneca was terminated due to lack of efficacy, while the development of 
TBA-354, a nitroimidazole, was discontinued due to toxicity in a Phase I 
clinical trial.10 
Generally, it is estimated that attrition rate is about 80% in the discovery 
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phase and 90% during the development stage. Overall, close to 99% of 
nominated drug candidates fail at some stage in development, suggesting 
that only about 1 in 50 projects make it through the arduous drug discovery 
and development process.176–178 A 2015 analysis by Waring and colleagues 
on progression status of 812 oral small-molecule drug candidates from four 
major pharmaceutical companies (AstraZeneca, Eli Lilly and Company, 
GlaxoSmithKline (GSK) and Pfizer) in the period 2000–2010, gives a clear 
illustration of the general attrition trend in drug development as depicted in 
Figure 1.11.179  
 
Figure 1.11: Progression of drug candidates during discovery and development phases.179 
Causes of attrition of drug candidates are multiple and can be categorized 
into three major classes: compound-related, biology-related, and 
organization-related. Compound-related failures are associated with 
unfavorable drug metabolism and pharmacokinetics (DMPK), safety, 
formulation, and synthesis. Biology-related attrition arises from failures in 
target-disease linkage, clinical efficacy, as well as target-based toxicity 
(exaggerated pharmacology), while the organization-related terminations are 
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associated with companies’ portfolio rationalization, disease priorities, and 
costs.176,179–181 Table 1.2, obtained from the work of Waring et al., is a 
summary of the causes and their associated percentage contribution to the 
attrition of drug candidates that were studied.179 In summary, these results 
demonstrate and suggest that the major reasons for termination are non-
clinical toxicology (59%) for the preclinical phase; clinical safety (25%) for 
phase I; lack of efficacy (35%) and clinical safety (25%) for phase II; and 
rationalization of company portfolio, which was generally constant for the 
three phases at 20%. Moreover, it was noted that there was an overall 
decrease in the drug candidates’ failure between compounds developed in 
the period 2000–2005 compared to those developed in 2006–2010, a likely 
indication of some success in efforts towards curbing attrition.179 







Phase I Phase II 
Clinical safety 68 (11%) 48 (13%) 20 (8%) 5 (1%) 40 (25%) 22 (25%) 
Commercial  40 (7%) 23 (6%) 17 (7%) 26 (7%) 10 (6%) 4 (4%) 
Efficacy  55 (9%) 45 (11%) 10 (4%) 10 (3%) 14 (9%) 31 (35%) 
Formulation  9 (1%) 4 (1%) 5 (2%) 8 (2%) 1 (0.6%) 0 
Non-clinical 
toxicology 
240 (40%) 144 (40%) 96 (40%) 211 (59%) 21 (13%) 7 (8%) 
Patent issue 1 (0.2%) 0 1 (0.4%) 1 (0.3%) 0 0 
Pharmacokinetics 
or bioavailability  
29 (5%) 19 (5%) 10 (4%) 3 (0.8%) 25 (16%) 1 (1%) 
Rationalization of 
company portfolio 
124 (21%) 46 (13%) 78 (32%) 75 (21%) 29 (18%) 19 (21%) 
Regulatory 2 (0.3%) 2 (0.6%) 0 1 (0.3%) 1 (0.6%) 0 
Scientific 33 (5%) 28 (8%) 5 (2%) 13 (4%) 15 (10%) 5 (6%) 
Technical 3 (1%) 3 (1%) 0 2 (0.6%) 1 (0.6%) 0 
Other 1 (0.2%) 0 1 (0.4%) 1 (0.3%) 0 0 
Total 605 362 243 356 157 89 
Furthermore, the analysis by Waring et al. reaffirms the existence of a 
relationship between compounds’ physicochemical properties and clinical 
failures. In this regard, most pharmacologically active compounds fail to 
progress to drugs mainly because they have less than optimal 
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physicochemical properties, which place them in a chemical space devoid of 
drug-likeness. Such suboptimal properties result in pharmacokinetics-, 
safety-, and efficacy-related failures due to poor and unfavorable absorption, 
distribution, metabolism, elimination, and toxicology (ADMET) 
profiles.180,182–185 Aqueous solubility, size, lipophilicity, and polarity are 
fundamental physicochemical properties, which influence the drug-likeness 
of candidate molecules. 
Previous studies have led to the establishment of a set of acceptable cut-off 
values for calculated molecular descriptors, which are paramount in 
predicting optimal physicochemical properties for an oral drug-like space. 
Examples of these parameters include those of the Lipinski’s rule of five 
(RO5), which states that good oral absorption and permeation are more 
likely when a compound’s calculated logarithm of n-octanol/water partition 
coefficient (cLogP) is ≤ 5; molecular weight (Mwt) is ≤ 500 Daltons (Da); the 
number of hydrogen-bond donors (OH plus NH count) is ≤ 5; and the 
number of hydrogen-bond acceptors (O plus N atoms) is ≤ 10.186–188 Also, 
Veber and co-workers, in a 2002 study of oral bioavailability of about 1100 
drug candidates in rats, observed and suggested that compounds, which 
have 10 or fewer rotatable bonds and total polar surface area (tPSA) ≤ 140 
Å2 (or total number of both H-bond donors and acceptors ≤ 12) have an 
increased chance of achieving acceptable oral bioavailability.189,190 
Caveats and challenges notwithstanding,191 these rules and guidelines are 
invaluable tools applicable during potential drug candidate design and 
optimization campaigns in efforts to achieve drug-likeness. Thus, it is highly 
beneficial to optimize physicochemical properties such as aqueous solubility 
in the early stages of drug discovery since this serves to ensure that 
sufficient screening out of suboptimal compounds takes place at the earliest 
opportunity. Consequently, there is an element of cost-saving where such 
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1.7 Strategies to improve aqueous solubility of drug candidates 
Solubility of a compound in a solvent is the maximum amount of the most 
stable crystalline form that can remain in solution in a given volume of 
solvent at a given temperature and pressure under equilibrium 
conditions.192 Aqueous solubility, dissolution rate, gastrointestinal tract 
permeability, first-pass metabolism, and susceptibility to efflux are key 
factors affecting the overall bioavailability of orally administered drugs. 
Water solubility is an important drug property that not only affects the rate 
and extent of drug absorption but also the success of pharmaceutical 
formulation processes. In addition, high water solubility is essential for 
drugs designed for parenteral administration.193 For drugs to have sufficient 
oral bioavailability, optimal aqueous solubility and gastrointestinal tract 
(GIT) permeability are fundamental. These two parameters form the basis of 
the Biopharmaceutical Classification System (BCS), which classifies drugs 
into four classes as proposed by Amidon and colleagues in 1995: class I are 
high solubility-high permeability; class II are low solubility-high 
permeability; class III are high solubility-low permeability; while class IV are 
Low solubility-low permeability compounds.194    
It is estimated that about 40% of marketed drugs and up to 75% of new 
chemical entities (NCE) are poorly water-soluble and the problems 
associated with low water solubility seem to be increasing.195 Multiple 
factors have contributed to discovery of compounds with poor aqueous 
solubility, including the use of parallel and combinatorial chemistry to 
generate chemical libraries; high-throughput screening methods often 
performed in non-aqueous solvents such as dimethyl sulfoxide (DMSO);196 
focus on increased potency; quest to explore novel drug targets, some of 
which are associated with highly lipophilic endogenous ligands; as well as 
increased application of in vitro target-based drug discovery approaches, 
whereby target binding is partially mediated by hydrophobic interactions.195 
Low-solubility compounds are plagued by numerous negative effects such as 
poor and inconsistent oral absorption and bioavailability; insufficient 
solubility for intravenous dosing; artificially low activity values and 
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decreased test sensitivity in bioassays due to precipitation of compounds in 
assay media; erratic and inconsistent assay results; drug development 
challenges leading to expensive formulations and increased development 
time and costs; and burden on patients due to the frequent high-dose 
administrations because poorly soluble drugs often require high doses in 
order to reach the desired therapeutic plasma concentrations, and this may 
be associated with adverse events and noncompliance.197,198 
Low oral bioavailability of drugs due to poor aqueous solubility is a concern 
for BCS classes II and IV compounds. There are several medicinal chemistry 
approaches involving chemical structural modification of compounds to 
address solubility insufficiencies. These include introduction of polar and 
ionizable groups, salt formation, reduction of lipophilicity (Log P), addition of 
hydrogen-bonding moieties, disruption of molecular planarity and 
symmetry, reduction of aromaticity, lowering of molecular weight, design of 
chiral non-flat compounds, as well as construction of prodrugs. Modification 
of a compound’s chemical structure affects physicochemical properties such 
as lipophilicity (determined by van der Waals, dipolar, hydrogen bonds, ionic 
interactions), size (molecular weight and shape), acid-base dissociation 
constant (pKa) (determined by functional group ionizability), and crystal 
lattice energy that is determined by crystal stacking and melting point.197 
However, for some targets, reducing lipophilicity and increasing water 
solubility by modification of a compound’s structure may result in an 
unacceptable reduction or loss of potency. Thus, a number of formulation 
strategies are designed to address a compound’s poor solubility without 
affecting their parent chemical structures. Such approaches include the use 
of cosolvents, surfactants, cyclodextrins, particle size reduction, co-crystals, 
polymorphs, complexation, and amorphous solid dispersions.195,197–201 
1.7.1 Chemical structural modification strategies 
1.7.1.1 Addition of ionizable groups and salt formation 
It is estimated that about 70% of drugs are ionizable with a majority being 
basic.201 Introducing an ionizable group in the structure of a compound is a 
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common and effective technique applied to enhance water solubility. For 
example, introduction of a side chain with a basic amine or a carboxylic acid 
enhances aqueous solubility, particularly in pH buffers where such groups 
exist in their ionized forms, due to improved interactions with water 
molecules. These groups influence the pKa of a compound and are thus 
important groups in salt formation, another technique with widespread 
application to improve aqueous solubility.202  
Indeed, salt formation is the most preferred approach for the development of 
parenteral formulations.203 For example artemisinin derivatives containing 
an amino group or a carboxylic acid and their corresponding salts are more 
water soluble than the parent artemisinin.204 Salt formation by acidic or 
basic drugs and their dissociation back into their free forms depends on 
factors such as intrinsic solubility, pH, pKa, solubility product (Ksp), and pH 
of maximum solubility.205 It is therefore necessary to carefully analyze the 
interrelationship between these factors for successful selection of 
appropriate counterions to prepare salts. Examples of counterions for the 
formation of salts of basic drugs include hydrochloride, methanesulfonate 
(mesylate) hydrobromide/bromide, acetate, fumarate, sulfate/bisulfate, 
succinate, citrate, phosphate, maleate, nitrate, tartrate, benzoate, 
carbonate, and pamoate. On the other hand, for acidic drugs, the most 
commonly used counterions  are sodium, calcium, potassium, and 
tromethamine.205    
In addition to improving solubility, salts also modify other physicochemical 
properties such as dissolution rate, crystallinity, hygroscopicity, and 
mechanical properties (hardness, elasticity). These properties greatly impact 
on a compound’s bioavailability, stability, and manufacturability.197  
1.7.1.2 Lowering of Log P and Molecular Weight 
Structural modifications aimed at reducing log P can be achieved by 
introducing hydrophilic groups, replacement of phenyl groups with 
heterocycles such as pyridyl and pyrimidinyl, as well as reducing the size of 
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a molecule. Hydrophilic groups increase the polarity of a compound and 
enhance solubility as discussed in the next subsection.197 
1.7.1.3 Introduction of polar groups and use of prodrugs 
Introduction of hydrogen bond donors such as hydroxyl and amino groups 
and acceptors such as carbonyl groups into a molecule enhances solubility 
by facilitating hydrogen bonding interaction between water molecules and 
solutes.206,207 These polar and sometimes charged groups form the basis of 
construction of prodrugs that have higher solubility than the parent 
compounds. Ester, carbonate, amide, carbamate, oxime, and amino acid-
conjugated prodrugs are common, highly soluble, bioreversible derivatives 
designed to undergo enzymatic hydrolysis in vivo to release the active parent 
drug.208–210 For example, fosphenytoin, a prodrug of phenytoin with an 
added phosphate, has a greatly increased solubility, and undergoes 
enzymatic hydrolysis in the intestines to release phenytoin for absorption.197 
1.7.1.4 Disruption of Crystal-stacking 
Solubility of a compound is a function of its log P and melting point as 
depicted by the general solubility equation (GSE): log [solubility (M)] = 0.5-
(log P)-0.01[melting point (ºC)-25].211,212 Melting point is related to crystal 
lattice and crystal packing energies. Crystallinity affects the interaction of a 
compound with water molecules and thus amorphous compounds have 
better solubilities than crystalline ones. Therefore, strategies that reduce 
crystallinity or disrupt crystal packing generally increase aqueous solubility. 
Examples of these approaches include reduction of aromaticity by 
increasing the fraction of sp3-hybridized carbons (escape from flatland), 
which results in decreased melting points.213 Also, increasing the dihedral 
angle of biaryl compounds reduces the molecular planarity, and thus 
disruption of the crystal-stacking efficiency. This, for example, is achieved 
by adding ortho-substituents such as methyl and fluoro groups on biaryl 
compounds.212 Figure 1.12 depicts examples of strategies to improve water 
solubility by various structural modifications. 
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Figure 1.12: Examples of chemical modifications for enhancement of aqueous 
solubility.197,212 
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1.7.2 Physical Modification Strategies 
1.7.2.1 Use of Cosolvents 
Cosolvents are water-miscible organic solvents that are less polar than 
water. They are believed to enhance aqueous solubility of poorly soluble 
drugs by disrupting the intermolecular hydrogen bonding networks that are 
present in aqueous systems, thus lowering the polarity of the bulk solvent to 
a level that is almost similar to that of the drug.214 Examples of widely used 
cosolvents in drugs include ethanol, propylene glycol, polyethylene glycol 
(PEG) 300/400, glycerol, DMSO, and dimethyl acetamide (DMA). Cosolvents 
have been used at concentrations above 50% v/v and are reported to 
solubilize 10–15% of FDA-approved parenteral products, both neutral and 
ionizable compounds.195,215 
1.7.2.2 Surfactants 
Surfactants are surface active agents that reduce the surface tension 
between two liquids or between a liquid and a solid. Due to their 
amphiphilic nature, surfactants self-associate in aqueous environments to 
form micelles that improve wetting of hydrophobic materials. Micelle 
formation takes place at a surfactant concentration above the critical micelle 
concentration (CMC). Poorly soluble drugs are solubilized by incorporation 
into the hydrophobic micelle core as well as via favourable interaction and 
orientation into the polar/nonpolar water-micelle interface. Both drug 
hydrophobicity and surfactant charge influence the location of 
solubilization. Examples used in drug formulations include tween 20/80, 
cremophor RH 40/60, cremophor EL, and solutol HS-15, typically used at 
final concentrations of 5–10% v/v.195 Despite their increased use in drug 
formulation, surfactants may be poorly tolerated in chronic use and may 
pose a significant threat of drug precipitation on dilution.216 
Additionally, surfactants have been reported to possess the potential to 
enhance drug bioavailability through their inhibitory effects on metabolic 
and anti-transport processes such as cellular efflux where they demonstrate 
a transporter-specific interaction. These effects might be expected to 
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increase the bioavailability of drugs, particularly where intestinal efflux 
transporters such as P-glycoproteins limit absorption, as well as enhance 
drug access to cells such as those of the CNS.217 
1.7.2.3 Particle Size Reduction 
Particle size reduction enhances solubility and dissolution rate by increasing 
the surface area available for solvation. This technique is achieved through 
either top-down or bottom-up processes.195 In the top-down processes, 
commonly referred to as micronization, larger particles are fragmented into 
smaller particles of micron sizes by dry-impact techniques, which utilize 
mills such as hammer, ball, and air-jet mills. On the other hand, the 
bottom-up processes involve harvesting of small particles after 
recrystallization of a drug from a supersaturated solution. Similarly, nano-
sized particles are achieved by using nanomilling technologies and 
stabilization systems.218 Nonetheless, due to their highly cohesive nature, 
nanoparticles are beset by shortcomings associated with aggregation. Also, 
nanoparticles have the propensity to undergo polymorphic transition during 
manufacturing or storage.219 Furthermore, not all drugs have the necessary 
physicochemical properties to withstand effective size reduction.  
1.7.2.4 Solid Dispersions 
A solid dispersion contains a poorly soluble drug dispersed within an inert, 
more hydrophilic carrier matrix such as water soluble sugars, polymers, or 
surface active emulsifiers. Solid dispersions increase drug dissolution 
through reduced effective particle size, improved wetting, enhanced 
solubilization, and stabilization of a drug in the more soluble amorphous 
state.195,220 
1.7.2.5 Supramolecular Derivatization 
1.7.2.5.1 Crystal Habit Engineering 
Examples of crystal engineering techniques for enhancement of aqueous 
solubility include utilization of polymorphism and formation of cocrystals. 
Different polymorphs (different crystalline forms of a compound) or the 
 
 
Chapter 1: Introduction and Literature Review 
Paul M. Njaria – PhD Thesis 2017 
 
43 
amorphous form have different aqueous solubilities. Where low aqueous 
solubility is a significant limitation to absorption, it is important to select 
the most soluble polymorph or polymorphic mixture, whether anhydrous or 
solvate/hydrate forms.221 
A pharmaceutical cocrystal is a single crystalline solid that incorporates two 
molecules, one being an active pharmaceutical ingredient (API) and the other 
a cocrystal former (co-former), in the same crystal lattice.222,223 Favourable 
geometries of cocrystals lead to self-assembled supramolecular networks. 
The cocrystal former may be an excipient or another drug whose main 
purpose is to improve the drug’s physicochemical properties such as 
solubility, dissolution rate, stability, hygroscopicity, and compressibility. It 
is important to select co-formers from the FDA-approved generally regarded 
as safe (GRAS) additives to ensure non-toxicity.224 Unlike salts, which are 
formed only with ionizable compounds, cocrystals are advantageous because 
they can be applied on both ionizable and neutral compounds, since no 
proton exchange is required. Hydrogen bonding is critical in cocrystal 
formation, and arrangements are mainly based on synthons of strong and 
weak hydrogen bonds as shown in Figure 1.13.225,226 
 
Figure 1.13: Examples of synthons for cocrystal formation.225 
1.7.2.5.2 Cyclodextrin Complexes 
Cyclodextrins (CDs) are macrocyclic oligosaccharides with a hydrophilic 
exterior and a hydrophobic inner core. They are classified as , β, or γ 
depending on their size, number of monosaccharides, and physicochemical 
properties, as illustrated in Figure 1.14.  
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Figure 1.14: Classification of cyclodextrins.227 
CDs form inclusion complexes whereby lipophilic portions of drug molecules 
are taken into the lipophilic central cavities of CDs to form complexes, which 
may self-assemble to supramolecular structures that act as drug carriers 
(Figure 1.15).227,228 CD absorption into cells is limited by the high molecular 
weight, high hydrophilicity, and the large number of H-bond donors and 
acceptors. They improve physicochemical properties of drugs such as 
aqueous solubility and dissolution rates. In addition, they have been shown 
to reduce gastrointestinal and ocular irritation, eliminate unpleasant odours 
or taste, and in some instances prevent drug-additive interactions.229 
Although bulkiness is a challenge for use of cyclodextrins in solid 
formulations, increasing complexation efficiency has been shown to mitigate 
this setback.230 
 
Figure 1.15: Cyclodextrin-drug inclusion complexes in aqueous solution.227 
In conclusion, both chemical and physical strategies of improving aqueous 
solubility of some benzoheterocyclic compounds were explored in this thesis 
work, particularly the introduction of polar and ionizable substituents, 
formation of salts, cocrystals, and cyclodextrin inclusion complexes.  
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1.8 Benzoheterocyclic Chemotypes 
Benzoheterocyclic structural motifs are composed of a benzene ring fused to 
oxygen-, sulfur-, or in most cases nitrogen-containing rings. Examples 
include benzoxazole, benzothiazole, benzofuran, indole, benzothiophene, 
benzimidazole, quinoline, quinaxaline, and quinazoline. They form 
privileged, unique, versatile, readily accessible, chemically tractable, and 
biologically important scaffolds with widespread applications in the design of 
organic compounds such as drugs, food flavors, biocides, and other 
industrial chemicals.231 In addition, heterocycles are immensely interwoven 
in many natural products such as nucleic acids, amino acids, 
carbohydrates, vitamins, and alkaloids. Thus, they are important in drug 
discovery programs because therapeutic effects of many drugs are mainly 
mediated by mechanisms that mimic or inhibit actions of naturally 
occurring biochemical compounds.232 Moreover, in the pharmaceutical 
industry, heterocycles play key roles in drug design because they are easily 
modified and derivatized to modulate physicochemical properties such as 
lipophilicity, polarity, hydrogen bonding, and solubility, all aimed at 
achieving favourable pharmacological, pharmacokinetic, and toxicological 
profiles of drug candidates and ultimately drugs.232 
In this thesis work, quinazolinone and benzoxazole motifs were the 
benzoheterocyclic skeletons (Figure 1.16) that were appropriately 
derivatized to a range of novel compounds, which were then subjected to 
various biological and pharmacological studies with the aim of investigating 
their antimycobacterial structure-activity relationship (SAR) profiles. An 
attendant aim was to explore structure-property relationship (SPR) for the 
target compounds, and supramolecular derivatization of selected analogues. 
 
Figure 1.16: Scaffolds of 2-aminoquinazolinone and benzoxazole-based oxime.  
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1.8.1    2-Aminoquinazolinones 
2-Aminoquinazolinone is an invaluable heterocyclic moiety derived from the 
4-quinazolinone ring system. This structural motif is synthetically versatile, 
chemically stable, and possesses immense biological and medicinal 
significance. There is a large array of quinazolinone-based pharmacologically 
active compounds, including approved drugs, which exhibit diverse 
spectrum of biological activities233,234 such as antiviral;235 antibacterial;236 
antimalarial;237 antifungal;238 anticancer;239 anti-inflammatory/analgesic;240 
sedative-hypnotic;241 antitubercular;242–244 anticoccidiosis in poultry;245 
antihypertensive and diuretic;246 antiallergy;247 antidepressant;248 and 
anticonvulsant.249,250 It is also estimated that the quinazolinone moiety 
forms a core element in over 150 natural products, particularly alkaloids.233 
Despite the immense studies carried out on quinazolinone-based 
compounds, literature review on biologically active 2-aminoquinazolinone-
containing compounds, including approved drugs, reveals that 2-
aminoquinazolinones are the least exploited in drug discovery programs, 
particularly compounds with a primary amine at position 2. Nevertheless, 
more quinazolinone compounds with secondary or tertiary amines at 
position 2 have been studied and reported. Examples of these compounds 
are shown in Figure 1.17.   
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Figure 1.17: Examples of 2-aminoquinazolinones: antimycobacterial A,251 antimycobacterial B,252 antimalarial,237,253 antiviral,254,255 
antibacterial A,236 antibacterial B,256 anticancer A,257 anticancer B,239 antifungal,258 analgesic.259 
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Comparatively, there are fewer 2-aminoquinazolinone-containing 
compounds that have been studied for their bioactivities against Mtb. 
Indeed, to the best of our knowledge, there are no published patents on 
anti-TB compounds containing the 2-aminoquinazolinone skeleton. On the 
other hand, recent studies conducted by Couturier and colleagues in 2016, 
revealed quinazolinone-based compounds (antimycobacterial A in Figure 
1.17) with high in vitro activity against Mycobacterium smegmatis (MIC = 10 
nm) but lacking in vivo efficacy in mice.251 Poor aqueous solubility, non-
proportional oral mice PK, and overall poor drug-likeness were cited as the 
probable causes of the lack of in vivo efficacy.251  
In summary, owing to the large number of quinazolinone-based drug 
candidates and approved drugs with versatile bioactivities, the 
quinazolinone moiety may be termed as a privileged scaffold, which is a 
building block with many sites of modification to yield drug-like compounds. 
Therefore, there is a high probability of delivering novel anti-TB 
quinazolinone-based compounds by appropriate chemical functionalization 
and early optimization of physicochemical properties. Nonetheless, the 
diverse bioactivities displayed by quinazolinones may also be an indication 
of their promiscuity and therefore could probably be plagued by unwanted 
side effects.    
1.8.2      Benzoxazole-Based Oximes 
Benzoxazole-based oximes have been reported to exhibit antimicrobial 
activities260 as well as act as emitters of blue light.261 Although literature on 
them is scarce, a lot more has been reported about benzoxazole- or oxime-
containing compounds in an independent manner. 
Benzoxazole, like quinazolinone, has widespread applications and forms 
part of many compounds with biological activities such as antibacterial, 
anti-inflammatory, anticonvulsant, analgesic, anticancer, as well as 
herbicidal.262–265  
Similarly, compounds with oxime functionalities have a wide spectrum of 
pharmacological activities such as antibacterial,266 antifungal,267 
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antimycobacterial,268–270 as well as antidotes such as obidoxime, which is 
used in the treatment of organophosphate (nerve agents) poisoning.271 
Examples of benzoxazole- and/or oxime-containing drugs are shown in 
Figure 1.18.  
 
Figure 1.18: Chemical structures of oxime- or benzoxazole-containing drugs. 
By and large, we were encouraged by the diverse bioactivities as well as 
drug-likeness exhibited by benzoxazole- and/or oxime-based compounds to 
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1.9 Research Program 
1.9.1 Study Justification 
Research gaps, which formed the foundation of this thesis work, were 
identified. Firstly, there is an urgent need to develop new anti-TB drugs to 
alleviate the setbacks hampering the current therapeutic agents. Indeed, the 
WHO global tuberculosis report 2015 states that “without new TB drugs and 
regimens, it will be very difficult to improve treatment outcomes in the near 
future.”272 Development of new anti-TB agents is driven by objectives such 
as to improve and simplify the current treatment by shortening the 
treatment duration; improve on the MDR-TB treatment by developing well 
tolerated drugs with novel mechanisms of action; reduce drug-drug 
interactions, especially for TB treatment in patients taking ARVs; and to 
provide more effective LTBI treatment. Furthermore, intensified research 
and innovation is the third pillar of the End TB Strategy 2015, which 
advocates for discovery, development, and rapid uptake of new tools, 
interventions, and strategies to combat TB. 
Secondly, attrition of drug candidates is a challenge to successful 
development of new drugs, and has been identified as a probable cause of 
gaps in the anti-TB drug discovery pipeline. It is thus imperative to 
continually replenish the reservoir of new drug candidates in the discovery 
pipeline to effectively cover for failures. Attrition is partially attributed to 
suboptimal physicochemical properties of drug candidates, which have links 
to several causes of failures including unfavorable DMPK profiles, toxicity, 
lack of efficacy, and formulation difficulties. It is therefore important to 
optimize physicochemical properties early enough to promote success of 
drug discovery and development projects. This will go a long way towards 
successful and hastened delivery of new anti-TB agents.  
Also, to overcome the problem of drug resistance, new, affordable, better-
tolerated, and more effective agents with novel mechanisms of action are 
needed. In this thesis work, we investigated two classes of benzoheterocyclic 
chemotypes as potential anti-TB agents: the 2-aminoquinazolinones, and 
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the benzoxazole-based oximes. A literature search based on these privileged 
structural motifs revealed that compounds containing them have 
widespread industrial applications, including drugs. This is encouraging 
because of the high probability of drug-likeness associated with these 
scaffolds. Equally important, there is limited application of these 
benzoheterocycles, both as anti-TB drugs or potential anti-TB agents. 
Indeed, none of the approved anti-TB drugs and drug candidates contains 
these skeletons, further augmenting the chances of novel mechanisms of 
action. Moreover, the literature review has revealed adequate intellectual 
property space to study and investigate 2-aminoquinazolinones and 
benzoxazole-based oximes as potential anti-TB drug leads.    
1.9.2 Hypothesis 
2-Aminoquinazolinones and benzoxazole-based oximes are potential novel 
antituberculosis drug leads with favorable potency, pharmacokinetics and 
physicochemical properties. 
1.9.3 Objective 
The overall objective was to optimize previously identified antimycobacterial 
2-aminoquinazolinones and benzoxazole-based oximes by investigating their 
antimycobacterial structure-activity relationship (SAR) profiles. An 
attendant aim was to explore structure-property relationships (SPR) for the 
target compounds and perform supramolecular derivatization of selected 
analogues. 
1.9.4 Specific Aims 
 To synthesize 2-aminoquinazolinones and benzoxazole-based analogues 
as potential antituberculosis agents (Chapter 2). 
 To biologically evaluate the synthesized target compounds for 
antimycobacterial potency, cytotoxicity, and DMPK profiles (Chapter 3). 
 To profile all final target compounds with respect to physicochemical 
properties, including aqueous solubility; deduce structure-property 
relationships (SPR); and carry out supramolecular derivatization of 
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selected potent compounds (Chapter 4). 
The workflow or screening cascade that was followed towards achieving the 
above-mentioned objectives is illustrated in Figure 1.19 below. 
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CHAPTER 2  
DESIGN, SYNTHESIS AND CHARACTERIZATION OF 
BENZOHETEROCYCLES 
2.1 Chapter Overview 
Chapter 2 provides a discussion of the studies, and the results thereof, 
which were carried out in order to address the first specific aim of this thesis 
work, which was: To synthesize 2-aminoquinazolinones and benzoxazole-
based oximes as potential antituberculosis agents.  
This chapter begins with a brief introduction to the sources of drug leads, 
particularly the process of identifying hits in drug discovery programs. 
Thereafter, the chapter is divided into two broad sections; one covers the 2-
aminoquinazolinones, while the other one highlights the benzoxazole-based 
oximes. Accordingly, each section describes the genesis, design, synthesis, 
and characterization of target analogues. 
2.2 Identification of Hit Compounds 
Drug discovery mainly begins with the identification of hit molecules, 
and/or biological targets for a particular disease state. A hit, in this context, 
is a biologically active and chemically tractable small molecule, which is 
amenable to medicinal chemistry-based modifications associated with hit-to-
lead optimization campaigns. Generally, hits are identified from either 
natural products or chemically synthesized compounds. Natural products 
are generally identified as unmodified compounds, or used as starting points 
and/or building blocks for chemical synthesis of more complex molecules. 
They have the benefit of structural and biological diversity and complexity, 
which are sometimes lacking in chemically synthesized compounds.1–5 In 
some instances, diverse natural products are organized into libraries from 
which screening can be undertaken for purposes of hit identification.6 
Chemical synthesis, on the other hand, particularly combinatorial 
chemistry, has been instrumental in accelerated generation of vast 
numbers, running into millions, of new chemical entities.7 These, in most 
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cases, are then collated into chemical libraries and databases from which 
drug hits can be discovered through screening.8,9 
Predominantly, compound screening is carried out either biologically, or 
through the use of computer-based (virtual or in silico) techniques. 
Automation of screening protocols has resulted in simplification, 
miniaturization, and speeding up of screening assays. In this regard, high-
throughput screening promotes screening of large numbers of diverse 
compounds in relatively short periods of time, along with tremendous 
information harvest.10,11 Furthermore, screening can either be target-based, 
or phenotypic whole-cell-based; two opposing, but nevertheless 
complimentary approaches towards hit discovery.  
Phenotypic whole-cell screening more often leads to the identification of 
molecules that modify a particular disease phenotype by influencing an 
undescribed target, or by acting simultaneously on more than one target at 
the cellular level, and without target bias. Thus, one of the benefits of whole-
cell screens is that the identified hits are endowed with the appropriate 
physicochemical properties to reach their destined molecular target(s) in the 
biologically robust cellular environment. In addition, this holistic, target-
naive approach allows for testing of hit compounds against complex, 
multifaceted biological systems and disease states where the exact disease 
mechanism(s) may not be fully understood. The downside, however, is that 
the subsequent mechanistic deconvolution studies towards the identification 
of the relevant molecular target(s) as well as the process of elucidating the 
mechanism(s) of action, are often slow, or in worst cases impossible. 
Furthermore, these screens are less feasible for large chemical libraries, and 
reproducibility of results may sometimes be hampered by multiple 
physiological variables.12,13  
On the other hand, advances in molecular biology, genomics, and 
proteomics have led to a surge in target-based screens, which are believed to 
relatively accelerate the drug discovery process, particularly in structure-
based rational drug design. In that case, with a known, fully characterized, 
and validated biological target, screening can be performed biologically or 
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virtually. Virtual screening is generally practicable in cases where crystal 
structures of biological targets are available.14 Indeed, virtual screening has 
proved to be indispensable in the identification of drug hits,15–17 some of 
which have contributed to the discovery of hitherto approved drugs.18 
Target-based screens are highly amenable to high-throughput screening; 
however, they may not be effective where more than one target is involved in 
a particular disease phenotype or where biological compensation comes into 
play.12 Also, target druggability is sometimes difficult to predict, and this 
has intermittently been implicated in challenges associated with translating 
in vitro activity to in vivo efficacy. This, for instance, is due to physiological 
differences between biological systems and isolated targets.19  
Moreover, approaches whereby pre-existing drugs are tested for new disease 
indications have become a common practice. In this case, where a pre-
existing drug is used for new indications without any structural 
modification, the process is referred to as drug repurposing. Conversely, 
drug repositioning is a term used whenever the chemical structure of a pre-
existing drug is modified, for instance, to make it suitable for the new 
disease indication. The major benefits derived from these approaches are, 
for example, the pharmacokinetics and the safety profiles of the approved 
drugs are already known, which in turn leads to substantial cost and time 
saving compared to the de novo drug discovery and development process.20–22  
Within the context of this thesis work, the hits for the two series of 
benzoheterocycles were identified through the phenotypic whole-cell 
screening approach. 
2.3 2-Aminoquinazolinones 
2.3.1 General Introduction  
The research work on 2-aminoquinazolinones as antimycobacterial agents 
has its origins in studies involving the exploration of 2-aminopyridines as 
antimalarial agents. This work was conducted by researchers at the 
University of Cape Town, Drug Discovery and Development Centre (H3D). 
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Figure 2.1 below summarizes the process that led to the identification of 
antimycobacterial 2-aminoquinazolinones.  
 
Figure 2.1: Identification of 2-aminoquinazolinones as antimycobacterial compounds. 
In earlier studies, the 2-aminopyridines were identified as highly potent 
antiplasmodial compounds from phenotypic whole-cell high-throughput 
screening of a commercially available SoftFocus kinase library. Subsequent 
medicinal chemistry explorations and preclinical assessment of this series 
led to the selection of MMV-390048 (Figure 2.1 above) as a potential 
clinical candidate.23 Further SAR exploration around the 2-aminopyridine 
core24,25 resulted in the identification of the 2-aminoquinazolinones. To this 
effect, the pyridine ring was replaced with the 4-quinazolinone ring system. 
Consequently, compounds 1 and 2, shown in Figure 2.1 above, were 
synthesized and evaluated in vitro for their antiplasmodial activity against 
the drug-susceptible NF54 Plasmodium falciparum strain, and cross-
screened for their antimycobacterial activity against the H37Rv Mtb strain, 
in phenotypic whole-cell assays. In this case, the replacement of the 2-
aminopyridine core with the 2-aminoquinazolinone core led to loss of 
antiplasmodial activity. Compound 2, on the other hand, exhibited potent in 
vitro antimycobacterial activity (MIC99 = 5 μM), and was therefore identified 
as the hit compound for the 2-aminoquinazolinone series. Notably, 
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compound 1 was inactive against Mtb despite the fact that it only differs 
from compound 2 at the position of the methylsulfonyl substituent relative 
to the quinazolinone core [para-position (4−SO2MePh) for 1 and meta-
position (3−SO2MePh) for 2]. Interestingly, these results suggested that the 
2-aminoquinazolinone-based compounds could have selectivity and 
specificity towards yet unknown Mtb biological target(s), such that minor 
structural changes would yield compounds exhibiting varying 
antimycobacterial activities. 
Encouraged by the above mentioned preliminary results, this thesis work 
was aimed at conducting further medicinal chemistry exploratory studies 
with respect to hit-to-lead optimization. This entailed synthesis, biological 
assessment, as well as SAR and SPR analyses, in efforts to explore the 
opportunities and liabilities associated with the 2-aminoquinazolinone class 
of compounds as potential anti-TB agents. 
2.3.2 Design  
In designing analogues of compound 2, it was postulated that making 
structural modifications around the 2-aminoquinazolinone core would be 
essential in exploring the preliminary SAR around this series of compounds. 
Consequently, two points of diversity, SAR 1 and SAR 2 as shown in Figure 
2.2 below, were selected, while the 2-aminoquinazolinone core was kept 
constant.  
Initially, both the SAR 2 moiety at position 3 [the 4-trifluoromethyl phenyl 
group (4−CF3Ph)], on the right-hand side and the 2-aminoquinazolinone core 
were kept constant while structural changes were made around the SAR 1 
moiety at position 6 [the methylsulfonyl phenyl group (3-SO2MePh)] on the 
left-hand side.  
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Figure 2.2: Design of 2-aminoquinazolinone analogues. 
In order to introduce structural diversity, and explore different chemical 
spaces, SAR 1 groups were selected from appropriately substituted ring 
structures, which ranged from phenyl to 5- and 6-membered heterocycles. 
Based on medicinal chemistry practices, substituents R were chosen in 
such a manner as to bring variety in terms of electronic, steric, and 
hydrophobicity effects on the target compounds. Thus, the Craig Plot 
(Figure 2.3 below) played a key role in guiding the selection of various 
substituents, whereby all its four quadrants were appropriately considered 
and represented.26,27 In addition, water-solubilizing groups, such as 
morpholinyl and piperazinyl, which are not part of the Craig Plot but 
capable of enhancing intermolecular hydrogen-bonding, were selected as 
substituents in attempts to improve the aqueous solubility. The choice of 
SAR 1 groups was also informed by the commercial availability of the 
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relevant synthetic starting materials and reagents, though not central to the 
design strategy.  
 
Figure 2.3: Craig Plot of Hammett constants () [electronic effects] against hydrophobicity 
() values.27  
Based on the antimycobacterial activities of compound 1 and 2 [Figure 2.1 
above], the preferred position of the phenyl substitution by these diverse 
groups was the meta-position. Other phenyl positions, however, were 
explored, including di-substitution in some of the target analogues. In 
addition, substitution patterns were partially guided by the Topliss decision 
tree.27   
The design of SAR 2 analogues followed the same rationale as that of SAR 
1. This was after fixing the SAR 1 (left-hand side) moiety as 3-methylsulfinyl 
phenyl (3-SOMePh). This sulfoxide analogue of 2 had the best balance of 
aqueous solubility and potency. In addition, it was found to be an active 
‘prodrug’ that underwent biotransformation in vivo to yield the parent 
sulfone-based compound 2. The overall design strategy was to then combine 
the best structural features from SAR 1 with those from SAR 2 in the 
subsequent hit-to-lead optimization steps. 
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2.3.3.1 Synthesis of SAR 1 Analogues  
The quinazolinone motif is one of the most established and extensively 
studied ring systems. Thus, there are a multitude of protocols, which have 
been published and reported for the synthesis of quinazolinone-based 
compounds.28–31 However, publications describing the synthesis of the 2,3-
disubstituted  quinazolinones are scarce, particularly the literature on the 
2-aminoquinazolinones. The synthesis of 2-aminoquinazolinones studied in 
this thesis work is mainly based on the work of Leivers and coworkers who 
recently published results of a study on various type III phosphatidylinositol 
4‑kinase alpha (PI4KIII) 2-aminoquinazolinone inhibitors with antihepatitis 
C virus (HCV) activity.32 As such, all the SAR 1 target compounds were 
obtained following a five-step synthetic procedure as shown in Scheme 2.1 
below, and their yields are listed in Table 2.1. 
 
Scheme 2.1: Synthetic protocol towards SAR 1 2-aminoquinazolinone target compounds 2–
31. Reagents and conditions: (i) Dioxane, TEA, reflux (110 °C), 6 h; (ii) POCl3, PCl5, 110 °C, 
12–15 h; (iii) DMF, 4-methoxybenzylamine, DIPEA, 80 °C, 4 h; (iv) TFA, reflux, 48 h or MW, 
110 °C, 20 min; (v) Dioxane-water solvent mixture, appropriate arylboronic acid (Ar1B(OH)2) 
or ester, Pd(dppf)Cl2-DCM, Cs2CO3, 80 °C, 1–3 h. 
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Table 2.1: Isolated yields for SAR 1 2-aminoquinazolinone target analogues. 
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Table 2.1: Isolated yields for SAR 1 2-aminoquinazolinone target analogues. 
Compound 
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Table 2.1: Isolated yields for SAR 1 2-aminoquinazolinone target analogues. 
Compound 
 













The synthesis started with the dehydrative cyclocondensation of the 
commercially available 2-amino-5-iodobenzoic acid with 4-(trifluoromethyl) 
phenyl isothiocyanate. This was achieved by refluxing the mixture in 
dioxane under the mediation of triethylamine (TEA) to afford the 2-
thioxoquinazolinone intermediate 2.1a in high yields.   
 
Scheme 2.2: Proposed reaction mechanism for the formation of the 2-thioxoquinazolinone 
intermediate. 
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In this case, as schematically represented in Scheme 2.2 above, the 
nucleophilic amino nitrogen of the 2-amino-5-iodobenzoic acid attacks the 
electrophilic isothiocyanate carbon to form the thiourea intermediate A. 
Triethylamine (TEA) then abstracts a proton from the carboxylic acid leading 
to its preferential existence as a nucleophilic carboxylate ion.  The attack of 
the electron-deficient thiourea A carbon by the nucleophilic carboxylate 
group leads to loss of aniline affording a thiono-isatoic anhydride 
intermediate B, which then undergoes a nucleophilic attack by the liberated 
aniline. This is followed by dehydrative cyclization to yield the 2-
thioxoquinazolinone intermediate 2.1a.33 
The next step was a chlorination reaction, which was accomplished by 
heating the intermediate 2.1a in phosphorus oxychloride (POCl3) in the 
presence of phosphorus pentachloride (PCl5) to furnish the 2-
chloroquinazolinone intermediate 2.2a. The chlorination reaction 
mechanism is believed to occur via a 2-dichlorophosphoryl 
thioquinazolinone intermediate resulting from preferential nucleophilic 
attack of the phosphorus in POCl3 by the sulfur atom followed by 
elimination of a chloride ion. Then, attack on the electron-deficient sulfur-
bearing carbon by the chloride ion results in the elimination of 
phosphenothioic chloride and hydrochloric acid to yield the 2-
chloroquinazolinone intermediate 2.2a. The regioselectivity for chlorination 
of the thiocarbonyl at position 2 versus the carbonyl at position 4 is due to 
the chemoselectivity of phosphorous (V) for sulphur versus oxygen caused 
by the substantially better orbital overlap between their 3p orbitals. Both 
POCl3 and PCl5 are believed to take part in the chlorination process through 
a similar mechanism, which is depicted in Scheme 2.3 below.34  
 
Scheme 2.3: Proposed chlorination reaction mechanism. 
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The step that followed was the introduction of the 2-amino group through 
the substitution of the chloro substituent with 4-methoxybenzylamine. In 
this case, the reaction was executed by heating a mixture of 2.2a and 4-
methoxybenzylamine in N,N-dimethylformamide (DMF), and in the presence 
of diisopropylethylamine (DIPEA) to yield the intermediate 2.3a. The reaction 
mechanism involved is the addition-elimination nucleophilic aromatic 
substitution (SNAr). The SNAr reaction, in this instance, regioselectively takes 
place at the choro-bearing carbon (C-2) due to its more enhanced electron 
deficiency than the iodo-bearing carbon. This is attributable to the fact that 
C-2 is attached to two electron-withdrawing nitrogen atoms, which exhibit 
an ortho-directing effect, as well as acting as electron sinks. The electron 
deficiency of C-2 is further promoted by the inductive electron-withdrawing 
chloro group. In addition, the aromaticity of the quinazolinone ring system 
leads to resonance stabilization while the carbonyl oxygen at position 4 acts 
as an anion-stabilizing group. These factors act in concert to make the 
chloro an excellent leaving group while the iodo serves to further activate the 
quinazolinone ring system through its inductive electron-withdrawing effect. 
Generally, the first step involves the nucleophilic amino nitrogen of the 4-
methoxybenzylamine attacking the chloro-bearing carbon to form an 
intermediate with disrupted aromaticity. This is the rate-limiting addition 
step. In the second step, there is regeneration of the aromatic quinazolinone 
ring system followed by the elimination of the chloride ion. Finally, the 
chloride ion abstracts a proton to form HCl, which is then mopped up by 
DIPEA as a hydrochloride salt. The proposed SNAr reaction mechanism is 
summarized in Scheme 2.4 below.34 
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Scheme 2.4: Proposed SNAr reaction mechanism. 
Thereafter, an acid-catalysed cleavage of the 4-methoxybenzyl moiety was 
attained by heating compound 2.3a in trifluoroacetic acid (TFA) under reflux 
or microwave (MW) conditions to afford the penultimate intermediate 2.4a. 
Firstly, the benzyl nitrogen atom is protonated, and then the breaking of the 
C−N bond is facilitated by the push of electrons through the benzyl ring 
system from the methoxyl oxygen, as indicated in Scheme 2.5 below. The 
free primary amine was then obtained by acid-base exchange using 
Amberlyst® A21 free base resin. 
 
Scheme 2.5: Proposed mechanism of acid-catalysed cleavage of the 4-methoxybenzyl 
moiety. 
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Finally, the Suzuki-Miyaura cross-coupling reaction of 2.4a with the 
appropriate arylboronic acids was undertaken to yield the desired target 
compounds 2–31 in good yields. The catalyst employed in this reaction was 
[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with 
dichloromethane (Pd(dppf)Cl2-DCM), while cesium carbonate (Cs2CO3) was 
the base used. The Suzuki-Miyaura cross-coupling is a versatile reaction 
with many advantages such as the commercial availability of large numbers 
of diverse boronic acids; the stability of key reagents to heat, air and 
moisture; and the ease of separation of reaction products.35,36 This reaction, 
on the other hand, may be plagued by impediments such as unwanted 
byproducts as a result of self-coupling and coupling of phosphine-bound 
aryls, which could result in decreased isolated yields.37  
The Suzuki-Miyaura cross-coupling reaction proceeds via a catalytic cycle as 
shown in Scheme 2.6 below. Three major steps are involved: oxidative 
addition, transmetallation, and reductive elimination. Oxidative addition of 
the arylhalide to the palladium (0) complex (Pd0L2) affords a stable trans-σ-
palladium (II) complex. This is the rate-determining step, which is followed 
by displacement of the halide ion by a base to yield a more reactive 
organopalladium hydroxide. This then undergoes transmetallation with the 
organoboronic acid or ester. The base accelerates the transmetallation step, 
presumably through a more nucleophilic complex. This step yields a 
complex from which the desired product is expelled by reductive elimination, 
and regeneration of the ligand-bound Pd0 catalyst ensues.34,38–40 
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Scheme 2.6: Catalytic cycle for Pd-catalysed Suzuki-Miyaura cross-coupling reaction. 
2.3.3.2 Synthesis of SAR 2 Analogues  
Some of the SAR 2 analogues were accessed through the same synthetic 
approach as that described in the foregoing discussion regarding the 
synthesis of SAR 1 target compounds.  In this case, structural modifications 
were made on the right-hand side of the quinazolinone core. However, due to 
the scarcity of commercially available arylisothiocyanates, it was not 
possible to create adequate structural heterogeneity by adapting the SAR 1 
synthetic protocol described in Scheme 2.1 above. As such, synthesis of 
some arylisothiocyanates from commercially available anilines was 
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attempted.41–43 Despite the potential associated with this approach, the use 
of highly toxic reagents such as carbon disulfide, coupled with low product 
yields, and the chemical instability of some isothiocyanates discouraged 
further exploration of this option.  
Consequently, other synthetic protocols were investigated, particularly those 
involving the use of diverse and readily available primary anilines, as this 
would allow the creation of diversity in SAR 2 analogues. In this regard, the 
work of Lecoutey and colleagues was adapted. These researchers previously 
reported a one-pot procedure for the synthesis of 2-amino-3-aryl-quinazolin-
4(3H)-ones.44 In this particular study, several methyl 2-aminobenzoates 
were used as key starting materials, which were reacted with ethoxycarbonyl 
isothiocyanate and primary amines in a one-pot reaction mediated by 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), to yield the desired 
quinazolinone-based products. However, our attempts to use methyl 2-
amino-5-bromobenzoate in the one-pot synthetic protocol failed. 
Nonetheless, in search of a solution, investigations were carried out into this 
protocol based on the chemistry and the reaction mechanisms involved. To 
our delight, it became discernible that one of the synthetic intermediates 
was precipitating out of solution, and thus hindering further reaction 
progress. The procedure was therefore modified to a four-step protocol as 
shown in Scheme 2.7 below. Interestingly, the compound that was crushing 
out of solution was identified as the versatile intermediate 2.5, which was 
isolated in quantitative yields. In addition, although ethoxycarbonyl 
isothiocyanate is commercially available, it was successfully generated in 
situ from relatively inexpensive and readily available ethyl chloroformate and 
potassium thiocyanate.45 
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Scheme 2.7: Synthetic protocol towards SAR 2 2-aminoquinazolinone target compounds 32–44. Reagents and conditions: Pathway A (same as Scheme 
2.1): (i) Dioxane, TEA, reflux (110 °C), 6 h; (ii) POCl3, PCl5, 110 °C, 12–15 h; (iii) DMF, 4-methoxybenzylamine, DIPEA, 80 °C, 4 h; (iv) TFA, reflux, 48 h or 
MW, 110 °C, 20 min; (v) Dioxane/water, appropriate boronic acid (Ar1B(OH)2) or ester, PdCl2(dppf)-DCM, Cs2CO3, 80 °C, 1–3 h. Pathway B: (a) MeCN, 25 ºC, 
2 h; (b) MeCN, 0 ºC, 30 min; (c) DCM, appropriate primary aromatic amine (Ar2NH2), EDCI, 25 °C, 6–29 h; (d) TFA, MW, 110 °C, 20 min; (e) DMF, 
appropriate arylboronic acid, Pd(PPh3)2Cl2, K2CO3, 100 °C, 1–4 h. 
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Compound Ar2 Yield (%) 





































*Same as 43 but with a –SO2Me instead of –SOMe on the left-hand side. 
The reaction of methyl 2-amino-5-bromobenzoate with ethoxycarbonyl 
isothiocyanate was accomplished by stirring a mixture of the two in 
acetonitrile (MeCN) at 25 ºC to afford the thiourea intermediate 2.5 in high 
yields.  
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The step that followed was the coupling and cyclization of this intermediate 
with the appropriate primary amine. This was attained by stirring at 25 ºC a 
mixture of 2.5, the appropriate aniline, and EDCI in dichloromethane (DCM) 
to generate the desired 2-carbamate quinazolinone-based intermediates 
2.6a–2.6j. This reaction is believed to proceed through the mechanism 
depicted in Scheme 2.8 below. Accordingly, the relatively more electron-
deficient carbon atom of the EDCI is nucleophilically attacked by the 
thiourea sulfur atom, making it a better leaving group while increasing the 
electrophilicity of the thiourea carbon. The nucleophilic nitrogen atom of the 
amine then attacks the thiourea carbon followed by loss of EDCI as a stable, 
water-soluble thiourea byproduct. The resulting intermediate then cyclizes 
when the more nucleophilic nitrogen atom attacks the carbonyl carbon of 
the methyl ester to form the desired compound via loss of methanol.46 
 
Scheme 2.8: Reaction mechanism for the formation of 2-carbamate quinazolinone 
intermediates. 
Then, the acid-catalysed cleavage of the carbamate amide bond followed. 
This was accomplished by heating the appropriate starting material in 
trifluoroacetic acid under microwave energy to furnish the corresponding 
primary amine intermediates 2.7a–2.7j. This reaction proceeds via a 
mechanism depicted in Scheme 2.9 below, whereby the ester portion is lost 
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as ethyltrifluoroacetate and carbon dioxide. Acid-base exchange using 
Amberlyst® A21 free base resin then affords the desired products as neutral 
primary amines. 
 
Scheme 2.9: Proposed reaction mechanism for the acid-catalysed deprotection.  
The 2-aminoquinazolinone penultimate intermediates were then subjected to 
a Suzuki-Miyaura cross-coupling reaction with 3-methylsulfinylphenyl
boronic acid to afford the desired SAR 2 target compounds in yields ranging 
from low to high, as shown in Table 2.2 above. The bromo-containing 
penultimate intermediates were poorly soluble in the dioxane-water solvent 
mixture, which was successfully used with the iodo-containing 
counterparts. Thus, the solvent was changed to DMF while the Pd(dppf)Cl2-
DCM catalyst was replaced by the more soluble catalyst, 
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2.3.4 Spectroscopic and Chromatographic Characterization 
All the synthesized intermediates and final target compounds were subjected 
to various spectroscopic and chromatographic techniques for purposes of 
monitoring reactions; purification and purity determination; as well as 
elucidation and confirmation of chemical structures. To this effect, thin 
layer chromatography (TLC), and reversed phase high performance liquid 
chromatography coupled to mass spectrometry (LC-MS) were applied to 
monitor the progress of all the reactions. LC-MS played a vital role in 
determining the chromatographic purities, which were calculated as 
percentage peak areas. Also, LC-MS was applied in confirming molecular 
formulas of compounds by using parameters such as the pseudo-molecular 
ions (M+H)+, and fragmentation patterns derived from the LC mass spectra. 
Another important piece of information obtained from the LC-MS was the 
ultraviolet/visible electromagnetic radiation (UV-VIS) scan, which was 
facilitated by the use of diode array HPLC detector (DAD). This was 
instrumental in determining the wavelength of maximum absorption (λmax) 
at which eluates were monitored and collected during the chromatographic 
purification of most compounds using the Biotage Isolera One® flash 
chromatograph. 
Proton (1H) NMR spectroscopy, and carbon-13 (13C) NMR spectroscopy, on 
the other hand, were important in the elucidation and confirmation of 
chemical structures for all the synthesized compounds. 
The characterization of compound 2, as an example, is discussed herein, 
including that of the associated synthetic intermediates 2.1a–2.4a. Figure 
2.4 below shows the stacked one-dimensional (1D) 1H NMR spectra for these 
intermediates.  All the spectra were consistent with the chemical structures 
of the corresponding compounds. As such, the spectrum corresponding to 
compound 2.1a showed a highly deshielded quinazolinone NH proton (H-7) 
resonating most downfield at chemical shift (δ) 13.15 as a broad singlet (br, 
s). Proton H-1 produced a doublet (d) signal at δ 8.18 and exhibited a long-
range coupling (4J = 2.0 Hz) with proton H-2. As a result, proton H-2 yielded 
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a doublet of doublets (dd, 3J = 8.6 and 4J = 2.0 Hz) signal at δ 8.08 due to 
the second coupling with proton H-3 (d, 3J = 8.6 Hz).  
 
Figure 2.4: Stacked 1D 1H NMR spectra for the synthetic intermediates 2.1a–2.4a in 
DMSO-d6 at 400 MHz. 
The presence the iodo group makes protons H-1 and H-2 the most 
deshielded aromatic protons due to its inductive electron-withdrawing effect. 
Proton H-3 was the most shielded aromatic proton (δ 7.25) due to the 
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delocalization of the ring electrons making the carbon bearing it negatively 
charged in one of the resonance structures. The two pairs of chemical shift-
equivalent phenyl protons H-4 and H-5 couple with each other, and 
therefore yielded two doublets with each integrating for two protons, and 
with similar coupling constants (J = 8.2 Hz). As expected, protons H-5 were 
more deshielded (δ 7.86) than the H-4 protons (δ 7.54) due to the electron-
withdrawing effect of the trifluoromethyl (-CF3) group.  
Since the quinazolinone and the 4-CF3Ph groups were constant in the 
subsequent compounds, the 1H NMR signals corresponding to the protons 
described in the foregoing discussion were generally expected to remain the 
same. 
The diagnostic features for the successful chlorination reaction leading to 
compound 2.2a were the loss of proton H-1, and the more downfield 
resonance for all the other protons due to the inductive electron-
withdrawing effect of the chloro group. 
The 1H NMR spectrum corresponding to the SNAr reaction product 2.3a 
showed additional protons characteristic of the added 4-
methoxybenzylamine group: the three methoxyl protons H-10 yielded a 
singlet at δ 3.69; the two methylene protons H-7 gave a doublet (J = 5.9 Hz) 
at δ 4.42 due to its coupling with the H-6 NH proton, which afforded a broad 
triplet (J = 5.9 Hz) at δ 6.65; and the aromatic benzyl protons H-8 and H-9 
yielded two doublet (J = 8.8 Hz) signals, each integrating for two protons at δ 
7.22 and δ 6.83, respectively. Protons H-9 are more shielded than H-8 due 
to the electron-donating effect of the methoxy group, and therefore resonate 
more upfield.  
Likewise, the 1H NMR spectrum of the deprotection product 2.4a showed a 
diagnostic broad singlet signal at δ 6.61, attributable to the free primary 
amine. In addition, another diagnostic feature in this spectrum was the loss 
of all the signals corresponding to the 4-methoxybenzyl group.  
The synthetic step that followed was the Suzuki coupling to yield the final 
target compound 2. As shown in Figure 2.5 below, there were additional 
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signals compared to the spectrum for the penultimate intermediate 2.4a. 
After the analysis of the spectrum, the signals were consistent with the 
chemical structure of compound 2.  
 
Figure 2.5: 1H NMR spectrum of 2 in DMSO-d6 at 400 MHz. 
Briefly, the singlet at δ 3.34, which integrated for three protons, was 
assigned to the methyl protons H-11. The downfield triplet signal at δ 8.23 
corresponded to proton H-7, which experienced two equal long-range 
couplings (4J = 1.7 Hz) from protons H-8 and H-10. In this case, protons H-8 
and H-10 each experienced a short-range coupling with proton H-9, a long-
range coupling with H-7, and a long-range coupling with each other. 
Consequently, the signals that split into doublet of doublet of doublets (ddd) 
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7.8, 1.8, 1.0 Hz) at δ 8.11. H-10 is more deshielded, and thus resonated 
more downfield than H-8 due to its close proximity to the electron-
withdrawing ortho-methylsulfonyl group. Although the H-10 signal 
coincidentally overlapped with the H-2 dd signal, independent manual 
integration of the two signals enabled assignment of the two protons, which 
otherwise yielded a multiplet (m) integrating for two protons. The triplet 
signal at δ 7.79 was assigned to proton H-9, which experienced two equal 
couplings (t, J = 7.8 Hz) from H-8 and H-10. The other signals in this 
spectrum were characteristically consistent with the rest of the chemical 
structure for compound 2 as described for the penultimate intermediate 
2.4a in Figure 2.4. 
In addition, 13C NMR spectroscopy was used to provide further evidence to 
support the chemical structure of compound 2. As depicted in Figure 2.6 
below, although 20 distinct signals were obtained, the chemical shift-
equivalent pairs of carbons in the trifluoromethylphenyl moiety resonated at 
the same chemical shifts, and therefore all the 22 carbons were accounted 
for. The diagnostic signals were those due to the most deshielded carbonyl 
carbon (C-12) resonating most downfield at δ 161.87, and the most shielded 
methyl carbon (C-17) resonating most upfield at δ 43.57. Also, the relatively 
more downfield and shorter signals were assigned to the quaternary carbons 
bearing electronegative atoms like nitrogen and sulfur, besides oxygen. In 
this case, C-13, C-14, C-15, and C-16 resonated at δ 151.80, 150.51, 
141.85, and 140.59, respectively. 
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Figure 2.6: 13C NMR spectrum of compound 2 in DMSO-d6 at 400 MHz. 
Data obtained from the LC-MS, as shown in Figure 2.7 below, provided 
more information on the structural characteristics of compound 2. This 
information was three-fold: The LC chromatogram provided the purity as > 
99%, based on the percentage peak area; the mass spectrum exhibited a 
pseudo-molecular ion [(M+H)+] of 460.1 as the base peak (100%),  
corresponding to the calculated one for C22H16F3N3O3S; the UV-VIS 
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Figure 2.7: LC-MS readout for compound 2. 
The Experimental chapter (Chapter 6) describes the full characterization 
data for each of the synthesized compounds. 
LC-MS Purity Chromatogram at 280 nm 
LC-MS UV-VIS Absorption Spectrum LC Mass Spectrum 
λmax = 240, 300 nm 
(M+H)+ 
= 460.1 (100%) 
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2.4 Benzoxazole-Based Oximes 
2.4.1 General Introduction  
The Novartis Institute for Tropical Diseases (NITD) carried out 
antimycobacterial phenotypic whole-cell high-throughput screening of a 
library of about 6000 compounds comprising of small polar compounds. The 
profiles of the compounds, which formed the selection criteria, included Mwt 
= 150–350, cLogP = -1–3, rotatable bonds ≤ 5, tPSA < 140 Å2, non-reactive 
with no toxicophores, and MIC99 ≤ 20 μM. From this exercise, nine hit series 
of compounds were selected and designated NITD S1–S9. The nine series of 
NCEs were transferred to H3D as part of a collaborative agreement between 
NITD and H3D. The main objective was to initiate hit-to-lead and lead 
optimization campaigns on these series, as well as to conduct studies on 
target identification.  
The NITD S6 and S7 series formed part of this thesis work. The 
representative S6 hit is benzothiazole-based while the representative S7 hit 
is benzoxazole-based, and both contain a dimethyl carbamate-functionalized 
oxime moiety. Figure 2.8 below summarizes the genesis of this thesis work 
on benzoxazole-based oximes. Also, the figure shows unpublished 
preliminary SAR and biological evaluation studies conducted at H3D, along 
with the general liabilities associated with the S6 and S7 series of 
compounds. In summary, the compounds exhibited clear SAR trends 
whereby the benzoxazole- and benzothiazole-based compounds were found 
to be equipotent, while benzimidazoles had very weak antimycobacterial 
activities. A dimethyl carbamate group on the oxime moiety was found to be 
essential for activity for all nitrile-containing compounds, while their free 
oxime counterparts were inactive. However, the dimethyl carbamate moiety 
was associated with low microsomal metabolic stability exhibited by these 
agents. Besides, the replacement of the nitrile group with groups such as 
thiazole resulted in compounds that were active as free oximes. Additionally, 
replacement of the benzothiazole phenyl ring with a pyridyl led to loss of 
antimycobacterial activity.     
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Figure 2.8: Identification and preliminary SAR for the oxime-based NITD S6 and S7 series.  
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This thesis work aimed to design and synthesize compounds in such a 
manner as to mitigate some of the reported liabilities such as low metabolic 
stability and poor aqueous solubility, along with expanding the SAR studies 
particularly on the benzoxazole-based compounds (NITD S7), which were 
least explored in the preliminary studies. 
2.4.2 Design  
Three positions were identified for structural modifications while the 
benzoxazole motif was maintained constant. Accordingly, these medicinal 
chemistry plans were designated SAR 1, SAR 2, and SAR 3 as shown in 
Figure 2.9 below. 
 
Figure 2.9: Design of benzoxazole-based oxime analogues. 
With regard to SAR 1 analogues, it was hypothesized that replacing the 
metabolically labile dimethyl carbamate with β-amino alcohols, linked to the 
oxime via an ether linkage, would produce compounds with enhanced 
metabolic stability. The choice of β-amino alcohols was also informed by the 
fact that they would introduce hydrophilic amino and hydroxyl groups, 
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which generally would enhance both intermolecular and intramolecular 
hydrogen bonding, along with improved aqueous solubility. In addition, the 
introduced chirality would reduce the flatness of these compounds, hence 
affecting their crystallinity, and in turn have the overall effect of improving 
aqueous solubility. Moreover, there are some known anti-TB drugs that 
contain the β-amino alcohol substructure, for instance ethambutol and 
mefloquine, whose chemical structures are depicted in Figure 2.10 below. 
In effect, β-amino alcohols would further impart drug-likeness to this class 
of compounds.  
 
Figure 2.10: Chemical structures of β-amino alcohol-containing drugs. 
Other SAR 1 analogues were also designed to replace the oxime-ester 
linkage with an oxime-ether linkage in order to improve metabolic stability, 
and potentially permeability. The choice of the groups such as benzyl and 
alkyl ethers was inspired by some approved drugs containing various 
functionalized oxime-ether moieties, for example oxiconazole and cefixime, 
as shown in Figure 2.11 below.   
 
Figure 2.11: Chemical structures of drugs containing an oxime-ether linkage.  
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SAR 2 analogues were designed in such a manner as to replace the 
metabolically labile methyl group with the relatively more metabolically 
stable substituents such as the halogens. The halogens, being good leaving 
groups, would also serve as points of further derivatizations through 
nucleophilic substitution, Buchwald-Hartwig amination, or Suzuki-Miyaura 
cross-coupling reactions. Also, the effect of different substituents at different 
positions on the phenyl group was explored. In addition, plans were made to 
introduce polar groups such as amino, ester, and amide, all geared towards 
improving the aqueous solubility. These changes would further serve to 
expand the SAR exploration for this series of compounds. 
As shown in Figure 2.9 above, SAR 3 analogues were designed to evaluate 
the effect of replacing the oxime with hydrazonoyl- or alkenyl-based 
moieties. The decision was informed by the fact that the 2-benzoxazolyl 
acetonitrile is a versatile intermediate for such modifications. Indeed, in 
2005, Rida and colleagues synthesized novel benzoxazole-based compounds 
from 2-benzoxazolyl acetonitrile, which were evaluated for their anti-HIV, 
anticancer, and antibacterial activities.47 In addition, the effect of various 
modifications based on cyclizations involving the nitrile group were 
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2.4.3.1 Synthesis of SAR 1 and SAR 2 Analogues  
The benzoxazole-based oxime analogues, designated under SAR 1 and SAR 
2, were obtained following a common synthetic pathway. This pathway was 
successfully conceived through the retrosynthetic analysis of the final 
targeted compounds, as well as by following literature protocols. The 
retrosynthetic scheme is illustrated in Figure 2.12 below, with the 
disconnection of carbon-heteroatom bonds taking center stage. As such, the 
disconnection of the group attached to the oxime oxygen atom would yield a 
free oxime. Thus, during synthesis, the introduction of this group would 
form the last step, and this was envisaged to be achieved, in the case of 
oxime esters, through reactions involving the nucleophilic oxime hydroxyl 
group with a carboxylic acid, acyl chloride, or an acid anhydride. Similarly, 
the synthesis of oxime ethers would follow the same protocol while using 
appropriate alkyl halides. The formation of the oxime substructure was then 
planned to be accessed through reactions between the methylene carbon 
and nitrous acid. The last two disconnections revealed that the commercially 
available and appropriately substituted 2-aminophenols, as well as 
malononitrile, would serve as key starting materials for the synthesis of all 
benzoxazole-based oximes through the 2-benzoxazolyl acetonitrile-based 
intermediates.   
 
Figure 2.12: Retrosynthetic analysis of benzoxazole-based oximes. 
The synthesis of SAR 1 and SAR 2 target compounds followed the protocols 
outlined in Scheme 2.10 and Scheme 2.13 below.  
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Scheme 2.10: Synthetic protocol towards SAR 2 benzoxazole-based target compounds. 
Reagents and conditions: (i) EtOH, TMSCl, 0 ºC, 17 h; (ii) DCM, appropriately substituted 2-
aminophenol, 25 ºC, 10 min then 50 ºC, 20 h; (iii) H2, Pd/C, 15 h; (iv) MeCN, K2CO3, acetyl 
chloride, 40 ºC, 0.5 h (v) AcOH, NaNO2, 0 ºC–25 ºC, 12 h; (vi) DCM, dimethylcarbamoyl 
chloride, TEA, 50 ºC, 15 h or MeCN, K2CO3, dimethylcarbamoyl chloride, 90 ºC, 1 h. 
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Although SAR 1 compounds were the first to be synthesized and biologically 
evaluated, for purposes of logical flow herein, the synthesis of SAR 2 
analogues is reported first. In addition, due to the loss of antimycobacterial 
activity following all attempts to replace the dimethyl carbamate moiety in 
SAR 1 analogues, all SAR 2 target final compounds bear the oxime 
functionalized with the dimethyl carbamate moiety.  
Attempts were made to synthesize the 2-benzoxazolyl acetonitrile 
intermediate 2.9a by reacting 2-aminophenol with malononitrile as reported 
by Das and colleagues.48 However, the yields obtained were in the range of 
20%.  After several attempts with different reagents and conditions in an 
effort to increase the yields, a different protocol was adapted, which involved 
the activation of malononitrile before reacting it with the appropriately 
substituted 2-aminophenols. This protocol was published by Ammar and 
colleagues in 2003, and the yield of 2-benzoxazolyl acetonitrile increased 
significantly to about 69%.49 Thus, in the synthesis of all target compounds, 
the starting point was the activation of malononitrile with absolute ethanol 
in the presence of chlorotrimethylsilane (TMSCl) to give a more reactive 2-
cyanoacetimidic acid ethyl ester hydrochloride intermediate 2.8 in high 
yields. The appropriately substituted 2-aminophenols were then reacted 
with 2.8 by refluxing the mixture in dichloromethane (DCM) for about 20 
hours to give the corresponding 2-benzoxazolyl acetonitrile-based 
intermediates 2.9a–2.9o in moderate to high yields.49 This reaction is 
believed to proceed via the reaction mechanism shown in Scheme 2.11 
below. Briefly, the primary amine nitrogen atom attacks the electron 
deficient carbon of the ester resulting in loss of ethanol and formation of a 
stable carbocation, which is then attacked by the nucleophilic phenoxyl 
oxygen atom to form a 5-membered ring. The aromatic benzoxazole ring 
system is then formed after a proton abstraction from the benzoxazolyl 
nitrogen atom by the chloride ions, and the subsequent loss of ammonia as 
ammonium chloride.  
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Scheme 2.11: Proposed reaction mechanism for the formation of 2-benzoxazolyl 
acetonitrile-based intermediates. 
Oxime formation at the methylene carbon was achieved by a nitrosation 
reaction, following a literature protocol.50 In this case, a frozen solution of 
the appropriate 2-benzoxazolyl acetonitrile-based intermediate in glacial 
acetic acid (AcOH) was slowly treated with sodium nitrite. The reaction 
mechanism involved in this step is proposed to proceed as shown in 
Scheme 2.12 below.34  
 
Scheme 2.12: Proposed reaction mechanism for the oxime formation.  
Initially, the electron-deficient nitrosonium ion (NO) is formed from the 
nitrous acid (HONO) generated in situ. At the same time, the acid-catalysed 
nitrile-ketenimine tautomerism is believed to occur when glacial acetic acid 
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protonates the nitrile nitrogen atom to yield a cation, which can be 
represented by two resonance structures, as shown in Scheme 2.12.51 This 
process activates the -protons leading to the abstraction of one of them by 
the acetate ions [conjugate base] yielding the ketenimine intermediate, as 
well as regenerating the acetic acid. The resulting ketenimine C=C double 
bond provides electrons for the nucleophilic attack by the -carbon on the 
electron-deficient nitrosonium ion. This in turn is followed by loss of a 
proton to furnish the free oxime intermediate, generally as a mixture of E- 
and Z-isomers. Literature reports indicate that the E-isomer is 
predominantly formed (90%).50 For all the SAR 2 analogues, the oxime 
intermediates were functionalized to yield dimethyl carbamate oxime esters 
as the final target compounds. This was executed by reacting the oximes 
with dimethyl carbamoyl chloride in a reaction mediated by triethylamine or 
anhydrous potassium carbonate. 
The -amino alcohol-based target compounds for SAR 1 were accessed 
through the epoxide intermediates 59 and 60 as shown in Scheme 2.13 
below. Epoxide 60, with a chloro substituent, was preferred over the methyl-
bearing 59 because of its expected higher metabolic stability. Both epoxides 
were synthesized by heating a mixture of the free oxime and epichlorohydrin 
in acetonitrile under mediation of anhydrous potassium carbonate.52 Several 
attempts to apply literature procedures, where the use of sodium hydride as 
the base is prescribed, were unsuccessful.53–55 The proposed reaction 
mechanism for the epoxide formation is illustrated in Scheme 2.14 below. 
Briefly, K2CO3 abstracts a proton from the oxime hydroxyl group, thus 
enhancing its nucleophilicity, which then attacks the electron deficient 
carbon of epichlorohydrin to form a transition intermediate. An attack on 
the more electron-deficient chloro-bearing carbon by the oxygen atom leads 
to the formation of the epoxide along with elimination of KCl. 
Synthesis of aryl and alkyl ethers 70–74 utilized similar reaction conditions 
and reagents as the epoxidation reaction. In this case, in place of 
epichlorohydrin, an appropriately substituted aryl halide was used, for 
instance benzyl chloride.   
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Scheme 2.13: Synthetic protocol towards SAR 1 benzoxazole-based target compounds. 
Reagents and conditions: (a) MeCN, K2CO3, epichlorohydrin, 90 ºC, 18 h; (b) MeCN, 
appropriate amine, lithium perchlorate, 25 ºC, 2–24 h; (i) MeCN, K2CO3, appropriate alkyl 
halide, 90 ºC, 1–2 h. 
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Scheme 2.14: Proposed reaction mechanism for epoxide formation. 
The β-amino alcohol-based final target compounds were obtained in 
moderate to high yields through the opening of the epoxide intermediates by 
the appropriate primary or secondary amines. This reaction took place at 
room temperature in acetonitrile under mediation of lithium perchlorate as a 
catalyst.55,56 Previous attempts to react the epoxide and amines by heating 
the mixtures in toluene in the absence of a catalyst, as reported in some 
literature protocols, were unsuccessful.53,57 This reaction is believed to 
proceed through the mechanism illustrated in Scheme 2.15 below. In 
summary, lithium ions coordinate between the epoxide oxygen and the 
oxime oxygen resulting in enhanced electron withdrawal from the two 
epoxide carbons. This enhances regioselectivity whereby amines 
nucleophilically attack the less substituted epoxide carbon resulting in ring 
opening. Subsequent proton-lithium exchange with the generated perchloric 
acid affords the desired β-amino alcohol-based target compound as a 
racemate or an enantiomeric mixture, coupled with the regeneration of 
lithium perchlorate. 
 
Scheme 2.15: Proposed reaction mechanism for nucleophilic epoxide ring opening by 
amines. 
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2.4.3.2 Synthesis of SAR 3 Analogues  
In order to investigate the effect of replacing the oxime moiety, the versatile 
2-benzoxazolyl acetonitrile (2.9a) was derivatized to a number of small and 
polar oxime-free target compounds. To achieve this, the work of Rida and 
colleagues was adapted.47 They previously reported some novel benzoxazole-
based compounds with potential anti-HIV, anticancer, and antibacterial 
properties.47 The procedures, which were followed in the synthesis of SAR 3 
analogues, are outlined in Scheme 2.16 below. 
 
Scheme 2.16: Synthetic protocols towards SAR 3 benzoxazole-based target compounds. 
Reagents and conditions: (i) EtOH, cyclohexanone, ammonium acetate, 25 ºC, 1 h; (ii) 
AcOH, freshly prepared benzenediazonium acetate, 25 ºC, 30 min; (iii) EtOH, ethyl 
acetoacetate, ammonium acetate, reflux (90 ºC), 7 h; (iv) EtOH, thioglycolic acid, reflux (90 
ºC), 7 h; (v) DMF, KOH, phenyl isothiocyanate, 0–25 ºC, 3 h; (vi) DMF, Chloroacetyl 
chloride, 0–25 ºC, 6 h; (vii) 0.1 N HCl to pH 3–4; (viii) EtOH, finely divided sulfur, TEA, 25 
ºC, 30 min, then phenyl isothiocyanate,  25 ºC, 1 h; (ix) EtOH, 3,4-dimethoxybenzaldehyde, 
TEA, 25 ºC, 2 h. 
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As shown in Scheme 2.16, 2-benzoxazolyl-2-cyclohexylideneacetonitrile 75 
was prepared by reacting 2.9a with cyclohexanone in ethanol using 
ammonium acetate as a catalyst. Similarly, treating a solution of 2.9a in 
ethanol with 3,4-dimethoxybenzaldehyde in the presence of a catalytic 
amount of triethylamine (TEA), delivered compound 82 in high yields. As 
earlier discussed in Scheme 2.12, the same reaction mechanism is believed 
to be involved, except that in this case a base-catalysed tautomerism occurs. 
The ketenimine facilitates the nucleophilic reaction with the electron-
deficient carbonyl carbon of ketones or aldehydes. Likewise, the reactions 
leading to all the other compounds listed in Scheme 2.16 follow related 
mechanisms, with the main mechanism being nucleophilic attack on a 
selected electron-deficient atom of the appropriate reactant by the 
ketenimine -carbon of 2.9a.  
The benzenediazonium acetate used in procedure ii was freshly prepared by 
treating aniline with an equimolar aqueous solution of sodium nitrite at 0 
ºC. It was then mixed with a solution of 2.9a in glacial acetic acid to yield 
the hydrazonoyl benzoxazole 76 in good yield.  
Refluxing 2.9a with an equivalent amount of ethyl acetoacetate or 
thioglycolic acid in ethanol yielded 77 or 78, respectively. 
Synthesis of compounds 79 and 80 proceeded through the formation of a 
common thiocarbamoyl potassium salt intermediate. This was achieved by 
treating 2.9a with phenyl isothiocyanate in dimethylformamide (DMF) under 
mediation of potassium hydroxide. Cyclization of the potassium salt 
intermediate with chloro acetylchloride in DMF yielded 79 in moderate yield. 
On the other hand, acidification of the potassium salt intermediate using 
HCl furnished 80 in good yield.58 
Treating a mixture of 2.9a, sulfur, and TEA in absolute ethanol with phenyl 
isothiocyanate furnished benzoxazolyl aminothiazole 81 in low yield.59  
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2.4.4 Spectroscopic and Chromatographic Characterization 
As described for the 2-aminoquinazolinones in section 2.3.4, all the 
synthesized benzoxazole-based compounds were fully characterized by 
subjecting them to various spectroscopic and chromatographic techniques. 
The NMR spectra, for example, which were used to confirm the chemical 
structure of the -amino alcohol-based compound 63, along with all the 
associated intermediates, will herein be used to represent how the 
characterization of compounds was carried out. In this case, the 6-chloro-2-
benzoxazolyl acetonitrile 2.9i was the first intermediate to be synthesized 
and its structure was confirmed using the 1H NMR spectrum shown in 
Figure 2.13 below. The signal corresponding to the two diagnostic 
methylene protons (H-4) appeared as a singlet (s) resonating at δ 4.12, while 
all the three aromatic protons were accounted for. As such, proton H-1 
yielded a doublet signal at δ 7.59 with a small coupling constant (4J = 1.7) 
due to a long-range coupling with proton H-2. In this case, proton H-2 and 
proton H-3 produced a doublet of doublets and a doublet, respectively.  
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The 1H NMR spectrum of the oxime intermediate 2.10i is also shown in 
Figure 2.13. The characteristic features include the appearance of a broad 
singlet signal at δ 15.10 due to the oxime proton H-4, and the absence of the 
signal due to the methylene protons in the aliphatic region. Also, all the 
aromatic protons appeared relatively more deshielded, and therefore 
resonated more downfield compared to those of 2.9i. This is most likely due 
to withdrawal of electrons from the benzoxazole nucleus by the oxime 
moiety. 
The synthetic step that followed was the formation of the epoxide 
intermediate 60. As shown in Figure 2.14 below, there were five diagnostic 
signals in the aliphatic region of the 1H NMR spectrum attributable to the 
diastereotopic methyloxiranyl protons [H-4 (×2), and H-6 (×2)] and proton H-
5 on the chiral center. The diastereotopicity arises from the stereogenic 
influence of the chiral center, which results in no symmetry element, and 
therefore the methylene protons H-4 and H-6 are diastereotopic. 
 
Figure 2.14: 1H NMR spectrum of 60 in CDCl3 at 400 MHz. 
The signals due to protons H-4, for instance, exhibited a pair of finely 
resolved doublet of doublets: one at δ 4.62 (H-4a) with coupling constants J 
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6.2 Hz. The larger coupling constant is attributable to geminal coupling 
between the pair, while the other two are due to vicinal coupling of the 
respective proton to proton H-5 on the chiral center. Consequently, proton 
H-5 yielded a doublet of doublet of doublet of doublets (dddd) due to four 
unequal couplings from the diastereotopes H-4 and H-6, as shown in Figure 
2.14 above. 
Figure 2.15 below is a 1H NMR spectrum for the target compound 63. The 
opening of the epoxide by morpholine was confirmed by the appearance of a 
doublet signal in the aliphatic region (δ 5.04) due to the hydroxyl proton H-7 
coupling with proton H-5. In addition, extra signals in the spectrum 
corresponding to the morpholinyl protons H-8 and H-9 were observed. 
Notably, the equivalent two pairs of aliphatic protons H-9 yielded a triplet (3J 
= 4.7 Hz) due to coupling with protons H-8, and integrated for four protons 
at δ 3.58.  
 
Figure 2.15: 1H NMR spectrum of the target compound 63 in DMSO-d6 at 400 MHz. 
13C NMR spectroscopy also played an important role in confirming the 
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compounds. For example, with respect to compound 63, there were 14 
distinct signals in its 13C NMR spectrum attributable to the 16 carbons of 
the compound, as shown in Figure 2.16 below. In all cases, the aromatic 
benzoxazolyl carbons resonated most downfield whereby the carbons 
attached to the relatively more electronegative oxygen and/or nitrogen atoms 
were the most deshielded. C-13, for instance, is the most downfield-
resonating carbon (δ 155.61) because of the neighbouring oxygen and 
nitrogen atoms, which act as electron sinks, and therefore highly 
deshielding.  Signals due to the morpholinyl carbons, on the other hand, 
appeared upfield, and had greater intensities compared to others because 
each signal arose from two chemical shift-equivalent carbons C-8 or C-9. In 
addition, carbons C-9 (δ 66.72) by virtue of being attached to the 
morpholinyl oxygen atom, were more deshielded than carbons C-8 (δ 54.49), 
and therefore resonated more downfield. All the other signals were 
successfully assigned to their corresponding carbons by taking into 
consideration their electronic environments, and the carbon type (aromatic, 
aliphatic, quaternary, or proton-bearing). 
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As shown in Figure 2.17 below, a single run on the LC-MS provided more 
characteristic information about compound 63.  
 
Figure 2.17: LC-MS readout for compound 63. 
 
LC-MS Purity Chromatogram at 280 nm 
LC-MS UV-VIS Absorption Spectrum 
  
LC Mass Spectrum 
  
λmax = 325 nm  
(M+H)+ = 365.1 (100%) 
              367.1 (32%) 
(Chloro Pattern) 
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In this regard, the chromatogram was used to determine the purity of 63 as 
> 99%, which was based on the percentage peak area. The mass spectrum,
on the other hand, afforded pseudo-molecular ions (M+H)+ at m/z = 365.1 
(100%), and 367.1 (32%), which were similar to the calculated ones for 
C16H17ClN4O4. In this case, the mass spectrum exhibited a pattern 
characteristic of a compound containing a chloro group, due to the two 
isotopes of chlorine.  In addition, the UV-VIS spectrum revealed the 
wavelength of maximum absorption for compound 63 as 325 nm. 
In brief, the 1H NMR spectra for the dimethyl carbamate-containing target 
compounds exhibited two diagnostic upfield singlets, each integrating for 
three protons, and therefore attributable to the two sets of methyl protons. 
Similarly, the corresponding 13C NMR spectra manifested the two methyl 
carbons as two distinct signals. The restricted rotation about the N–CO bond 
makes the two methyl groups different. This is due to significant double-
bond character of the amide bond, which is linked to conjugation, whereby 
the lone pair of electrons on the nitrogen is delocalized into the carbonyl 
group. The aforementioned rationale is illustrated in Figure 2.18 below. 
Figure 2.18: Effect of N–CO partial double bond on NMR spectra. 
In conclusion, two-dimensional correlation NMR spectroscopic techniques 
(2D NMR) were paramount in the assignment of signals to their contributing 
protons. This was necessary, for instance, where multiplicity ambiguities, as 
well as coincidental overlaps of signals, were encountered in the 1D 1H NMR 
spectra. These, for example, included the through-bond correlation methods 
such as the homonuclear correlation spectroscopy (COSY) and the 
heteronuclear single-quantum correlation spectroscopy (HSQC). 
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This chapter described the synthesis and characterization of compounds 
belonging to the two classes of benzoheterocycles studied in this thesis 
work: the 2-aminoquinazolinones and the benzoxazole-based oximes. The 
compounds were designed by employing rational medicinal chemistry 
principles, and thereafter successfully synthesized in accordance with 
protocols adapted from published synthetic methods. All the synthesized 
compounds were fully characterized using spectroscopic techniques such as 
NMR spectroscopy; chromatographic methods, including TLC and HPLC-MS; 
along with physical attributes such as melting points and appearance.  
The final target compounds, as well as some selected intermediates, were 
subjected to biological evaluation and physicochemical profiling. The 
chapter, which follows [that is, Chapter 3], discusses the results of biological 
studies, while Chapter 4 discusses the analyses of the relevant 
physicochemical properties. In addition, the data relating to the 
characterization of each of the synthesized compounds is fully described in 
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CHAPTER 3  
BIOLOGICAL EVALUATION 
3.1 Chapter Overview 
Chapter 3 describes the biological studies that were conducted in order to 
address the second specific aim of this thesis work, which was: To 
biologically evaluate the synthesized target compounds for antimycobacterial 
potency, cytotoxicity, and DMPK profiles.  
Sequentially, these studies followed a well-defined screening cascade as 
illustrated in Figure 3.1 below, which also depicts the criteria [cut-off 
values] that informed the advancement of compounds to various biological 
studies. The cut-off values, adapted from the H3D, played a major role in 
the prioritization of compounds for various assays.  
 
Figure 3.1: The screening cascade adapted in the biological evaluation of target 
compounds. CHO: Chinese Hamster Ovarian cells; HepG2: Human hepatic cells; Biology 
Triage: counter-screen against MtbΔcyd mutant, bioluminescence reporter (LUX) assays 
[PrecA-LUX and Pini-LUX]; Target identification: spontaneous mutant generation studies; 
MLM: Mouse liver microsomes; PPB: Plasma protein binding; F: Oral bioavailability; Cl: Rate 




 > 25 μM 
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In summary, this chapter principally highlights the hit-to-lead optimization 
screens. It begins with a discussion on in vitro antimycobacterial assays, the 
associated SAR analysis as well as various counter-screen assays, which 
were carried out on selected potent analogues. What follows is a discussion 
on in vitro cytotoxicity assays and the subsequent in vitro microsomal 
metabolic stability studies. With respect to the 2-aminoquinazolinones, 
Chapter 3 also provides an overview of the in vivo pharmacokinetics and 
efficacy studies in mice, which were conducted on the frontrunner 
compounds. In addition, a brief description of the preliminary target 
identification studies is provided, which involved generation of spontaneous 
resistant mutants. 
3.2 2-Aminoquinazolinones 
3.2.1 In vitro Antimycobacterial Activity 
Once synthesized, all target compounds were evaluated in vitro for their 
antimycobacterial activity against the drug-susceptible Mtb H37Rv strain, 
under replicating conditions. These assays were conducted by Mrs. Ronnett 
Seldon at the Institute of Infectious Disease and Molecular Medicine, 
University of Cape Town, South Africa.   In all cases, two types of culture 
media were employed in an effort to create diversity in the in vitro assay 
conditions: GAST-Fe (Glycerol-Alanine-Salts supplemented with Tween 80 
and Iron), and 7H9/ADC (Middlebrook 7H9 broth enriched with Albumin-
Dextrose Complex, glycerol, and tween 80). Generally, literature protocols 
were adapted, wherein broth microdilution in a 96-well microplate was 
utilized.1–3 Briefly, a 12.8 mM stock solution of a test compound was 
prepared in DMSO and then diluted with the desired growth medium to a 
concentration of 640 μM. This was followed by stepwise two-fold serial 
dilutions up to a concentration of 0.3125 μM. Afterwards, a 1:100 diluted 
culture of Mtb H37Rv at an optical density of 0.6–0.7 at 600 nm (OD600) was 
added into the wells except those in row 1 [the contamination controls] and 
incubated at 37 °C. Finally, the lowest concentration of the test compound 
that inhibited the growth of more than 99% of Mtb population [Minimum 
Inhibitory Concentration (MIC99)] was scored visually at day 7 and day 14 
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post-inoculation. MIC99 scoring was facilitated by the use of Alamar blue dye 
in a technique commonly referred to as the Microplate Alamar Blue Assay 
(MABA), which is paramount in the visual or fluorimetric cell-growth 
reading. In some instances, however, the green fluorescent protein (GFP)-
tagged Mtb H37Rv (pMSP12::GFP) was used in the assays. In this case, the 
MICs were determined using a dose-response curve analysis of the relative 
fluorescence [excitation wavelength at 485 nm and emission wavelength at 
520 nm] measured on a FLUOstar OPTIMA® microplate reader. 
3.2.1.1 Phase I Structure-Activity Relationship (SAR 1) Analysis 
The antimycobacterial SAR of the 2-aminoquinazolinones was evaluated by 
introducing structural variations at position 6 [SAR 1] and position 3 [SAR 
2] of the quinazolin-4(3H)-one core, and then screening the final target 
compounds for their in vitro activity against Mtb. Figure 3.2 below is a 
recapitulation of the general structure of the target analogues of compound 
2, as earlier described in Chapter 2. 
 
Figure 3.2: The positions of the structural modifications of 2 to yield SAR 1 and SAR 2  
2-aminoquinazolinone analogues. 
The in vitro antimycobacterial activities (MIC99 values) displayed by the SAR 
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Table 3.1: In vitro antimycobacterial activities of SAR 1 2-aminoquinazolinones. 
  
In vitro antimycobacterial 
activity^ against Mtb H37Rv; 
MIC99 (μM) [Day 14] 




Me 1 >160 >160 
3−SO
2
Me 2 0.625 1.25 
3−SOMe 3 1.25 1.25 
H 4 >160 >160 
3−CONH
2





 6 >125* >125* 
3−CN 7 >160 >160 
3−Cl 8 0.675 2.31 
2−Cl 9 >160 >160 
4−Cl 10 >160 >160 
3,4−Cl
2
 11 >160 >160 
3−F 12 >160 >160 
3−CF
3
 13 0.31 1.25 
3−NH
2
 14 40 80 
3−OMe 15 10 >160 
3−t-butyl 16 20 80 
4−t-butyl 17 >160 >160 
3−N(Me)
2
 18 2.5 6.25 
 
19 >125* >125* 
 
6−Me 
20 >125* >125* 
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Table 3.1: In vitro antimycobacterial activities of SAR 1 2-aminoquinazolinones. 
  
In vitro antimycobacterial 
activity^ against Mtb H37Rv; 
MIC99 (μM) [Day 14] 
Ar1 R1 Code GAST-Fe 7H9/ADC 
 
H 21 0.625 5 
3−SO
2
Me 22 >160 >160 
3−Me 23 2.5 10 





25 >160 >160 
 
3−F 26 >160 >160 
3,5−F
2
 27 >160 >160 
 
H 28 10 80 
OMe 29 >160 >160 
 
H 30 >160 >160 
 
Me 31 >160 >160 
Controls  
Rifampicin 0.0039 0.0039 
Kanamycin 1.562 3.125 
Fusidic acid 0.156 2.5 
^Activity determined using the Microplate Alamar Blue Assay (MABA) method; *Activity determined by 
GFP-based fluorimetric assay method; H37RV: Drug-susceptible Mtb strain; GAST-Fe: Glycerol-
Alanine-Salts supplemented with Tween 80 and Iron; 7H9/ADC: Middlebrook 7H9 broth enriched 
with Albumin-Dextrose Complex, Glycerol, and Tween 80. 
As shown in Table 3.1 above, a general trend of relatively higher MIC99 
values from the 7H9/ADC medium compared to those recorded in the GAST-
Fe medium was observed. This is most likely attributable to protein binding 
of the test compounds by the albumin in the 7H9/ADC medium. 
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Based on their MIC99 values, the test compounds were stratified into four 
categories, chiefly for purposes of SAR analysis: all compounds with MIC99 ≤ 
10 μM were regarded as active; those with MIC99 ranging from 10–20 μM 
had moderate activity; MIC99 = 20–125 μM denoted poor activity; whereas 
compounds exhibiting MIC99 > 125 μM were categorized as inactive.   
For compounds bearing a phenyl group as the Ar1 moiety, substitution at 
the meta-position, relative to the quinazolinone ring system, was found to be 
essential for antimycobacterial activity. Generally, the activity was 
independent of the electronic properties as well as the degree of 
hydrophobicity imparted by various substituents. This was augmented by 
the observation that substituents expected to introduce similar properties to 
a molecule, in some cases, yielded compounds with varying 
antimycobacterial potencies. As such, various substituents from each of the 
four Craig Plot quadrants yielded both active and inactive compounds. For 
instance, compound 2 [3−SO2Me-bearing] was active (MIC99 = 0.625 μM), 
whereas, in stark contrast, analogue 6 [3−SO2NH2-bearing] was inactive 
(MIC99 > 125 μM), despite the two substituents having similar electron 
withdrawing and hydrophobicity properties. Comparatively, the more active 
compounds mainly gravitated towards having an electron withdrawing 
substituent at the meta-position. Accordingly, the −CF3-, −SO2Me-, −SOMe-, 
−CONH2-, and −Cl-bearing compounds 13, 2, 3, 5, and 8 respectively, were
the most active and exhibited MIC99 values ranging from 0.31 to 1.25 μM. 
Conversely, all attempts to introduce substituents on the other phenyl 
positions resulted in loss of activity. For example, ortho-substitution (2−Cl, 
9), para-substitution (4−SO2Me, 1; 4−t-butyl, 17; and 4−Cl, 10), as well as 
di-substitution (3,4−Cl2, 11) yielded inactive compounds with MIC99 > 160
μM. In contrast, compounds containing these same substituents at the 
meta-position were all active; an observation that revealed the right 
pharmacophore responsible for specificity in target interactions. Besides, 
lack of a substituent on the phenyl ring led to loss of activity (analogue 4).     
Like the phenyl-based analogues, heterocycles as the Ar1 moiety delivered 
compounds with varying antimycobacterial activities. In an intriguing 
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observation, the pyridyl-based compounds 21 and 22 exhibited contrasting 
activities compared to their phenyl-based counterparts 4 and 2, respectively. 
As such, the unsubstituted pyridyl-based 21 was active (MIC99 = 0.625 μM) 
while the phenyl-based 4 was inactive. Likewise, the 3-
methylsulfonylphenyl-based 2 was active (MIC99 = 0.625 μM) whereas the 3-
methylsulphonylpyridyl-containing 22 was not. In addition, the position of 
the pyridyl nitrogen atom was found to be critical for activity: compounds 
bearing the pyridyl nitrogen atom at the para-position [26 and 27] were 
inactive, whereas distinctly, the active pyridyl-based compounds [21, 23, 
and 24; MIC99 = 0.625, 2.5, and 10 μM respectively] bear the pyridyl 
nitrogen atom at the meta-position.  
Moreover, the unsubstituted pyrimidinyl-based compound 28 was active 
(MIC99 = 10 μM) while its methoxy-substituted counterpart (29) lacked 
antimycobacterial activity. Also, the 5-membered heterocycles, thiophene 
and pyrazole (in analogues 30 and 31 respectively) were not tolerated, and 
therefore both compounds lacked antimycobacterial activity. 
In conclusion, the SAR 1 analogues exhibit clear in vitro antimycobacterial 
SAR trends, which are informed by the diverse potencies manifested by 
different compounds, some having relatively minor structural differences. 
This is most likely due to specific interactions between the compounds and 
the relevant Mtb molecular target(s), such that changes in the 
pharmacophore result in varying levels of potencies. At this juncture, 
inactive compounds were deprioritized, and were therefore not advanced to 
other biological studies in the screening cascade.  
Subsequently, having fixed the Ar1 moiety as 3-SOMePh [borne by 
compound 3] that manifested the best balance of potency and aqueous 
solubility, further expansion of the 2-aminoquinazolinone chemical space 
was undertaken by exploring the right-hand side in the proposed Phase II 





Chapter 3: Biological Evaluation  
Paul M. Njaria – PhD Thesis 2017 
 
142 
3.2.1.2 Phase II Structure-Activity Relationship (SAR 2) Analysis 
All SAR 2 target compounds were evaluated in vitro for their 
antimycobacterial activities against the GFP-expressing Mtb H37Rv strain, in 
which both GAST-Fe and 7H9/ADC were employed as the culture media. 
The results obtained are listed in Table 3.2 below as MIC99 values obtained 
after 14 days of incubation. 
Table 3.2: In vitro antimycobacterial activities for SAR 2 target compounds. 
 
 
In vitro antimycobacterial 
activity* against Mtb H37Rv; 
MIC99 (μM) [Day 14] 
Code R2  GAST-Fe 7H9/ADC 
32 H  33.4 13.0 
33 4−Me  3.09 2.28 
34 3−CF3  14.8 5.21 
35 2−CF3  >125 >125 
36 4−CF3  0.922 0.769 
37 4−CN  9.28 7.36 
38 3−CN  43 23.1 
39 4−SO2Me  >125 >125 
40 4−OMe  6.75 9.34 
41 4−OH  >125 >125 
42 4−F  4.84 5.32 
43 2−F  67 90.3 
44 
2−F,  
but R1 = 
3−SO2Me 
 >125 >125 
*Activity determined by GFP-based fluorimetric assay method; H37RV: Drug-susceptible Mtb strain 
(GFP-expressing); GAST-Fe: Glycerol-Alanine-Salts supplemented with Tween 80 and Iron; 7H9/ADC: 
Middlebrook 7H9 broth enriched with Albumin-Dextrose Complex, Glycerol, and Tween 80. 
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The compounds studied in phase II plans exhibited relatively 
comprehensible SAR trends, which were mainly driven by the type of 
substituent as well as the position of substitution on the phenyl ring. In this 
case, the MIC99 values obtained with the GAST-Fe medium are used for 
purposes of describing the SAR. Overall, substitution at the para-position (4) 
of the phenyl ring appeared to be the optimal position for antimycobacterial 
activity. As a result, shifting the position of the −CF3 moiety from the para-
position [analogue 3; MIC99 = 1.25 μM] to the meta-position [analogue 34; 
MIC99 = 14.8 μM] led to an approximately 12-fold reduction in activity, 
whereas a shift to the ortho-position [analogue 35; MIC99 > 125 μM] led to 
complete loss of activity. A similar trend was observed with the nitrile and 
fluoro substituents. In this case, the 4−CN-bearing analogue 37 (MIC99 = 
9.28 μM) and the 4−F-bearing analogue 42 (MIC99 = 4.84 μM) exhibited 
significantly higher activity compared to their ortho-substituted peers 38 
(MIC99 = 43 μM) and 43 (MIC99 = 67 μM) respectively, which displayed poor 
activity. In a peculiar case where a 2-FPh as the Ar2 moiety was combined 
with a 3-SO2MePh as the Ar1 moiety [analogue 44; MIC99 > 125 μM], 
antimycobacterial activity was severely affected. 
Comparatively, replacement of the 4−CF3 group with other substituents 
generally led to reduction in activity. For instance, although active, the 
4−Me, 4−CN, 4−OMe, and 4−F substituents in analogues 33 (MIC99 = 3.09 
μM), 37 (MIC99 = 9.28 μM), 40 (MIC99 = 6.75 μM), and 42 (MIC99 = 4.84 μM) 
respectively, resulted in a slight decrease in activity compared to the 4−CF3-
based analogue 3 (MIC99 = 1.25 μM). Likewise, the unsubstituted phenyl-
based analogue 32 exhibited moderate antimycobacterial activity (MIC99 = 
33.4 μM). On the other hand, the replacement of the 4−CF3 moiety with 
groups such as 4−SO2Me [39; MIC99 > 125 μM], and 4−OH [41; MIC99 > 125 
μM] led to complete loss of activity.  
Furthermore, replacing the phenyl ring with a pyridyl, while maintaining the 
4−CF3 substituent, yielded analogue 36 with markedly enhanced 
antimycobacterial activity (MIC99 = 0.922 μM). It suffices, therefore, at this 
juncture to conclude that a pyridyl bearing a 4−CF3 group is the optimal Ar2 
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moiety for antimycobacterial activity. Figure 3.3 below provides a graphical 
representation of the foregoing SAR 2 analysis, displaying the effect on 
antimycobacterial activity by various substituents at different aromatic ring 
positions. In order to promote visualization of potencies, MIC99 were 
converted to pMIC99, and therefore manifest a direct proportionality between 
the pMIC99 values and the antimycobacterial activity.                           
 
Figure 3.3: Three-dimensional graphical representation of SAR 2 analysis. 
After determining the in vitro antimycobacterial activities of 2-
aminoquinazolinones, potent compounds were selected and subjected to 
other biological screens, principally aimed at rapidly assessing the 
provisional mechanism(s) of action for triage purposes in an effort to 
facilitate further ranking and prioritization. Although these assays do not 
furnish definitive mechanism(s) of action, they nonetheless provide a 
convenient insight into the cellular processes involved in the displayed 
activity. Therefore, there are two main reasons for carrying out biology triage 
 
R2 = 
Active: pMIC99 = >5.0 (MIC99 <10 μM) 
Moderately active: pMIC99 = 4.7–5.0 (MIC99 = 10–20 μM) 
Poorly active: pMIC99 = 3.9–4.7 (MIC99 = 20–125 μM) 
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studies: Firstly, to provide information about whether or not active 
compounds exert their activity through known mechanism(s) of action; and 
secondly, to deprioritize compounds whose tentative biochemical targets are 
known to be promiscuous (unselective). These assays, for instance, include 
the counter-screen assay against the MtbΔcyd [cytochrome bd oxidase 
knockout] mutant, as well as the luminescence-based (LUX) assays 
described in the following subsections. These biology triage (Tier 1) assays 
were conducted in Associate Professor Digby Warner’s laboratory, Molecular 
Mycobacteriology Research Unit, Division of Medical Microbiology, University 
of Cape Town, South Africa. 
3.2.2 In vitro Antimycobacterial Counter-screen Assay against MtbΔcyd 
A representative batch of compounds, which demonstrated potent whole-cell 
activity [that is, MIC99 ≤ 10 μM] against the GFP-expressing Mtb H37Rv 
strain, was counter-screened against the MtbΔcyd mutant. This mutant 
lacks a functional cytochrome bd oxidase, and therefore it is entirely 
dependent on the cytochrome bc1 complex for oxidative phosphorylation-
driven respiration. Consequently, the mutant is hypersusceptible to 
compounds that inhibit the QcrB-containing cytochrome bc1 complex. QcrB 
is a putative ubiquinol [a form of coenzyme Q10] cytochrome c reductase, 
subunit b, which is an integral member of the bc1 complex of the respiratory 
electron transport chain.4 From a drug discovery perspective, QcrB is a 
biochemical target to a significantly high number of structurally diverse 
compounds, and therefore it is considered a promiscuous target. In addition, 
the oxidative phosphorylation pathway is largely conserved between 
prokaryotes and eukaryotes. Therefore, in some cases, unselective inhibition 
of the QcrB leads to unwanted target-based toxicity. This notwithstanding, it 
is a promising novel target pathway, particularly in instances where there is 
compelling evidence of selective inhibition of Mtb oxidative phosphorylation 
while sparing the homologous energy metabolism pathway in humans. For 
instance, bedaquiline interferes with Mtb energy metabolism via selective 
inhibition of ATP synthase, while Q203 and lansoprazole are potential anti-
TB drugs that selectively inhibit the cytochrome bc1 complex.5–9 
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Accordingly, this counter-screen assay was performed for two reasons: 
Firstly, to identify compounds that might be targeting the QcrB, as this is 
considered a “red flag” in TB drug discovery programs due to possible target-
based toxicities in humans. Secondly, to establish whether active 
compounds also display activity against a non-GFP expressing Mtb strain, 
hence confirming that indeed the inferred in vitro inhibitory activity is real, 
and not a function of interrupted GFP production. The in vitro 
antimycobacterial activities of the selected 2-aminoquinazolinone analogues 
against the MtbΔcyd mutant are shown in Table 3.3 below.  
Table 3.3: In vitro antimycobacterial  activity against the MtbΔcyd. 
 
 In vitro 
antimycobacterial 
activity against  
Mtb H37Rv; 










MIC99 (μM) [Day 14] 




Me 2 0.625 1.25  ND ND 
3−SOMe 3 1.25 1.25  2.5 2.5 
3−CONH
2
 5 0.625 1.25  5 2.5 
3−Cl 8 0.675 2.31  ND ND 
3−CF
3
 13 0.31 1.25  5 2.5 
3−N(Me)
2
 18 2.5 6.25  5 10 
 
H 21 0.625 5  1.25 5 
3−Me 23 2.5 10  1.25 >10 
3−OMe 24 10 10  10 >10 
 
H 28 10 80  >10 >10 
H37RV: Drug-susceptible Mtb strain; MtbΔcyd: Mtb mutant with cytochrome bd oxidase knockout; 
GAST-Fe: Glycerol-Alanine-Salts supplemented with Tween 80 and Iron; 7H9/ADC: Middlebrook 7H9 
broth enriched with Albumin-Dextrose Complex, Glycerol, and Tween 80. 
These results depict comparable activity trends of the tested compounds 
against the two Mtb strains, with no observed decrease in MIC99 against the 
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MtbΔcyd. Therefore, QcrB was excluded as a possible target for the 2-
aminoquinazolinones. 
3.2.3 Luminescence-Based (LUX) Assays 
LUX assays are designed to provide preliminary insights into mechanism of 
action through a rapid, first-pass detection of compounds that disrupt two 
macromolecular cellular pathways: the Mtb cell wall biosynthesis and 
homeostasis, and the maintenance of DNA integrity. These assays are based 
on luminescence signals generated by mycobacterial luciferase (luxAB) 
operons, whose expression is driven by gene promoters, which are induced 
by either cell wall or DNA damage. In this regard, the three-gene iniBAC 
operon is known to be stimulated in response to many agents that disrupt 
the Mtb cell wall homeostasis, including the frontline anti-TB drug, 
isoniazid, as well as inhibitors of peptidoglycan, arabinogalactan, mycolic 
acids, and fatty acids biosynthesis.10 Accordingly, this response is referred 
to as PiniB-LUX. On the other hand, recA and radA promoters are known to 
be upregulated in response to genotoxic agents as part of mycobacterial DNA 
damage (SOS response). These responses, therefore, are denoted as either 
PrecA-LUX or PradA-LUX.11 
Three representative 2-aminoquinazolinone analogues [3, 5, and 13] were 
evaluated for their ability to induce either a cell wall (PiniB-LUX) or a DNA 
damage (PrecA-LUX) response. In this assay, two-fold serial dilutions of each 
test compound were prepared in 96-well microplates containing the reporter 
Mtb H37Rv strain [transformants of lux plasmids], followed by incubation at 
37°C for 12 days. Luminescence, recorded as relative luminescence units 
[RLU], was measured every 24 hours. Isoniazid and ciprofloxacin served as 
the maximum luminescence controls for PiniB-LUX and PrecA-LUX assays, 
respectively.11 All the three compounds yielded negative results for both LUX 
assays. Therefore, it was highly likely that the apparent in vitro inhibitory 
activities displayed by the 2-aminoquinazolinone analogues were not 
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3.2.4 Carbon Starvation Assay 
In most cases, a significant subpopulation of Mtb exists in a non-replicating 
state during the active TB disease. These Mtb bacilli are refractory to some 
anti-TB drugs, and therefore contribute to the need for prolonged antibiotic 
therapy. As such, development of drugs capable of sterilizing the non-
replicating Mtb will significantly contribute to the shortening of TB therapy. 
In this regard, in vitro carbon (nutrient) starvation (tolerance) assays are 
used to evaluate compounds for their ability to inhibit non-replicating Mtb.12 
In effect, the media for nutrient starvation, such as Middlebrook 7H9 
enriched with 0.05% Tyloxapol, should ideally contain essential cofactors 
and trace elements to maintain live bacilli, but not sufficient carbon to 
support growth. 
Four 2-aminoquinazolinone analogues, which exhibited high potency 
against the replicating Mtb H37Rv strain, were selected and submitted for 
carbon starvation assays at the Centre of Excellence for Biomedical TB 
Research, National Health Laboratory Service, University of Witwatersrand, 
South Africa. The results are shown in Table 3.4 below.  
Under starvation conditions, there was a general increase in Mtb tolerance 
for the tested analogues, with majority of the compounds exhibiting >16-fold 
increase in MIC99 compared to the replicating conditions, except analogue 
13, which yielded a two-fold increase in MIC99. This assay, therefore, 
generally indicates that the 2-aminoquinazolinones most likely do not 
inhibit the non-replicating Mtb, although a bigger sample size would be 
required to draw a clear-cut conclusion about this series. Alternatively; the 
differences in the displayed MIC99 values could as well be attributed to 
differences in the growth media employed. Notably, rifampicin and isoniazid 
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Day 14 MIC99 (μM) 
Starvation (Tolerance); 
7H9/Tyloxapol 













Rifampicin 32-fold increase in MIC99 
Isoniazid 4-fold increase in MIC99 
7H9/ADC-Fe: Middlebrook 7H9 broth enriched with Albumin-Dextrose Complex, Glycerol, Tween 80, 
and iron. 
3.2.5 Cytotoxicity Studies 
In an effort to determine the selectivity of 2-aminoquinazolinones for Mtb, 
and in essence provide the predictive evidence of their safety profile, in vitro 
cytotoxicity studies were performed on selected potent analogues against 
two cell lines. Accordingly, cytotoxicity studies against the Chinese Hamster 
Ovarian (CHO) cells were conducted at the Division of Clinical 
Pharmacology, University of Cape Town, while studies against the human 
hepatic cell line, HepG2, were carried out at the Tuberculosis Research 
Section, Laboratory of Clinical Infectious Diseases, National Institute for 
Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH), 
United States of America.  
Cytotoxicity assays against the CHO cells were conducted using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), which facilitates 
the measurement of  cell proliferation and chemosensitivity. Emetine was 
used as the positive control while DMSO was the negative control. 
 
 
Chapter 3: Biological Evaluation  
Paul M. Njaria – PhD Thesis 2017 
 
150 
The assay against HepG2 cells was carried out in both glucose- and 
galactose-containing media. This was to facilitate the detection of drug-
induced mitochondrial dysfunction; that is, HepG2 cells are forced to rely on 
mitochondrial oxidative phosphorylation rather than glycolysis when 
galactose is substituted for glucose in growth media. Consequently, oxygen 
consumption increases in the galactose-grown HepG2 cells, and therefore 
their susceptibility to mitochondrial toxicants increases.13 In all cases, the 
CellTiter-Glo® luminescent cell viability/proliferation assay protocol was 
adapted. Cytotoxicity data for the representative 2-aminoquinazolinone 
analogues are listed in Table 3.5 below. 













Me 2 190±2 >50 >50 
3−SOMe 3 >226±ND 26.7 >50 
3−CONH
2
 5 >236±ND 37.7 >50 
3−Cl 8 >241±ND >50 >50 
3−CF
3
 13 >223±ND >50 >50 
3−N(Me)
2
 18 >236±ND >50 >50 
 
H 21 >262±ND >50 >50 
3−Me 23 177±27.2 >50 >50 
3−OMe 24 >243±ND >50 >50 
 
H 28 >261±ND >50 >50 
Emetine 0.319±0.09 ND ND 
ND: Not determined; CHO: Chinese Hamster Ovarian cells; HepG2: human hepatic cell line. 
The cytotoxicity results from these two assays were expressed as 50% 
inhibitory concentration (IC50), which was obtained from the analysis of the 
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dose-response curves. On the other hand, the in vitro antimycobacterial 
activities were expressed as MIC99, and therefore it would be inaccurate to 
calculate selectivity indices based on the two inhibitory concentrations. As 
such, the acceptable level of cytotoxicity was set at a cut-off value of IC50 > 
25 μM. 
The tested compounds exhibited low cytotoxicity (IC50 > 25 μM) against the 
two cell lines. Of particular interest, analogues 2 and 5 exhibited higher 
cytotoxicity [IC50 = 26.7 and 37.7 μM, respectively] against the HepG2 cells 
grown in the galactose-containing medium compared to those in the 
glucose-containing medium [IC50 > 50 μM for both analogues]. In view of 
this, although the cytotoxicity level was within the acceptable range, the two 
compounds could be considered as potential mitochondrial toxicants. 
However, the differences could also have resulted from possible higher 
solubility of these compounds in the galactose-containing medium. 
Within the context of cytotoxicity and selectivity, selected active compounds 
with low cytotoxicity were further evaluated for their potential to inhibit the 
cardiac potassium ion channel as described below.  
3.2.6 HERG Electrophysiological Patch Clamp Assay 
The human Ether-à-go-go-Related Gene (hERG) encodes for the alpha 
subunit of a voltage-dependent cardiac potassium ion channel (usually 
denoted as hERG), which contributes to the electrical activity of the heart, 
and thus coordinates the heart's rhythmic beating. A loss of function or a 
drug-related inhibition of this channel in humans more often leads to a fatal 
heart disorder known as the long QT syndrome or Torsades de Pointes (TdP) 
ventricular tachycardia, which is associated with cardiac arrhythmia that 
usually leads to sudden death.14 It is for this reason that it is essential to 
screen compounds for their potential to inhibit the hERG channel during the 
early stages of drug discovery. In cases where significant hERG blockade is 
revealed, appropriate medicinal chemistry approaches are triggered to 
address this liability at the earliest.15,16 Electrophysiology-based assay 
methods as well as virtual predictions are available for hERG screening.17–20  
 
 
Chapter 3: Biological Evaluation  
Paul M. Njaria – PhD Thesis 2017 
 
152 
Four representative 2-aminoqunazolinone analogues were selected and 
submitted for in vitro hERG inhibition assay at the Ion Channel Discovery 
Services, Essen Bioscience, United Kingdom. The IonWorks patch clamp 
electrophysiology protocol was applied. Briefly, electrophysiological 
recordings were made from a Chinese Hamster Lung cell line, which stably 
expresses the full length hERG channel. In effect, 8-point concentration-
response curves were generated using 3-fold serial dilutions from the 
maximum final assay concentration equivalent to 33 μM. These curves plot 
the log of molar concentration of a test compound against its effect on the 
hERG current, which is expressed as a percentage of the pre-compound 
signal. The results are shown in Table 3.6 below. 
Table 3.6: HERG inhibition assay results.  
 IC50 (μM)
a 95% CI Commentsb 




-20 ± 17% inhibition 
at 3.7 μM, solubility 










5 ± 13% inhibition at 
3.7 μM, solubility 





19 ± 36% inhibition 
at 1.2 μM, solubility 
issues at 3.7, 11, 
and 33 μM 
Quinidine 1.6 0.8–3.1 - 
CI = Confidence interval; aDenotes values were obtained from a 4-parameter logistic fit of the 
concentration-response data; bDenotes maximal percentage inhibition where the IC50 values could not 
be determined. 
For most compounds (those with > values), the inhibition potency could not 
be fully resolved mainly due to limited concentration range, particularly 
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because of poor solubility. Analogue 3, however, did not have solubility 
issues at low concentration, and therefore its IC50 value was considered 
more accurate. According to a general potency ranking system used to 
indicate the potency of test compounds in inhibiting the hERG channel, 
though not absolute cut-offs [low, IC50 > 10 μM; moderate, 1 μM ≤ IC50 ≤ 10 
μM; high, IC50 < 1 μM],21 it can be concluded that compound 3 has a 
moderate inhibition of the hERG channel. Moreover, these results highlight 
the poor aqueous solubility associated with this 2-aminoquinazolinone 
series. 
3.2.7 Metabolic Stability Assay 
The most potent (MIC99 ≤ 10 μM) and less cytotoxic (IC50 > 25 μM versus 
CHO and HepG2) analogues were selected for evaluation of their in vitro 
metabolic stability. This study was conducted by Dr. Mathew Njoroge at the 
Division of Clinical Pharmacology, University of Cape Town, South Africa.  
In summary, hepatic metabolism is the primary elimination mechanism for 
most exogenous compounds, which influences the bioavailability, clearance, 
and elimination half-life of a xenobiotic. Thus, it is important to screen 
compounds for the extent of hepatic metabolism, usually in an in vitro assay 
that utilizes liver microsomes. Three types of liver microsomes are commonly 
employed, which to a large extent are composed of membrane-bound 
enzymes such as the CYP450 [Phase I metabolism]: the human liver 
microsomes (HLM), the rat liver microsomes (RLM), and the mouse liver 
microsomes (MLM); in order to determine any interspecies differences.22 
Alternatively, metabolic stability can be assessed using the S9 fraction, 
which has more Phase I and Phase II drug metabolizing enzymes compared 
to microsomes. In addition, cytosol, which is mainly composed of soluble 
Phase II enzymes, can be employed. In this thesis study, however, MLM were 
prioritized over the other options because it was anticipated that the in vivo 
pharmacokinetics and efficacy studies would be conducted in mice models.  
A single time-point [30 minutes] assay protocol was applied. Briefly, the test 
compounds were appropriately diluted to 0.1 μM using a phosphate buffer 
pH 7.4 in a 96-well microtiter plate. The MLM (0.4 mg/mL) were then added 
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into the wells along with NADPH, which served as an enzyme cofactor for 
initiation of the enzymatic reactions involved. This mixture was then 
incubated at 37 ºC for 30 minutes, while shaking the microplates. 
Subsequently, the reaction was stopped by adding ice cold acetonitrile. The 
mixture was then centrifuged to remove proteins as sediments, while the 
supernatant was analyzed using liquid chromatography tandem mass 
spectrometry (LC-MS/MS).23 The LC-MS/MS readout was then used to 
determine the percentage amount of intact compound remaining after 30 
minutes of incubation in the MLM, as shown in Table 3.7 below.  















Me 2 97 ND 





 5 88 ND 
3−Cl 8 88 Hydroxylation 
3−CF
3
 13 97 ND 
3−N(Me)
2
 18 37 
N-demethylation 
(mono- and di-) 
 
H 21 68 Hydroxylation 
3−Me 23 87 ND 
3−OMe 24 72 O-demethylation 
 
H 28 94 ND 
References 
Midazolam <5 - 
MMV390048 >99 - 
ND: Not determined; MLM: Mouse Liver Microsomes. 
The MLM-unstable midazolam as well as the metabolically stable 
MMV390048 were used as controls in this assay. A value ≥ 75% remaining 
after 30 minutes is generally an acceptable measure of microsomal 
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metabolic stability that can be translated to indicate favourable in vivo half-
life (t12). 
All the tested compounds, except 18, displayed high microsomal metabolic 
stability. The low metabolic stability (37% remaining) of 18 was most likely 
due to the metabolically labile N,N-dimethyl moiety, which undergoes rapid 
mono- and di-demethylation by the microsomal enzymes.  
In instances where the analytical sensitivity as well as the extent of 
metabolism permitted, preliminary metabolite identification was carried out. 
Notably, the sulfoxide-based analogue 3 was mainly metabolised to the more 
metabolically stable sulfone-based 2. This, therefore, allowed advancing of 
analogue 3 to other studies in the screening cascade, although its 
microsomal metabolic stability was 73%, which was outside the set criteria 
of ≥ 75% remaining after 30 minutes.  
At this juncture, it was apparent that analogue 3 was the most favourable 
candidate for in vivo pharmacokinetic (PK) studies due to its favourable 
profile with respect to in vitro potency (MIC99 = 1.25 μM), aqueous solubility 
(80 μM), cytotoxicity (IC50 > 25 μM), and metabolic stability (73% remaining). 
The choice of 3 as the lead compound was further augmented by its 
‘prodrug’ predisposition, whereby it was postulated that it would facilitate 
the in vivo delivery of the active (MIC99 = 0.625 μM), more metabolically 
stable (97% remaining) analogue 2, which, on the other hand, was beset by 
poor aqueous solubility (10 μM). 
3.2.8 Plasma Protein Binding 
Plasma protein binding (PPB) is an important parameter that modulates the 
effective drug concentration at a particular pharmacological target site, and 
is known to significantly influence the rate of drug diffusion between plasma 
and tissues. This, for instance, affects the clearance (Cl) and the volume of 
distribution (Vd) of xenobiotics.24 In the early stages of drug discovery, PPB 
values are paramount in adjusting the pharmacokinetics parameters such 
as exposure, which are then considered when establishing the dose levels for 
in vivo efficacy studies. This is influenced by the fact that it is the unbound 
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fraction of a particular compound that is responsible for its efficacy and 
toxicity. 
Analogues 3 and 13 were selected for plasma protein binding assay, which 
was conducted at the Centre for Drug Candidate Optimisation (CDCO), 
Australia. In summary, aliquots of mouse plasma were spiked with 
DMSO/acetonitrile/water solutions of each test compound individually to a 
nominal concentration of 1000 ng/mL. Following ultracentrifugation, an 
aliquot of protein-free supernatant was taken from each of the 
ultracentrifuge tubes for determination of the unbound compound 
concentration by LC-MS.   
The PPB data, as shown in Table 3.8 below, revealed that the tested 
compounds were highly bound to mouse plasma proteins (> 95% bound). 
These results were thereafter used to correct the in vivo PK indices for 
purposes of dose evaluation in preparation for in vivo efficacy studies in 
mice. 
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3.2.9 In vivo Pharmacokinetics Study 
The sulfoxide-based analogue 3 was selected as the candidate for in vivo 
pharmacokinetics assessment in mice. This study was performed by Dr. 
Dale Taylor at the Division of Clinical Pharmacology, University of Cape 
Town, South Africa.  
Initially, snapshot 24-hour PK experiments were conducted on compounds 2 
and 3. This was chiefly to establish whether the sulfone-based analogue 2 
would significantly be generated in vivo from 3. In addition, these 
experiments were essential in comparing the PK profile of the orally 
administered 2 versus 2 as a metabolite of 3. Each compound was 
administered orally [per oral (po)] as a suspension in hydroxypropyl 
methylcellulose (HPMC) in phosphate-buffered saline (PBS), pH 7.4, and at 
dose levels of 25 × 2, 100, and 200 mg/kg, with three mice (n = 3) at each 
dose level. 
As hypothesized, the sulfoxide-based 3 was significantly metabolised to the 
sulfone-based 2 as shown in plots C in Figure 3.4 below. These PK profiles 
depicted the mean circulating plasma concentrations of the active metabolite 
2 increasing steadily as the concentration of 3 decreased. This pattern was 
replicated for the three dose levels. Although the conversion of 3 was 
extensive, it did not go to completion within 24 hours. Furthermore, the 
metabolism of 3 was fast, with metabolite 2 being detected immediately after 
administration of the parent compound 3, even at the lowest dose level.  
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Figure 3.4: Concentration-time (rising dose) profiles (mean of n = 3 mice at each dose level) 
for the orally administered 2 [Plots A], 3 [Plots B], and 2 as a metabolite of 3 [Plots C], at 25 
× 2 (second dose after 8 hours), 100, and 200 mg/kg (mpk) dose levels. 
The average half-life (t12) of 3 was estimated to be 7.2 hours (plots B). 
Comparatively, although not conclusively determined, the active metabolite 
2 exhibited longer t12 [33–251 hours; that is, the metabolite appeared far 
from elimination after 24 hours as shown in plots C]. Moreover, the 
exposure of metabolite 2 was greater than that of the parent compound 3 as 
demonstrated by the area under the curve (AUC) equivalent to 810.1 
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h.μmol/L for 2 versus 269.1 h.μmol/L for 3 at 200 mg/kg. Also, the oral 
administration of 2 yielded lower plasma concentrations [maximum 
concentration (Cmax) of 4.1, 4.7, and 7.0 μM at 25 × 2, 100, and 200 mg/kg 
respectively – plots A] compared to its peak plasma concentrations as a 
metabolite of 3 [Cmax = 20.0, 40.9, and 39.0 μM – plots C]. This was most 
likely attributable to solubility-limited absorption of 2. However, on the 
upside, higher exposure of 2 could be achieved by orally administering the 
more soluble analogue 3. Accordingly, it was considered more desirable and 
advantageous to administer analogue 3 for subsequent in vivo experiments. 
The kinetics of compound 3 were fairly linear up to 100 mg/kg before some 
measure of saturation occurred. At all doses, the exposure of the metabolite 
exceeded that of the parent compound; however, exposure maximized at the 
intermediate dose of 100 mg/kg [Cmax = 40.9 μM], and not at the highest 
dose of 200 mg/kg [Cmax = 40.5 μM], most likely suggesting a limited 
absorption of 3 from the gut at the highest dose.  
Subsequently, the full mouse rising dose (single) PK and tolerability 
assessment of compound 3 was performed over 48 hours at 50, 100, and 
200 mg/kg po; and 5 mg/kg intravenous (IV) dose. The compound was 
administered orally as a suspension in 0.5% w/v carboxymethylcellulose 
(CMC) solution, while the IV solution was made in N,N-dimethylacetamide 
(DMA): polyethylene glycol (PEG400): 5% dextrose (D5W) [15:50:35; v/v/v] 
mixture. Circulating plasma concentrations of both the parent compound (3) 
and the active metabolite (2) were quantified, and their PK profiles are 
shown in Figure 3.5 below. 
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Figure 3.5: Concentration-time profiles (mean of n = 3 mice) for compound 3 [graph on the 
left-hand side], and its active metabolite 2 at 50, 100, and 200 mg/kg (mpk) oral doses (po); 
and 5 mg/kg (mpk) intravenous (IV) dose. 
The PK profiles obtained were similar to those of the aforementioned 
snapshot 24-hour PK studies. The calculated PK properties for both the 
parent compound and the active metabolite are presented in Table 3.9 
below. Compound 3, complemented by its active metabolite 2, exhibited 
favourable PK properties that satisfied the criteria for progression to in vivo 
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Table 3.9: Pharmacokinetics parameters of analogue 3 and its active metabolite 2. 
Abbreviations: t1/2 (h) = Half-life in hours; tmax = Time taken to reach the maximum concentration; Cmax = Maximum (peak) plasma concentration; AUC0-inf = 
Area under the concentration-time curve extrapolated to infinity; Vd = Volume of distribution; Cltot = Total rate of clearance of an IV dose; F = Bioavailability 
expressed as a percentage. 
 




Oral dose (mg/kg) IV dose  Oral dose of 3 (mg/kg) IV dose (3) 
50 100 200 5 mg/kg  50 100 200 5 mg/kg 
t1/2 (h) 6.2 7.3 8.0 7.1  13.4 8.7 12.2 14.0 
tmax (h) 1.0 1.0 1.0 0.4  3.6 10.0 10.0 8.0 
Cmax (μM) 21.1 21.1 31.3 8.1  29.0 36.0 56.7 7.1 
Vd (L/kg) - - - 4.5  - - - - 
Cltot (mL/min/kg) - - - 7.2  - - - - 
AUC0-inf (min.μmol/L) 9012 10273 21781 1572  48430 57149 128342 9347 
F (%) 57 33 35 -  - - - - 
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Moreover, absorption of 3 was fast, resulting in significantly high Cmax of 
21.1 μM at 50 and 100 mg/kg oral dose, and 31.3 μM at 200 mg/kg within 
one hour. Likewise, the metabolism was fast, which resulted in metabolite 2 
being detected immediately after both the oral and the IV administration of 
3. Both compounds exhibited long half-lives [t1/2 > 6 hours], with 3 
displaying a moderate volume of distribution (Vd) [4.5 L/kg], low rate of 
clearance (Cltot) [7.2 mL/min/kg], and oral bioavailability (% F) ranging from 
33–57%. In addition, there was a linear dose-response relationship between 
the 100 and 200 mg/kg regimen; that is, as the dose doubled, the response 
(AUC) also doubled. This was unlike the preliminary 24-hour experiments 
that revealed some degree of saturation at 100 mg/kg dose, most likely due 
to differences in the vehicles used to make the oral suspensions. 
By factoring in the PPB of 95.5%, the adjusted concentration-time profile 
(Figure 3.6) with respect to the free fraction at 100 and 200 mg/kg oral 
doses revealed favourable free fraction exposure of the active metabolite (2), 
which was above the highest recorded MIC99 of 1.5 μM. Furthermore, both 
compounds were well tolerated by the mice throughout the exposure at the 
three dose levels, wherein neither death nor acute toxic effects were 
observed. Accordingly, compound 3 was selected for in vivo efficacy studies 
in mice at oral doses of 100 and 200 mg/kg. 
 
Figure 3.6: Concentration-time profiles (mean of n = 3) for the free fractions of 2 and 3 at 
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3.2.10 In vivo Efficacy Study 
The in vivo proof-of-concept efficacy assessment of compound 3 was 
conducted by Prof. Anne Lenaerts and Dr. Gregory Robertson, at the 
Mycobacteria Research Laboratories, Department of Microbiology, 
Immunology and Pathology, Colorado State University, USA.  
This study was performed in an acute infection BALB/c mouse model. 
Although these mice do not develop and recapitulate the necrotizing lesions 
and granulomas observed in humans, they are essential and efficient for 
initial, fast in vivo efficacy screening of compounds against Mtb, with 
minimal compound requirements during the early stages of drug 
discovery.25–27 
Initially, compound 3 was screened for tolerability in mice by administering 
it by oral gavage at 100, 200, and 300 mg/kg once per day (QD) for 3 
consecutive days, followed by seven days of observation. Three mice were 
employed for each dose level. The compound was well tolerated by all the 
mice at the administered doses and no acute toxic effects were observed at 
the end of the ten days; therefore permitting initiation of efficacy studies. In 
summary, 6–8 weeks old female BALB/c mice were infected with low dose 
aerosol (LDA) of the Mtb Erdman-Lux (luciferase-expressing) strain (50–100 
bacilli/mouse) in an aerosol infection chamber. Thereafter, treatment with 
the appropriate control drugs as well as 3 was initiated in groups of 5–6 
mice per compound on day 7 post-infection for twelve consecutive days [day 
7 to day 18]. In this case, compound 3 was administered by oral gavage at 
100 and 200 mg/kg QD. Samples for in-study PK profiling in the infected 
mice were obtained by bleeding the compound 3-treated mice during the last 
week of dosing at 1 and 24 hours post-administration. On day 21 post-
infection [that is, 72 h after the last dose – the drug washout period], all 
treatment and vehicle control groups were sacrificed. Then, the bioburden 
analysis was carried out by enumerating the colony forming units (CFU) 
following 3–4 weeks of incubation of homogenates of the aseptically 
harvested lung tissues.28 
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Unexpectedly, no reduction in the lung mycobacterial burdens was observed 
following 12 consecutive days of treatment with 3 at 100 and 200 mg/kg 
oral daily doses. All controls, on the other hand, yielded the expected 
responses; wherein bedaquiline (25 mg/kg), isoniazid (25 mg/kg) and 
moxifloxacin (100 mg/kg) all promoted significant reductions in lung 
burdens, and in most cases to levels at or near the limit of detection. 
Linezolid (100 mg/kg), PA-824 (50 mg/kg), and ethambutol (100 mg/kg) all 
displayed intermediate activity, while rifampicin (10 mg/kg) and 
pyrazinamide (150 mg/kg) were found to be largely static in this model. 
These results are presented graphically in Figure 3.7 below. 
 
Figure 3.7: Bar graph representing the lung Mtb bioburdens [colony forming units (CFU)] 
following 12 consecutive days of oral dosing with 3 and the appropriate drug controls. 
*Denotes the number of mice with CFU below the LOD. The drug washout period for the 
bedaquiline (BDQ) group and the corresponding untreated control group was 5 days. 
Further investigative studies were initiated in an attempt to decipher the 
disconnect between the apparent good in vitro inhibitory activity and the 
lack of in vivo efficacy displayed by 3. Firstly, the PK properties of 3 and its 
metabolite 2 in the infected mice were analyzed. Of particular interest were 
the circulating plasma concentrations as a measure of the exposure of 3 
during treatment. This was carried out in order to establish whether any PK 
differences between the healthy mice and the infected mice could be the 
cause of in vivo inactivity. 
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Concentration of 3 
(μM) 
 












1 hour 21 21  33 16 
24 hour 2.5 1.3  32 18 
200 
1 hour 34 31  55 20 
24 hour 5.8 5.1  50 52 
CSU denotes concentration determined at the Colorado State University; UCT denotes concentration 
determined at the University of Cape Town.  
As shown in Table 3.10 above, favourable plasma concentrations of both 
compounds in the infected [in-study] mice were recorded. These 
concentrations were similar to the historical values recorded with the single 
dose PK studies conducted on the healthy mice at UCT. Furthermore, the 
circulating plasma levels of metabolite 2 in the infected mice were higher at 
the steady state compared to those after single dose in the healthy mice; 
most likely reflecting the long half-life of metabolite 2 after daily dosing with 
3. Therefore, it was concluded that lack of exposure was unlikely to account 
for the lack of in vivo efficacy by 3 in mice. 
The step that followed was to test compound 3 in vitro using different Mtb 
strains cultured in different media. These assays were carried out at the 
Mycobacteria Research Laboratories, Department of Microbiology, 
Immunology and Pathology, Colorado State University, USA. As shown in 
Table 3.11 below, analogue 3 was active against both H37Rv and Erdman 
Mtb strains [MIC99 = 1 and 0.5 mg/L, respectively] when grown in media 
containing glycerol as the carbon source. In stark contrast, 3 lost activity 
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Table 3.11: In vitro antimycobacterial activity of analogue 3 in different assay conditions. 
Strain Media 
MIC99 (mg/L): 
3 RIF INH 
Erdman 7H9 + glycerol + ADC 1 0.03 0.016 
H37Rv 7H9 + glycerol + ADC 0.5 0.016 0.016 
Erdman 
7H12 + casitone + palmitic acid 
+ BSA + catalase + Tween-80 
>16 <0.008 0.016 
H37Rv 
7H12 + casitone + palmitic acid 
+ BSA + catalase + Tween-80 
>16 <0.008 0.016 
Erdman and H37Rv = Virulent strains of Mtb; ADC = Albumin-dextrose complex; BSA = Bovine serum 
albumin; MIC = Minimum inhibitory concentration; RIF = Rifampicin; INH = Isoniazid. 
Further independent in vitro antimycobacterial testing performed at the 
National Institute of Allergy and Infectious Diseases (NIAID), National 
Institutes of Health (NIH), USA, revealed that 3 was only active in media 
where glycerol was the sole carbon source. These assays at the NIAID were 
expanded to include 15 additional 2-aminoquinazolinone actives, including 
three compounds studied in this thesis work.  The results revealed that the 
2-aminoquinazolinones only exhibited antimycobacterial activity in glycerol-
containing media, hence linking their activity to the Mtb’s ability to 
metabolize glycerol. The results are shown in Table 3.12 below. Moreover, 
the glycerol-dependent activity was independently confirmed by the in vitro 
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H37RV = Drug-susceptible Mtb strain; GAST-Fe = Glycerol-Alanine-Salts supplemented with Tween 80 
and Iron; 7H9/ADC = Middlebrook 7H9 broth enriched with Albumin-Dextrose Complex, Glycerol, 
and Tween 80; BSA = Bovine serum albumin; NIH = National Institutes of Health; UCT = University of 
Cape Town. 
3.2.11 Spontaneous Resistant Mutant Generation Study 
The spontaneous resistant mutant generation experiments were performed 
by Dr. Atica Moosa in Associate Professor Digby Warner’s laboratory, 
Molecular Mycobacteriology Research Unit, Division of Medical Microbiology, 
University of Cape Town. The whole genome sequencing (WGS) analysis was 
conducted by Dr. Thomas R. Ioerger at the Department of Computer Science 
and Engineering, Texas A&M University (TAMU), USA.  
This study independently and unambiguously substantiated the glycerol-
dependent mechanism of action of 3. In this case, six resistant mutants 
were generated and the WGS analysis revealed that all had mutations 
mapping exclusively to glycerol metabolism genes, which encode for glycerol 
kinase (glpK; Rv3696c) and glycerol-3-phosphate dehydrogenase (glpD2; 
Rv3302c). Three of these mutants had polymorphism in glpK resulting from 
substitution of threonine (T) residue 69 for a methionine (M) [T69M] in one 
Table 3.12: In vitro antimycobacterial activity of 2-aminoquinazolinones in diverse media. 
Medium 
MIC99 (μM) [14 days] against H37Rv 
3 13 36 
GAST-Fe [NIH] 1.2 3.13 4.7 
7H9/ADC [NIH] 9.4 12.5 9.4 
GAST-Fe [UCT] 1.25 0.31 0.922 
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mutant, and cytosine (C) insertion in codons 189 and 517 in the other two 
mutants. Likewise, polymorphism in glpD2 was observed in three mutants, 
wherein substitution of the phenylalanine (F) residue 122 for valine (V) 
[F122V] was observed in one mutant, while substitution of F for leucine (L) 
at the same position [F122L] occurred in the other two mutants. The roles of 
glpK and glpD2 in glycerol metabolism by Mtb are illustrated in Figure 3.8 
below. 
 
Figure 3.8: Schematic representation of part of the Mtb Central Carbon Metabolism 
network depicting the roles of glycerol kinase and glycerol-3-phosphate dehydrogenase in 
glycerol metabolism.29 
Although the resistant mutants depicted the Mtb mechanism of resistance to 
3; taken together with the glycerol-dependent in vitro activity of 2-
aminoquinazolinones, along with the lack of in vivo efficacy, these results 
highly suggested that the mechanism of action of 2-aminoquinazolinones is 
associated with glycerol dissimilation. In addition, the mutations revealed 
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that glycerol kinase [the first committing enzyme for glycerol metabolism] 
and glycerol-3-phosphate dehydrogenase enzymes are most likely the 
molecular targets of 2-aminoquinazolinone analogues. Consequently, the 
fact that glycerol is not the primary sole source of carbon utilized in vivo by 
Mtb, clearly explains the lack of in vivo efficacy as well as the in vitro 
inactivity in glycerol-free media by compounds targeting the glycerol 
metabolism pathway. Thus, glycerol metabolizing enzymes are futile as drug 
targets. 
The carbon source-dependent disconnect between in vitro activity and lack 
of in vivo efficacy has previously been reported by other researchers.30–34 For 
instance, in 2010, Pethe and coworkers identified novel, in vitro-potent 
antimycobacterial pyrimidine–imidazoles (PIs) devoid of in vivo efficacy.30 In 
this case, the researchers carried out the mechanism of action studies using 
a chemical genetic screen, which linked the activity of PIs to glycerol 
metabolism. The killing mechanism was found to be due to the induction of 
Mtb self-poisoning arising from the accumulation of glycerol-3-phosphate as 
well as rapid depletion of the intracellular ATP pool. Moreover, the killing 
mechanism of PIs has been associated with the interference of methyl 
glyoxal [a reactive cytotoxic metabolite] detoxification pathway, leading to its 
accumulation to levels that are toxic to Mtb.33  
In conclusion, the biological evaluation of 2-aminoquinazolinones highlights 
the importance of developing and applying in vitro antimycobacterial 
screening conditions as well as animal models that highly reflect the in vivo 
biology at play during an active TB infection in humans. This, therefore, will 
increase the chances of translating in vitro activity to in vivo efficacy. 
Although the current practice is to screen compounds in more than one 
media [that is, utilization of different carbon sources such as glycerol, 
glucose, cholesterol, lipids, and fatty acids], the challenge still remains that 
the assay conditions may not adequately mimic the in vivo TB infection. This 
appears to be reinforced by the lack of clear consensus within the TB 
community on the in vitro phenotypic assay conditions as well as animal 
models that best mirror the in vivo TB infection in humans. 
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3.3 Benzoxazole-Based Oximes 
3.3.1 In vitro Antimycobacterial Activity 
The in vitro antimycobacterial assays on benzoxazole-based oximes were 
conducted under conditions similar to those employed in the screening of 2-
aminoquinazolinones, except that in this case, the Middlebrook 7H9 broth 
was supplemented with glucose instead of glycerol. Antimycobacterial 
activities were determined using the GFP-based fluorimetric assay method. 
The MIC99 values are presented in Table 3.13 [SAR 1 and SAR 2 analogues] 
and Table 3.14 [SAR 3 analogues] below. In this regard, the target 
analogues are based on the general structure depicted in Figure 3.9. 
 
Figure 3.9: General structure of benzoxazole-based oxime analogues depicting the three 
positions of structural variation. 
Table 3.13: In vitro antimycobacterial activities of SAR 1 and SAR 2 benzoxazole-based 




In vitro antimycobacterial 
activity* against Mtb H37Rv; 
MIC99 (μM) [Day 14] 
Code R1 R2  GAST-Fe 7H9-GLU-ADC 
45 −CONMe2 H  <0.244 1.37 
46 −CONMe2 2−Me  <0.244 <0.244 
47 −CONMe2 4−Me  <0.244 0.598 
48 −CONMe2 3−Me  <0.244 7.82 
49 −CONMe2 3−Br  <0.244 2.13 
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Table 3.13: In vitro antimycobacterial activities of SAR 1 and SAR 2 benzoxazole-based 




In vitro antimycobacterial 
activity* against Mtb H37Rv; 
MIC99 (μM) [Day 14] 
Code R1 R2  GAST-Fe 7H9-GLU-ADC 
50 −CONMe2 2−Br  <0.244 6.14 
51 −CONMe2 2−CO2Me  <0.244 37.60 
52 −CONMe2 2−CF3  <0.244 12.60 
53 −CONMe2 2−Cl  <0.244 7.82 
54 −CONMe2 3−Cl  <0.244 1.31 
55 −CONMe2 2−F  <0.244 1.73 
56 −CONMe2 3−F  <0.244 2.13 
57 −CONMe2 2−NO2  <0.244 5.04 
58 −CONMe2 2−NHCOMe  5.20 23.10 
59 
 
2−Me  23.20 >125 
60 
 
2−Cl  22.40 >125 
61 
 
2−Me  >125 >125 
62 
 
2−Cl  >125 >125 
63 
 
2−Cl  >125 >125 
64 
 
2−Cl  >125 >125 
65 
 
2−Cl  >125 >125 
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Table 3.13: In vitro antimycobacterial activities of SAR 1 and SAR 2 benzoxazole-based 




In vitro antimycobacterial 
activity* against Mtb H37Rv; 
MIC99 (μM) [Day 14] 
Code R1 R2  GAST-Fe 7H9-GLU-ADC 
66 
 
2−Cl  >125 >125 
67 
 
2−Cl  >125 >125 
68 
 
2−Cl  >125 >125 
69 
 
2−Cl  >125 >125 
70 
 
H  >125 >125 
71 
 
H  >125 >125 
72 
 
H  >125 >125 
73 
 
H  >125 >125 
74 
 
H  >125 >125 
Rifampicin  0.00318 0.00681 
*Activity determined by GFP-based fluorimetric assay method; H37RV: Drug-susceptible Mtb strain; 
GAST-Fe: Glycerol-Alanine-Salts supplemented with Tween 80 and Iron; 7H9-GLU-ADC: Middlebrook 








Chapter 3: Biological Evaluation  
Paul M. Njaria – PhD Thesis 2017 
 
173 
Table 3.14: In vitro antimycobacterial activities of SAR 3 benzoxazole-based target   
compounds. 
 
In vitro antimycobacterial 
activity* against Mtb H37Rv; 
MIC99 (μM) [Day 14] 

























Rifampicin 0.00318 0.00681 
*Activity determined by GFP-based fluorimetric assay method; H37RV: Drug-susceptible Mtb strain; 
GAST-Fe: Glycerol-Alanine-Salts supplemented with Tween 80 and Iron; 7H9-GLU-ADC: Middlebrook 
7H9 broth enriched with Albumin-Dextrose Complex, Glucose, and Tween 80. 
Unlike the 2-aminoquinazolinones, benzoxazole-based oximes exhibited a 
tight SAR, with only SAR 2 modifications being tolerated. As such, all 
attempts to introduce changes at the SAR 1 and SAR 3 positions yielded 
inactive compounds [most compounds had MIC99 > 125 μM]. For instance, 
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all the oxime ether-based SAR 1 analogues were inactive except the epoxide-
bearing analogues 59 and 60, which displayed moderate activity in GAST-Fe 
medium (MIC99 = 23.2 and 22.4 μM, respectively), although they were 
inactive in the 7H9-GLU-ADC medium. These findings imply that only the 
dimethyl carbamate moiety is tolerated at the oxime oxygen atom. Similarly, 
all attempts to replace the oxime moiety with other groups such as the 
hydrazonoyl, alkenyl, or ring systems [SAR 3] resulted in complete loss of 
antimycobacterial activity in both media.  
Despite being active, SAR 2 analogues exhibited a flat SAR, which was 
informed by the display of similar antimycobacterial activities for analogues 
with different substituents at varying positions on the phenyl ring. For 
instance, all SAR 2 compounds exhibited MIC99 < 0.244 μM when tested in 
GAST-Fe medium, except the amide-bearing (2–NHCOMe) compound 58, 
which had an MIC99 = 5.2 μM. Conversely, these compounds manifested 
relatively higher MICs in the 7H9-GLU-ADC medium, most likely due to 
significant compound-binding effect of albumin contained in this medium. 
Nonetheless, the MIC shifts were generally not conclusive to suspect a 
glycerol-dependent mechanism of action because most compounds retained 
potent activity [MIC99 < 10 μM] in both media. Accordingly, the SAR trends 
associated with SAR 2 analogues could be deduced from the results 
obtained with the 7H9-GLU-ADC medium. In this regard, the hit compound 
46, bearing a methyl group at position 2, was the most active compound [R2 
= 2–Me; MIC99 < 0.244 μM]. Shifting the methyl group to position 3 led to a 
significant decline in activity [48; MIC99 = 7.82 μM], whereas a methyl group 
at position 4 resulted in a very slight reduction in activity [47; MIC99 = 0.598 
μM]. Overall, the replacement of the methyl group with other moities had 
diverse impact on activity. Notably, some groups led to greater than a 100-
fold reduction in activity; for instance, compound 51 (2–CO2Me) exhibited an 
MIC99 value of 37.6 μM, while the MIC99 of 58 (2–NHCOMe) was 23.1 μM. 
In summary, two intriguing observations were made from the 
aforementioned SAR: firstly, all active compounds bear an acyl group (N,N-
dimethyl carbamate moiety; –CONMe2) on the oxime oxygen atom, 
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irrespective of the nature of the group on the SAR 2 position. The acyl group 
had previously been implicated in the low microsomal metabolic stability 
observed in these analogues. Considering the high antimycobacterial 
activity, along with the low metabolic stability, it can thus be hypothesized 
that the acyl-functionalized oxime compounds act as prodrugs. As such, it 
can be postulated that the dimethyl carbamate moiety affords the 
appropriate physicochemical properties necessary for the compounds to 
penetrate the lipid-rich Mtb cell wall. Therefore, once in the cytoplasm, the 
acyl group is cleaved by the Mtb esterases and amidases to yield a free 
oxime, which is highly believed to be the active entity. This hypothesis is 
further supported by the observation that the oxime ethers lack activity, 
perhaps because they are not substrates of the Mtb esterases and amidases, 
and therefore do not yield an active free oxime-bearing compound. Overall, it 
is postulated that the free oxime-based compounds bearing a nitrile group 
do not penetrate the Mtb cell wall, and therefore lack antimycobacterial 
activity. This hypothesis is illustrated in Figure 3.10 below.    
 
Figure 3.10: Hypothetical description of a probable prodrug-based activity of acyl-
functionalized oxime compounds. 
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On the other hand, replacement of the nitrile group with more lipophilic 
groups such as substituted thiadiazole (Figure 3.10), yields active free 
oxime-based compounds [benzothiazole-based free oximes], suggesting that 
a lipophilicity-driven mode of action could be involved. Thus, this hypothesis 
could be tested by designing experiments that measure the degree of 
permeability of these compounds into the Mtb cell. If the hypothesis is 
indeed true, the challenge of in vivo activation of the prodrugs by the 
circulating esterases as well as hepatic hydrolysis, before reaching the Mtb, 
could prevent further development of the acyl-functionalized oximes.   
The second observation is that intramolecular hydrogen bonding between 
the oxime hydroxyl hydrogen and a heteroatom appears to contribute to the 
exhibited activity. This is informed by the observation that the replacement 
of the nitrile group with lipophilic groups lacking a heteroatom, for instance 
a phenyl group (Figure 3.11 below), leads to loss of antimycobacterial 
activity. Therefore, most likely the intramolecular hydrogen bonding 
contributes to permeability as well as compound-target interactions. 
 
Figure 3.11: Oxime-based compounds depicting intramolecular hydrogen bonding. 
3.3.2 Cytotoxicity Studies 
Selected active compounds were subsequently evaluated for their 
cytotoxicity against the CHO cells in a study conducted at the Division of 
Clinical Pharmacology, University of Cape Town. The cytotoxicity values 
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Cytotoxicity against CHO 
cells 
Code R1 R2  IC50 (μM) Std Dev 
45 −CONMe2 H  >387 ND 
46 −CONMe2 2−Me  339 9.90 
47 −CONMe2 4−Me  286 17.8 
48 −CONMe2 3−Me  175 12.6 
50 −CONMe2 2−Br  158 13.6 
51 −CONMe2 2−CO2Me  7.05 0.78 
52 −CONMe2 2−CF3  46.3 4.91 
53 −CONMe2 2−Cl  182 33.7 
54 −CONMe2 3−Cl  131 29.5 
55 −CONMe2 2−F  162 54.1 
57 −CONMe2 2−NO2  46.8 11.1 
58 −CONMe2 2−NHCOMe  >317 ND 
CHO = Chinese Hamster Ovarian; Std Dev = Standard Deviation. 
All compounds exhibited favourably low cytotoxicity levels except the methyl 
ester-bearing 51, which yielded an IC50 of 7.05 ± 0.78 μM. 
To this end, the low microsomal metabolic stability exhibited by the 
representative compound (46) [7.3, 26.0, and 7.3% remaining after 30 
minutes of incubation in HLM, RLM, and MLM respectively] posed a major 
hurdle against advancement of the active benzoxazole-based oximes 
[functionalized with the dimethyl carbamate moiety] to the other proposed 
studies in the screening cascade. Accordingly, other studies such as 
determination of the permeability of these compounds into macrophages 
and Mtb cells [intracellular antimycobacterial assays], as well as stability in 
plasma would be essential at this juncture. 
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This chapter described the various hit-to-lead biological investigations 
performed on the final target compounds. Briefly, the 2-aminoquinazolinone 
analogues manifested clear SAR trends following in vitro evaluation of their 
antimycobacterial activity against the drug-susceptible Mtb H37Rv strain 
cultured in GAST-Fe and 7H9/ADC. In addition, the selected potent 
compounds exhibited low cytotoxicity against the CHO and HepG2 cell lines, 
along with high microsomal metabolic stability in MLM. Besides, the 
proposed hypothesis behind the design of the sulfoxide-based analogue 3 
was supported by experimental findings. The empirical evidence behind this 
was provided by the extensive in vivo biotransformation of 3 in mice to the 
active sulfone-based analogue 2. Both compounds exhibited favourable 
pharmacokinetic properties and were well tolerated at the highest 
administered dose of 300 mg/kg. Despite the good pharmacological profiles 
exhibited by the 2-aminoquinazolinones, the frontrunner analogue 3 was 
devoid of in vivo efficacy in an acute TB infection mouse model [BALB/c] at 
100 and 200 mg/kg doses. Further studies, including the use of different in 
vitro assay conditions such as glycerol-free media, revealed that the 2-
aminoquinazolinones killed Mtb in vitro via a glycerol-dependent mechanism 
of action, hence lacking in vivo efficacy. These findings correlated well with 
the results of studies on generation of spontaneous resistant mutants, 
whereby all strains resistant to 3 had mutations mapping to the glycerol 
metabolism genes, which encode for glycerol kinase (glpK) and glycerol-3-
phosphate dehydrogenase (glpD2). Overall, these biological studies highlight 
the importance of developing and applying in vitro antimycobacterial 
phenotypic screening conditions, in early drug discovery, which are reflective 
of the in vivo biological conditions during TB infection. 
The intermediates synthesized towards delivering SAR 2 target analogues 
were all evaluated for their antimycobacterial activity against the Mtb H37Rv 
strain. All were inactive (MIC99 > 125 μM) except intermediate 2.6g (Figure 
3.12), which had interesting results in that its in vitro antimycobacterial 
activity was independent of the media used in the assays. However, SAR 
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exploration studies revealed that 2.6g exhibited an idiosyncratic 
antimycobacterial activity, wherein any modification on the chemical 
structure led to complete loss of activity (Jessica Akester, MSc Dissertation 
2017, UCT). This includes the subsequent intermediate 2.7g (primary amine 
at position 2) and the final target compound 41 studied in this thesis work, 
which had MIC99 > 125 μM. 
 
Figure 3.12: Chemical structure of the active intermediate 2.6g. 
Benzoxazole-based oximes, on the other hand, exhibited a tight SAR, with 
only SAR 2 modifications being tolerated. As such, all attempts to introduce 
changes at SAR 1 and SAR 3 yielded inactive compounds. To this end, 
although the active compounds exhibited low in vitro cytotoxicity against the 
CHO cells, the low microsomal metabolic stability exhibited by the 
representative compound (46) [7.3% remaining after 30 minutes in MLM] 
was the major impediment to advancing the active benzoxazole-based 
oximes to the other studies in the screening cascade.  
All target compounds, regardless of their activity, were evaluated for their 
aqueous solubility, which was thereafter correlated with selected 
physicochemical factors in an attempt to deduce structure-property 
relationships (SPR). These studies, along with the supramolecular 
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CHAPTER 4  
PHYSICOCHEMICAL PROFILING AND SUPRAMOLECULAR 
DERIVATIZATION 
4.1 Chapter Overview 
Chapter 4 provides a discussion of the studies that were performed towards 
addressing the third specific aim of this thesis work, which was: To profile 
all final target compounds with respect to physicochemical properties, 
including aqueous solubility; deduce structure-property relationships (SPR); 
and carry out supramolecular derivatization of selected potent compounds. 
The chapter begins with an outline of the in silico and experimental 
physicochemical properties of the synthesized final target compounds. These 
properties were then subjected to statistical analyses in order to establish 
their distribution profiles across each compound dataset. In addition, 
statistical evaluation and comparison of various compound datasets is 
explored, including conventional anti-TB drugs (TB.Ds) and drug candidates 
(DCs) in clinical development, in an effort to establish the chemical space 
occupied by each cluster. Then, correlation and SPR studies aimed at 
unravelling the main factors responsible for the observed aqueous solubility 
are highlighted. The chapter ends with a discussion of supramolecular 
derivatization studies conducted on compound 3. 
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4.2 General Introduction 
Physicochemical properties make a considerable contribution to the in vitro 
potency and in vivo efficacy exhibited by compounds. More often, 
unfavourable ADMET profiles and formulation challenges are mainly 
attributable to poor physicochemical properties, particularly aqueous 
solubility.1–4  
Several studies have revealed relationships between physicochemical 
properties and drug-likeness. This has led to the establishment of a set of 
acceptable cut-off values for the calculated surrogate molecular descriptors, 
which are paramount in predicting optimal physicochemical properties for 
an oral drug-like space. For instance, the Lipinski’s rule of five (RO5) 
postulates that good oral absorption and permeation of a compound are 
more likely when cLogP ≤ 5; molecular weight (Mwt) ≤ 500 Daltons (Da); the 
number of hydrogen-bond donors (HBD) ≤ 5; and the number of hydrogen-
bond acceptors (HBA) ≤ 10.5,6 Furthermore, Veber and colleagues suggested 
that compounds with 10 or fewer rotatable bonds (RB) [measure of 
molecular flexibility] and topological polar surface area (tPSA) ≤ 140 Å2 (or 
total number of both HBD and HBA ≤ 12) have an increased chance of 
achieving acceptable oral bioavailability.7 
4.3 Evaluation of Physicochemical Properties 
The aforementioned molecular descriptors [Mwt, cLogP, tPSA, HBD, and 
HBA] relating to the synthesized 2-aminoquinazolinones (AQZs) and 
benzoxazole-based oximes (BZOs) were predicted using StarDrop® 6.4 
Software. The main aim was to establish whether these compounds fall 
within the chemical space prescribed by the Lipinski’s RO5 and Veber et al., 
in order to predict good oral bioavailability during hit-to-lead optimization. 
In addition, on account of these compounds exhibiting antimycobacterial 
activity, a statistical comparison of their predicted physicochemical 
properties versus those of conventional anti-TB drugs and drug candidates 
currently in clinical development [described in Chapter 1] was performed. 
This was mainly to establish the significance of any differences or 
similarities between the pairs, which would in turn partially explain the 
 
 
Chapter 4: Physicochemical Profiling and Supramolecular Derivatization 
Paul M. Njaria – PhD Thesis 2017 
 
186 
observed activity as well as inform the design of analogues with ‘drug-like’ 
properties close to those of anti-TB drugs. For each compound, therefore, a 
Simplified Molecular-Input Line-Entry System (SMILES) was generated 
using ChemBioDraw Ultra 16.0 and used as the primary format of data 
entry into StarDrop® 6.4 for property prediction. All statistical analyses were 
performed using Microsoft® Office Excel 2010, supplemented by XLSTAT 
2017 add-in. 
Aqueous solubility, permeability, and metabolic stability considerably 
influence the oral bioavailability of drugs. Of these factors, this thesis work 
focused mainly on strategies of improving aqueous solubility as well as 
analyzing the structural factors responsible for improved solubility. 
Accordingly, kinetic solubility of all the synthesized target compounds was 
determined using the turbidimetric assay method.8 Briefly, the procedure 
involved serial dilution of a 10 mM stock solution in DMSO using 
phosphate-buffered saline (PBS) at pH 7.4 to obtain triplicate final 
concentrations of 0.0, 5.0, 10.0, 20.0, 40.0, 80.0, 160.0, and 200 μM in 
clear, flat-bottomed 96-well microtiter plates. The concentration of DMSO in 
the assay solutions was 2% v/v. The plates were then left to equilibrate for 
two hours at ambient temperature. After incubation, UV-VIS absorbance 
readings were measured at 620 nm using a SpectraMax 340PC384 
spectrophotometer. Absorbance readings were then plotted against 
concentration, and the point at which absorbance rose from the baseline 
was taken as the limit of solubility in PBS pH 7.4. Therefore, compared to 
HPLC methods, turbidimetric solubility is far less accurate, mainly because 
solubility values can only be of the order of the aforementioned 
concentrations as opposed to the exact compound concentration in solution. 
Also, non-specificity is a pitfall of the turbidimetric method because 
observed values only depend on turbidity. Nonetheless, the turbidimetric 
method is simpler, less costly, and time-saving, particularly when handling 
large sample sizes.  
The recorded solubility values were then statistically correlated with the 
experimentally determined factors such as melting point, HPLC retention 
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time (tR), and TLC retardation factor (Rf). Each of these factors was used as a 
measure of a particular inherent compound characteristic, which in turn 
influences aqueous solubility. For example, melting point was used as a 
measure of crystal packing energy; tR and Rf as a measure of polarity; while 
cLogP was indicative of lipophilicity. In this regard, similar HPLC and TLC 
methods were applied for all compounds in each of the two classes of 
compounds studied in this thesis work, in order to have comparable data 
among the compounds.  
4.3.1 Results and Discussion 
The calculated and experimentally determined physicochemical properties of 
the 2-aminoquinazolinones and the benzoxazole-based oximes are listed in 
Tables 4.1–4.4 below.  
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Table 4.1: Physicochemical properties of the SAR 1 2-aminoquinazolinones. 
 
 Calculated Physicochemical Properties†  
Experimental Physicochemical 
Properties 
















Me 2 459.4 3.727 95.05 1 6  0.33 4.29 253 10 
3−SOMe 3 443.4 4.101 77.98 1 5  0.19 4.28 174 80 
H 4 381.4 4.316 60.91 1 4  0.41 4.68 298 5 
3−CONH
2





 6 460.4 3.281 121.1 2 7  0.20 4.18 311 80 
3−CN 7 406.4 4.495 84.7 1 5  0.33 4.48 303 40 
3−Cl 8 415.8 4.818 60.91 1 4  0.43 4.89 278 5 
2−Cl 9 415.8 4.818 60.91 1 4  0.43 4.73 250 5 
4−Cl 10 415.8 4.818 60.91 1 4  0.43 4.89 306 5 
3,4−Cl
2
 11 450.2 5.302 60.91 1 4  0.38 5.17 273 5 
3−F 12 399.3 4.421 60.91 1 4  0.38 4.70 289 10 
3−CF
3
 13 449.4 5.014 60.91 1 4  0.35 4.85 244 10 
3−NH
2
 14 396.4 3.762 86.93 2 5  0.26 4.30 283 160 
3−OMe 15 411.4 4.192 70.14 1 5  0.37 4.65 276 5 
3−t-butyl 16 437.5 5.781 60.91 1 4  0.44 5.27 258 5 
4−t-butyl 17 437.5 5.781 60.91 1 4  0.42 5.33 270 10 
3−N(Me)
2
 18 424.4 4.281 64.15 1 5  0.33 4.73 240 10 
 
19 530.5 3.321 107.5 1 8  0.36 4.08 279 20 
 
6−Me 
20 544.5 3.627 107.5 1 8  0.31 4.13 222 10 
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Table 4.1: Physicochemical properties of the SAR 1 2-aminoquinazolinones. 
 
 Calculated Physicochemical Properties†  
Experimental Physicochemical 
Properties 














H 21 382.3 3.406 73.8 1 5  0.18 4.28 288 20 
3−SO
2
Me 22 460.4 2.804 107.9 1 7  0.21 4.16 326 10 
3−Me 23 396.4 3.785 73.8 1 5  0.22 4.41 274 5 





25 480.4 4.085 83.03 1 6  0.41 4.83 257 10 
 
3−F 26 400.3 3.532 73.8 1 5  0.33 4.41 350 20 
3,5−F
2
 27 418.3 3.646 73.8 1 5  0.39 4.57 365 20 
 
H 28 383.3 3.526 86.69 1 6  0.18 4.18 327 40 
OMe 29 413.4 3.673 95.92 1 7  0.28 4.33 287 10 
 
H 30 387.4 4.333 60.91 1 4  0.40 4.57 311 5 
 
Me 31 385.3 3.412 78.73 1 6  0.24 4.20 271 20 
Abbreviations: Mwt = Molecular weight; cLogP = Calculated logarithm of n-octanol/water partition coefficient; tPSA = Topological polar surface area; HBD = 
Hydrogen bond donors; HBA = Hydrogen bond acceptors; Rf = Retardation factor (TLC); tR = Retention time (HPLC); m.p. = Melting point; Sol. = Aqueous 
solubility at pH 7.4. 
†Denotes properties predicted using StarDrop® 6.4; aAnalytical TLC with 5% methanol in dichloromethane as the mobile phase; bHPLC method described in 
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 Table 4.2: Physicochemical properties of the SAR 2 2-aminoquinazolinones. 
 
 Calculated Physicochemical Properties†  
Experimental Physicochemical 
Properties 













32 H  375.4 2.802 77.98 1 5  0.17 3.78 231 20 
33 4−Me  389.5 3.216 77.98 1 5  0.19 3.42 247 20 
34 3−CF3  443.4 4.101 77.98 1 5  0.18 3.72 153 40 
35 2−CF3  443.4 4.101 77.98 1 5  0.15 3.35 137 80 
36 4−CF3  444.4 3.199 90.87 1 6  0.11 3.38 154 80 
37 4−CN  400.5 2.883 101.8 1 6  0.13 2.94 333 40 
38 3−CN  400.5 2.883 101.8 1 6  0.16 2.88 258 40 
39 4−SO2Me  453.5 1.984 112.1 1 7  0.13 2.67 300 40 
40 4−OMe  405.5 2.696 87.21 1 6  0.14 3.16 240 40 
41 4−OH  391.4 2.290 98.21 2 6  0.08 2.66 297 160 
42 4−F  393.4 2.953 77.98 1 5  0.12 3.05 235 40 
43 2−F  393.4 2.953 77.98 1 5  0.12 3.08 266 80 
44* 2−F  409.4 2.501 95.05 1 6  0.24 3.04 272 20 
Abbreviations: Mwt = Molecular weight; cLogP = Calculated logarithm of n-octanol/water partition coefficient; tPSA = Topological polar surface area; HBD = 
Hydrogen bond donors; HBA = Hydrogen bond acceptors; Rf = Retardation factor (TLC); tR = Retention time (HPLC); m.p. = Melting point; Sol. = Aqueous 
solubility at pH 7.4. 
†Denotes properties predicted using StarDrop® 6.4; aAnalytical TLC with 5% methanol in dichloromethane as the mobile phase; bHPLC method described in 





Chapter 4: Physicochemical Profiling and Supramolecular Derivatization 
   
Paul M. Njaria – PhD Thesis 2017 
 
191 
Table 4.3: Physicochemical properties of the SAR 1 and SAR 2 benzoxazole-based oximes. 
 
 
 Calculated Physicochemical Properties†  
Experimental 
Physicochemical Properties 













45 −CONMe2 H  258.2 1.750 91.72 0 7   0.75 3.97 219 40 
46 −CONMe2 2−Me  272.3 2.154 91.72 0 7   0.75 4.43 206 20 
47 −CONMe2 4−Me  272.3 2.154 91.72 0 7   0.74 4.39 186 40 
48 −CONMe2 3−Me  272.3 2.154 91.72 0 7   0.74 4.33 196 40 
49 −CONMe2 3−Br  337.1 2.406 91.72 0 7   0.81 4.45 232 ND 
50 −CONMe2 2−Br  337.1 2.406 91.72 0 7   0.81 4.46 235 20 
51 −CONMe2 2−CO2Me  316.3 1.764 118.0 0 9   0.76 4.19 235 40 
52 −CONMe2 2−CF3  326.2 2.570 91.72 0 7   0.81 4.51 191 10 
53 −CONMe2 2−Cl  292.7 2.345 91.72 0 7   0.80 4.38 229 20 
54 −CONMe2 3−Cl  292.7 2.345 91.72 0 7   0.80 4.38 192 5 
55 −CONMe2 2−F  276.2 1.887 91.72 0 7   0.78 4.07 204 10 
56 −CONMe2 3−F  276.2 1.887 91.72 0 7   0.76 4.14 197 ND 
57 −CONMe2 2−NO2  303.2 1.691 137.5 0 10   0.78 4.37 212 20 
58 −CONMe2 2−NHCOMe  315.3 1.298 120.8 1 9   0.30 3.09 242 80 
59  2−Me 
 257.2 2.244 83.94 0 6   0.77 4.32 117 20 
60 
 
2−Cl  277.7 2.488 83.94 0 6   0.79 4.54 145 10 
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Table 4.3: Physicochemical properties of the SAR 1 and SAR 2 benzoxazole-based oximes. 
 
 
 Calculated Physicochemical Properties†  
Experimental 
Physicochemical Properties 















2−Me  316.4 2.364 103.7 2 7   0.08 3.36 244 80 
62 
 
2−Cl  336.8 2.543 103.7 2 7   0.11 3.46 221 80 
63 
 
2−Cl  364.8 1.802 104.1 1 8   0.40 3.43 105 160 
64 
 
2−Cl  362.8 2.746 94.88 1 7   0.19 3.37 108 80 
65 
 
2−Cl  363.8 1.508 106.9 2 8   0.04 3.45 180 160 
66 
 
2−Cl  377.8 1.934 98.12 1 8   0.04 3.43 158 >200 
67 
 
2−Cl  348.8 2.358 94.88 1 7   0.11 3.28 167 >200 
68 
 
2−Cl  439.9 3.307 98.12 1 8   0.58 4.38 155 80 
69 
 
2−Cl  440.9 2.458 111.0 1 9   0.34 4.09 164 80 
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Table 4.3: Physicochemical properties of the SAR 1 and SAR 2 benzoxazole-based oximes. 
Calculated Physicochemical Properties† 
Experimental 
Physicochemical Properties 













70 H 277.3 3.51 71.41 0 5 0.80 4.96 133 10 
71 H 311.7 4.123 71.41 0 5 0.80 4.99 122 10 
72 H 346.2 4.682 71.41 0 5 0.78 5.11 117 10 
73 H 311.7 4.123 71.41 0 5 0.80 4.95 140 10 
74 H 245.2 1.395 108.7 1 7 0.02 2.98 231 ND 
Abbreviations: Mwt = Molecular weight; cLogP = Calculated logarithm of n-octanol/water partition coefficient; tPSA = Topological polar surface area; HBD = 
Hydrogen bond donors; HBA = Hydrogen bond acceptors; Rf = Retardation factor (TLC); tR = Retention time (HPLC); m.p. = Melting point; Sol. = Aqueous 
solubility at pH 7.4; ND = not determined. 
†Denotes properties predicted using StarDrop® 6.4; aAnalytical TLC with 5% methanol in dichloromethane as the mobile phase; bHPLC method described in 
Chapter 6; cAverage of the melting range; dTurbidimetric solubility.
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Table 4.4: Physicochemical properties of the SAR 3 benzoxazole-based analogues. 
  Calculated Physicochemical Properties†  
Experimental Physicochemical 
Properties 
Code Structure Mwt (g.mol-1) cLogP tPSA (Å2) HBD HBA  Rfa tR (Min)b m.p. (ºC)c Sol. (μM)d 
75 
 
238.3 3.679 49.82 0 3  0.79 4.87 101 10 
76 
 
262.3 2.788 74.21 1 5  0.81 5.31 195 5 
77 
 
224.2 1.894 58.41 0 4  0.67 3.82 223 20 
78 
 
232.3 1.246 55.13 1 4  0.37 3.87 210 40 
79 
 
333.4 3.213 70.13 0 5  0.72 4.21 317 5 
80 
 
293.3 3.880 61.85 1 4  0.30 4.46 205 5 
81 
 
325.4 3.998 56.98 1 4  0.81 4.98 238 10 
82 
 
306.3 3.605 68.28 0 5  0.77 4.84 171 5 
Abbreviations: Mwt = Molecular weight; cLogP = Calculated logarithm of n-octanol/water partition coefficient; tPSA = Topological polar surface area; HBD = 
Hydrogen bond donors; HBA = Hydrogen bond acceptors; Rf = Retardation factor (TLC); tR = Retention time (HPLC); m.p. = Melting point; Sol. = Aqueous 
solubility at pH 7.4. 
†Denotes properties predicted using StarDrop® 6.4; aAnalytical TLC with 5% methanol in dichloromethane as the mobile phase; bHPLC method described in 
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Generally, most of the predicted properties of AQZs and BZOs exhibited 
normal distribution profiles, most likely due to close similarities among 
analogues in each class. The conventional anti-TB drugs (TB.Ds) and anti-
TB drug candidates (DCs), on the other hand, exhibited non-normal 
distribution of their physicochemical properties due to the diverse classes of 
compounds making up each category. For effective statistical comparison, 
all physicochemical properties were considered to be non-normally 
distributed. Therefore, the calculated median values were used as the basis 
of comparison and analysis instead of the calculated mean values. The use 
of the calculated median, as the more robust variable, was also augmented 
by the small number of compounds in each class (n < 45). Table 4.5 below 
depicts the calculated median values and ranges of each property across the 
various datasets. 
Table 4.5: The calculated median values of the predicted physicochemical parameters. 
Property 
Calculated Median Values (Range) 




























HBD 1 (1–2) 0 (0–2) 3 (0–13) 1 (0–7) 
HBA 5 (4–8) 7 (3–10) 7 (2–21) 8 (2–22) 
Abbreviations: AQZs = 2-aminoquinazolinones; BZOs = Benzoxazole-based oximes; TB.Ds = 
Conventional anti-TB drugs; DCs = Anti-TB drug candidates; Mwt = Molecular weight; cLogP = 
Calculated logarithm of n-octanol/water partition coefficient; tPSA = Topological polar surface area; 
HBD = Hydrogen bond donors; HBA = Hydrogen bond acceptors. Values in brackets represent range. 
The calculated median values indicated full compliance with the Lipinski’s 
RO5 by all the studied compound sets. However, the ranges manifested 
some degree of deviation from the RO5, particularly in properties associated 
with TB.Ds and DCs, which further highlighted the structural diversity of 
compounds in these classes. 
Since property distributions were considered non-normal for all compound 
sets, the non-parametric Mann-Whitney-Wilcoxon statistical comparison 
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test9,10 was carried out to establish whether there were any statistical 
differences between the predicted properties of AQZs and BZOs compared 
with those of TB.Ds and DCs. In this case, the test was performed by 
comparing a pair of compound sets for all the predicted properties and 
determining the p-value at the 95% confidence level. The null hypothesis 
(Ho) for the Mann-Whitney-Wilcoxon comparison was that there is no 
significant statistical difference in the distribution and the median values of 
the compared datasets. Since the significance value was 0.05, the null 
hypothesis was rejected in all cases wherein the p-value was less than this 
cut-off. Conversely, p-values greater than 0.05 signified a failure to reject 
the null hypothesis, and therefore, that there was no statistically significant 
difference between the compared parameters. Table 4.6 below shows the 
results of the Mann-Whitney-Wilcoxon tests between the relevant pairs of 
compound clusters. 
Table 4.6: The Mann-Whitney-Wilcoxon Test (p-value) results comparing the differences 
between the predicted physicochemical properties of AQZs and BZOs versus those of 




Mwt cLogP tPSA HBD HBA 
AQZs vs TB.Ds 0.075 0.000 0.082 0.000 0.012 
AQZs vs DCs 0.388 0.207 0.274 0.474 0.001 
BZOs vs TB.Ds 0.061 0.000 0.529 0.000 0.429 
BZOs vs DCs 0.000 0.458 0.848 0.017 0.052 
Abbreviations: AQZs = 2-aminoquinazolinones; BZOs = Benzoxazole-based oximes; TB.Ds = 
Conventional anti-TB drugs; DCs = Anti-TB drug candidates; Mwt = Molecular weight; cLogP = 
Calculated logarithm of n-octanol/water partition coefficient; tPSA = Topological polar surface area; 
HBD = Hydrogen bond donors; HBA = Hydrogen bond acceptors. Values in red (p < 0.05) denote 
rejection of the null hypothesis at the significance level [that is, there is a difference in the compared 
datasets]. 
Consequently, significant differences between AQZs and TB.Ds, with respect 
to cLogP, HBD, and HBA, were revealed. AQZs and DCs, on the other hand, 
had similar predicted properties except HBA. BZOs differed from TB.Ds in 
terms of cLogP and HBD, while when compared to DCs, the differences were 
mainly in the Mwt and HBD. Frequency distribution histograms were plotted 
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as shown in Figure 4.2 and Figure 4.3 below. As depicted in Figure 4.2 A, 
the molecular weights of AQZs and BZOs ranged from 200 to 550 Da.  
 
Figure 4.2: Frequency distribution histograms of: A. molecular weight; and B. cLogP. C. 
Plot showing the chemical space occupied by the studied compound sets with respect to 
molecular weight and cLogP. Abbreviations: AQZs = 2-aminoquinazolinones; BZOs = 
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The Mwt of 95% of AQZs fell between 350 and 450 while 45% of BZOs had 
Mwt below 300 Da. On the other hand, 60% of TB.Ds and 36% of DCs had 
Mwt below 400. Moreover, taking into consideration the RO5 violations, 5% 
AQZs, 30% TB.Ds, and 36% DCs had Mwt > 500, whereas all BZOs had Mwt 
< 500. Significant differences in cLogP were observed between the compound 
sets, as illustrated in Figure 4.2 B above, and the p-values in Table 4.6 
above. As such, while 60% and 18% of TB.Ds and DCs, respectively, had 
cLogP < 1.0, none of the AQZs and BZOs had cLogP values in this range. 
TB.Ds, therefore, displayed uniquely lower cLogP values compared to the 
other clusters. Values of cLogP for 68% of AQZs lay between 3.0 and 5.0, 
while only 10% of TB.Ds and 30% of DCs exhibited cLogP in this range. In 
addition, 32% of BZOs had cLogP in the range of 1.0–2.0, while the majority 
(60%) had values between 2.0 and 4.0. Lipinski’s RO5 was violated [cLogP > 
5.0] by 9.1%, 6.6%, and 18.2% of AQZs, TB.Ds, and DCs respectively. 
In order to visualize the various chemical spaces [with respect to Mwt and 
cLogP] occupied by the four compound sets, cLogP values were then plotted 
against Mwt as shown in Figure 4.2, plot C above. This plot revealed that 
TB.Ds occupied a unique chemical space compared to the other compound 
sets. In this case, 63% of TB.Ds had cLogP values < 2 and Mwt < 400 Da. 
Anti-TB drugs outside this space belong mainly to two classes of 
compounds: rifamycins and aminoglycosides. Conversely, both AQZs and 
DCs occupied a chemical space that was distinct from that occupied by 
TB.Ds. In this regard, 73% of DCs had Mwt ranging from 300 to 600 and 
cLogP between 1.5 and 6.5. All AQZs fell within this space. BZOs, however, 
occupied a different chemical space compared to the other categories. This 
space differed from that occupied by TB.Ds mainly in cLogP values. For 
instance, 84% of the BZOs had Mwt ranging from 200 to 300 and cLogP 
values between 1.0 and 4.5. Therefore, this observation implies that for 
BZOs to occupy a chemical space similar to most TB.Ds, a design strategy 
leading to lowering of cLogP to values < 1.0 would be most appropriate. 
Notably, the most recently approved anti-TB drugs, bedaquiline and 
delamanid, occupy a chemical space similar to the DCs. This may suggest 
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utilization of similar approaches and compound libraries in the discovery of 
small molecule anti-TB drugs during the last few decades. 
Generally, the ability of a compound to form hydrogen bonds enhances its 
aqueous solubility and facilitates drug-target interactions at the sub-cellular 
active sites. However, it is imperative to strike a balance such that the 
number of HBD and HBA are not too high to limit permeation of compounds 
across lipid-rich cell membranes. As such, the Lipinski’s RO5 prescribes 
that in an oral drug-like compound, the ideal number of HBD should be ≤ 5, 
while HBA should be ≤ 10.6 The total number of HBA and HBD significantly 
impact on the tPSA of a compound, which in turn affects the solubility and 
permeability of a compound. As mentioned earlier, according to Veber et al., 
the total number of HBD and HBA in a drug-like compound should ideally 
be ≤ 12, while the tPSA should be ≤ 140 Å2.7  
In this study, as shown in Figure 4.3 A below, most compounds exhibited 
tPSA values between 50 and 140 Å2, and are therefore in compliance with 
the Veber et al. rule. Notably, injectable TB.Ds [aminoglycosides] as well as 
the orally administered rifamycins exhibited relatively high tPSA values. It 
was also observed that all HBD distributions were skewed towards the left, 
as shown in Figure 4.3 B below. For instance, 60% of BZOs had no HBD 
while 91% of AQZs had one HBD. Similarly, 27% of TB.Ds and DCs had one 
HBD. In contrast, 13% of TB.Ds and 9% of DCs had > 5 HBD, hence in 
violation of the RO5. All compound sets exhibited fairly normal distributions 
of HBA, with values ranging from 2 to 10 as depicted in Figure 4.3 C below. 
About 25% of TB.Ds had > 11 HBA, which was mainly attributable to 
rifamycins, clarithromycin, and aminoglycosides. 
Most compounds in this study occupied a similar chemical space with 
respect to tPSA [< 140 Å2] and the total number of HBD and HBA [< 12]. 
This is illustrated in Figure 4.3 D below. Also, from this plot, it was evident 
that a strong linear correlation between the tPSA and the total number of 
HBD and HBA existed in all the four compound sets, which resulted in 
linear regression factors (R2) ranging from 0.88 to 0.99. 
 
Chapter 4: Physicochemical Profiling and Supramolecular Derivatization 
Paul M. Njaria – PhD Thesis 2017 200 
Figure 4.3: Frequency distribution histograms of: A. topological polar surface area (tPSA); 
B. hydrogen bond donors (HBD); and C. hydrogen bond acceptors (HBA). D. Plot showing
the chemical space occupied by the studied compound sets with respect to tPSA and the
total number of HBD and HBA. Abbreviations: AQZs = 2-aminoquinazolinones; BZOs =
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4.4 Structure-Property Relationships (SPR) 
Aqueous solubility is a key compound attribute with tremendous 
implications during the drug discovery and development process. For 
instance, solubility influences in vitro assays, oral bioavailability as well as 
formulation processes. In this thesis study, some compounds were designed 
by taking into consideration strategies that have previously been shown to 
improve aqueous solubility. These strategies included the classical 
approaches such as introduction of more hydrophilic polar substituents 
[increase in HBD]; replacement of phenyl groups with comparable 
heterocycles such as pyridyl or pyrimidinyl [increase in HBA]; disruption of 
crystal stacking, for example by introducing chiral center(s) in a molecule to 
influence crystallinity.  
Although majority of compounds studied in this thesis work exhibited low (< 
20 μM) and moderate (20−100 μM) aqueous solubility, this section attempts 
to decipher the factors responsible for any observed solubility improvement. 
In this regard, factors responsible for improved solubility could be deduced 
by measuring properties that are inherent and dependent on a compound’s 
structural features. Accordingly, melting points were measured to provide 
information about crystal packing energies; TLC Rf values and HPLC 
retention times were determined for all final compounds and used as a 
measure of relative polarity, while cLogP values were generated in silico and 
used as a measure of lipophilicity. In an effort to establish whether or not 
any relationship between the aforementioned factors and aqueous solubility 
existed across a particular class of compounds, correlation graphs of 
aqueous solubility against the appropriate factor were plotted for each class 
of compounds, as shown in Figure 4.4 below. 
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Figure 4.4: Correlation plots of Log solubility [determined by the turbidimetric method 
using PBS pH 7.4, and expressed in μM] against: A. Melting point; B. cLogP; C. TLC 
retardation factor; D. HPLC retention time. Abbreviations: AQZs = 2-aminoquinazolinones; 
BZOs = Benzoxazole-based oximes. 
These plots revealed that, in both classes of compounds, there was a 
moderately strong correlation between solubility and TLC Rf values [R2 = 
0.64 for AQZs and 0.57 for BZOs]. A similar pattern was noted with the 
HPLC retention times [R2 = 0.45 for AQZs and 0.65 for BZOs]. Therefore, it 
suffices to conclude at this juncture that, generally, increasing the polarity 
of both AQZs and BZOs led to improved aqueous solubility. 
The two classes of compounds exhibited a relatively weaker correlation 
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Melting points exhibited no correlation with solubility [R2 = 0.05 for AQZs 
and 0.01 for BZOs]. Although compounds with high melting points are 
generally expected to have lower solubility and vice versa, it is highly likely 
that the lack of correlation was due to other factors coming into play to 
reduce the effect of crystal packing energy on solubility.   
These correlation studies indicate that many factors simultaneously affect 
the solubility of compounds across a particular class, and therefore it is 
important to examine the factors responsible for aqueous solubility on a 
case by case basis as opposed to examining a whole class of compounds. 
This is illustrated using examples shown in Figure 4.5 below. Accordingly, 
the specific strategies employed in this thesis study were considered. It was 
observed that the replacement of a methylsulfonyl moiety [SO2Me: 2] with a 
methylsulfinyl [SOMe: 3] led to improved solubility from 10 to 80 μM. The 
melting point of 3 [174 ºC] was lower than that of 2 [253 ºC], therefore 
signifying a decrease in crystal packing energy and hence the improved 
solubility. This is most likely due to the chiral sulfur atom in the sulfoxide 
analogue 3 that affects the crystallinity of the compound leading to less 
stacking and in turn improved solubility. Notably also, the TLC Rf of 3 was 
0.19 compared to 0.33 for 2. This is an indication that 3 is more polar than 
2 and it is thus possible that the increased polarity also has a significant 
contribution to the enhanced solubility.  
Furthermore, it was noted that in instances where a phenyl group in AQZs 
was replaced with a pyridyl, the resulting compounds exhibited higher 
melting points despite the observed solubility enhancement, most likely due 
to increased intermolecular hydrogen bonding. The same general trend was 
observed whenever more polar hydrophilic substituents were introduced. 
For example, the carboxamide (−CONH2)-bearing 5 [solubility = 40 μM; Rf = 
0.12; m.p. = 300 ºC] and the aminosulfonyl (−SO2NH2)-containing 6 
[solubility = 80 μM; Rf = 0.20; m.p. = 311 ºC] had better solubility than 2. 
These data revealed that the intended improvement in solubility by addition 
of polar hydrophilic substituents is inadvertently limited by increased 
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intermolecular hydrogen bonding, which leads to tighter crystal packing, as 
supported by the increased melting points. 
A similar trend was observed with the BZOs. For instance, replacement of 
the dimethyl carbamate moiety with -amino alcohols yielded compounds 
with improved solubility. This was attributed to reduced crystal stacking, 
perhaps due to the chiral carbon, as evidenced by the reduced melting 
points. It could also be due to increased polarity arising from the polar 
hydroxyl and amino moieties. For instance, the dimethyl carbamate-
containing compound 53 had a solubility of 20 μM, melting point of 229 ºC, 
and an Rf value of 0.80 compared to the -morpholinyl alcohol-bearing 63 
with a solubility of 160 μM, melting point of 105 ºC, and an Rf value of 0.40. 
 
Figure 4.5: Graphical representation of solubility of some selected compounds and the 
associated experimental factors: A. 2-Aminoquinazolinones; B. Benzoxazole-based Oximes. 
Although the above-mentioned strategies led to relatively improved 
solubility, albeit modest, structural modification of compounds led to 
reduced or complete loss of antimycobacterial activity in some instances 
[Figure 4.5]. For example, all the -amino alcohol-containing BZOs were 
devoid of antimycobacterial activity, despite their relatively high aqueous 
solubility. This could be attributable to changes in the pharmacophore 
necessary for compound-target interaction, or reduced permeability of the 
compounds across the Mtb cell wall. In an effort to investigate whether 
physical modification of compounds would be a better strategy of improving 
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4.5 Supramolecular Derivatization 
Compound 3 was subjected to a number of physical derivatization processes 
aimed at synthesizing cocrystals, salts, and cyclodextrin inclusion 
complexes, which were largely expected to exhibit improved aqueous 
solubility. To achieve this, the cascade shown in Figure 4.6 below was 
followed. 
4.5.1 Single Crystals of 3  
Crystal structures provide information on the intrinsic properties of 
compounds such as molecular geometry, hydrogen bonding interactions, - 
stacking, polymorphism, and solvation profile.11 These properties in turn 
influence the solubility profile of a compound as well as facilitate the 
selection of potential cocrystal co-formers. Therefore, experiments aimed at 
obtaining single crystals of 3 were initiated for purposes of elucidating its 
crystal structure. The slow evaporation method was used to crystallize 
compound 3 in a variety of solvents: ethanol, methanol, acetone, 
acetonitrile, ethyl acetate, tetrahydrofuran, and chloroform. In all cases, an 
amount equivalent to about 5 mg of 3 was weighed and dissolved in a 
minimum amount of the appropriate solvent, aided by heating the mixture 
to a temperature that was 10 ºC below the boiling point of the solvent. After 
dissolution, a slight excess of the solvent was added, and the mixture 
filtered through a 0.22 μm nylon filter into a clean vial. The solution was 
then left to cool to room temperature and evaporate gradually [controlled by 
using perforated vial stoppers]. Of the seven solvents studied, only ethanol 
and ethyl acetate produced crystals of adequate size and quality for further 
characterization. 
Single crystal X-ray diffraction (SCXRD) experiments were then conducted 
on the crystals in order to elucidate the crystal structure of 3. In addition, 
the crystals were characterized by thermal methods: thermomicroscopy [hot-
stage microscopy (HSM)], thermogravimetric analysis (TGA), and differential 
scanning calorimetry (DSC).  
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Figure 4.6: The cascade followed in supramolecular derivatization studies. 
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4.5.2 Thermal Analysis  
The results of thermal analysis conducted on the ethyl acetate crystal of 3 
immersed in silicone oil are summarized in Figure 4.7 below.  
 
Figure 4.7: Hot-stage microscopy (HSM) micrographs, traces from thermogravimetric 
analysis (TGA), and differential scanning calorimetry (DSC) of crystals of 3 recrystallized 
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Thermomicroscopic analysis of a single crystal of 3 was conducted from 
room temperature (22.1 ºC) to 350 ºC at a ramp rate of 10 ºC min-1. The 
crystal was mounted on the hot stage and covered with a drop of silicone oil. 
As shown in Figure 4.7 above, desolvation was observed in the form of 
bubbling and cracking that started at 100 ºC and peaked at 123.4 ºC. 
Melting onset temperature was recorded as 170 ºC and the endset point at 
178.3 ºC. The melt darkened at temperatures above 300 ºC due to 
decomposition. 
The TGA traces (n = 2) showed a three-step mass loss. The initial average 
mass loss of 1.3% took place over a wide temperature range, beginning 
shortly after the start of the experiment from 29.5 to 114 ºC. This could be 
due to loss of surface volatiles or initial loss of a volatile solvent of 
crystallization. The second average mass loss of 9.3% occurred more 
drastically, ranging over 115 to 150 ºC, and was most likely due to a 
desolvation process. The total mass loss that could be attributed to 
desolvation was 10.6 ± 0.1% (n = 2). As discussed in the next section, this 
loss was confirmed from the crystal structure to be due to loss of 0.5 mole of 
both water and ethyl acetate per mole of 3 [that is, the crystals existed as a 
solvate (3 hemi-ethyl acetate hemihydrate)], which gives a calculated 
percentage mass of solvent as 10.7%. The third mass loss with an onset of 
270 ºC was due to decomposition of the desolvated compound. 
The DSC traces further reaffirmed the results of HSM and TGA. A small 
endotherm is noticeable peaking at around 50 ºC, perhaps arising from the 
energy absorbed to release the surface volatiles. However, two distinct 
endotherms were recorded. The first one corresponded to the desolvation 
process, meaning that heat was absorbed to eject the solvent molecules from 
the crystals. This endotherm was broad, occurring over a wide temperature 
range from 75 ºC to 160 ºC. The second endotherm with an onset 
temperature of 168 ºC and an endset temperature of 187 ºC corresponded to 
the melting of the anhydrous compound. Notably, the second endotherm is 
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4.5.3 Single Crystal XRD Analysis 
The single crystal XRD and refinement data for 3 hemi-ethyl acetate 
hemihydrate are outlined in Table 4.7 below. 
Table 4.7: Data-collection and refinement parameters for 3 hemi-ethyl acetate hemihydrate. 
Parameter Value 
Molecular Formula C22H16F3N3O2S•0.5(C4H8O2)•0.5(H2O) 
Formula Weight 496.50 
Crystal System Monoclinic 
Space Group C2/c 
a (Å) 15.2738(6) 
b (Å) 18.2613(8) 
c (Å) 16.7701(7) 
 (º) 90 
 (º) 103.1953(8) 
γ (º) 90 
V (Å3) 4554.0(6) 
Z 8 
D (calc) (g.cm-3) 1.445 
μ (MoK) (mm-1) 0.202 
F (000) 2048 
Crystal Size (mm3) 0.16 × 0.20 × 0.40 
Temperature (K) 105(2) 
Radiation (Å) MoK (0.71073) 
θ Min–Max (º) 1.8–28.3 
Index ranges ±h, ±k, ±l -20: 20; -24: 24; -22: 22 
Reflections (total)  62842    
Reflections (unique)  5675   
R (int) 0.041 
Reflections with I>2σ(I)  5043 
Nref, Npar 5675, 356 
R1, wR2, S 0.0421, 0.1129, 1.04 
Max. and Av. Shift/Error <0.001, <0.001 
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4.5.3.1 Crystal Structure 
Figure 4.8 represents the crystal structure of 3 hemi-ethyl acetate 
hemihydrate. Full lists of geometrical data (bond lengths, bond angles, 
torsion angles) for this and other crystal structures were obtained in the 
form of crystallographic information (CIF) files. 
 
Figure 4.8: The asymmetric unit (ASU) depicting the molecular structure of 3 and the 
included solvent molecules, with non-H atoms drawn as thermal ellipsoids at the 50% 
probability level. No H atoms were placed on the disordered water oxygen atom (O38). 
The −SOMe group (C31−S29−O30) was found to be disordered over two 
positions due to high thermal vibrations or the SMe group existing as a pair 
of rotamers. Nevertheless, S29B and C31B were refined isotropically 
because the −SOMe group existed with a site-occupancy of 93% at one of the 
positions. This moiety was found to exhibit a tetrahedral geometry as 
anticipated. The fused quinazolinone ring system was found to be planar as 
expected. Similarly, the −NH2 group exhibited a trigonal planar geometry 
and was coplanar with the fused quinazolinone ring system. The phenyl ring 
attached to the nitrogen atom N2 was non-coplanar with the quinazolinone 
ring system [torsion angle C1−N2−C13−C18 = 92.3(2)º], while the phenyl 
ring attached to C7, on the other hand, had a torsion angle 
C6−C7−C23−C24 of 149.9(2)º. The ethyl acetate and the oxygen atom of the 
water molecule (O38) were both included with a site-occupancy factor of 0.5. 
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4.5.3.2 Hydrogen Bonding Interactions 
The principal intermolecular hydrogen bonding interactions are 
N12−H12A•••N4a and N12−H12B•••O30b. These bonds appear to be 
responsible for maintaining the crystal architecture because no significant 
interactions were recorded between the molecule of 3 and the solvent 
molecules. These interactions are illustrated in Figure 4.9 below. The water 
molecule was found to be hydrogen bonded to atom O34 of the ethyl acetate 
molecule (O•••O = 2.914(6) Å). 
 
Figure 4.9: Stick diagram showing the principal intermolecular hydrogen bonding 
interactions in 3. Molecules of 3 linked by the N-H•••N hydrogen bonds are related by a 
crystallographic twofold axis parallel to the b-axis (normal to the view direction). 
Additional hydrogen bonds are outlined in Table 4.8. 
Table 4.8: Hydrogen bonding interactions for 3 hemi-ethyl acetate hemihydrate. 
D−H•••A (Interactions) d(D−H) d(H•••A) d(D•••A) D−H•••A 
N12−H12A•••N4a 0.88 2.12 2.986(2) 166 
N12−H12B•••O30b   0.88 2.13 2.925(2) 149 
C6−H6•••O38c 0.95 2.52 3.352(6) 146 
C17−H17•••F22 [Intra] 0.95 2.39 2.716(2) 100 
C18−H18•••O30c 0.95 2.58 3.279(2) 131 
D = Donor; A = Acceptor; d = distance (Å);  = angle (º). 
Symmetry codes: a 1-x, y, 3/2-z; b -1+x, y, z; c 3/2-x, 1/2-y, 1-z. 
Since there were very weak interactions between the solvent molecules and 
3, their main purpose appears to be that of filling voids in the crystal. This 
is depicted in the packing diagram shown in Figure 4.10 below, wherein the 
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ethyl acetate and water molecules [shown as space-filling models for clarity] 
appear to be surrounded by the molecules of 3, and thus tightly embedded 
within the crystal. This is likely be the reason why the desolvation 
transition, as recorded by TGA, occurred at temperatures higher than those 
expected for ethyl acetate and water. 
Figure 4.10: Packing characteristics of 3 hemi-ethyl acetate hemihydrate viewed parallel to 
the a-axis. 
The crystal structure of an ethanol solvate of 3 was also solved but could 
not be conclusively refined to an acceptable level because of severe disorder 
in the trifluoromethyl group and the presence of isolated spurious electron 
density peaks in the difference Fourier map. Nonetheless, the hydrogen-
bonded motif observed for 3 with the hemi-ethyl acetate hemihydrate phase 
was also observed in this structure. In this case, however, the ASU, as 
shown in Figure 4.11 below, contains a dimer of two symmetry-independent 
molecules of 3 held together by the N12A−H12A•••N4B and 
N12B−H12B•••N4A hydrogen bonds. 
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Figure 4.11: The two symmetry-independent molecules of 3 in the ethanol solvate.  Solvent 
molecules are omitted for image clarity. 
4.5.4 Cocrystal Screening 
Based on the foregoing description of the crystal structure of 3 and its 
molecular geometry, it was noted that the compound was inclined to form 
supramolecular structures involving the quinazolinone nitrogen atoms (N4) 
as the hydrogen bond acceptors and the 2-amino moieties (N12−H12A and 
N12−H12B) as the hydrogen bond donors. This, therefore, as well as 
previous work involving compounds with similar functional groups,12 formed 
the basis of postulation that co-formers containing a carboxylic acid or an 
amide functional group were the most suitable candidates for co-
crystallization with 3. The hypothesized supramolecular motifs are shown in 
Figure 4.12 below. As such, 11 potential co-formers [urea, nicotinamide, 
malonic acid, maleic acid, L-tartaric acid, L-proline, L-malic acid, glutaric 
acid, citric acid, ascorbic acid, and adipic acid] were selected from a list of 
generally regarded as safe (GRAS) compounds, and prioritized based on their 
aqueous solubility, since the main aim of these experiments was to 
physically modify 3 in order to improve its aqueous solubility.  
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Figure 4.12: Proposed supramolecular synthons involving 3 and a carboxylic acid or an 
amide functional group. 
4.5.4.1 Dry Co-grinding (DCG) Experiments  
About 5 mg of compound 3 was accurately weighed and gently pulverized 
together with an equimolar amount of the appropriate co-former for 15–20 
minutes using an agate mortar and pestle. The mixture was then analyzed 
by powder X-ray diffraction (PXRD) in order to establish whether or not new 
phases were formed. In all cases, the PXRD trace of a particular mixture was 
compared with the traces of the separate components. New phases were 
considered formed in all cases where new peaks could be identified in the 
PXRD patterns. A physical mixture, on the other hand, was presumed in all 
instances where the PXRD trace was composed of peaks emanating only 
from 3 and the appropriate co-former. The results of DCG experiments, as 
shown in Figure 4.13 below, indicated that most of the products were 
physical mixtures. The products from malonic acid and L-malic acid, 
however, signified formation of new phases, while that of adipic acid was 
largely an amorphous product. 
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Figure 4.13: PXRD traces of 3 and its products of dry co-grinding with various GRAS 
potential co-formers. 
4.5.4.2 Liquid-assisted Co-grinding (LAG) 
The above-mentioned experiments were repeated, but this time, minute 
amounts of ethanol were added dropwise at intervals during the co-grinding 
process, which lasted for 15–20 minutes. The resulting PXRD traces for each 
product are shown in Figure 4.14 below. Products from the dicarboxylic 
acids and citric acid produced PXRD traces indicative of the formation of 
new phases, and were therefore considered hits for co-precipitation and 
recrystallization experiments. Conversely, products from urea, nicotinamide, 
L-proline, and ascorbic acid were physical mixtures, and were thus not 
explored further. Furthermore, the PXRD traces of 3:malonic acid, 3:glutaric 
acid, and 3:maleic acid were similar, though not identical. The same pattern 
was observed with those of 3:L-malic acid and 3:citric acid. This was 
interpreted as a pointer to compound 3 being inclined to form isostructural 
products when combined with these acids.  
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Figure 4.14: PXRD traces of 3 and its products of liquid (ethanol)-assisted co-grinding with 
various GRAS potential co-formers. 
4.5.4.3 Co-precipitation 
In order to grow crystals for further characterization experiments such as 
determination of stoichiometry, products resulting from the LAG 
experiments, which were new phases, were dissolved in a minimum amount 
of hot ethanol (50 ºC) and left to crystallize by slow evaporation at ambient 
temperature. None of the mixtures produced crystals of appreciable size and 
shape. Therefore, crystallization by co-precipitation was explored. 
Accordingly, in each case, about 10 mg of 3 was accurately weighed, mixed 
with an equimolar amount of the appropriate co-former, and dissolved in hot 
ethanol. The mixture of 3 and maleic acid could not dissolve appreciably in 
any of the attempted solvents: ethanol, methanol, acetone, and acetonitrile. 
Within 10 days, all the six solutions had formed crystals. Of these, the citric 
acid- and the L-malic acid-containing solutions formed crystals of adequate 
size and quality for SCXRD. On the other hand, the adipic acid- and malonic 
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acid-containing solutions produced thread-like crystals, which were too 
small for SCXRD. All attempts to increase their sizes by reducing the rate of 
evaporation as well as using different solvents were futile. In addition, the L-
tartaric acid- and glutaric acid-containing solutions resulted in 
crystallization of the parent compound 3 only, as established by 1H NMR 
spectroscopy, and were therefore not explored further. 
Products containing L-malic acid, citric acid, malonic acid, and adipic acid 
were characterized using 1H NMR spectroscopy, thermal analysis, and 
PXRD. In addition, the single crystals of L-malic acid- and citric acid-
containing products were subjected to SCXRD experiments. The main roles 
of these characterization techniques were to determine the: 1. Stoichiometric 
ratio of interaction between 3 and the appropriate co-former [1H NMR 
spectroscopy]; 2. Melting point, presence of solvent/water, and thermal 
behaviour [thermal analysis]; 3. Formation of a new phase [PXRD]; 4. 
Molecular geometry, hydrogen bonding interactions, and whether a salt or a 
cocrystal was formed [SCXRD]. 
4.5.5 Compound 3:L-malic acid (2:1) Salt 
SCXRD studies confirmed that the product of co-precipitation of 3 and L-
malic acid was a salt resulting from the transfer of a proton to the nitrogen 
atom N4. 1H NMR spectroscopy as well as SCXRD confirmed the 
stoichiometry of 3:L-malic acid to be 2:1. Figure 4.15 below depicts the 1H 
NMR spectrum, TGA and PXRD traces of 3 malate. The TGA trace showed a 
two-step mass loss. The first mass loss at 50 ºC of 8.2 ± 0.2% (n = 2) was 
attributed to dehydration that resulted in loss of 2.53 ± 0.06 moles of water 
per mole of 3 [calculated mass loss of 2.5 moles of water = 8.1%]. The 
second mass loss at 230 ºC coincided with the melting point of 3 malate. 
This was attributed to decomposition of the malic acid component of the 
product. The PXRD trace depicted the diffraction pattern resulting from 3 
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Figure 4.15: 1H NMR spectrum, TGA and PXRD traces of 3 malate (2:1). 
4.5.5.1 Single Crystal X-Ray Analysis of 3 malate. 
The single crystal XRD and the refinement data for a hydrated crystal of 3 
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Table 4.9: Data-collection and refinement parameters for 3 malate. 
Parameter Value 
Molecular Formula 2(C22H17N3O2S1F3)+ (C4H4O5)2- •5(H2O) 
Formula Weight 1111.04 
Crystal System Triclinic 
Space Group P 1̅
a (Å) 5.1440(8) 
b (Å) 13.819(2) 
c (Å) 18.262(3) 
 (º) 78.836(3) 
 (º) 84.768(3) 
γ (º) 86.041(3) 
V (Å3) 1266.5(5) 
Z 1 
D (calc) (g.cm-3) 1.431 
μ (MoK) (mm-1) 0.200 
F (000) 559 
Crystal Size (mm3) 0.13 × 0.17 × 0.52 
Temperature (K) 100(2) 
Radiation (Å) MoK (0.71073) 
θ Min–Max (º) 2.1–28.3 
Index ranges ±h; ±k; ±l -6: 6; -18: 18; -24: 24
Reflections (total) 27510 
Reflections (unique) 6257 
R (int) 0.028 
Reflections with I>2σ(I) 5219 
Nref, Npar 6257, 342 
R1, wR2, S 0.1005, 0.2687, 1.10 
Max. and Av. Shift/Error <0.001, <0.001 
Δρmin, max (e Å-3) -0.67, 1.04
From the above information, the fact that the product crystallised in a 
centrosymmetric space group (P 1̅) could have resulted from racemization of 
L-malic acid after heating during the co-precipitation process. In the crystal,
the malate ion is disordered over two overlapping inversion-related 
positions, a result that has been observed previously when racemic malic 
acid was employed in co-crystallization.13 The crystal structure of 3 malate 
is shown in Figure 4.16 below. Notably, a proton from the carboxylic acid 
group of malic acid is transferred to the nitrogen atom N4 of 3, making the 
product a salt instead of a cocrystal.  
 
 
Chapter 4: Physicochemical Profiling and Supramolecular Derivatization 




Figure 4.16: The ASU of 3 malate with thermal ellipsoids of non-H atoms drawn at the 50% 
probability level. The disordered water molecules have been omitted for image clarity. 
As observed in the crystal structure of 3 hemi-ethyl acetate hemihydrate, the 
–SOMe moiety in 3 malate was also disordered over two positions. 
As hypothesized, the main hydrogen bonding interactions observed were 
N4−H4•••O33, N12−H12A•••O34, and N12−H12B•••O30a. These, along with 
other hydrogen bonds are outlined in Table 4.10 below. 
Table 4.10: Hydrogen bonding interactions for 3 malate. 
D−H•••A (Interactions) d(D−H) d(H•••A) d(D•••A) D−H•••A 
N4−H4•••O33  0.88 1.74 2.619(4) 176 
N12−H12A•••O34  0.88 1.87 2.730(6) 167 
N12−H12B•••O30a    0.88 2.01 2.805(5) 150 
C14−H14•••O11b 0.95 2.33 3.197(5) 152 
C15−H15•••O11c 0.95 2.47 3.307(4) 147 
C26−H26•••O30 [Intra] 0.95 2.45 2.861(7) 106 
C31A−H31B•••O30b 0.98 2.57 3.350(10) 136 
D = Donor; A = Acceptor; d = distance (Å);  = angle (º) 
Symmetry codes: a 1+x, 1+y, z; b 1+x, y, z; c 1-x, 1-y, 1-z 
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Figure 4.17 below illustrates the aforementioned hydrogen bonding 
interactions in 3 malate. 
 
Figure 4.17: Stick diagram depicting the main intermolecular hydrogen bonding 
interactions in 3 malate. 
Although the water molecules are expected to interact with the 3 malate 
molecules via hydrogen bonding, this was not observed due to the high level 
of disorder of the water molecules in the crystal structure. The diagram in 
Figure 4.18 below shows the packing characteristics of 3 malate 
counterions. This figure depicts a feature of hydrophilic-hydrophobic 
alternation in layers parallel to the b-direction. The hydrophilic layers 
contain the malate ions and water molecules whereas the hydrophobic 
layers are composed of cations of 3.  
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Figure 4.18: Packing characteristics of the 3 malate crystal viewed parallel to the a-axis. 
The red spheres represent the oxygen atoms of the disordered water molecules. 
4.5.6 Compound 3:Citric acid (2:1) Salt 
Like 3 malate, the crystal structure of 3 citrate was elucidated and found to 
be a salt. The 1H NMR spectrum, TGA and PXRD traces are shown in 
appendix A1. The SCXRD and the refinement data for 3 citrate are listed in 
Table 4.11 below. 
Table 4.11: Data-collection and refinement parameters for 3 citrate. 
Parameter Value 
Molecular Formula 2(C22H17N3O2S1F3)+ (C6H6O7)2- •5(H2O) 
Formula Weight 1169.08 
Crystal System Triclinic 
Space Group P 1̅ 
a (Å) 5.1224(7) 
b (Å) 13.805(2) 
c (Å) 18.581(2) 
 (º) 83.284(2) 
 (º) 82.780(3) 
γ (º) 86.555(2) 
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Table 4.11: Data-collection and refinement parameters for 3 citrate. 
Parameter Value 
V (Å3) 1293.2(5) 
Z 1 
D (calc) (g.cm-3) 1.480 
μ (MoK) (mm-1) 0.202 
F (000) 590 
Crystal Size (mm3) 0.14 × 0.15 × 0.32 
Temperature (K) 173(2) 
Radiation (Å) MoK (0.71073) 
θ Min–Max (º) 1.5–28.4 
Index ranges ±h; ±k; ±l -6:  6; -18: 18; -24: 24 
Reflections (total)  27680 
Reflections (unique)  6426 
R (int) 0.031 
Reflections with I>2σ(I)  5009 
Nref, Npar 6426, 430 
R1, wR2, S 0.0579, 0.1713, 1.04 
Max. and Av. Shift/Error <0.001, <0.001 
Δρmin, max (e Å-3) -0.49, 0.98 
The crystal structure of 3 citrate had similar characteristics to those 
observed with the 3 malate one, as depicted in Figure 4.19 below. The 
citrate ion is disordered over a center of inversion and only the labelled half 
belongs to the asymmetric unit. The water molecules were also disordered 
and hydrogen atoms could not be placed on them. Also, the –SOMe moiety 
was disordered over two positions.  
Furthermore, comparison of the unit cell data of the two crystals suggested 
isostructural arrangements of the parent molecules 3 and location of the 
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Figure 4.19: The ASU of 3 citrate with thermal ellipsoids represented at the 50% 
probability level. The disordered water molecules have been omitted for image clarity. 
The principal hydrogen bonding interactions are shown in Table 4.12 below. 
Table 4.12: Hydrogen bonding interactions for 3 citrate. 
D−H•••A (Interactions) d(D−H) d(H•••A) d(D•••A) D−H•••A 
N4−H4•••O33  0.88 1.87 2.754(4) 177 
N12−H12A•••O34  0.88 1.89 2.752(2) 165 
N12−H12B•••O30a    0.88 2.11 2.880(11) 146 
C17−H17•••O11b 0.95 2.49 3.342(3) 149 
C18−H18•••O11c 0.95 2.36 3.218(3) 150 
C26−H26•••O30 [Intra] 0.95 2.43 2.857(11) 107 
D = Donor; A = Acceptor; d = distance (Å);  = angle (º) 
Symmetry codes: a 1+x, 1+y, z; b 1-x, 1-y, 1-z; c 1+x, y, z 
The above-mentioned interactions and the packing characteristics are 
illustrated in Figure 4.20. As observed with 3 malate, the supramolecular 
architecture of 3 citrate is characterized by hydrophilic water/citrate ion 
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Figure 4.20: Packing characteristics of the 3 citrate crystal viewed parallel to the a-axis. 
The red spheres represent the oxygen atoms of the disordered water molecules. 
From the foregoing discussion, it was hypothesized that 3 had the 
propensity to form isostructural products with dicarboxylic acids. To test 
this hypothesis, succinic acid, being a symmetrical dicarboxylic acid, was 
studied. Unfortunately, all attempts to grow single crystals of appreciable 
size were unsuccessful. However, the product of co-precipitation of 3 and 
succinic acid (2:1) by slow evaporation in ethanol was characterized by 1H 
NMR spectroscopy and PXRD. Based on the established isostructurality of 3 
malate and 3 citrate, a succinate salt of 3 was assumed in this case. The 
PXRD traces of the three salts were very similar, as shown in Figure 4.21 
below, proving that indeed the three salts were isostructural and had similar 
packing characteristics. 
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Figure 4.21: PXRD traces of 3 malate, citrate and succinate. 
4.5.7 Other Salts of 3 
Salt formation is a classical technique usually applied to modify and 
optimize the physicochemical properties of an ionizable compound. 
Pharmaceutically acceptable counterions are often used to influence 
properties such as solubility, dissolution rate, hygroscopicity, thermal 
stability, impurity profiles, compressibility, and crystal habit.14–16 Examples 
of anionic counter-ions commonly used for salt formation with basic active 
pharmaceutical ingredients (APIs) are summarised in Figure 4.22 below. 
Figure 4.22: Distribution (2002–2006) of anions commonly used with basic APIs containing 
at least one atom suitable for protonation.14  
In this thesis work, salts of 3 were prepared by direct acid addition, whereby 
an equimolar amount of the acid was added to a solution of 3 in chloroform. 
The precipitate that formed was washed with chloroform and dried in vacuo. 
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These products included the hydrochloride, hydrobromide, sulfate, 
phosphate, and methanesulfonate (mesylate) salts of 3. These, together with 
the salts of 3 with the aforementioned dicarboxylic acids, were then 
subjected to kinetic solubility studies. 
4.5.8 Kinetic Solubility by HPLC 
A protocol similar to the turbidimetric assay method was employed to 
determine the aqueous solubility of the above-mentioned salts. However, 
instead of taking the concentration at which solids form in PBS solution as 
the solubility, the exact amount of compound 3 in a 200 μM solution in PBS 
pH 7.4 (2% DMSO) was determined by a HPLC method. A 9-point calibration 
curve was prepared using solutions of 3 in DMSO [5, 10, 20, 25, 40, 80, 
160, 200, and 250 μM: Appendix A5 (R2 = 0.9998)]. Table 4.13 below 
summarizes the observed solubilities of the studied salts. Notably, the 
solubility of 3 as determined by HPLC was 21 μM compared to 80 μM 
observed with the turbidimetric method. This further highlights the fact that 
the turbidimetric solubility method is less accurate than HPLC, and is thus 
prone to overestimating solubility values. All the salts, except the malate, 
had improved solubility, albeit modest, in the range of 1.5- to 2-fold 
increase. 3 mesylate exhibited the best aqueous solubility of 38 μM. 
Table 4.13: Kinetic solubility (HPLC) results and melting points for the various salts of 3. 
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Table 4.13: Kinetic solubility (HPLC) results and melting points for the various salts of 3. 







3 hydrochloride 3.HCl 299–304 31 
3 hydrobromide 3.HBr 289–292 36 
3 sulfate 3.H2SO4 228–230 29 
3 phosphate 3.H3PO4 225–226 30 
3 mesylate 3.CH3SO3H 299–302 38 
4.6 Conclusion 
This chapter described the studies conducted with respect to 
physicochemical profiling and supramolecular derivatization. 
Physicochemical profiling revealed that the 2-aminoquinazolinones (AQZs) 
and benzoxazole-based oximes (BZOs) occupy different chemical spaces 
[Mwt and cLogP], which are distinct from that occupied by a majority of the 
conventional anti-TB drugs. Very few violations of the Lipinski’s RO5 were 
observed. In addition, the SPR studies showed that solubility was 
moderately correlated to HPLC retention time (tR) [R2 = 0.49 for AQZs and 
0.65 for BZOs] and TLC retardation factor (Rf) [R2 = 0.64 for AQZs and 0.57 
for BZOs], weakly correlated to cLogP [R2 = 0.37 for AQZs and 0.30 for 
BZOs], whereas no correlation was observed with melting point [R2 < 0.05 
for both classes]. 
Formation of cocrystals of 3 with selected potential co-formers was 
attempted. However, all attempts resulted in salt formation, which was 
attributed to the transfer of a proton from the acidic co-former to the 
quinazolinone nitrogen atom N4. All the salts had a moderate improvement 
in solubility at pH 7.4 in the range of 1.5- to 2-fold that of 3 (21 μM), except 
3 malate, which recorded a decline (7 μM). Moreover, the higher melting 
points of all the salts indicate improved thermal stability. Attempts to 
complex 3 with the native cyclodextrins [-, -, and γ-CD] by co-precipitation 
using water as the solvent were unsuccessful.  
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CHAPTER 5  
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS FOR 
FUTURE WORK 
5.1 Summary and Conclusions 
This thesis work aimed to optimize previously identified antimycobacterial 
benzoheterocyclic hit compounds containing either the quinazolin-4(3H)-one 
or the benzoxazole scaffold. Classical hit-to-lead optimization strategies were 
adapted in order to achieve the overall objective of investigating the 
antimycobacterial structure-activity relationship (SAR) profiles. An attendant 
aim was to explore structure-property relationships (SPR) for the target 
compounds and perform supramolecular derivatization of selected 
analogues. 
The first aim of the study was to design, synthesize, and characterize novel 
2-aminoquinazolinone and benzoxazole-based oxime analogues. Several new 
benzoheterocycles were designed by employing rational medicinal chemistry 
principles, and thereafter successfully synthesized in accordance with 
protocols adapted from literature. All the synthesized compounds were fully 
characterized using spectroscopic techniques such as NMR spectroscopy; 
chromatographic methods, including TLC and HPLC-MS; along with 
physicochemical attributes such as appearance, melting point, and aqueous 
solubility. 
The second objective of the study was to biologically evaluate the 
synthesized compounds for their in vitro antimycobacterial potency, 
cytotoxicity, in vitro and in vivo DMPK profiles, and in vivo efficacy [proof-of-
concept studies]. Accordingly, the 2-aminoquinazolinone analogues 
manifested clear SAR trends (Figure 5.1 below) following in vitro evaluation 
of their antimycobacterial activity against the drug-susceptible Mtb H37Rv 
strain cultured in GAST-Fe and 7H9/ADC media. In addition, the selected 
potent compounds exhibited low cytotoxicity against the CHO and HepG2 
cell lines, as well as high microsomal metabolic stability in MLM. Besides, 
the proposed hypothesis behind the design of the sulfoxide-based analogue 
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3 [Figure 5.1: Ar1 = 3−SOMePh; Ar2 = 4−CF3Ph] was supported by 
experimental findings.  
 
Figure 5.1: Summary of the antimycobacterial SAR for the 2-aminoquinazolinones. 
The empirical evidence behind this was provided by the extensive in vivo 
biotransformation of 3 in mice to the equally active but more metabolically 
stable sulfone-based analogue 2 [Figure 5.1: Ar1 = 3−SO2MePh; Ar2 = 
4−CF3Ph]. Both compounds exhibited favourable pharmacokinetic profiles 
and were well tolerated at the highest administered dose of 300 mg/kg. 
Despite the good pharmacological profiles exhibited by the 2-
aminoquinazolinones, the frontrunner analogue 3 was devoid of in vivo 
efficacy in an acute TB infection mouse model [BALB/c] at 100 and 200 
mg/kg doses. 
Further studies, including the use of different in vitro assay conditions such 
as glycerol-free media, revealed that the 2-aminoquinazolinones killed Mtb in 
vitro via a glycerol-dependent mechanism of action, hence lacking in vivo 
efficacy. These findings correlated well with the results of studies on 
generation of spontaneous resistant mutants, whereby all strains resistant 
to 3 had mutations mapping to the glycerol metabolism genes, which encode 
for glycerol kinase (glpK) and glycerol-3-phosphate dehydrogenase (glpD2). 
Overall, these biological studies highlighted the importance of developing 
and applying in vitro antimycobacterial phenotypic screening conditions, in 
the early drug discovery stages, which are reflective of the in vivo biological 
 Ar1 = Phenyl 
• Meta substituents R1 
enhance activity: −CF3, 
−SO2Me, −SOMe, −CONH2 
[0.3–1.2 μM]; −NMe2, −t-Bu, 
−OMe, −Cl [2.5–20 μM] 
• Inactive meta R1: H, 
−SO2NH2, −CN, −F, −NH
2
  
[40–>160 μM]  
• Ortho & para substituents: 
inactive; −SO2Me, −Cl, −t-Bu 
[>160 μM] 
 Ar1 = Heterocycles: 
• 3-Pyridyl: [0.6 μM] (few 
substituents tolerated) 
• 4-Pyridyl, Thienyl, 
Pyrazolyl: inactive 
SAR 1 SAR 2 
 Ar2 = Phenyl 
• Para substituents  R2 
enhance activity: −CF3, −Me, 
−F [1.2–4.9 μM]; −OMe, −CN, 
H [6.8–33.4 μM] 
• Inactive para R2: −SO2Me, 
−OH [>125 μM]  
• Meta substituents: neutral; 
−CF3, −CN [14.8–43 μM] 
• Ortho substituents: 
inactive; −CF3, −F [>160 μM] 
 Ar2 = Heterocycles:  Active; 
 4-Pyridyl (4−CF3) [0.9 μM] 
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conditions during TB infection. 
Benzoxazole-based oximes, on the other hand, exhibited a tight SAR, with 
only SAR 2 modifications being tolerated. As such, all attempts to introduce 
changes at SAR 1 and SAR 3 (Figure 5.2) yielded inactive compounds.  
Figure 5.2: Summary of the antimycobacterial SAR for the benzoxazole-based oximes. 
To this end, although the active compounds exhibited low in vitro 
cytotoxicity against the CHO cells, the low microsomal metabolic stability 
exhibited by the representative compound (46) [7.3% remaining after 30 
minutes in MLM] was the major impediment to advancing the active 
benzoxazole-based oximes to the other studies in the screening cascade.  
The third objective of the study was to profile all final target compounds 
with respect to physicochemical properties, including aqueous solubility, 
deduce structure−property relationships (SPR), and carry out 
supramolecular derivatization of selected potent compounds. Therefore, all 
target compounds were subjected to aqueous solubility studies, wherein the 
turbidimetric assay method was employed. The solubility values obtained 
were then correlated with the experimentally determined melting points, 
HPLC retention times (tR), TLC retardation factors (Rf) as well as the virtually 
predicted physicochemical properties such as cLogP, in order to establish 
structure-property relationships (SPR). In effect, correlations were deduced, 
and tR [R2 = 0.49 for AQZs and 0.65 for BZOs] and Rf [R2 = 0.64 for AQZs 
and 0.57 for BZOs] were found to be the most correlated factors with 
aqueous solubility, albeit moderate. 
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Further, compound 3 was selected for supramolecular derivatization studies 
in an effort to enhance its aqueous solubility [kinetic (HPLC) solubility of 3 = 
21 μM], which involved formation of cocrystals, salts, and cyclodextrin 
inclusion complexes. The crystal structure of 3 revealed the molecular 
geometry and the main intermolecular interactions, which facilitated the 
selection of potential co-formers for co-crystallization. All attempts to 
synthesize cocrystals were, however, unsuccessful, as salts were formed 
instead. All the new solid states of 3 were characterized by XRD, thermal 
analysis, NMR spectroscopy, and thereafter subjected to solubility 
assessment by HPLC. In effect, only a moderate increase in solubility was 
observed in the salts of 3, whereby the 3 mesylate exhibited the most 
improved solubility in the range of 2-fold increase (38 μM).  
5.2 Recommendations for Future Work 
Based on the good pharmacological profiles exhibited by the 2-
aminoquinazolinones, it will be worthwhile to test these compounds in other 
disease models.  
More quinazolinone analogues with improved solubility can be designed by 
adapting other strategies of solubility enhancement. For instance, a fluoro or 
a methyl substituent can be introduced at the ortho-position of the phenyl 
ring on the left-hand side (Figure 5.3 I), in order to increase the dihedral 
angle and therefore twist the ring out of coplanarity with the fused 
quinazolinone ring system. This will in turn reduce crystal stacking and 
thus the potential to improve aqueous solubility. Another viable approach 
for solubility improvement will be to remove the aromaticity of the phenyl 
rings in order to reduce the associated - stacking (Figure 5.3 II). 
 
Figure 5.3: Proposed 2-aminoquinazolinone analogues with potential to exhibit improved solubility. 
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Furthermore, the salts of 3 can be studied for other beneficial effects they 
may have besides the enhanced solubility and melting point. Indeed, it will 
be quite informative to investigate how the dissolution rates of these salts 
would compare to that of the parent compound. In addition, permeability 
studies can be conducted on selected analogues using the in vitro Caco-2 
assay or in silico permeability prediction. This will provide valuable 
information regarding whether or not permeability would compensate for the 
observed low solubility to yield acceptable oral absorption. 
As for the benzoxazole-based oximes, the only active compounds were those 
bearing a dimethyl carbamate-functionalized oxime moiety, while the free 
oxime-bearing counterparts were not. Given the low metabolic stability of 
these compounds, it was hypothesized (Chapter 3, Figure 3.10) that they 
could have a prodrug mode of action, wherein they are metabolised 
intracellularly to the active free oxime-based metabolites by the Mtb 
esterases and amidases. This can be a platform for future prospects towards 
exploring these hypotheses, which can be two-fold: Firstly, studies regarding 
permeability into cells can be initiated to test the hypothesis that the free 
oximes do not penetrate the Mtb cells and hence inactive, while the dimethyl 
carbamate-bearing counterparts permeate the cells. The second stage of 
investigations would involve studies to monitor the metabolism of the active 
compounds inside the Mtb cells, to prove that indeed the free oximes are the 
active metabolites. The results of these studies can further be augmented by 
mechanistic deconvolution of the mode of action(s) involved, which will 
provide valuable insights into the underlying subcellular compound-target 
interactions. Moreover, intracellular antimycobacterial assays in 
macrophages is another possible and viable area for exploration. 
Finally, supramolecular derivatization can be applied on the potent 
benzoxazole-based oximes, which may generate interesting derivatives with 
better physicochemical attributes. In this regard, the more soluble 
amorphous cyclodextrin derivatives, such as 2-hydroxypropyl- and 
sulfobutyl ether--CD, can be prioritized due to their potential to 
significantly improve the solubility of poorly soluble compounds. 
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CHAPTER 6  
EXPERIMENTAL 
6.1 Chapter Overview 
Chapter 6 supplements the result-oriented Chapters 2, 3, and 4 by 
describing the experimental protocols involved, particularly those that are 
not outlined in the main text. In addition, this chapter provides the complete 
set of characterization information with respect to all the synthesized 
compounds.  
6.2 Chemistry 
6.2.1 Reagents and Solvents  
All commercially available chemicals and reagents were purchased from 
either Sigma-Aldrich (South Africa) or Combi-Blocks Limited (USA), and 
were used without prior purification. Besides, anhydrous solvents such as 
1,4-dioxane, acetonitrile, and DMF were purchased as such from Sigma-
Aldrich, South Africa. In addition, column chromatography solvents, for 
example ethyl acetate (EtOAc), dichloromethane (DCM), hexane (Hex), and 
methanol (MeOH), were purchased as Analytical Reagent (AR grade) solvents 
from Kimix Chemicals, South Africa, and used directly. HPLC grade 
acetonitrile and methanol for LC-MS mobile phase preparation were 
purchased from Romil Ltd (Cambridge, UK). 
6.2.2 Physical and Spectroscopic Characterization 
Melting points were determined using STUART® SMP 40 automatic melting 
point apparatus, and are reported as uncorrected values. 
NMR spectra were recorded on a Varian Mercury spectrometer [1H: 300 
MHz; 13C: 75 MHz], Bruker Ultrashield-Plus spectrometer [1H: 400 MHz; 13C: 
101 MHz], or Bruker Ascend™-600 spectrometer [1H: 600 MHz; 13C: 150 
MHz]. Samples for NMR spectroscopy were dissolved in deuterated solvents 
such as dimethylsulfoxide (DMSO-d6), chloroform (CDCl3), or methanol 
(Methanol-d4). Chemical shifts (δ) are reported in parts per million (ppm) and 
rounded off to two decimal places, while coupling constants (J) are reported 
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in Hertz (Hz), and rounded off to one decimal place. Abbreviations used to 
describe lH-NMR signal multiplicities are: br (broad), d (doublet), dd (doublet 
of doublets), ddd (doublet of doublet of doublets), dddd (doublet of doublet of 
doublet of doublets), dt (doublet of triplets), dtd (doublet of triplet of 
doublets), hept (heptet), m (multiplet), q (quartet), s (singlet), t (triplet), td 
(triplet of doublets), tdd (triplet of doublet of doublets), and tt (triplet of 
triplets). 13C-NMR spectra were recorded in the complete proton-decoupled 
mode, and the chemical shifts are listed without assigning them to the 
corresponding carbon atoms; a format accepted by most international 
journals. 
6.2.3 Chromatography 
Target compound peak purity, retention time, and molecular ion were 
determined on an Agilent HPLC system, which was equipped with Agilent 
1260® Infinity Binary Pump, Agilent 1260® Infinity Diode Array Detector, 
Agilent 1290® Infinity Column Compartment, Agilent 1260® Infinity 
Autosampler, low resolution Agilent 6120® Quadrupole mass spectrometer, 
and Peak Scientific® Genius 1050 Nitrogen Generator. The reverse-phase 
column used was an X-bridge® C18; 2.5 μm (particle size); 3.0 mm (internal 
diameter) × 50 mm (length); and maintained at 35 °C. Table 6.14 below lists 
the composition, and the gradient conditions of the mobile phase used at a 
flow rate of 0.9 mL/min. The injection volume was 2 μL while the mass 
spectra were obtained through the Electron Spray Ionization (ESI) as well as 
the Atmospheric Pressure Chemical Ionization (APCI), which were set up in 
either positive or negative mode of ionization. The diode array detector (DAD) 
was programmed to scan the eluents at absorption wavelengths ranging 
from 210 to 640 nm. All the reported LC-MS purity values are based on the 
maximum chromatograms resulting from the DAD [210–640 nm] scans. 
Table 6.14: LC-MS Gradient conditions. 
Time 
(min) 
% A % B 
Composition 
A B 
0.00-1.00 90 10 10 mM ammonium 
acetate buffer (0.4% 
acetic acid) 
10 mM ammonium 
acetate (0.4% acetic 
acid) in 90% HPLC 
grade MeOH in H2O 
1.00-3.00 5 95 
3.00-5.00 5 95 
5.00-6.50 90 10 
6.50-7.00 90 10 
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Reactions were monitored by analytical thin layer chromatography (TLC) 
using Fluka or Merck F254 aluminium-backed pre-coated silica gel plates, 
which were visualized under UV light at a wavelength of 254 or 366 nm, and 
in some instances, staining was performed to facilitate direct visualization. 
Gravity column chromatography was performed using Merck Kieselgel® 60 
[70–230 mesh] silica gel, while Biotage SNAP® cartridges were packed with 
40–65 μm diameter KP-Sil silica gel for flash column chromatography on a 
Biotage Isolera One® system (Biotage AB, Uppsala, Sweden). 
6.2.4 Synthesis and Characterization 
6.2.4.1 2-Aminoquinazolinones 
Protocols reported in literature were adapted and applied in the synthesis of 
the target compounds belonging to the 2-aminoquinazolinone series.1–3 
General procedure 1: Synthesis of intermediates 2.1a–2.1d 
A solution of 2-amino-5-iodobenzoic acid (1.0 Eq) and the appropriate aryl 
isothiocyanate (1.0 Eq) in anhydrous 1,4-dioxane (4 mL/mmol) was treated 
with triethylamine (1.5 Eq) at ambient room temperature. This solution was 
then heated under reflux for 6 hours, cooled to room temperature, and the 
solids that formed filtered, triturated with diethyl ether, and dried in vacuo 
to furnish the desired 2-thioxo-quinazolinone-based intermediate. 
6-Iodo-2-thioxo-3-(4-(trifluoromethyl)phenyl)-2,3-dihydroquinazolin-4(1H)-one, 2.1a 
White solid (6.85 g, 89%); Rf (EtOAc:Hex, 1:4) 0.33; 1H NMR (400 MHz, 
DMSO-d6) δ 13.15 (br s, 1H, H6), 8.18 (d, J = 2.0 Hz, 
1H, H1), 8.08 (dd, J = 8.6, 2.0 Hz, 1H, H2), 7.86 (d, J 
= 8.2 Hz, 2H, H5), 7.54 (d, J = 8.2 Hz, 2H, H4), 7.25 
(d, J = 8.6 Hz, 1H, H3); 13C NMR (101 MHz, DMSO-
d6) δ 175.77, 158.62, 143.84, 142.92, 139.21, 
135.32, 130.34 (2C), 128.99, 128.68, 126.22, 
126.19, 118.38, 118.12, 87.82; LC-MS (APCI/ESI): 
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White solid (3.77 g, 87%); Rf (EtOAc:Hex, 2:8) 0.35; 1H NMR (400 MHz, DMSO-d6) 
δ 13.07 (br s, 1H, H6), 8.19 (d, J = 2.0 Hz, 1H, H1), 8.08 (dd, 
J = 8.6, 2.0 Hz, 1H, H2), 7.51–7.45 (m, 2H, H5), 7.44–7.39 
(m, 1H, H7), 7.30–7.23 (m, 3H, H3,4); 13C NMR (101 MHz, 
DMSO-d6) δ 176.58, 159.02, 144.08, 139.59, 135.76, 
129.38 (5C), 128.64, 118.72, 118.43, 88.02; LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.35 min, m/z [M+H]+ = 
380.9. 
6-Iodo-2-thioxo-3-(p-tolyl)-2,3-dihydroquinazolin-4(1H)-one, 2.1c  
White solid (4.22 g, 86%); Rf (EtOAc:Hex, 1:4) 0.34; 1H NMR (400 MHz, 
DMSO-d6) δ 13.02 (br s, 1H, H6), 8.18 (d, J = 2.0 Hz, 
1H, H1), 8.07 (dd, J = 8.6, 2.0 Hz, 1H, H2), 7.28 (d, J 
= 8.2 Hz, 2H, H4), 7.25 (d, J = 8.6 Hz, 1H, H3), 7.13 
(d, J = 8.2 Hz, 2H, H5), 2.38 (s, 3H, H7); 13C NMR 
(101 MHz, DMSO-d6) δ 176.70, 159.08, 144.06, 
139.50, 137.98, 137.01, 135.78, 129.94 (2C), 129.06 
(2C), 118.69, 118.41, 88.05, 21.27; LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.48 min, m/z [M+H]+ = 395.0 
6-Iodo-2-thioxo-3-(3-(trifluoromethyl)phenyl)-2,3-dihydroquinazolin-4(1H)-one, 2.1d 
Off-white solid (4.06 g, 86%); Rf (EtOAc:Hex, 3:7) 0.67; 1H NMR (400 MHz, DMSO-
d6) δ 12.17 (br s, 1H, H8), 8.20 (d, J = 2.0 Hz, 1H, H1), 
8.10 (dd, J = 8.6, 2.0 Hz, 1H, H2), 7.83–7.70 (m, 3H, 
H5,6,7), 7.64 (d, J = 7.8 Hz, 1H, H5), 7.29 (d, J = 8.6 Hz, 
1H, H3); 13C NMR (101 MHz, DMSO-d6) δ 176.36, 
159.14, 144.18, 140.40, 139.63, 135.71, 134.00, 
130.62, 130.41, 130.09, 126.75, 125.57, 118.83, 
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General procedure 2: Synthesis of intermediates 2.2a–2.2d 
A suspension of intermediate 2.1 (a–d) (1.0 Eq) in phosphorus oxychloride 
(POCl3) (23.9 Eq) was treated with phosphorus pentachloride (PCl5) (1.7 Eq) 
in one portion, stirred at room temperature for 15 minutes, and then heated 
at 110 °C for 12–15 hours. The solution was then cooled to room 
temperature and concentrated to yield a residue that was taken up in ethyl 
acetate (EtOAc). This mixture was added dropwise into a stirred 
ice/saturated sodium bicarbonate mixture. The organic layer was then 
separated, washed with water, brine, dried with anhydrous sodium sulfate, 
and concentrated under reduced pressure. The residue was then triturated 
by stirring in diethyl ether, filtered and dried to afford the desired 
intermediate 2.2 (a–d), which was used in the subsequent step without 
further purification. 
2-Chloro-6-iodo-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 2.2a
Off-white solid (5.77 g, 85%); Rf (EtOAc:Hex, 1:9) 0.32; 1H NMR (400 MHz, 
DMSO-d6) δ 8.38 (d, J = 2.1 Hz, 1H, H1), 8.20 (dd, J 
= 8.5, 2.1 Hz, 1H, H2), 7.97 (d, J = 8.3 Hz, 2H, H5), 
7.79 (d, J = 8.2 Hz, 2H, H4), 7.50 (d, J = 8.5 Hz, 1H, 
H3); 13C NMR (101 MHz, DMSO-d6) δ 160.21, 
145.82, 143.91, 143.84, 141.16, 135.03, 130.20, 
130.04 (2C), 129.87, 128.83, 126.75, 126.71, 
122.60, 92.78; LC-MS (APCI/ESI): Purity = 98%, tR = 
4.83 min, m/z [M+H]+ = 450.9. 
2-Chloro-6-iodo-3-phenylquinazolin-4(3H)-one, 2.2b
White solid (2.91 g, 75%); Rf (EtOAc:Hex, 3:17) 0.51; 1H NMR (400 MHz, 
DMSO-d6) δ 8.17 (d, J = 2.1 Hz, 1H, H1), 7.99 (dd, J = 
8.6, 2.1 Hz, 1H, H2), 7.50–7.46 (m, 2H, H5), 7.46–7.40 
(m, 1H, H6), 7.35–7.29 (m, 2H, H4), 7.07 (d, J = 8.6 Hz, 
1H, H3); 13C NMR (101 MHz, DMSO-d6) δ 161.47, 
150.40, 143.63, 139.86, 135.98, 135.89, 129.44 (2C), 
129.25 (2C), 128.63, 118.13, 117.00, 85.51; LC-MS 
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(APCI/ESI): Purity = 97%, tR = 4.55 min, m/z [M+H]+ = 382.9. 
2-Chloro-6-iodo-3-(p-tolyl)quinazolin-4(3H)-one, 2.2c 
White solid (3.0 g, 73%); Rf (EtOAc:Hex, 1:4) 0.58; 1H NMR (400 MHz, 
DMSO-d6) δ 8.37 (d, J = 2.1 Hz, 1H, H1), 8.19 (dd, J 
= 8.5, 2.1 Hz, 1H, H2), 7.49 (d, J = 8.5 Hz, 1H, H3), 
7.36 (s, 4H, H4,5), 2.41 (s, 3H, H6); 13C NMR (101 
MHz, DMSO-d6) δ 160.69, 146.20, 145.45, 144.03, 
139.55, 135.46, 130.37 (2C), 129.77, 129.15, 128.74 
(2C), 123.01, 92.99, 21.27; LC-MS (APCI/ESI): Purity 
= 98%, tR = 4.74 min, m/z [M+H]+ = 397.0 
2-Chloro-6-iodo-3-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 2.2d 
Off-white solid (2.46 g, 63%); Rf (EtOAc:Hex, 1:9) 0.35; 1H NMR (400 MHz, 
DMSO-d6) δ 8.40 (d, J = 2.1 Hz, 1H, H1), 8.22 (dd, J 
= 8.5, 2.1 Hz, 1H, H2), 8.06 (s, 1H, H4), 7.93 (d, J = 
7.5 Hz, 1H, H5), 7.91–7.80 (m, 2H, H6,7), 7.52 (d, J = 
8.5 Hz, 1H, H3); 13C NMR (101 MHz, DMSO-d6) δ 
160.71, 146.19, 144.52, 144.23, 138.72, 135.42, 
133.63, 131.25, 130.85, 130.53, 129.21, 126.89, 
126.39, 122.99, 93.14; LC-MS (APCI/ESI): Purity = 
98%, tR = 4.83 min, m/z [M+H]+ = 450.9. 
General procedure 3: Synthesis of intermediates 2.3a–2.3d 
To a solution of N,N-Diisopropylethylamine (DIPEA) (2.0 Eq) and 4-
methoxybenzylamine (1.3 Eq) in DMF, the appropriate intermediate 2.2 (a–
d) (1.0 Eq) was added portionwise. The solution was then heated at 80 °C for 
4 h, cooled to room temperature, and diluted with EtOAc. The organic layer 
was washed with 5% LiCl (×4), brine (×3), dried over anhydrous sodium 
sulfate, and concentrated to yield a yellow semisolid, which was triturated in 
diethyl ether, filtered, and dried in vacuo to furnish intermediate 2.3 (a–d). 
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Yellow solid (6.0 g, 87%); Rf (EtOAc:Hex, 1:4) 0.32; 1H NMR (400 MHz, 
DMSO-d6) δ 8.13 (d, J = 2.2 Hz, 1H, H1), 7.95 
(d, J = 8.2 Hz, 2H, H5), 7.85 (dd, J = 8.7, 2.2 
Hz, 1H, H2), 7.65 (d, J = 8.1 Hz, 2H, H4), 7.22 
(d, J = 8.8 Hz, 2H, H8), 7.09 (d, J = 8.7 Hz, 1H, 
H3), 6.83 (d, J = 8.8 Hz, 2H, H9), 6.65 (d, J = 
5.9 Hz, 1H, H6), 4.42 (d, J = 5.9 Hz, 2H, H7), 
3.69 (s, 3H, H10); 13C NMR (101 MHz, DMSO-
d6) δ 160.62, 158.18, 150.21, 149.20, 142.69, 
138.67, 134.57, 131.64, 130.59 (2C), 130.10, 129.79, 128.50 (2C), 127.37, 
127.34, 127.21, 119.12, 113.62 (2C), 84.35, 55.11, 43.80; LC-MS 
(APCI/ESI): Purity = 98%, tR = 5.20 min, m/z [M+H]+ = 552.0. 
6-Iodo-2-((4-methoxybenzyl)amino)-3-phenylquinazolin-4(3H)-one, 2.3b 
Off-white solid (2.57 g, 72%); Rf (EtOAc:Hex, 1:4) 0.20; 1H NMR (400 MHz, 
DMSO-d6) δ 8.15 (d, J = 2.2 Hz, 1H, H1), 7.86 
(dd, J = 8.6, 2.2 Hz, 1H, H2), 7.64–7.58 (m, 2H, 
H5), 7.58–7.53 (m, 1H, H6), 7.41–7.36 (m, 2H, 
H4), 7.23 (d, J = 8.8 Hz, 2H, H9), 7.10 (d, J = 
8.6 Hz, 1H, H3), 6.84 (d, J = 8.8 Hz, 2H, H10), 
6.41 (t, J = 5.9 Hz, 1H, H7), 4.44 (d, J = 5.9 Hz, 
2H, H8), 3.71 (s, 3H, H11); 13C NMR (101 MHz, 
DMSO-d6) δ 161.01, 158.57, 150.97, 149.51, 
142.92, 135.11, 135.00, 132.06, 130.63 (2C), 129.90, 129.57 (2C), 128.92 
(2C), 127.56, 119.64, 114.02 (2C), 84.64, 55.49, 44.26; LC-MS (APCI/ESI): 
Purity = 98%, tR = 4.87 min, m/z [M+H]+ = 484.0. 
6-Iodo-2-((4-methoxybenzyl)amino)-3-(p-tolyl)quinazolin-4(3H)-one, 2.3c 
Yellow solid (3.0 g, 82%); Rf (EtOAc:Hex, 1:4) 0.31; 1H NMR (400 MHz, 
DMSO-d6) δ 8.14 (d, J = 2.2 Hz, 1H, H1), 7.85 (dd, J = 8.6, 2.2 Hz, 1H, H2), 
7.40 (d, J = 8.6 Hz, 2H, H9), 7.27–7.21 (m, 4H, H4,5), 7.10 (d, J = 8.6 Hz, 1H, 
H3), 6.84 (d, J = 8.6 Hz, 2H, H10), 6.40 (t, J = 5.9 Hz, 1H, H7), 4.43 (d, J = 
5.9 Hz, 2H, H8), 3.71 (s, 3H, H11), 2.42 (s, 3H, H6); 13C NMR (101 MHz, 
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DMSO-d6) δ 161.08, 158.57, 151.11, 149.51, 
142.88, 139.34, 135.01, 132.42, 132.11, 
131.20 (2C), 129.26 (2C), 128.98 (2C), 127.56, 
119.63, 114.01 (2C), 84.61, 55.49, 44.23, 
21.34; LC-MS (APCI/ESI): Purity = 99%, tR = 
4.90 min, m/z [M+H]+ = 498.1.   
6-Iodo-2-((4-methoxybenzyl)amino)-3-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 2.3d 
Yellow solid (1.67 g, 58%); Rf (EtOAc:Hex, 1:4) 0.33; 1H NMR (400 MHz, 
DMSO-d6) δ 8.15 (d, J = 2.1 Hz, 1H, H1), 7.95–
7.79 (m, 4H, H2,4,6,7), 7.74 (d, J = 8.7 Hz, 1H, 
H5), 7.25 (d, J = 8.7 Hz, 2H, H10), 7.11 (d, J = 
8.6 Hz, 1H, H3), 6.85 (d, J = 8.7 Hz, 2H, H11), 
6.69 (t, J = 5.8 Hz, 1H, H8), 4.49 (d, J = 5.8 Hz, 
2H, H9), 3.71 (s, 3H, H12); 13C NMR (101 MHz, 
DMSO-d6) δ 161.13, 158.58, 150.76, 149.60, 
143.03, 136.10, 134.99, 134.14, 132.04, 
131.76, 128.88 (2C), 128.75, 127.59, 127.12, 126.84, 125.66, 119.60, 
113.99 (2C), 84.67, 55.50, 44.22; LC-MS (APCI/ESI): Purity = 97%, tR = 5.16 
min, m/z [M+H]+ = 552.0. 
General procedure 4: Synthesis of intermediates 2.4a–2.4d 
The appropriate intermediate 2.3 (a–d) (1.0 Eq) was dissolved in 
trifluoroacetic acid (TFA) (63.4 Eq) and heated under reflux at 85 °C for 48 
hours, or under microwave conditions at 110 °C for 20 minutes. The 
solution was then cooled to room temperature, concentrated under reduced 
pressure, and the residue resuspended in DCM. This suspension was added 
portionwise to a stirred ice/saturated sodium bicarbonate mixture, and the 
organic phase was separated together with the solids. Diethyl ether (Et2O) 
was added to the DCM suspension in a ratio of DCM:Et2O (1:1), followed by 
filtration of the solids, which were then triturated with Et2O, and dried to 
afford the desired intermediate 2.4 (a–d).  
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White solid (3.96 g, 85%); Rf (EtOAc:Hex, 2:3) 0.22; 1H NMR (400 MHz, 
DMSO-d6) δ 8.12 (d, J = 2.2 Hz, 1H, H1), 7.91 (d, J = 
8.2 Hz, 2H, H5), 7.86 (dd, J = 8.7, 2.2 Hz, 1H, H2), 
7.62 (d, J = 8.1 Hz, 2H, H4), 7.06 (d, J = 8.7 Hz, 1H, 
H3), 6.61 (br s, 2H, H6); 13C NMR (101 MHz, DMSO-
d6) δ 160.63, 151.82, 149.58, 142.69, 139.07, 
134.64, 130.21 (2C), 129.97, 129.66, 127.22, 
127.18, 126.41, 118.83, 84.06; LC-MS (APCI/ESI): 
Purity = 99%, tR = 4.6 min, m/z [M+H]+ = 432.0. 
2-Amino-6-iodo-3-phenylquinazolin-4(3H)-one, 2.4b 
Light brown crystals (1.06 g, 69%); Rf (EtOAc:Hex, 4:1) 0.38; 1H NMR (400 
MHz, DMSO-d6) δ 8.14 (d, J = 2.2 Hz, 1H, H1), 7.86 (dd, 
J = 8.7, 2.2 Hz, 1H, H2), 7.62–7.55 (m, 2H, H5), 7.55–
7.49 (m, 1H, H6), 7.41–7.32 (m, 2H, H4), 7.07 (d, J = 8.7 
Hz, 1H, H3), 6.39 (s, 2H, H7); 13C NMR (101 MHz, 
DMSO-d6) δ 161.07, 152.61, 150.07, 142.89, 135.65, 
135.05, 130.46 (2C), 129.75, 129.20 (2C), 126.92, 
119.45, 84.31; LC-MS (APCI/ESI): Purity = 97%, tR = 
4.23 min, m/z [M+H]+ = 364.0. 
2-Amino-6-iodo-3-(p-tolyl)quinazolin-4(3H)-one, 2.4c 
White solid (1.88 g, 86%); Rf (EtOAc:Hex, 1:1) 0.39; 1H NMR (400 MHz, 
DMSO-d6) δ 8.13 (d, J = 2.2 Hz, 1H, H1), 7.84 (dd, J = 
8.7, 2.2 Hz, 1H, H2), 7.37 (d, J = 8.5 Hz, 2H, H4), 
7.22 (d, J = 8.5 Hz, 2H, H5), 7.05 (d, J = 8.7 Hz, 1H, 
H3), 6.37 (br s, 2H, H7), 2.40 (s, 3H, H6); 13C NMR 
(101 MHz, DMSO-d6) δ 161.14, 152.78, 150.07, 
142.85, 139.17, 135.06, 133.01, 131.00 (2C), 128.90 
(2C), 126.91, 119.43, 84.28, 21.33; LC-MS 
(APCI/ESI): Purity = 99%, tR = 4.34 min, m/z [M+H]+ = 378.0. 
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White solid (0.97 g, 78%); Rf (EtOAc:Hex, 1:1) 0.30; 1H NMR (400 MHz, 
DMSO-d6) δ 8.14 (d, J = 2.1 Hz, 1H, H1), 7.91–7.83 
(m, 3H, H2,4,5), 7.80 (t, J = 7.9 Hz, 1H, H6), 7.70 (d, J 
= 7.9 Hz, 1H, H5), 7.07 (d, J = 8.7 Hz, 1H, H3), 6.59 
(br s, 2H, H8); 13C NMR (101 MHz, DMSO-d6) δ 
161.20, 152.38, 150.21, 142.99, 136.54, 135.03, 
133.78, 131.59, 131.31, 130.99, 126.93, 126.71, 
122.96, 119.34, 84.28; LC-MS (APCI/ESI): Purity = 
98%, tR = 4.65 min, m/z [M+H]+ = 432.0. 
General procedure 5: Suzuki-Miyaura cross-coupling reaction for the 
synthesis of SAR 1 2-aminoquinazolinone target compounds 2–31 
To a solution of 2-amino-6-iodo-3-(4-(trifluoromethyl)phenyl)quinazolin-
4(3H)-one [2.4a] (0.2 g, 0.46 mmol, 1.0 Eq) and the appropriate arylboronic 
acid or ester (1.2 Eq) in 1,4-dioxane (1.84 mL), was added a solution of 
cesium carbonate (3.0 Eq) in water (0.46 mL). This mixture was treated with 
PdCl2(dppf)-CH2Cl2 (0.1 Eq), and heated at 80 °C for 1–3 hours, while 
monitoring the reaction for completeness using TLC and LC-MS. After 
cooling to room temperature, the mixture was diluted with EtOAc, then 
washed with water, brine, dried over anhydrous sodium sulphate, and 
filtered through a pad of celite. The filtrate was then concentrated under 
reduced pressure to yield a residue that was purified by flash column 
chromatography using Biotage Isolera One® machine, SiO2 (10 g cartridge), 
and EtOAc/Hexane mixture, with fractions being collected at the λmax 
(determined by LC-MS) and monitored at 254 nm. Finally, the solvents were 
rotary evaporated to give a solid that was then triturated with Et2O or 
absolute ethanol, filtered, and dried to furnish the desired target analogue. 
2-Amino-6-(3-(methylsulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 2 
Off-white solid (0.164 g, 77%); m.p. 251.1–255.0 °C; Rf (EtOAc:Hex, 1:1) 
0.41; 1H NMR (400 MHz, DMSO-d6) δ 8.22 (d, J = 2.1 Hz, 1H, H1), 8.18 (t, J 
= 1.7 Hz, 1H, H7), 8.11 (ddd, J = 7.8, 1.8, 1.1 Hz, 1H, H10), 8.09 (dd, J = 8.6, 
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2.4 Hz, 1H, H2), 7.94 (d, J = 8.3 Hz, 2H, 
H5), 7.88 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H, 
H8), 7.73 (t, J = 7.8 Hz, 1H, H9), 7.65 (d, 
J = 8.1 Hz, 2H, H4), 7.37 (d, J = 8.4 Hz, 
1H, H3), 6.57 (br s, 2H, H6), 3.29 (s, 3H, 
H11); 13C NMR (101 MHz, DMSO-d6) δ 
161.87, 151.80, 150.51, 141.85, 140.59, 
139.32, 133.28, 131.48, 131.28, 130.27 (3C), 129.92, 129.61, 127.23, 
127.20, 125.45, 125.03, 124.59, 124.49, 117.03, 43.57; LC-MS (APCI/ESI): 
Purity > 98%, tR = 4.29 min, m/z [M+H]+ = 460.1. 
2-Amino-6-(3-(methylsulfinyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 3 
Off-white solid (0.115 g, 57%); m.p. 173.1–175.0 °C; Rf (MeOH:DCM, 1:24) 
0.20; 1H NMR (400 MHz, DMSO-d6) δ 
8.20 (d, J = 2.2 Hz, 1H, H1), 8.03 (dd, J = 
8.6, 2.2 Hz, 1H, H2), 7.98 (t, J = 2.2 Hz, 
1H, H7), 7.95 (d, J = 8.2 Hz, 2H, H5), 7.86 
(dt, J = 6.6, 2.2 Hz, 1H, H10), 7.70–7.62 
(m, 4H, H4,8,9), 7.37 (d, J = 8.6 Hz, 1H, 
H3), 6.55 (br s, 2H, H6), 2.81 (s, 3H, H11); 
13C NMR (101 MHz, DMSO-d6) δ 162.29, 152.09, 150.69, 147.90, 140.82, 
139.74, 133.65, 132.56, 130.67 (2C), 130.46, 130.30, 129.99, 128.87, 
127.61, 127.58, 125.35, 124.75, 122.64, 121.50, 117.38, 43.75; LC-MS 
(APCI/ESI): Purity = 99%, tR = 4.28 min, m/z [M+H]+ = 444.1. 
2-Amino-6-phenyl-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 4
Off-white solid (0.097 g, 55%); m.p. 294.4–300.6 °C; Rf (EtOAc:Hex, 3:7) 
0.30; 1H NMR (300 MHz, DMSO-d6) δ 8.14 (d, 
J = 2.3 Hz, 1H, H1), 7.97 (dd, J = 8.6, 2.4 Hz, 
1H, H2), 7.95 (d, J = 8.3 Hz, 2H, H5), 7.69 (dd, 
J = 8.6, 2.4 Hz, 2H, H7), 7.66 (d, J = 8.1 Hz, 
2H, H4), 7.48 (t, J = 7.5 Hz, 2H, H8), 7.40–
7.32 (m, 2H, H3,9), 6.52 (br s, 2H, H6); 13C 
NMR (101 MHz, DMSO-d6) δ 162.34, 151.85, 
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150.20, 139.86, 139.78, 133.84, 133.60, 130.68 (2C), 130.28, 129.96, 
129.54 (2C), 127.65, 127.58, 127.55, 126.72 (2C), 125.22, 124.33, 117.31; 
LC-MS (APCI/ESI): Purity = 98%, tR = 4.68 min, m/z [M+H]+ = 382.1. 
3-(2-Amino-4-oxo-3-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)benzamide, 5 
Off-white solid (0.110 g, 56%); m.p. 299.7–301.2 °C; Rf (MeOH:DCM, 1:24) 
0.41; 1H NMR (400 MHz, DMSO-d6) δ 
8.22 (d, J = 2.3 Hz, 1H, H1), 8.20 (t, J = 
1.6 Hz, 1H, H7), 8.13 (br s, 1H, H11a), 
8.02 (dd, J = 8.6, 2.3 Hz, 1H, H2), 7.94 
(d, J = 8.4 Hz, 2H, H5), 7.88–7.81 (m, 
2H, H8,10), 7.66 (d, J = 8.2 Hz, 2H, H4), 
7.54 (t, J = 7.7 Hz, 1H, H9), 7.37 (d, J = 
8.6 Hz, 1H, H3), 7.36 (br s, 1H, H11b), 6.53 (br s, 2H, H6); 13C NMR (101 
MHz, DMSO-d6) δ 168.30, 162.34, 151.97, 150.43, 139.82, 135.52, 133.68, 
133.19, 130.68 (2C), 130.29, 129.98, 129.52, 129.42, 127.61, 127.58, 
126.79, 125.93, 125.70, 125.25, 124.66, 117.37; LC-MS (APCI/ESI): Purity 
> 99%, tR = 4.25 min, m/z [M+H]+ = 425.1. 
3-(2-Amino-4-oxo-3-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)benzenesulfonamide, 6 
Off-white solid (0.161 g, 71%); m.p. 309.5–313.0 °C; Rf (MeOH:DCM, 1:24) 
0.24; 1H NMR (400 MHz, DMSO-d6) δ 
8.21 (d, J = 2.1 Hz, 1H, H1), 8.15 (t, J = 
1.7 Hz, 1H, H7), 8.00 (dd, J = 8.6, 2.1 
Hz, 1H, H2), 7.95 (d, J = 8.3 Hz, 2H, H5), 
7.93 (ddd, J = 7.7, 1.9, 1.1 Hz, 1H, H10), 
7.79 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H, H8), 
7.70–7.63 (m, 3H, H4,9), 7.43–7.37 (m, 
3H, H3,11), 6.57 (br s, 2H, H6); 13C NMR (101 MHz, DMSO-d6) δ 161.90, 
151.76, 150.40, 145.05, 140.12, 139.33, 133.06, 131.82, 130.27 (2C), 
129.85, 129.60, 129.48, 127.23, 127.20, 125.53, 125.07, 124.32, 124.14, 




Chapter 6: Experimental 




White solid (0.110 g, 58%); m.p. 300.6–304.7 °C; Rf (EtOAc:Hex, 1:1) 0.4; 1H 
NMR (400 MHz, DMSO-d6) δ 8.20 (d, J = 2.0 
Hz, 1H, H1), 8.17 (t, J = 1.5 Hz, 1H, H7), 
8.04 (ddd, J = 7.5, 1.9, 1.1 Hz, 1H, H10), 
8.03 (dd, J = 8.6, 2.4 Hz, 1H, H2), 7.95 (d, J 
= 8.3 Hz, 2H, H5), 7.79 (dt, J = 7.7, 1.3 Hz, 
1H, H8), 7.70–7.63 (m, 3H, H4,9), 7.37 (d, J = 
8.6 Hz, 1H, H3), 6.63 (br s, 2H, H6); 13C 
NMR (101 MHz, DMSO-d6) δ 161.76, 151.80, 150.20, 140.59, 139.25, 
133.27, 131.24, 131.13, 130.78, 130.31, 130.27 (2C), 129.88, 129.63, 
127.24, 127.20, 125.53, 124.79, 124.64, 118.87, 116.97, 112.30; LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.48 min, m/z [M+H]+ = 407.1. 
2-Amino-6-(3-chlorophenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 8 
White solid (0.128 g, 67%); m.p. 276.1–280.4 °C; Rf (EtOAc:Hex, 1:1) 0.59; 
1H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 
2.3 Hz, 1H, H1), 7.98 (dd, J = 8.6, 2.4 Hz, 
1H, H2), 7.94 (d, J = 8.3 Hz, 2H, H5), 7.72 (t, 
J = 1.9 Hz, 1H, H7), 7.67 (ddd, J = 7.7, 1.8, 
1.1 Hz, 1H, H10), 7.65 (d, J = 8.1 Hz, 2H, 
H4), 7.49 (t, J = 7.9 Hz, 1H, H9), 7.40 (ddd, J 
= 8.0, 2.1, 1.0 Hz, 1H, H8), 7.35 (d, J = 8.6 
Hz, 1H, H3), 6.55 (br s, 2H, H6); 13C NMR (101 MHz, DMSO-d6) δ 162.25, 
152.09, 150.70, 142.07, 139.72, 134.33, 133.62, 132.17, 131.36, 130.67 
(2C), 130.30, 129.99, 127.60, 127.57, 127.44, 126.42, 125.45, 125.30, 
124.74, 117.33; LC-MS (APCI/ESI): Purity = 98%, tR = 4.89 min, m/z [M+H]+ 
= 416.1. 
2-Amino-6-(2-chlorophenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 9 
White solid (0.151 g, 79%); m.p. 247.5–252.7 °C; Rf (EtOAc:Hex, 1:1) 0.49; 
1H NMR (400 MHz, DMSO-d6) δ 7.94 (d, J = 8.4 Hz, 2H, H5), 7.92 (d, J = 2.2 
Hz, 1H, H1), 7.70 (dd, J = 8.5, 2.2 Hz, 1H, H2), 7.65 (d, J = 8.2 Hz, 2H, H4), 
7.57 (dd, J = 7.5, 1.2 Hz, 1H, H10), 7.48–7.37 (m, 3H, H7,8,9), 7.34 (d, J = 8.5 
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Hz, 1H, H3), 6.54 (br s, 2H, H6); 13C NMR (101 
MHz, DMSO-d6) δ 162.21, 152.12, 150.32, 
139.74, 139.57, 136.08, 132.26, 131.92, 
131.87, 130.68 (2C), 130.39, 130.29, 129.97, 
129.62, 128.13, 127.57, 127.54, 127.36, 
124.34, 116.74; LC-MS (APCI/ESI): Purity = 
97%, tR = 4.73 min, m/z [M+H]+ = 416.1. 
2-Amino-6-(4-chlorophenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 10 
White solid (0.126 g, 66%); m.p. 303.5–309.1 °C; Rf (EtOAc:Hex, 1:1) 0.58; 
1H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 
2.2 Hz, 1H, H1), 7.95 (dd, J = 8.6, 2.4 Hz, 
1H, H2), 7.94 (d, J = 8.2 Hz, 2H, H5), 7.72 (d, 
J = 8.7 Hz, 2H, H8), 7.65 (d, J = 8.1 Hz, 2H, 
H4), 7.51 (d, J = 8.7 Hz, 2H, H7), 7.35 (d, J = 
8.6 Hz, 1H, H3), 6.54 (br s, 2H, H6); 13C NMR 
(101 MHz, DMSO-d6) δ 162.27, 152.00, 
150.47, 139.74, 138.67, 133.44, 132.45, 132.40, 130.67 (2C), 130.29, 
129.98, 129.46 (2C), 128.47 (2C), 127.59, 127.56, 125.30, 124.41, 117.33; 
LC-MS (APCI/ESI): Purity = 95%, tR = 4.89 min, m/z [M+H]+ = 416.1. 
2-Amino-6-(3,4-dichlorophenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 11 
White solid (0.120 g, 58%); m.p. 270.9–275.1 °C; Rf (EtOAc:Hex, 3:7) 0.45; 
1H NMR (400 MHz, DMSO-d6) δ 8.04 (d, J = 
2.3 Hz, 1H, H1), 7.88 (dd, J = 8.6, 2.4 Hz, 
1H, H2), 7.85–7.80 (m, 3H, H5,7), 7.59–7.57 
(m, 2H, H8,9), 7.54 (d, J = 8.2 Hz, 2H, H4), 
7.23 (d, J = 8.6 Hz, 1H, H3), 6.47 (br s, 2H, 
H6); 13C NMR (101 MHz, DMSO-d6) δ 162.20, 
152.19, 150.88, 140.54, 139.69, 133.52, 
132.27, 131.55, 131.04, 130.66 (2C), 130.31, 130.24, 130.00, 128.46, 
127.62, 127.58, 126.95, 125.33, 124.84, 117.33; LC-MS (APCI/ESI): Purity 
= 98%, tR = 5.17 min, m/z [M+H]+ = 450.0. 
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Off-white solid (0.103 g, 56%); m.p. 286.4–292.2 °C; Rf (EtOAc:Hex, 1:1) 
0.47; 1H NMR (400 MHz, DMSO-d6) δ 8.04 (d, 
J = 2.1 Hz, 1H, H1), 7.88 (dd, J = 8.6, 2.2 Hz, 
1H, H2), 7.83 (d, J = 8.2 Hz, 2H, H5), 7.54 (d, 
J = 8.1 Hz, 2H, H4), 7.47–7.34 (m, 3H, 
H7,8,10), 7.24 (d, J = 8.6 Hz, 1H, H3), 7.06 (t, J 
= 8.0 Hz, 1H, H9), 6.44 (br s, 2H, H6); 13C 
NMR (101 MHz, DMSO-d6) δ 164.49, 162.26, 
152.07, 150.67, 142.40, 139.74, 133.61, 132.35, 131.49, 130.67 (2C), 
130.30, 127.57, 125.26, 124.69, 122.78, 117.30, 114.40, 114.19, 113.49, 
113.27; LC-MS (APCI/ESI): Purity = 98%, tR = 4.70 min, m/z [M+H]+ = 
400.1. 
2-amino-6-(3-(trifluoromethyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 13 
As an off-white solid (0.114 g, 55%); m.p. 241.4–246.1 °C; Rf (EtOAc:Hex, 
1:1) 0.53; 1H NMR (400 MHz, DMSO-d6) δ 
8.18 (d, J = 2.4 Hz, 1H, H1), 8.03 (dd, J = 
8.6, 2.4 Hz, 1H, H2), 8.01–7.98 (m, 1H, 
H10), 7.96 (s, 1H, H7), 7.94 (d, J = 8.2 Hz, 
2H, H5), 7.72–7.68 (m, 2H, H8,9), 7.66 (d, J 
= 8.1 Hz, 2H, H4), 7.37 (d, J = 8.6 Hz, 1H, 
H3), 6.57 (br s, 2H, H6); 13C NMR (101 MHz, 
DMSO-d6) δ 162.25, 152.16, 150.81, 140.96, 139.72, 133.71, 132.08, 
130.86, 130.66 (2C), 130.52, 130.32, 130.00, 127.61, 127.58, 125.39, 
124.92, 124.19, 124.16, 123.06, 123.03, 117.38; LC-MS (APCI/ESI): Purity 
= 99%, tR = 4.85 min, m/z [M+H]+ = 450.1. 
2-amino-6-(3-aminophenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 14 
Off-white solid (0.120 g, 66%); m.p. 281.1–284.2 °C; Rf (EtOAc:100%) 0.54; 
1H NMR (400 MHz, DMSO-d6) δ 8.06 (d, J = 2.3 Hz, 1H, H1), 7.94 (d, J = 8.2 
Hz, 2H, H5), 7.86 (dd, J = 8.6, 2.3 Hz, 1H, H2), 7.65 (d, J = 8.1 Hz, 2H, H4), 
7.32 (d, J = 8.5 Hz, 1H, H3), 7.10 (t, J = 7.8 Hz, 1H, H9), 6.89 (t, J = 1.9 Hz, 
1H, H7), 6.80 (ddd, J = 7.6, 1.8, 1.0 Hz, 1H, H8), 6.55 (ddd, J = 8.0, 2.2, 0.9 
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Hz, 1H, H10), 6.46 (br s, 2H, H6), 5.14 (br s, 
2H, H11); 13C NMR (101 MHz, DMSO-d6) δ 
162.39, 151.68, 149.96, 149.71, 140.45, 
139.85, 134.67, 133.39, 130.70 (2C), 
130.25, 129.99, 129.93, 127.56, 127.53, 
124.99, 123.92, 117.20, 114.33, 113.47, 
112.08; LC-MS (APCI/ESI): Purity > 99%, tR 
= 4.30 min, m/z [M+H]+ = 397.1. 
2-amino-6-(3-methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 15 
Off-white solid (0.125 g, 66%); m.p. 272.9–278.9 °C; Rf (EtOAc:Hex, 3:2) 
0.41; 1H NMR (400 MHz, DMSO-d6) δ 8.12 
(d, J = 2.3 Hz, 1H, H1), 7.96 (dd, J = 8.6, 
2.4 Hz, 1H, H2), 7.94 (d, J = 8.3 Hz, 2H, 
H5), 7.65 (d, J = 8.1 Hz, 2H, H4), 7.38 (t, J 
= 8.0 Hz, 1H, H9), 7.34 (d, J = 8.6 Hz, 1H, 
H3), 7.24 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H, 
H8), 7.18 (t, J = 1.8 Hz, 1H, H7), 6.93 (ddd, 
J = 8.2, 2.5, 0.9 Hz, 1H, H10), 6.51 (br s, 2H, H6), 3.83 (s, 3H, H11); 13C NMR 
(101 MHz, DMSO-d6) δ 161.92, 159.95, 151.47, 149.93, 141.02, 139.39, 
133.32, 130.28 (2C), 130.20, 129.88, 129.56, 127.18, 127.14, 124.74, 
124.62, 124.06, 118.72, 116.85, 112.87, 111.87, 55.24; LC-MS (APCI/ESI): 
Purity = 98%, tR = 4.65 min, m/z [M+H]+ = 412.1. 
2-amino-6-(3-(tert-butyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 16 
As an off-white solid (0.099 g, 49%); m.p. 256.1–258.9 °C; Rf (EtOAc:Hex, 
3:7) 0.45; 1H NMR (400 MHz, DMSO-d6) δ 
8.11 (d, J = 2.1 Hz, 1H, H1), 7.95 (dd, J = 
8.5, 2.5 Hz, 1H, H2), 7.94 (d, J = 8.3 Hz, 
2H, H5), 7.70–7.60 (m, 3H, H4,7), 7.51–
7.44 (m, 1H, H8), 7.41–7.37 (m, 2H, H9,10), 
7.35 (d, J = 8.5 Hz, 1H, H3), 6.49 (br s, 2H, 
H6), 1.34 (s, 9H, H11); 13C NMR (101 MHz, 
DMSO-d6) δ 162.35, 151.89, 151.78, 150.12, 139.80, 139.70, 134.45, 
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133.84, 130.69 (2C), 130.27, 129.95, 129.28, 127.56, 127.53, 125.16, 
124.62, 124.35, 124.08, 123.51, 117.27, 35.01, 31.65 (3C); LC-MS 
(APCI/ESI): Purity = 98%, tR = 5.27 min, m/z [M+H]+ = 438.2. 
2-amino-6-(4-(tert-butyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 17 
Off-white solid (0.123 g, 61%); m.p. 268.1–272.3 °C; Rf (EtOAc:Hex, 3:7) 
0.46; 1H NMR (400 MHz, DMSO-d6) δ 8.11 
(d, J = 2.3 Hz, 1H, H1), 7.97–7.91 (m, 3H, 
H2,5), 7.65 (d, J = 8.1 Hz, 2H, H4), 7.61 (d, 
J = 8.6 Hz, 2H, H7), 7.48 (d, J = 8.6 Hz, 2H, 
H8), 7.34 (d, J = 8.5 Hz, 1H, H3), 6.48 (br s, 
2H, H6), 1.32 (s, 9H, H9); 13C NMR (101 
MHz, DMSO-d6) δ 162.34, 151.74, 150.12, 
150.02, 139.81, 136.99, 133.73, 133.46, 
130.69 (2C), 130.26, 129.94, 127.56, 127.53, 126.39 (2C), 126.31 (2C), 
125.16, 124.00, 117.31, 34.71, 31.59 (3C); LC-MS (APCI/ESI): Purity > 99%, 
tR = 5.33 min, m/z [M+H]+ = 438.2. 
2-amino-6-(3-(dimethylamino)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 18 
Off-white solid (0.107 g, 55%); m.p. 238.4–242.3 °C; Rf (EtOAc:Hex, 1:1) 
0.48; 1H NMR (400 MHz, DMSO-d6) δ 8.08 
(d, J = 2.3 Hz, 1H, H1), 7.97–7.88 (m, 3H, 
H2,5), 7.63 (d, J = 8.1 Hz, 2H, H4), 7.32 (d, 
J = 8.6 Hz, 1H, H3), 7.25 (t, J = 8.0 Hz, 
1H, H9), 6.96–6.87 (m, 2H, H7,8), 6.71 
(ddd, J = 8.4, 2.3, 1.0 Hz, 1H, H10), 6.47 
(br s, 2H, H6), 2.95 (s, 6H, H11); 13C NMR 
(101 MHz, DMSO-d6) δ 161.97, 151.31, 151.05, 149.66, 140.34, 139.43, 
134.59, 133.46, 130.29 (2C), 129.86, 129.62, 129.54, 129.22, 127.12, 
124.60, 123.92, 116.78, 114.52, 111.54, 110.24, 40.30 (2C); LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.73 min, m/z [M+H]+ = 425.2. 
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2-amino-6-(3-(morpholinosulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 19 
Off-white solid (0.288 g, 78%); m.p. 278.0–280.1 ºC; Rf (100% EtOAc) 0.27; 
1H NMR (300 MHz, DMSO-d6) δ 8.18 (d, 
J = 2.2 Hz, 1H, H1), 8.08 (dt, J = 7.6, 
1.5 Hz, 1H, H8), 8.03 (dd, J = 8.6, 2.4 
Hz, 1H, H2), 7.95 (d, J = 8.3 Hz, 2H, 
H5), 7.92 (t, J = 1.5 Hz, 1H, H7), 7.77 (t, 
J = 7.7 Hz, 1H, H9), 7.72 (dt, J = 7.8, 
1.4 Hz, 1H, H10), 7.66 (d, J = 8.1 Hz, 
2H, H4), 7.39 (d, J = 8.6 Hz, 1H, H3), 6.61 (br s, 2H, H6), 3.72–3.57 (m, 4H, 
H12), 3.02–2.85 (m, 4H, H11); 13C NMR (101 MHz, DMSO-d6) δ 162.24, 
152.20, 150.92, 141.10, 139.68, 135.91, 133.71, 131.80, 131.62, 130.84, 
130.65 (2C), 130.32, 130.01, 127.58, 126.61, 125.92, 125.46, 125.20, 
124.97, 117.38, 65.80 (2C), 46.42 (2C); LC-MS (APCI/ESI): Purity > 99%, tR
= 4.08 min, m/z [M+H]+ = 531.1.  
2-amino-6-(2-methyl-5-(morpholinosulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 20 
Off-white solid (0.354 g, 81%); m.p. 219.8–224.8 ºC; Rf (EtOAc:Hex, 80:20) 
0.16; 1H NMR (400 MHz, CDCl3) δ 8.09 
(d, J = 2.0 Hz, 1H, H1), 7.91 (d, J = 8.0 
Hz, 2H, H5), 7.75 (d, J = 1.9 Hz, 1H, 
H7), 7.67 (dd, J = 8.0, 2.0 Hz, 1H, H10), 
7.62 (dd, J = 8.4, 2.0 Hz, 1H, H2), 7.57 
(d, J = 8.0 Hz, 2H, H4), 7.48 (d, J = 8.1 
Hz, 1H, H9), 7.42 (d, J = 8.4 Hz, 1H, 
H3), 3.82–3.71 (m, 4H, H12), 3.12–3.01 (m, 4H, H11), 2.39 (s, 3H, H8); 13C 
NMR (101 MHz, CDCl3) δ 161.50, 150.36, 146.98, 141.62, 141.56, 137.72, 
136.09, 135.41, 132.83, 132.76, 131.28, 129.43 (2C), 129.09, 127.85, 
127.82, 127.65, 126.89, 123.83, 122.04, 117.05, 66.12 (2C), 46.08 (2C), 
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Off-white solid (0.132 g, 74%); m.p. 286.5–288.9 °C; Rf (100% EtOAc) 0.21; 
1H NMR (600 MHz, DMSO-d6) δ 8.92 (s, 1H, 
H8), 8.56 (d, J = 4.7 Hz, 1H, H9), 8.18 (d, J = 
2.3 Hz, 1H, H1), 8.10 (d, J = 8.0 Hz, 1H, H7), 
8.02 (dd, J = 8.6, 2.2 Hz, 1H, H2), 7.95 (d, J = 
8.4 Hz, 2H, H5), 7.67 (d, J = 8.3 Hz, 2H, H4), 
7.49 (dd, J = 7.9, 4.7 Hz, 1H, H10), 7.38 (d, J = 
8.6 Hz, 1H, H3), 6.61 (br s, 2H, H6); 13C NMR 
(151 MHz, DMSO-d6) δ 162.22, 152.12, 150.71, 148.63, 147.74, 139.71, 
135.37, 134.16, 133.59, 130.67 (2C), 130.59, 130.24, 130.03, 127.60, 
127.58, 125.41, 124.82, 124.41, 117.43; LC-MS (APCI/ESI): Purity = 98%, 
tR = 4.28 min, m/z [M+H]+ = 383.1. 
2-amino-6-(5-(methylsulfonyl)pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 22 
Off-white solid (0.150 g, 70%); m.p. 323.9–328.5 °C; Rf (100% EtOAc) 0.20; 
1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J 
= 2.2 Hz, 1H, H9), 9.02 (d, J = 2.2 Hz, 
1H, H8), 8.56 (t, J = 2.2 Hz, 1H, H7), 8.31 
(d, J = 2.2 Hz, 1H, H1), 8.13 (dd, J = 8.6, 
2.2 Hz, 1H, H2), 7.95 (d, J = 8.3 Hz, 2H, 
H5), 7.67 (d, J = 8.2 Hz, 2H, H4), 7.40 (d, 
J = 8.6 Hz, 1H, H3), 6.64 (br s, 2H, H6), 
3.41 (s, 3H, H10); 13C NMR (101 MHz, DMSO-d6) δ 161.77, 152.04, 151.67, 
150.98, 145.83, 139.26, 137.37, 135.38, 133.38, 132.39, 130.25 (2C), 
129.95, 129.63, 128.30, 127.25, 127.22, 125.30, 125.15, 117.17, 43.70; 
LC-MS (APCI/ESI): Purity > 99%, tR = 4.16 min, m/z [M+H]+ = 461.1. 
2-amino-6-(5-methylpyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 23 
Off-white solid (0.113 g, 61%); m.p. 271.9–275.5 °C; Rf (100% EtOAc) 0.20; 
1H NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H, H8), 8.39 (s, 1H, H9), 8.16 (d, J 
= 2.3 Hz, 1H, H1), 7.99 (dd, J = 8.6, 2.3 Hz, 1H, H2), 7.94 (d, J = 8.3 Hz, 2H, 
H5), 7.91 (s, 1H, H7), 7.66 (d, J = 8.1 Hz, 2H, H4), 7.36 (d, J = 8.6 Hz, 1H, 
H3), 6.56 (br s, 2H, H6), 2.37 (s, 3H, H10); 13C NMR (101 MHz, DMSO-d6) δ 
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161.83, 151.68, 150.25, 148.61, 144.54, 
139.34, 134.51, 134.14, 133.21, 130.27 
(2C), 129.91, 129.59, 127.21, 127.18, 
125.53, 124.97, 124.39, 122.83, 117.05, 
17.95; LC-MS (APCI/ESI): Purity = 97%, tR = 
4.41 min, m/z [M+H]+ = 397.1. 
2-amino-6-(5-methoxypyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 24 
Off-white solid (0.157 g, 82%); m.p. 253.5–256.8 °C; Rf (100% EtOAc) 0.24; 
1H NMR (400 MHz, DMSO-d6) δ 8.49 (d, J = 
1.8 Hz, 1H, H8), 8.27 (d, J = 2.7 Hz, 1H, 
H9), 8.18 (d, J = 2.3 Hz, 1H, H1), 8.01 (dd, 
J = 8.6, 2.3 Hz, 1H, H2), 7.94 (d, J = 8.2 
Hz, 2H, H5), 7.66 (d, J = 8.1 Hz, 2H, H4), 
7.62 (dd, J = 2.7, 1.9 Hz, 1H, H7), 7.36 (d, 
J = 8.6 Hz, 1H, H3), 6.57 (br s, 2H, H6), 
3.92 (s, 3H, H10); 13C NMR (101 MHz, DMSO-d6) δ 161.82, 155.77, 151.73, 
150.40, 139.54, 139.33, 136.27, 135.87, 133.49, 130.27 (2C), 130.08, 
129.91, 129.60, 127.21, 127.18, 124.92, 124.68, 117.96, 116.99, 55.74; 
LC-MS (APCI/ESI): Purity = 99%, tR = 4.39 min, m/z [M+H]+ = 413.1. 
2-amino-6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 25 
White solid (0.170 g, 76%); m.p. 254.2–259.6 °C; Rf (EtOAc:Hex, 1:1) 0.26; 
1H NMR (400 MHz, DMSO-d6) δ 8.75 (s, 
1H, H7), 8.29 (d, J = 2.2 Hz, 1H, H1), 8.14 
(s, 1H, H8), 7.99 (dd, J = 8.6, 2.2 Hz, 1H, 
H2), 7.93 (d, J = 8.7 Hz, 2H, H5), 7.64 (d, J 
= 8.6 Hz, 2H, H4), 7.34 (d, J = 8.6 Hz, 1H, 
H3), 6.55 (br s, 2H, H6), 4.02 (s, 3H, H9); 
13C NMR (101 MHz, DMSO-d6) δ 161.78, 
159.24, 151.68, 150.20, 148.58, 139.32, 134.98, 134.93, 133.21, 130.25 
(2C), 129.91, 129.60, 128.81, 128.77, 127.21, 127.19, 124.97, 124.51, 
124.38, 117.02, 54.34; LC-MS (APCI/ESI): Purity > 99%, tR = 4.83 min, m/z 
[M+H]+ = 481.1. 
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White solid (0.100 g, 54%); m.p. 348.1–352.7 °C; Rf (EtOAc:Hex, 3:2) 0.22; 
1H NMR (400 MHz, DMSO-d6) δ 8.30 (d, J = 
2.2 Hz, 1H, H1), 8.26 (d, J = 5.3 Hz, 1H, H8), 
8.10 (dd, J = 8.7, 2.2 Hz, 1H, H2), 7.93 (d, J = 
8.3 Hz, 2H, H5), 7.70 (d, J = 5.3 Hz, 1H, H9), 
7.65 (d, J = 8.2 Hz, 2H, H4), 7.51 (s, 1H, H7), 
7.35 (d, J = 8.7 Hz, 1H, H3), 6.68 (br s, 2H, 
H6); 13C NMR (101 MHz, DMSO-d6) δ 165.48, 
161.71, 152.24, 151.70, 148.28, 148.13, 139.19, 133.04, 130.24 (2C), 
129.96, 129.64, 128.77, 127.24, 125.23, 125.01, 119.09, 116.94, 106.08, 
105.70; LC-MS (APCI/ESI): Purity = 99%, tR = 4.41 min, m/z [M+H]+ = 
401.1. 
2-amino-6-(2,6-difluoropyridin-4-yl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 27 
White solid (0.116 g, 60%); m.p. 362.9–367.1 °C; Rf (EtOAc:Hex, 1:1) 0.22; 
1H NMR (400 MHz, DMSO-d6) δ 8.34 (d, J = 
2.4 Hz, 1H, H1), 8.13 (dd, J = 8.7, 2.4 Hz, 1H, 
H2), 7.94 (d, J = 8.2 Hz, 2H, H5), 7.65 (d, J = 
8.1 Hz, 2H, H4), 7.55 (s, 2H, H7), 7.34 (d, J = 
8.7 Hz, 1H, H3), 6.72 (br s, 2H, H6); 13C NMR 
(101 MHz, DMSO-d6) δ 163.13, 161.65, 
160.73, 160.56, 152.47, 152.19, 139.16, 
133.19, 130.24 (2C), 129.98, 129.67, 127.91, 
127.27, 127.24, 125.82, 124.96, 116.91, 103.43, 103.03; LC-MS 
(APCI/ESI): Purity = 97%, tR = 4.57 min, m/z [M+H]+ = 419.1. 
2-amino-6-(pyrimidin-5-yl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 28 
Off-white solid (0.148 g, 83%); m.p. 325.2–
328.3 °C; Rf (100% EtOAc) 0.20; 1H NMR (600 
MHz, DMSO-d6) δ 9.16 (s, 1H, H8), 9.14 (s, 2H, 
H7), 8.26 (d, J = 2.3 Hz, 1H, H1), 8.05 (dd, J = 
8.6, 2.3 Hz, 1H, H2), 7.94 (d, J = 8.3 Hz, 2H, 
H5), 7.66 (d, J = 8.2 Hz, 2H, H4), 7.40 (d, J = 
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8.6 Hz, 1H, H3), 6.52 (br s, 2H, H6); 13C NMR (151 MHz, DMSO-d6) δ 162.08, 
157.32, 154.75 (2C), 152.31, 151.22, 139.66, 133.45, 133.24, 130.63 (2C), 
130.36, 130.15, 127.55, 127.53, 127.35, 125.63, 125.25, 117.66; LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.18 min, m/z [M+H]+ = 384.1.  
2-amino-6-(2-methoxypyrimidin-5-yl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 29 
Off-white solid (0.156 g, 81%); m.p. 284.7–289.4 °C; Rf (100% EtOAc) 0.40; 
1H NMR (400 MHz, DMSO-d6) δ 8.92 (s, 
2H, H7), 8.13 (d, J = 2.3 Hz, 1H, H1), 7.96 
(dd, J = 8.6, 2.3 Hz, 1H, H2), 7.93 (d, J = 
8.5 Hz, 2H, H5), 7.64 (d, J = 8.1 Hz, 2H, 
H4), 7.34 (d, J = 8.6 Hz, 1H, H3), 6.55 (br s, 
2H, H6), 3.96 (s, 3H, H8); 13C NMR (101 
MHz, DMSO-d6) δ 164.45, 161.75, 157.03 
(2C), 151.67, 150.20, 139.32, 132.83, 130.26 (2C), 129.91, 129.59, 127.21, 
127.18, 127.12, 127.06, 125.03, 123.99, 117.08, 54.77; LC-MS (APCI/ESI): 
Purity > 99%, tR = 4.33 min, m/z [M+H]+ = 414.1. 
2-amino-6-(thiophen-3-yl)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 30 
Off-white solid (0.116 g, 64%); m.p. 309.9–312.3 °C; Rf (EtOAc:Hex, 1:1) 
0.25; 1H NMR (600 MHz, DMSO-d6) δ 8.16 (d, J 
= 2.2 Hz, 1H, H1), 8.00 (dd, J = 8.6, 2.3 Hz, 1H, 
H2), 7.95 (d, J = 8.3 Hz, 2H, H5), 7.87 (dd, J = 
2.9, 1.4 Hz, 1H, H7), 7.68–7.63 (m, 3H, H4,8), 
7.57 (dd, J = 5.0, 1.4 Hz, 1H, H9), 7.31 (d, J = 
8.6 Hz, 1H, H3), 6.50 (br s, 2H, H6); 13C NMR 
(151 MHz, DMSO-d6) δ 162.27, 151.71, 149.88, 
141.20, 139.81, 133.27, 130.67 (2C), 130.18, 129.97, 129.18, 127.71, 
127.57, 127.55, 126.43, 125.07, 123.55, 120.75, 117.21; LC-MS 
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Off-white solid (0.140 g, 78%); m.p. 268.7–272.3 °C; Rf (100% EtOAc) 0.31; 
1H NMR (600 MHz, DMSO-d6) δ 8.12 (s, 1H, 
H8), 8.02 (d, J = 2.2 Hz, 1H, H1), 7.93 (d, J = 
8.3 Hz, 2H, H5), 7.85–7.81 (m, 2H, H2,7), 7.64 
(d, J = 8.2 Hz, 2H, H4), 7.27 (d, J = 8.6 Hz, 1H, 
H3), 6.26 (br s, 2H, H6), 3.87 (s, 3H, H9); 13C 
NMR (151 MHz, DMSO-d6) δ 162.20, 151.24, 
149.00, 139.91, 136.23, 132.51, 130.65 (2C), 
130.02, 127.99, 127.47, 127.45, 126.89, 
125.46, 125.11, 122.23, 121.95, 117.46, 39.07; LC-MS (APCI/ESI): Purity = 
97%, tR = 4.20 min, m/z [M+H]+ = 386.1. 
Synthesis of methyl 5-bromo-2-(3-(ethoxycarbonyl)thioureido)benzoate, 2.5 
To a solution of potassium thiocyanate (3 g, 30.9 mmol, 1.04 Eq) in 
anhydrous acetonitrile (40 mL), ethyl chloroformate (2.84 mL, 29.7 mmol, 
1.0 Eq) was added dropwise while stirring at 25 °C. The solution was then 
heated at 70 °C for 2 h, cooled to room temperature, solids were filtered and 
discarded. Methyl 2-amino-5-bromobenzoate (4.55 g, 19.8 mmol, 1.0 Eq) 
was added to the filtrate [the in situ generated ethoxy carbonyl 
isothiocyanate] portionwise while stirring at 25 °C for 45 minutes. The solids 
were filtered, washed with acetonitrile, and dried to furnish methyl 5-bromo-
2-(3-(ethoxycarbonyl)thioureido) benzoate, 2.5. In the subsequent scale up 
reactions, 2.5 was obtained by dissolving Methyl 2-amino-5-bromobenzoate 
in acetonitrile and treating it with the commercially 
available ethoxy carbonyl isothiocyanate at 0 °C. In this 
case, the product formed within ten minutes as a 
precipitate, which was filtered, washed with acetonitrile, 
and dried to afford 2.5 as a white solid (6.6 g, 92%); m.p. 
155.7–158.9 °C; Rf (EtOAc:Hex, 1:4) 0.35; 1H NMR (400 
MHz, CDCl3) δ 12.60 (br s, 1H, H5), 8.47 (d, J = 8.9 Hz, 
1H, H3), 8.18 (br s, 1H, H6), 8.16 (d, J = 2.4 Hz, 1H, H1), 
7.68 (dd, J = 8.9, 2.4 Hz, 1H, H2), 4.35 (q, J = 7.1 Hz, 2H, 
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H7), 3.97 (s, 3H, H4), 1.37 (t, J = 7.1 Hz, 3H, H8); 13C NMR (101 MHz, CDCl3) 
δ 178.12, 165.47, 151.69, 137.96, 135.36, 133.43, 127.87, 123.55, 118.75, 
63.07, 52.81, 14.21; LC-MS (APCI/ESI): Purity > 99%, tR = 4.55 min, m/z 
[M+H]+ = 361.0, 363.0 (1:1). 
General procedure 6: Synthesis of intermediates 2.6a–2.6j 
The appropriate aniline (1.5 Eq) and N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDCI) (2.0 Eq) were successively added to 
a solution of 2.5 (1.0 Eq) in DCM, and stirred at 25 °C for 6 to 29 hours. 
After completeness of the reaction, more DCM was added, and washed with 
1N HCl/H2O (2-3%) (20 mL × 2), water (20 mL × 2), brine (20 mL × 2), dried 
over anhydrous sodium sulfate, and concentrated to yield a residue, which 
was triturated in diethyl ether, filtered, and dried in vacuo to afford the 
desired intermediate. 
Ethyl (6-bromo-3-(3-cyanophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate, 2.6a 
White solid (0.871 g, 87%); Rf (EtOAc:Hex, 50:50) 0.49; 1H NMR (400 MHz, 
CDCl3) δ 8.32 (d, J = 2.3 Hz, 1H, H1), 7.85 (dd, J = 
8.6, 2.3 Hz, 1H, H2), 7.77 (dt, J = 7.8, 1.3 Hz, 1H, 
H7), 7.66 (t, J = 8.1 Hz, 1H, H6), 7.58 (t, J = 2.0 Hz, 
1H, H4), 7.52 (ddd, J = 8.0, 2.1, 1.1 Hz, 1H, H5), 
7.18 (d, J = 8.6 Hz, 1H, H3), 4.13 (q, J = 7.1 Hz, 2H, 
H9), 1.27 (t, J = 7.1 Hz, 3H, H10); 13C NMR (101 
MHz, CDCl3) δ 163.73, 159.63, 154.07, 139.02, 
136.44, 135.83, 133.45, 132.66, 132.54, 131.12, 
130.36, 118.21, 118.00, 117.75, 117.39, 113.83, 
62.40, 14.24; LC-MS (APCI/ESI): Purity > 99%, tR = 4.27 min, m/z [M+H]+ = 
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Ethyl (6-bromo-3-(4-(methylsulfonyl)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate, 2.6b 
White solid (0.905 g, 81%); m.p. 273.3–278.1 ºC; 
Rf (100% EtOAc) 0.60; 1H NMR (400 MHz, 
DMSO-d6) δ 8.09 (d, J = 2.7 Hz, 1H, H1), 8.07 (d, 
J = 8.7 Hz, 2H, H4), 7.98 (dd, J = 8.8, 2.3 Hz, 
1H, H2), 7.77 (d, J = 8.6 Hz, 1H, H3), 7.64 (d, J = 
8.7 Hz, 2H, H5), 3.98 (q, J = 7.1 Hz, 2H, H8), 
3.32 (s, 3H, H6), 1.11 (t, J = 7.0 Hz, 3H, H9); LC-
MS (APCI/ESI): Purity = 96%, tR = 4.15 min, m/z 
[M+H]+ = 466.0, 468.0 (1:1). 
Ethyl (6-bromo-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-2-yl)carbamate, 2.6c 
White solid (0.551 g, 50%); m.p. 201.2–204.3 ºC; Rf (EtOAc:Hex, 50:50) 0.47; 
1H NMR (400 MHz, CDCl3) δ 8.33 (d, J = 2.3 Hz, 1H, 
H1), 7.85 (d, J = 8.0, 1H, H7), 7.83 (dd, J = 8.7, 2.3 Hz, 
1H, H2), 7.75 (td, J = 7.7, 1.0 Hz, 1H, H6), 7.63 (tt, J = 
7.8, 1.0 Hz, 1H, H5), 7.35 (d, J = 7.9 Hz, 1H, H4), 7.18 
(d, J = 8.7 Hz, 1H, H3), 4.07 (q, J = 7.1 Hz, 2H, H9), 
1.21 (t, J = 7.1 Hz, 3H, H10); 13C NMR (101 MHz, 
CDCl3) δ 163.53, 159.76, 154.15, 138.80, 136.76, 
133.25, 133.09, 131.10, 130.99, 129.66, 128.02, 
127.77, 127.72, 118.38, 117.82, 117.40, 62.41, 14.25; 
LC-MS (APCI/ESI): Purity = 90%, tR = 4.37 min, m/z [M+H]+ = 456.0, 458.0 
(1:1). 
Ethyl (6-bromo-4-oxo-3-(6-(trifluoromethyl)pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)carbamate, 2.6d 
White solid (0.645 g, 59%); Rf (EtOAc:Hex, 50:50) 0.49; 1H NMR (400 MHz, 
CDCl3) δ 8.65 (d, J = 1.9 Hz, 1H, H6), 8.34 (d, J = 
2.2 Hz, 1H, H1), 7.90–7.79 (m, 3H, H2,4,5), 7.19 (d, 
J = 8.6 Hz, 1H, H3), 4.13 (q, J = 7.1 Hz, 2H, H8), 
1.27 (t, J = 7.1 Hz, 3H, H9); 13C NMR (101 MHz, 
CDCl3) δ 163.80, 159.54, 154.05, 150.01, 148.14, 
147.79, 139.22, 137.97, 136.35, 134.16, 131.21, 
122.61, 121.07, 118.11, 117.17, 62.45, 14.21; LC-
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MS (APCI/ESI): Purity = 97%, tR = 4.42 min, m/z [M+H]+ = 457.0, 459.0 
(1:1). 
Ethyl (6-bromo-4-oxo-3-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-2-yl)carbamate, 2.6e 
White solid (0.960 g, 87%); Rf (EtOAc:Hex, 30:70) 0.30; 1H NMR (400 MHz, 
CDCl3) δ 8.33 (d, J = 2.3 Hz, 1H, H1), 7.84 (dd, J = 
8.6, 2.3 Hz, 1H, H2), 7.81 (d, J = 8.3 Hz, 2H, H5), 
7.40 (d, J = 8.1 Hz, 2H, H4), 7.18 (d, J = 8.7 Hz, 
1H, H3), 4.12 (q, J = 7.1 Hz, 2H, H7), 1.26 (t, J = 
7.1 Hz, 3H, H8); 13C NMR (101 MHz, CDCl3) δ 
159.74, 154.02, 138.87, 138.14, 136.67, 131.09, 
131.00, 129.20 (2C), 126.72, 126.68, 125.11, 
122.40, 118.35, 117.91, 117.58, 62.39, 14.24; LC-
MS (APCI/ESI): Purity > 99%, tR = 4.63 min, m/z [M+H]+ = 456.0, 458.0 
(1:1). 
Ethyl (6-bromo-3-(4-cyanophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate, 2.6f 
White solid (0.781 g, 78%); Rf (EtOAc:Hex, 50:50) 0.46; 1H NMR (400 MHz, 
CDCl3) δ 8.32 (d, J = 2.2 Hz, 1H, H1), 7.84 (dd, J = 
8.6, 2.3 Hz, 1H, H2), 7.81 (d, J = 8.7 Hz, 2H, H4), 
7.40 (d, J = 8.7 Hz, 2H, H5), 7.18 (d, J = 8.6 Hz, 1H, 
H3), 4.12 (q, J = 7.1 Hz, 2H, H7), 1.26 (t, J = 7.1 Hz, 
3H, H8); 13C NMR (101 MHz, CDCl3) δ 163.76, 
159.55, 153.96, 139.06, 139.02, 136.48, 133.33 
(2C), 131.11, 129.84 (2C), 118.21, 118.04, 117.99, 
117.41, 113.18, 62.39, 14.25; LC-MS (APCI/ESI): Purity = 96%, tR = 3.90 
min, m/z [M+H]+ = 413.0, 415.0 (1:1). 
Ethyl (6-bromo-3-(4-hydroxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate, 2.6g 
White solid (0.759 g, 78%); Rf (EtOAc:Hex, 80:20) 
0.57; 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 2.3 
Hz, 1H, H1), 7.84 (dd, J = 8.7, 2.3 Hz, 1H, H2), 7.25 
(d, J = 8.6 Hz, 1H, H3), 7.03 (d, J = 8.8 Hz, 2H, H4), 
6.82 (d, J = 8.8 Hz, 2H, H5), 4.19 (q, J = 7.1 Hz, 2H, 
H8), 1.28 (t, J = 7.1 Hz, 3H, H9); 13C NMR (101 MHz, 
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CDCl3) δ 161.20, 160.48, 157.06, 153.20, 138.62, 137.71, 130.92, 129.09 
(2C), 126.12, 119.80, 118.13, 117.27, 116.97 (2C), 62.43, 14.22; LC-MS 
(APCI/ESI): Purity > 99%, tR = 3.59 min, m/z [M+H]+ = 404.0, 406.0 (1:1).  
Ethyl (6-bromo-3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate, 2.6h 
Off-white solid (1.030 g, 92%); Rf (EtOAc:Hex, 30:70) 0.30; 1H NMR (300 
MHz, CDCl3) δ 8.32 (d, J = 2.3 Hz, 1H, H1), 7.82 (dd, 
J = 8.6, 2.3 Hz, 1H, H2), 7.29–7.22 (m, 4H, H4,5), 
7.20 (d, J = 8.6 Hz, 1H, H3), 4.12 (q, J = 7.1 Hz, 2H, 
H7), 1.25 (t, J = 7.1 Hz, 3H, H8); 13C NMR (101 MHz, 
CDCl3) δ 163.88, 162.96, 161.41, 160.05, 153.77, 
138.68, 137.09, 131.00, 130.65, 130.26, 130.18, 
118.84, 117.88, 116.80, 116.57, 62.38, 14.28; LC-
MS (APCI/ESI): Purity = 98%, tR = 4.08 min, m/z [M+H]+ = 406.0, 408.0 
(1:1).  
Ethyl (6-bromo-3-(2-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate, 2.6i 
White solid (1.050 g, 93%); Rf (EtOAc:Hex, 30:70) 0.26; 1H NMR (300 MHz, 
CDCl3) δ 8.34 (d, J = 2.2 Hz, 1H, H1), 7.83 (dd, J = 8.6, 
2.3 Hz, 1H, H2), 7.55–7.43 (m, 1H, H6), 7.33–7.23 (m, 
3H, H4,5,7), 7.19 (d, J = 8.6 Hz, 1H, H3), 4.11 (q, J = 
7.1 Hz, 2H, H9), 1.24 (t, J = 7.1 Hz, 3H, H10); 13C NMR 
(101 MHz, CDCl3) δ 163.58, 159.30, 158.92, 156.43, 
153.70, 138.72, 136.88, 131.12, 131.01, 130.24, 
124.80, 118.46, 117.80, 116.73, 116.54, 62.39, 14.27; 
LC-MS (APCI/ESI): Purity = 95%, tR = 4.14 min, m/z [M+H]+ = 406.0, 408.0 
(1:1). 
Ethyl (6-bromo-3-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate, 2.6j 
Brown solid (1.099 g, 94%); Rf (EtOAc:Hex, 50:50) 
0.49; 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 2.3 
Hz, 1H, H1), 7.80 (dd, J = 8.6, 2.3 Hz, 1H, H2), 
7.24 (d, J = 8.6 Hz, 1H, H3), 7.17 (d, J = 9.1 Hz, 
2H, H4), 7.05 (d, J = 9.1 Hz, 2H, H5), 4.13 (q, J = 
7.1 Hz, 2H, H8), 3.88 (s, 3H, H6), 1.25 (t, J = 7.1 
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Hz, 3H, H9); 13C NMR (101 MHz, CDCl3) δ 161.29, 160.37, 159.96, 152.65, 
138.42, 138.29, 130.79, 129.35 (2C), 127.16, 120.12, 118.35, 117.88, 
115.09 (2C), 62.34, 55.49, 14.29; LC-MS (APCI/ESI): Purity > 99%, tR = 4.05 
min, m/z [M+H]+ = 418.0, 420.0 (1:1).  
General procedure 7 [Deprotection]: Synthesis of 2-amino-6-bromo-
quinazolinone-based intermediates 2.7a–2.7j  
The 2-carbamate-based intermediate 2.6 (a–j) (1.0 Eq) was dissolved in TFA 
(20.0 Eq). This solution was heated under microwave conditions at 110 ºC 
for 20 min. After cooling to room temperature and evaporating the solvent, 
the residue was dissolved in DCM/MeOH (1:1). Amberlyst® A21 free base 
was then added to this solution, stirred at ambient temperature for 45 min, 
followed by filtration and rinsing of the resin with MeOH. The filtrate was 
then concentrated under reduced pressure to give a residue that was 
triturated in Et2O, filtered, and dried to afford the desired product. 
3-(2-amino-6-bromo-4-oxoquinazolin-3(4H)-yl)benzonitrile, 2.7a 
Off-white solid (0.360 g, 79%); Rf (100% EtOAc) 0.34; 1H NMR (400 MHz, 
DMSO-d6) δ 8.39 (br s, 2H, H8), 8.10 (d, J = 2.1 Hz, 
1H, H1), 8.09 (t, J = 1.6 Hz, 1H, H4), 8.06–8.00 (m, 
2H, H2,7), 7.92–7.82 (m, 2H, H5,6), 7.57 (d, J = 8.7 
Hz, 1H, H3); 13C NMR (101 MHz, DMSO-d6) δ 
159.14, 152.29, 139.21, 134.87, 134.82, 134.20, 
133.53, 132.24, 130.73, 129.70, 120.61, 118.40, 
117.57, 116.75, 113.64; LC-MS (APCI/ESI): Purity 
= 98%, tR = 3.32 min, m/z [M+H]+ = 341.0, 343.0 (1:1).  
2-amino-6-bromo-3-(4-(methylsulfonyl)phenyl)quinazolin-4(3H)-one, 2.7b 
White solid (0.571 g, 77%); Rf (100% EtOAc) 0.18; 
1H NMR (400 MHz, DMSO-d6) δ 8.15 (d, J = 8.7 Hz, 
2H, H4), 8.03 (d, J = 2.3 Hz, 1H, H1), 7.88 (dd, J = 
8.8, 2.4 Hz, 1H, H2), 7.74 (d, J = 8.7 Hz, 2H, H5), 
7.48 (br s, 2H, H7), 7.33 (d, J = 8.8 Hz, 1H, H3), 
3.30 (s, 3H, H6); 13C NMR (101 MHz, DMSO-d6) δ 
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160.34, 158.80, 152.16, 142.39, 139.19, 138.36, 130.74 (2C), 129.48 (2C), 
129.19, 124.11, 118.20, 114.81, 43.97; LC-MS (APCI/ESI): Purity = 99%, tR 
= 4.27 min, m/z [M+H]+ = 394.0, 396.0 (1:1).  
2-amino-6-bromo-3-(2-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 2.7c 
White solid (0.263 g, 71%); Rf (100% EtOAc) 0.37; 1H NMR (400 MHz, DMSO-
d6) δ 7.95 (d, J = 2.5 Hz, 1H, H1), 7.95–7.93 (m, 1H, 
H7), 7.89 (td, J = 7.7, 0.9 Hz, 1H, H5), 7.81–7.77 (m, 
1H, H6), 7.75 (dd, J = 8.8, 2.5 Hz, 1H, H2), 7.63 (d, J = 
7.8 Hz, 1H, H4), 7.22 (d, J = 8.8 Hz, 1H, H3), 6.66 (br 
s, 2H, H8); 13C NMR (101 MHz, DMSO-d6) δ 161.37, 
152.41, 149.98, 137.83, 135.06, 133.30, 132.30, 
130.98, 128.81, 128.39, 128.34, 127.70, 126.95, 
118.21, 113.40; LC-MS (APCI/ESI): Purity = 97%, tR = 3.80 min, m/z [M+H]+ 
= 384.0, 386.0 (1:1). 
2-amino-6-bromo-3-(6-(trifluoromethyl)pyridin-3-yl)quinazolin-4(3H)-one, 2.7d 
White solid (0.241 g, 64%); Rf (EtOAc:Hex, 80:20) 0.35; 1H NMR (400 MHz, 
DMSO-d6) δ 8.83 (d, J = 2.3 Hz, 1H, H6), 8.22 (dd, 
J = 7.7, 2.3 Hz, 1H, H4), 8.13 (d, J = 7.6 Hz, 1H, 
H5), 7.97 (d, J = 2.4 Hz, 1H, H1), 7.77 (dd, J = 8.8, 
2.5 Hz, 1H, H2), 7.23 (d, J = 8.7 Hz, 1H, H3), 6.80 
(br s, 2H, H7); 13C NMR (101 MHz, DMSO-d6) δ 
161.45, 152.06, 151.03, 149.99, 147.28, 146.94, 
139.92, 137.85, 135.80, 128.82, 126.97, 122.72, 
118.46, 113.42; LC-MS (APCI/ESI): Purity > 99%, tR = 3.73 min, m/z [M+H]+ 
= 385.0, 387.0 (1:1). 
2-amino-6-bromo-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 2.7e 
White crystalline solid (0.411 g, 57%); Rf 
(EtOAc:Hex, 70:30) 0.49; 1H NMR (400 MHz, 
DMSO-d6) δ 7.96 (d, J = 2.4 Hz, 1H, H1), 7.94 (d, J 
= 8.3 Hz, 2H, H5), 7.75 (dd, J = 8.8, 2.5 Hz, 1H, 
H2), 7.65 (d, J = 8.1 Hz, 2H, H4), 7.22 (d, J = 8.8 
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Hz, 1H, H3), 6.67 (br s, 2H, H6); 13C NMR (101 MHz, DMSO-d6) δ 161.19, 
152.18, 149.52, 139.40, 137.69, 130.60 (2C), 130.08, 128.85, 127.62, 
127.58, 126.68, 123.18, 118.64, 113.43; LC-MS (APCI/ESI): Purity > 99%, 
tR = 3.50 min, m/z [M+H]+ = 384.0, 386.0 (1:1).  
4-(2-amino-6-bromo-4-oxoquinazolin-3(4H)-yl)benzonitrile, 2.7f 
Off-white solid (0.302 g, 54%); Rf (EtOAc:Hex, 80:20) 0.22; 1H NMR (400 
MHz, DMSO-d6) δ 8.05 (d, J = 8.7 Hz, 2H, H4), 7.95 
(d, J = 2.5 Hz, 1H, H1), 7.74 (dd, J = 8.8, 2.5 Hz, 
1H, H2), 7.64 (d, J = 8.7 Hz, 2H, H5), 7.21 (d, J = 
8.8 Hz, 1H, H3), 6.59 (br s, 2H, H6); 13C NMR (101 
MHz, DMSO-d6) δ 161.16, 151.99, 149.90, 140.11, 
137.68, 134.62 (2C), 130.91 (2C), 128.80, 126.90, 
118.93, 118.65, 113.33, 112.74; LC-MS (APCI/ESI): 
Purity = 93%, tR = 3.32 min, m/z [M+H]+ = 341.0, 343.0 (1:1). 
2-amino-6-bromo-3-(4-hydroxyphenyl)quinazolin-4(3H)-one, 2.7g 
White solid (0.320 g, 58%); Rf (100% EtOAc) 0.39; 1H NMR (400 MHz, 
DMSO-d6) δ 9.81 (br s, 1H, H6), 7.94 (d, J = 2.5 Hz, 
1H, H1), 7.71 (dd, J = 8.8, 2.5 Hz, 1H, H2), 7.18 (d, 
J = 8.8 Hz, 1H, H3), 7.13 (d, J = 8.8 Hz, 2H, H4), 
6.91 (d, J = 8.8 Hz, 2H, H5), 6.36 (br s, 2H, H7); 13C 
NMR (101 MHz, DMSO-d6) δ 161.48, 158.46, 
153.13, 149.70, 137.39, 130.12 (2C), 128.85, 
126.82, 126.39, 118.87, 117.02 (2C), 113.17; LC-
MS (APCI/ESI): Purity > 99%, tR = 3.06 min, m/z [M+H]+ = 332.0, 334.0 
(1:1). 
2-amino-6-bromo-3-(4-fluorophenyl)quinazolin-4(3H)-one, 2.7h 
White solid (0.600 g, 77%); Rf (100% EtOAc) 0.36; 1H 
NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 2.4 Hz, 1H, 
H1), 7.73 (dd, J = 8.8, 2.5 Hz, 1H, H2), 7.48–7.35 (m, 
4H, H4,5), 7.20 (d, J = 8.8 Hz, 1H, H3), 6.52 (br s, 2H, 
H6); 13C NMR (101 MHz, DMSO-d6) δ 164.03, 161.40, 
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152.70, 149.83, 137.51, 131.85, 131.63, 131.54, 128.84, 126.85, 118.76, 
117.49, 117.26, 113.21; LC-MS (APCI/ESI): Purity > 99%, tR = 3.44 min, 
m/z [M+H]+ = 334.0, 336.0 (1:1).  
2-amino-6-bromo-3-(2-fluorophenyl)quinazolin-4(3H)-one, 2.7i 
White solid (0.573 g, 73%); Rf (100% EtOAc) 0.33; 1H NMR (400 MHz, 
DMSO-d6) δ 7.97 (d, J = 2.5 Hz, 1H, H1), 7.76 (dd, J = 
8.8, 2.5 Hz, 1H, H2), 7.60 (dddd, J = 8.4, 7.2, 5.2, 1.8 
Hz, 1H, H6), 7.52 (td, J = 7.8, 1.7 Hz, 1H, H5), 7.47 
(ddd, J = 9.8, 8.4, 1.2 Hz, 1H, H7), 7.40 (td, J = 7.7, 
1.3 Hz, 1H, H4), 7.22 (d, J = 8.8 Hz, 1H, H3), 6.73 (br 
s, 2H, H8); 13C NMR (101 MHz, DMSO-d6) δ 160.78, 
159.39, 156.92, 152.24, 149.83, 137.90, 132.29, 
131.42, 128.88, 126.93, 126.29, 118.20, 117.27, 113.57; LC-MS 
(APCI/ESI): Purity > 99%, tR = 3.51 min, m/z [M+H]+ = 334.0, 336.0 (1:1). 
2-amino-6-bromo-3-(4-methoxyphenyl)quinazolin-4(3H)-one, 2.7j 
Off-white solid (0.550 g, 80%); Rf (100% EtOAc) 0.24; 1H NMR (400 MHz, 
DMSO-d6) δ 7.95 (d, J = 2.4 Hz, 1H, H1), 7.72 (dd, 
J = 8.8, 2.5 Hz, 1H, H2), 7.28 (d, J = 8.9 Hz, 2H, 
H4), 7.19 (d, J = 8.8 Hz, 1H, H3), 7.11 (d, J = 8.9 
Hz, 2H, H5), 6.41 (br s, 2H, H7), 3.84 (s, 3H, H6); 
13C NMR (101 MHz, DMSO-d6) δ 161.47, 160.10, 
153.02, 149.76, 137.42, 130.31 (2C), 128.86, 
128.02, 126.84, 118.85, 115.72 (2C), 113.18, 
55.88; LC-MS (APCI/ESI): Purity = 99%, tR = 3.57 min, m/z [M+H]+ = 346.0, 
348.0 (1:1). 
General procedure 8: Synthesis of SAR 2 2-aminoquinazolinone-based 
target compounds 32−44 [Suzuki-Miyaura cross-coupling reaction] 
The appropriate arylboronic acid [in most cases, 3-(methylsulfinyl)phenyl) 
boronic acid] (1.2 Eq) and the corresponding 2-amino-6-bromo-
quinazolinone-based intermediate 2.7 (a−j) (1.0 Eq) were dissolved in DMF 
(5 mL). The mixture was flushed with nitrogen gas for about 10 min at room 
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temperature, after which Pd(PPh3)2Cl2 (0.05 Eq) and K2CO3 (3 Eq) were 
added successively, and the mixture heated at 100 °C for 1 to 4 h. After 
cooling to room temperature, the mixture was diluted with EtOAc (10 mL) 
and water (30 mL), and the extracted with EtOAc (20 mL × 3). The combined 
organic fractions were filtered through a pad of celite, washed with 5% LiCl 
(30 mL × 3), brine (30 mL × 2), and dried over anhydrous MgSO4. The 
solvents were then removed in vacuo to yield a residue that was purified by 
column chromatography using Biotage Isolera One® machine, SiO2 (10 g 
cartridge), DCM/MeOH, with fractions being collected at the λmax and 
monitored at 254 nm. Finally, the solvents were rotary evaporated to give a 
solid that was then triturated with Et2O, filtered, or recrystallized in an 
appropriate solvent [ethanol was used in most cases], and dried to furnish 
the desired final target compound. 
2-amino-6-(3-(methylsulfinyl)phenyl)-3-phenylquinazolin-4(3H)-one, 32
White solid (0.170 g, 55%); m.p. 229.6–232.8 ºC; Rf (MeOH:DCM, 8:92) 0.32; 
1H NMR (400 MHz, DMSO-d6) δ 8.22 (d, J = 
1.8 Hz, 1H, H1), 8.03 (dd, J = 8.5, 1.8 Hz, 1H, 
H2), 7.98 (s, 1H, H8), 7.90–7.82 (m, 1H, H9), 
7.73–7.51 (m, 5H, H4,5,6), 7.46–7.31 (m, 3H, 
H3,10,11), 6.39 (br s, 2H, H7), 2.82 (s, 3H, H12); 
13C NMR (101 MHz, DMSO-d6) δ 162.29, 
152.50, 150.48, 147.89, 140.86, 135.86, 
133.50, 132.53, 130.49 (2C), 129.74, 129.29 (2C), 128.86, 125.25, 124.79, 
122.61, 122.38, 121.49, 117.56, 43.75; LC-MS (APCI/ESI): Purity = 95%, tR
= 3.78 min, m/z [M+H]+ = 376.1. 
2-amino-6-(3-(methylsulfinyl)phenyl)-3-(p-tolyl)quinazolin-4(3H)-one, 33
Off-white solid (0.100 g, 32%); m.p. 243.9–
250.8 ºC; Rf (MeOH:DCM, 8:92) 0.42; 1H 
NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 
2.3 Hz, 1H, H1), 8.02 (dd, J = 8.6, 2.4 Hz, 
1H, H2), 7.98 (dd, J = 2.2, 1.3 Hz, 1H, H8), 
7.87 (dt, J = 6.6, 2.2 Hz, 1H, H9), 7.70–
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7.63 (m, 2H, H10,11), 7.40 (d, J = 8.5 Hz, 2H, H4), 7.37 (d, J = 8.8 Hz, 1H, 
H3), 7.26 (d, J = 8.3 Hz, 2H, H5), 6.36 (br s, 2H, H7), 2.82 (s, 3H, H12), 2.42 
(s, 3H, H6); 13C NMR (101 MHz, DMSO-d6) δ 162.34, 152.65, 150.50, 
147.88, 140.87, 139.13, 133.44, 133.22, 132.47, 131.02 (2C), 130.44, 
128.97 (2C), 128.85, 125.25, 124.79, 122.59, 121.48, 117.56, 43.74, 21.34; 
LC-MS (APCI/ESI): Purity = 97%, tR = 3.42 min, m/z [M+H]+ = 390.1.  
2-amino-6-(3-(methylsulfinyl)phenyl)-3-(3-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 34 
Off-white solid (0.169 g, 55%); m.p. 152.1–153.9 ºC; Rf (MeOH:DCM, 8:92) 
0.36; 1H NMR (400 MHz, DMSO-d6) δ 8.21 
(d, J = 2.3 Hz, 1H, H1), 8.03 (dd, J = 8.6, 
2.4 Hz, 1H, H2), 7.98 (s, 1H, H4), 7.90 (d, 
J = 8.3 Hz, 1H, H7), 7.88–7.84 (m, 2H, 
H5,12), 7.82 (t, J = 7.8 Hz, 1H, H11), 7.73 
(d, J = 8.0 Hz, 1H, H10), 7.68 (t, J = 6.1 
Hz, 1H, H6), 7.67 (s, 1H, H9), 7.38 (d, J = 
8.6 Hz, 1H, H3), 6.57 (br s, 2H, H8), 2.82 (s, 3H, H13); 13C NMR (101 MHz, 
DMSO-d6) δ 162.41, 152.24, 150.69, 147.90, 140.85, 136.75, 133.84, 
133.59, 132.50, 131.60, 131.32, 131.00, 130.46, 128.84, 126.80, 126.64, 
125.31, 124.76, 122.63, 121.47, 117.45, 43.74; LC-MS (APCI/ESI): Purity = 
96%, tR = 3.72 min, m/z [M+H]+ = 444.1. 
2-amino-6-(3-(methylsulfinyl)phenyl)-3-(2-(trifluoromethyl)phenyl)quinazolin-4(3H)-one, 35 
Off-white solid (0.080 g, 33%); m.p. 135.7–138.3 ºC; Rf (MeOH:DCM, 6:94) 
0.26; 1H NMR (400 MHz, DMSO-d6) δ 8.20 (d, 
J = 2.4 Hz, 1H, H1), 8.04 (dd, J = 8.6, 2.4 Hz, 
1H, H2), 8.00–7.94 (m, 2H, H9,10), 7.91 (dd, J 
= 7.7, 0.9 Hz, 1H, H7), 7.89–7.86 (m, 1H, 
H12), 7.82–7.75 (m, 1H, H11), 7.69–7.62 (m, 
3H, H4,5,6), 7.38 (d, J = 8.6 Hz, 1H, H3), 6.61 
(br s, 2H, H8), 2.82 (s, 3H, H13); 13C NMR 
(101 MHz, DMSO-d6) δ 162.38, 152.32, 150.76, 147.88, 140.75, 135.04, 
133.78, 133.59, 132.62, 132.36, 130.91, 130.43, 128.89, 128.40, 127.80, 
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127.50, 125.37, 124.75, 122.62, 121.55, 116.99, 43.76; LC-MS (APCI/ESI): 
Purity = 97%, tR = 3.35 min, m/z [M+H]+ = 444.1. 
2-amino-6-(3-(methylsulfinyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)quinazolin-4(3H)-one, 36 
Off-white solid (0.130 g, 56%); m.p. 153.0–155.8 ºC; Rf (MeOH:DCM, 6:94) 
0.16; 1H NMR (400 MHz, DMSO-d6) δ 
8.86 (d, J = 2.3 Hz, 1H, H6), 8.25 (dd, J = 
8.3, 2.3 Hz, 1H, H4), 8.22 (d, J = 2.3 Hz, 
1H, H1), 8.14 (d, J = 8.3 Hz, 1H, H5), 8.05 
(dd, J = 8.6, 2.4 Hz, 1H, H2), 7.98 (dd, J = 
2.2, 1.2 Hz, 1H, H8), 7.91–7.84 (m, 1H, 
H9), 7.71–7.64 (m, 2H, H10,11), 7.39 (d, J = 
8.6 Hz, 1H, H3), 6.78 (br s, 2H, H7), 2.82 (s, 3H, H12); 13C NMR (101 MHz, 
DMSO-d6) δ 162.46, 151.95, 151.09, 150.74, 147.90, 147.22, 146.88, 
140.73, 139.95, 136.01, 133.83, 132.67, 130.46, 128.87, 125.41, 124.74, 
123.42, 122.68, 121.50, 117.15, 43.74; LC-MS (APCI/ESI): Purity = 99%, tR 
= 3.38 min, m/z [M+H]+ = 445.1. 
4-(2-amino-6-(3-(methylsulfinyl)phenyl)-4-oxoquinazolin-3(4H)-yl)benzonitrile, 37 
Off-white solid (0.070 g, 32%); m.p. 331.7–334.5 ºC; Rf (MeOH:DCM, 6:94) 
0.19; 1H NMR (400 MHz, DMSO-d6) δ 8.21 
(d, J = 2.2 Hz, 1H, H1), 8.07 (d, J = 8.6 Hz, 
2H, H4), 8.03 (dd, J = 8.6, 2.4 Hz, 1H, H2), 
7.98 (s, 1H, H7), 7.86 (dt, J = 6.7, 2.1 Hz, 
1H, H8), 7.71–7.63 (m, 4H, H5,9,10), 7.37 
(d, J = 8.6 Hz, 1H, H3), 6.57 (br s, 2H, H6), 
2.82 (s, 3H, H11); 13C NMR (101 MHz, 
DMSO-d6) δ 162.17, 151.89, 150.67, 147.86, 140.79, 140.35, 134.63 (2C), 
133.67, 132.57, 130.98 (2C), 130.46, 128.86, 125.34, 124.73, 122.66, 
121.47, 118.96, 117.35, 112.70, 43.73; LC-MS (APCI/ESI): Purity = 98%, tR 
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Off-white solid (0.113 g, 38%); m.p. 255.6–259.5 ºC; Rf (MeOH:DCM, 6:94) 
0.19; 1H NMR (400 MHz, DMSO-d6) δ 8.21 
(d, J = 2.2 Hz, 1H, H1), 8.07–7.99 (m, 3H, 
H2,7,9), 7.98 (s, 1H, H4), 7.87 (dt, J = 6.6, 
2.1 Hz, 1H, H10), 7.81–7.75 (m, 2H, H5,11), 
7.71–7.63 (m, 2H, H6,12), 7.38 (d, J = 8.6 
Hz, 1H, H3), 6.60 (br s, 2H, H8), 2.82 (s, 
3H, H13); 13C NMR (101 MHz, DMSO-d6) δ 
162.31, 152.12, 150.67, 147.90, 140.80, 136.89, 134.90, 133.67 (3C), 
132.56, 131.74, 130.46, 128.86, 125.34, 124.74, 122.65, 121.48, 118.69, 
117.37, 113.47, 43.74; LC-MS (APCI/ESI): Purity > 99%, tR = 2.88 min, m/z 
[M+H]+ = 401.1.  
2-amino-6-(3-(methylsulfinyl)phenyl)-3-(4-(methylsulfonyl)phenyl)quinazolin-4(3H)-one, 39 
Off-white solid (0.070 g, 20%); m.p. 298.3–301.9 ºC; Rf (MeOH:DCM, 6:94) 
0.15; 1H NMR (400 MHz, DMSO-d6) δ 
8.21 (d, J = 2.2 Hz, 1H, H1), 8.13 (d, J = 
8.5 Hz, 2H, H4), 8.04 (dd, J = 8.6, 2.3 
Hz, 1H, H2), 7.98 (s, 1H, H8), 7.87 (dt, J 
= 7.4, 1.9 Hz, 1H, H9), 7.71 (d, J = 8.4 
Hz, 2H, H5), 7.69–7.63 (m, 2H, H10,11), 
7.39 (d, J = 8.6 Hz, 1H, H3), 6.57 (br s, 
2H, H7), 3.31 (s, 3H, H6), 2.82 (s, 3H, H12); 13C NMR (101 MHz, DMSO-d6) δ 
162.25, 151.99, 150.65, 147.85, 141.87, 140.80, 140.53, 133.70, 132.60, 
130.76 (2C), 130.47, 129.33 (2C), 128.89, 125.35, 124.73, 122.67, 121.48, 
117.34, 44.02, 43.73; LC-MS (APCI/ESI): Purity > 99%, tR = 2.67 min, m/z 
[M+H]+ = 454.1. 
2-amino-3-(4-methoxyphenyl)-6-(3-(methylsulfinyl)phenyl)quinazolin-4(3H)-one, 40 
Off-white solid (0.172 g, 81%); m.p. 237.7–241.7 ºC; Rf (MeOH:DCM, 5:95) 
0.14; 1H NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 2.3 Hz, 1H, H1), 8.01 (dd, 
J = 8.6, 2.3 Hz, 1H, H2), 7.98 (s, 1H, H8), 7.87 (dt, J = 6.7, 2.0 Hz, 1H, H9), 
7.71–7.63 (m, 2H, H10,11), 7.36 (d, J = 8.6 Hz, 1H, H3), 7.30 (d, J = 8.9 Hz, 
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2H, H4), 7.12 (d, J = 8.9 Hz, 2H, H5), 6.38 
(br s, 2H, H7), 3.85 (s, 3H, H6), 2.82 (s, 
3H, H12); 13C NMR (101 MHz, DMS-d6) δ 
162.48, 160.06, 152.92, 150.51, 147.87, 
140.89, 133.40, 132.41, 130.44, 130.37 
(2C), 128.84, 128.25, 125.23, 124.80, 
122.58, 121.46, 117.56, 115.73 (2C), 
55.88, 43.74; LC-MS (APCI/ESI): Purity = 97%, tR = 3.16 min, m/z [M+H]+ = 
406.1. 
2-amino-3-(4-hydroxyphenyl)-6-(3-(methylsulfinyl)phenyl)quinazolin-4(3H)-one, 41 
White solid (0.110 g, 40%); m.p. 294.4–300.1 ºC; Rf (MeOH:DCM, 10:90) 
0.32; 1H NMR (400 MHz, DMSO-d6) δ 9.80 
(br s, 1H, H6), 8.20 (d, J = 2.2 Hz, 1H, H1), 
8.01 (dd, J = 8.6, 2.3 Hz, 1H, H2), 7.97 (s, 
1H, H8), 7.86 (dt, J = 6.8, 2.0 Hz, 1H, H9), 
7.72–7.62 (m, 2H, H10,11), 7.35 (d, J = 8.6 
Hz, 1H, H3), 7.15 (d, J = 8.8 Hz, 2H, H4), 
6.93 (d, J = 8.8 Hz, 2H, H5), 6.33 (br s, 
2H, H7), 2.82 (s, 3H, H12); 13C NMR (101 MHz, DMSO-d6) δ 162.50, 158.41, 
153.05, 150.52, 147.87, 140.91, 133.36, 132.38, 130.44, 130.19 (2C), 
128.84, 126.65, 125.24, 124.81, 122.57, 121.47, 117.60, 117.03 (2C), 
43.74; LC-MS (APCI/ESI): Purity > 99%, tR = 2.66 min, m/z [M+H]+ = 392.1. 
2-amino-3-(4-fluorophenyl)-6-(3-(methylsulfinyl)phenyl)quinazolin-4(3H)-one, 42 
White solid (0.188 g, 71%); m.p. 232.6–238.1 ºC; Rf (MeOH:DCM, 6:94) 0.22; 
1H NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 
2.2 Hz, 1H, H1), 8.02 (dd, J = 8.6, 2.4 Hz, 
1H, H2), 7.98 (s, 1H, H7), 7.86 (dt, J = 6.7, 
2.1 Hz, 1H, H8), 7.71–7.63 (m, 2H, H9,10), 
7.50–7.38 (m, 4H, H4,5), 7.37 (d, J = 8.6 Hz, 
1H, H3), 6.49 (br s, 2H, H6), 2.82 (s, 3H, 
H11); 13C NMR (101 MHz, DMSO-d6) δ 
164.00, 162.41, 161.56, 152.61, 150.62, 147.89, 140.86, 133.49, 132.44, 
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132.09, 131.68, 131.59, 130.44, 128.83, 125.27, 124.77, 122.60, 121.46, 
117.48, 117.26, 43.74; LC-MS (APCI/ESI): Purity = 98%, tR = 3.05 min, m/z 
[M+H]+ = 394.1. 
2-amino-3-(2-fluorophenyl)-6-(3-(methylsulfinyl)phenyl)quinazolin-4(3H)-one, 43 
White solid (0.234 g, 66%); m.p. 263.1–268.4 ºC; Rf (MeOH:DCM, 6:94) 0.20; 
1H NMR (400 MHz, DMSO-d6) δ 8.22 (d, J = 
2.3 Hz, 1H, H1), 8.05 (dd, J = 8.6, 2.4 Hz, 1H, 
H2), 7.99 (s, 1H, H9), 7.88 (ddd, J = 6.4, 2.6, 
2.0 Hz, 1H, H10), 7.71–7.65 (m, 2H, H11,12), 
7.64–7.58 (m, 1H, H6), 7.54 (td, J = 7.8, 1.7 
Hz, 1H, H5), 7.48 (ddd, J = 9.8, 8.4, 1.2 Hz, 
1H, H7), 7.44–7.37 (m, 2H, H3,4), 6.68 (br s, 
2H, H8), 2.82 (s, 3H, H13); 13C NMR (101 MHz, DMSO-d6) δ 161.81, 159.48, 
157.00, 152.16, 150.67, 147.90, 140.76, 133.85, 132.76, 132.28, 131.49, 
130.45, 128.90, 126.28, 125.38, 124.82, 122.66, 121.56, 117.46, 116.98, 
43.74; LC-MS (APCI/ESI): Purity > 99%, tR = 3.08 min, m/z [M+H]+ = 394.1. 
2-amino-3-(2-fluorophenyl)-6-(3-(methylsulfonyl)phenyl)quinazolin-4(3H)-one, 44 
White solid (0.200 g, 76%); m.p. 270.0–273.9 ºC; Rf (MeOH:DCM, 6:94) 0.35; 
1H NMR (400 MHz, DMSO-d6) δ 8.25 (d, J = 
2.2 Hz, 1H, H1), 8.21 (t, J = 1.7 Hz, 1H, H9), 
8.11–8.04 (m, 2H, H2,12), 7.91 (ddd, J = 7.8, 
1.7, 1.0 Hz, 1H, H10), 7.75 (t, J = 7.8 Hz, 1H, 
H11), 7.65–7.58 (m, 1H, H6), 7.55 (td, J = 
7.8, 1.7 Hz, 1H, H5), 7.49 (ddd, J = 9.8, 8.4, 
1.2 Hz, 1H, H7), 7.45–7.37 (m, 2H, H3,4), 
6.71 (br s, 2H, H8), 3.31 (s, 3H, H13); 13C NMR (101 MHz, DMSO-d6) δ 
162.77, 161.79, 159.48, 157.00, 152.27, 150.87, 142.23, 140.94, 133.88, 
132.09, 131.71, 131.48, 130.67, 126.27, 125.86, 125.47, 125.06, 124.95, 
117.47, 117.02, 43.95; LC-MS (APCI/ESI): Purity = 98%, tR = 3.04 min, m/z 
[M+H]+ = 410.1. 
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6.2.4.2 Benzoxazole-Based Oxime Series 
The synthetic protocols followed in the synthesis of benzoxazole-based oxime 
analogues were based on various methods reported in literature, which were 
appropriately modified to generate the relevant synthetic schemes.4–9 
2-cyanoacetimidic acid ethyl ester hydrochloride, 2.8
Ethanol (13.3 mL, 228 mmol, 2.0 Eq), TMSCl (14.5 mL, 114 mmol, 1.0 Eq), 
and malononitrile (7.5 g, 114 mmol, 1.0 Eq) were sequentially added to a dry 
round bottom flask (100 mL) at 0 ºC, and stirred at this temperature for 17 
h under nitrogen atmosphere. The solids in the mixture were then filtered, 
washed thoroughly with dry Et2O, and dried in vacuo to 
furnish 2.8 as an off-white crystalline solid (14.1 g, 83%); 
1H NMR (300 MHz, DMSO-d6) δ 4.16 (q, J = 7.1 Hz, 2H, 
H3), 4.00 (s, 2H, H1), 3.87 (br s, 2H, H2), 1.21 (t, J = 7.1 
Hz, 3H, H4); 13C NMR (101 MHz, DMSO-d6) δ 164.75, 
115.51, 62.37, 24.98, 14.33. 
General procedure 9: Synthesis of Benzoxazole-2-acetonitrile-based 
intermediates 2.9a–2.9o 
An appropriately substituted 2-aminophenol (1.0 Eq) was added to a stirred 
suspension of 2.8 (1.2 Eq) in dry DCM and stirred at 25 ºC for 10 min. The 
mixture was then heated to reflux at 50 ºC for 20 h, cooled to room 
temperature, filtered, and the solids discarded. This was followed by 
concentration of the filtrate under reduced pressure to yield a crude residue, 
which was washed with water, dried, and recrystallized in EtOAc:Hex 
mixture to afford the desired product. 
2-(benzo[d]oxazol-2-yl)acetonitrile, 2.9a 
Off-white solid (6.800 g, 69%); Rf (EtOAc:Hex, 3:7) 0.30; 1H NMR (300 MHz, 
DMSO-d6) δ 7.81–7.71 (m, 1H, H4), 7.62–7.52 (m, 1H, 
H1), 7.48–7.33 (m, 2H, H2,3), 4.13 (s, 2H, H5); LC-MS 




Chapter 6: Experimental 




Brown crystalline solid (0.860 g, 73%); Rf (EtOAc:Hex, 20:80) 0.22; 1H NMR 
(300 MHz, DMSO-d6) δ 7.63 (d, J = 8.1 Hz, 1H, H3), 7.56 
(dt, J = 1.5, 0.7 Hz, 1H, H1), 7.23 (ddd, J = 8.1, 1.5, 0.6 
Hz, 1H, H2), 4.66 (s, 2H, H4), 2.45 (s, 3H, H5); 13C NMR 
(101 MHz, DMSO-d6) δ 157.37, 151.31, 138.68, 136.16, 
126.45, 119.61, 115.58, 111.29, 21.65, 18.78; LC-MS 
(APCI/ESI): Purity > 99%, tR = 2.43 min, m/z [M-H]− = 
171.1. 
2-(4-methylbenzo[d]oxazol-2-yl)acetonitrile, 2.9c 
Yellow solid (0.501 g, 43%); Rf (EtOAc:Hex, 50:50) 0.51; 
1H NMR (300 MHz, DMSO-d6) δ 7.55 (d, J = 8.1 Hz, 1H, 
H1), 7.32 (t, J = 7.8 Hz, 1H, H2), 7.22 (d, J = 7.5 Hz, 1H, 
H3), 4.68 (s, 2H, H4), 2.54 (s, 3H, H5); LC-MS 
(APCI/ESI): Purity > 99%, tR = 2.30 min, m/z [M-H]− = 
171.1. 
2-(5-methylbenzo[d]oxazol-2-yl)acetonitrile, 2.9d 
Yellow solid (1.010 g, 86%); Rf (EtOAc:Hex, 50:50) 0.53; 
1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 1.6 Hz, 1H, H3), 
7.43 (d, J = 8.4 Hz, 1H, H1), 7.22 (dd, J = 8.4, 1.2 Hz, 
1H, H2), 4.10 (s, 2H, H4), 2.49 (s, 3H, H5); LC-MS 
(APCI/ESI): Purity > 99%, tR = 2.25 min, m/z [M−H]− = 
171.1. 
2-(5-bromobenzo[d]oxazol-2-yl)acetonitrile, 2.9e 
Orange crystalline solid (1.13 g, 71%); Rf (EtOAc:Hex, 30:70) 0.26; 1H NMR 
(300 MHz, DMSO-d6) δ 8.04 (d, J = 1.8 Hz, 1H, H3), 7.77 
(d, J = 8.7 Hz, 1H, H1), 7.61 (dd, J = 8.7, 1.9 Hz, 1H, H2), 
4.71 (s, 2H, H4); 13C NMR (101 MHz, DMSO-d6) δ 159.68, 
150.21, 142.60, 128.92, 122.99, 117.31, 115.32, 
113.26, 18.98; LC-MS (APCI/ESI): Purity = 97%, tR = 
2.82 min, m/z [M-H]− = 235.0, 237.0 (1:1). 
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Brown solid (0.854 g, 54%); Rf (EtOAc:Hex, 50:50) 0.50; 1H NMR (400 MHz, 
DMSO-d6) δ 8.12 (d, J = 1.8 Hz, 1H, H1), 7.74 (d, J = 8.5 
Hz, 1H, H3), 7.59 (dd, J = 8.5, 1.8 Hz, 1H, H2), 4.69 (s, 
2H, H4); 13C NMR (101 MHz, DMSO-d6) δ 158.95, 
151.62, 140.27, 128.59, 121.72, 118.17, 115.32, 
114.80, 18.91; LC-MS (APCI/ESI): Purity > 99%, tR = 
2.69 min, m/z [M-H]− = 235.0, 237.0 (1:1). 
Methyl 2-(cyanomethyl)benzo[d]oxazole-6-carboxylate, 2.9g 
Yellow solid (1.16 g, 80%); Rf (EtOAc:Hex, 30:70) 0.15; 1H NMR (400 MHz, 
DMSO-d6) δ 8.29 (d, J = 1.1 Hz, 1H, H1), 8.03 (dd, J = 
8.4, 1.5 Hz, 1H, H2), 7.90 (d, J = 8.4 Hz, 1H, H3), 
4.76 (s, 2H, H4), 3.91 (s, 3H, H5); 13C NMR (101 MHz, 
DMSO-d6) δ 166.17, 161.26, 150.79, 144.79, 127.54, 
126.60, 120.31, 115.26, 112.47, 52.93, 19.19; LC-
MS (APCI/ESI): Purity = 97%, tR = 2.16 min, m/z [M-
H]− = 215.1. 
2-(6-(trifluoromethyl)benzo[d]oxazol-2-yl)acetonitrile, 2.9h 
Yellow solid (1.080 g, 71%); Rf (EtOAc:Hex, 50:50) 0.49; 
1H NMR (300 MHz, DMSO-d6) δ 8.30 (s, 1H, H1), 8.00 
(d, J = 8.4 Hz, 1H, H3), 7.78 (dd, J = 8.4, 1.0 Hz, 1H, 
H2), 4.78 (s, 2H, H4); LC-MS (APCI/ESI): Purity = 92%, 
tR = 2.96 min, m/z [M-H]− = 225.0. 
2-(6-chlorobenzo[d]oxazol-2-yl)acetonitrile, 2.9i 
Dark brown solid (0.950 g, 73%); Rf (EtOAc:Hex, 50:50) 
0.53; 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J = 8.5 Hz, 
1H, H3), 7.59 (d, J = 1.7 Hz, 1H, H1), 7.39 (dd, J = 8.5, 
1.9 Hz, 1H, H2), 4.12 (s, 2H, H4); LC-MS (APCI/ESI): 
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Yellow solid (0.570 g, 44%); Rf (EtOAc:Hex, 50:50) 0.53; 
1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 2.0 Hz, 1H, H3), 
7.50 (d, J = 8.7 Hz, 1H, H1), 7.39 (dd, J = 8.7, 2.1 Hz, 
1H, H2), 4.13 (s, 2H, H4); LC-MS (APCI/ESI): Purity > 99 
%, tR = 2.36 min, m/z [M-H]− = 191.0. 
2-(6-fluorobenzo[d]oxazol-2-yl)acetonitrile, 2.9k 
Dark brown solid (0.750 g, 63%); Rf (EtOAc:Hex, 50:50) 
0.49; 1H NMR (300 MHz, CDCl3) δ 7.70 (dd, J = 8.8, 4.8 
Hz, 1H, H3), 7.30 (dd, J = 7.7, 2.2 Hz, 1H, H1), 7.15 (ddd, 
J = 9.5, 8.8, 2.4 Hz, 1H, H2), 4.12 (s, 2H, H4); LC-MS 
(APCI/ESI): Purity = 95%, tR = 1.09 min, m/z [M-H]− = 
175.0. 
2-(5-fluorobenzo[d]oxazol-2-yl)acetonitrile, 2.9l 
Yellow solid (1.050 g, 87%); Rf (EtOAc:Hex, 50:50) 0.50; 
1H NMR (300 MHz, CDCl3) δ 7.51 (dd, J = 9.0, 4.2 Hz, 1H, 
H1), 7.44 (dd, J = 8.1, 2.5 Hz, 1H, H3), 7.16 (td, J = 9.1, 
2.6 Hz, 1H, H2), 4.13 (s, 2H, H4); LC-MS (APCI/ESI): 
Purity = 95%, tR = 1.07 min, m/z [M-H]− = 175.0. 
2-(6-nitrobenzo[d]oxazol-2-yl)acetonitrile, 2.9m 
Brown solid (1.400 g, 90%); Rf (100% DCM) 0.31; 1H 
NMR (300 MHz, DMSO-d6) δ 8.77 (d, J = 2.1 Hz, 1H, 
H1), 8.33 (dd, J = 8.8, 2.2 Hz, 1H, H2), 8.02 (d, J = 8.8 
Hz, 1H, H3), 4.81 (s, 2H, H4); LC-MS (APCI/ESI): Purity 
> 99%, tR = 0.67 min, m/z [M-H]− = 202.0. 
2-(6-aminobenzo[d]oxazol-2-yl)acetonitrile, 2.9n 
To a solution of 2-(6-nitrobenzo[d]oxazol-2-yl)acetonitrile, 2.9m (1.300 g, 
6.40 mmol, 1.0 Eq) in methanol (25 mL), 10% palladium on carbon catalyst 
[Pd/C] (0.390 g) was added. The reaction flask was then sealed, evacuated 
twice, filled with H2 gas, and stirred at 25 ºC for 15 h. The reaction mixture 
was then filtered through a pad of celite and concentrated. A black oily 
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substance was obtained, which was then purified by column 
chromatography (SiO2, 100% DCM) to furnish 2.9n as a 
yellow solid (0.620 g, 56%); Rf (MeOH:DCM, 2:98) 0.31; 
1H NMR (300 MHz, DMSO-d6) δ 7.36 (d, J = 8.5 Hz, 1H, 
H3), 6.77 (d, J = 2.0 Hz, 1H, H1), 6.63 (dd, J = 8.5, 2.0 
Hz, 1H, H2), 5.38 (br s, 2H, H5), 4.52 (s, 2H, H4); 13C 
NMR (101 MHz, DMSO-d6) δ 153.91, 152.65, 148.41, 
130.98, 119.99, 115.83, 112.82, 94.73, 18.48; LC-MS (APCI/ESI): Purity = 
97%, tR = 0.95 min, m/z [M-H]− = 172.1. 
N-(2-(cyanomethyl)benzo[d]oxazol-6-yl)acetamide, 2.9o 
To a mixture of 2.9n (0.25 g, 1.44 mmol, 1.0 Eq) and K2CO3 (3.0 Eq) in 
acetonitrile at 40 ºC, acetyl chloride (2.0 Eq) was added, and the mixture 
stirred at this temperature for 30 minutes. Upon removal of acetonitrile, the 
residue was suspended in water and extracted with DCM (×3). The combined 
organic extracts were then rinsed with brine, dried over anhydrous MgSO4, 
concentrated, and the residue purified by column chromatography (SiO2, 
100% DCM) to afford 2.9o as a brown solid (0.208 g, 
67%); Rf (100% DCM) 0.39; 1H NMR (400 MHz, 
DMSO-d6) δ 10.21 (br s, 1H, H5), 8.18 (d, J = 1.8 Hz, 
1H, H1), 7.68 (d, J = 8.7 Hz, 1H, H3), 7.41 (dd, J = 
8.6, 1.9 Hz, 1H, H2), 4.64 (s, 2H, H4), 2.09 (s, 3H, 
H6); 13C NMR (101 MHz, DMSO-d6) δ 169.00, 157.39, 
151.15, 137.86, 136.18, 119.94, 116.98, 115.52, 
101.66, 24.48, 18.77; LC-MS (APCI/ESI): Purity > 99%, tR = 1.27 min, m/z 
[M-H]− = 214.1. 
General procedure 10: Synthesis of oxime intermediates 2.10a–2.10o 
The appropriate benzoxazole-2-acetonitrile intermediate [2.9 (a–o)] (1.0 Eq) 
was dissolved in glacial acetic acid (10 mL) at ambient temperature. This 
solution was then cooled to 0 ºC resulting in a frozen mixture, after which 
sodium nitrite (2.0 Eq) was added at once. The reaction mixture was allowed 
to thaw slowly and then stirred at 25 ºC for 12 hours. Water (50 mL) was 
then added into the reaction mixture leading to a rapid precipitation of 
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solids, which were filtered, washed thoroughly with water, and dried in a 
desiccator charged with sodium hydroxide pellets. In instances whereby 
further purification was necessary, the solid was recrystallized in an 
appropriate solvent [absolute ethanol was used in most cases], or column 
chromatographed (SiO2, MeOH-DCM) to afford the desired product. 
N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10a 
Yellow crystalline solid (2.456 g, 83%); Rf (MeOH:DCM, 5:95) 0.37; 1H NMR 
(400 MHz, DMSO-d6) δ 15.04 (br s, 1H, H5), 7.89 (ddd, J 
= 7.7, 1.4, 0.7 Hz, 1H, H4), 7.82 (ddd, J = 8.2, 1.2, 0.7 
Hz, 1H, H1), 7.56–7.51 (m, 1H, H2), 7.48 (td, J = 7.7, 1.2 
Hz, 1H, H3); 13C NMR (101 MHz, DMSO-d6) δ 155.57, 
150.51, 140.87, 127.65, 126.04, 123.14, 121.09, 
111.77, 108.82; LC-MS (APCI/ESI): Purity = 98%, tR = 3.63 min, m/z [M-H]− 
= 186.1. 
N-hydroxy-6-methylbenzo[d]oxazole-2-carbimidoyl cyanide, 2.10b 
Yellow solid (1.050 g, 90%); m.p. 229.2–231.4 ºC; Rf (MeOH:DCM, 5:95) 
0.47; 1H NMR (300 MHz, DMSO-d6) δ 14.93 (br s, 1H, 
H4), 7.76 (d, J = 8.2 Hz, 1H, H3), 7.63 (s, 1H, H1), 7.30 
(dd, J = 8.2, 0.9 Hz, 1H, H2), 2.48 (s, 3H, H5); 13C 
NMR (101 MHz, DMSO-d6) δ 155.13, 150.82, 138.79, 
138.08, 127.29, 123.14, 120.47, 111.63, 108.90, 
21.84; LC-MS (APCI/ESI): Purity = 99%, tR = 4.08 min, m/z [M-H]− = 200.1. 
N-hydroxy-4-methylbenzo[d]oxazole-2-carbimidoyl cyanide, 2.10c 
Off-white solid (0.401 g, 84%); m.p. 234.4–236.8 ºC; Rf (MeOH:DCM, 5:95) 
0.45; 1H NMR (300 MHz, DMSO-d6) δ 14.98 (br s, 1H, 
H4), 7.61 (d, J = 8.1 Hz, 1H, H1), 7.41 (t, J = 7.9 Hz, 1H, 
H2), 7.28 (d, J = 7.5 Hz, 1H, H3), 2.58 (s, 3H, H5); 13C 
NMR (101 MHz, DMSO-d6) δ 154.85, 150.31, 140.21, 
131.31, 127.40, 126.32, 123.17, 108.99, 108.91, 16.55; 
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N-hydroxy-5-methylbenzo[d]oxazole-2-carbimidoyl cyanide, 2.10d 
Yellow solid (0.950 g, 92%); m.p. 207.5–209.0 ºC; Rf 
(MeOH:DCM, 5:95) 0.39; 1H NMR (300 MHz, DMSO-
d6) δ 14.97 (br s, 1H, H4), 7.72–7.64 (m, 2H, H1,3), 
7.34 (dd, J = 8.5, 1.1 Hz, 1H, H2), 2.46 (s, 3H, H5); 
13C NMR (101 MHz, DMSO-d6) δ 155.60, 148.79, 
141.09, 135.66, 128.74, 123.17, 120.74, 111.18, 
108.86, 21.40; LC-MS (APCI/ESI): Purity > 99%, tR = 3.28 min, m/z [M-H]− = 
200.0. 
5-bromo-N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10e 
Brown solid (0.800 g, 75%); m.p. 229.0–231.8 ºC; Rf (MeOH:DCM, 5:95) 
0.37; 1H NMR (300 MHz, DMSO-d6) δ 15.13 (br s, 1H, 
H4), 8.16 (d, J = 1.9 Hz, 1H, H3), 7.83 (d, J = 8.7 Hz, 
1H, H1), 7.69 (dd, J = 8.7, 2.0 Hz, 1H, H2); 13C NMR 
(101 MHz, DMSO-d6) δ 156.81, 149.73, 142.58, 
130.35, 123.72, 123.00, 117.95, 113.69, 108.75; LC-
MS (APCI/ESI): Purity > 99%, tR = 3.57 min, m/z [M-H]− = 263.9, 265.9 (1:1).  
6-bromo-N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10f 
Yellow solid (0.680 g, 71%); m.p. 224.3–226.9 ºC; Rf (MeOH:DCM, 5:95) 
0.37; 1H NMR (300 MHz, DMSO-d6) δ 15.13 (br s, 1H, 
H4), 8.19 (d, J = 1.5 Hz, 1H, H1), 7.86 (d, J = 8.5 Hz, 
1H, H3), 7.65 (dd, J = 8.5, 1.8 Hz, 1H, H2); 13C NMR 
(101 MHz, DMSO-d6) δ 156.21, 151.10, 140.30, 
129.31, 123.00, 122.50, 119.75, 115.21, 108.74; LC-
MS (APCI/ESI): Purity = 98%, tR = 3.54 min, m/z [M-
H]− = 263.9, 265.9 (1:1). 
Methyl 2-(cyano(hydroxyimino)methyl)benzo[d]oxazole-6-carboxylate, 2.10g 
Yellow solid (0.850 g, 81%); m.p. 236.1–240.7 ºC; Rf 
(MeOH:DCM, 5:95) 0.34; 1H NMR (300 MHz, DMSO-
d6) δ 15.23 (br s, 1H, H4), 8.33 (dd, J = 1.5, 0.6 Hz, 
1H, H1), 8.06 (dd, J = 8.4, 1.5 Hz, 1H, H2), 7.99 (dd, 
J = 8.4, 0.6 Hz, 1H, H3), 3.91 (s, 3H, H5); 13C NMR 
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(101 MHz, DMSO-d6) δ 166.01, 158.14, 150.28, 144.63, 128.65, 127.04, 
123.05, 121.10, 112.87, 108.72, 53.02; LC-MS (APCI/ESI): Purity > 99%, tR 
= 2.99 min, m/z [M-H]− = 244.0. 
N-hydroxy-6-(trifluoromethyl)benzo[d]oxazole-2-carbimidoyl cyanide, 2.10h 
Yellow solid (0.536 g, 65%); m.p. 180.0–184.8 ºC; Rf (MeOH:DCM, 5:95) 
0.34; 1H NMR (300 MHz, DMSO-d6) δ 15.12 (br s, 1H, 
H4), 8.27 (s, 1H, H1), 8.00 (d, J = 8.4 Hz, 1H, H3), 
7.77 (dd, J = 8.4, 1.1 Hz, 1H, H2); 13C NMR (101 MHz, 
DMSO-d6) δ 161.01, 150.00, 144.57, 126.55, 126.23, 
123.08, 122.65, 120.93, 110.63, 109.30; LC-MS 
(APCI/ESI): Purity = 99%, tR = 3.66 min, m/z [M-H]− = 
254.0. 
6-chloro-N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10i 
Pink solid (0.700 g, 77%); m.p. 221.8–224.6 ºC; Rf (MeOH:DCM, 5:95) 0.39; 
1H NMR (300 MHz, DMSO-d6) δ 15.11 (br s, 1H, H4), 
8.06 (d, J = 1.7 Hz, 1H, H1), 7.91 (d, J = 8.6 Hz, 1H, 
H3), 7.53 (dd, J = 8.6, 2.0 Hz, 1H, H2); 13C NMR (101 
MHz, DMSO-d6) δ 156.40, 150.84, 139.96, 131.88, 
126.59, 122.99, 122.10, 112.43, 108.73; LC-MS 
(APCI/ESI): Purity > 99%, tR = 3.40 min, m/z [M-H]− = 220.0. 
5-chloro-N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10j 
Yellow solid (0.501 g, 92%); m.p. 222.3–225.8 ºC; Rf (MeOH:DCM, 5:95) 
0.37; 1H NMR (300 MHz, DMSO-d6) δ 15.15 (br s, 1H, 
H4), 8.03 (d, J = 1.8 Hz, 1H, H3), 7.88 (d, J = 8.8 Hz, 
1H, H1), 7.57 (dd, J = 8.8, 2.1 Hz, 1H, H2); 13C NMR 
(101 MHz, DMSO-d6) δ 157.00, 149.35, 142.11, 
130.25, 127.66, 123.02, 120.79, 113.24, 108.73; LC-
MS (APCI/ESI): Purity > 99%, tR = 3.38 min, m/z [M-H]− = 220.0. 
6-fluoro-N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10k 
Brown solid (0.400 g, 57%); m.p. 183.5–187.4 ºC; Rf (MeOH:DCM, 5:95) 
0.45; 1H NMR (300 MHz, DMSO-d6) δ 15.11 (br s, 1H, H4), 7.90 (dd, J = 8.8, 
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5.0 Hz, 1H, H3), 7.83 (dd, J = 8.4, 2.4 Hz, 1H, H1), 7.35 
(ddd, J = 9.9, 8.9, 2.5 Hz, 1H, H2); 13C NMR (101 MHz, 
DMSO-d6) δ 162.48, 160.06, 156.96, 150.72, 137.65, 
121.77, 114.07, 109.22, 100.12; LC-MS (APCI/ESI): 
Purity > 99%, tR = 2.76 min, m/z [M-H]− = 204.0. 
5-fluoro-N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10l
Yellow solid (0.984 g, 92%); m.p. 143.1–148.0 ºC; Rf (MeOH:DCM, 5:95) 
0.39; 1H NMR (300 MHz, DMSO-d6) δ 15.11 (br s, 1H, 
H4), 7.88 (dd, J = 9.1, 4.1 Hz, 1H, H1), 7.80 (dd, J = 8.6, 
2.4 Hz, 1H, H3), 7.40 (ddd, J = 9.6, 9.1, 2.7 Hz, 1H, H2); 
13C NMR (101 MHz, DMSO-d6) δ 161.48, 159.10, 
157.30, 147.10, 141.67, 123.06, 115.43, 112.76, 
107.55; LC-MS (APCI/ESI): Purity > 99%, tR = 2.75 min, 
m/z [M-H]− = 204.0. 
N-hydroxy-6-nitrobenzo[d]oxazole-2-carbimidoyl cyanide, 2.10m
Yellow solid (1.003 g, 74%); m.p. 186.5–190.4 ºC; Rf (MeOH:DCM, 5:95) 
0.26; 1H NMR (300 MHz, DMSO-d6) δ 15.40 (br s, 1H, 
H4), 8.83 (d, J = 1.9 Hz, 1H, H1), 8.37 (dd, J = 8.8, 
2.2 Hz, 1H, H2), 8.13 (d, J = 8.8 Hz, 1H, H3); 13C NMR 
(101 MHz, DMSO-d6) δ 161.35, 149.82, 146.40, 
145.81, 123.17, 121.70, 120.83, 109.55, 108.33; LC-
MS (APCI/ESI): Purity = 96%, tR = 3.59 min, m/z [M-
H]− = 231.0. 
6-amino-N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10n
Brown solid (0.340 g, 44%); Rf (MeOH:DCM, 5:95) 0.19; 1H NMR (300 MHz, 
DMSO-d6) δ 13.54 (br s, 1H, H4), 7.31 (d, J = 8.2 Hz, 
1H, H3), 6.65 (d, J = 2.0 Hz, 1H, H1), 6.61 (dd, J = 
8.2, 2.0 Hz, 1H, H2), 4.95 (br s, 2H, H5); LC-MS 
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6-acetamido-N-hydroxybenzo[d]oxazole-2-carbimidoyl cyanide, 2.10o 
Brown solid (0.161 g, 71%); Rf (MeOH:DCM, 5:95) 0.37; 1H NMR (400 MHz, 
DMSO-d6) δ 14.92 (br s, 1H, H4), 10.32 (s, 1H, H5), 
8.26 (d, J = 1.7 Hz, 1H, H1), 7.81 (d, J = 8.7 Hz, 
1H, H3), 7.46 (dd, J = 8.7, 1.9 Hz, 1H, H2), 2.10 (s, 
3H, H6); 13C NMR (101 MHz, DMSO-d6) δ 169.18, 
155.12, 150.87, 139.29, 136.27, 123.01, 120.96, 
117.77, 108.82, 101.54, 24.54; LC-MS (APCI/ESI): 
Purity = 98%, tR = 2.94 min, m/z [M-H]− = 243.1. 
General procedure 11: Synthesis of SAR 2 benzoxazole-based target 
compounds 45–58 
Triethylamine (5.0 Eq) and dimethylcarbamoyl chloride (3.0 Eq) were 
successively added to a suspension of the appropriate oxime intermediate 
2.10 (a–o) (1.0 Eq) in anhydrous DCM at room temperature. This solution 
was purged with nitrogen gas for 10 minutes, heated to reflux at 50 ºC for 
15 h, then cooled to room temperature, and water (20 mL) was added. The 
mixture was extracted with DCM (20 mL × 3) and the combined organic 
phases rinsed with brine (50 mL × 2), dried over anhydrous MgSO4, and 
concentrated to give a residue, which was column chromatographed (SiO2, 
EtOAc-hexane) to give the desired product. Alternatively, the general 
procedure 12 described below was also successful, whereby 
dimethylcarbamoyl chloride was used in place of epichlorohydrin. 
N-((dimethylcarbamoyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 45 
Yellow solid (0.252 g, 79%); m.p. 217.2–220.7 ºC; Rf (EtOAc:Hex, 1:1) 0.39; 
1H NMR (400 MHz, CDCl3) δ 7.92 (ddd, J = 7.9, 1.3, 
0.7 Hz, 1H, H4), 7.67 (d, J = 8.27 Hz, 1H, H1), 7.57–
7.52 (m, 1H, H3), 7.51–7.45 (m, 1H, H2), 3.19 (s, 3H, 
H5a), 3.14 (s, 3H, H5b); 13C NMR (101 MHz, CDCl3) δ 
153.36, 151.24, 151.00, 141.04, 128.40, 126.88, 
125.95, 121.70, 111.61, 106.99, 37.53, 36.20; LC-
MS (APCI/ESI): Purity > 99%, tR = 3.97 min, m/z [M+46]+ = 304.1. 
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N-((dimethylcarbamoyl)oxy)-6-methylbenzo[d]oxazole-2-carbimidoyl cyanide, 46 
Off-white fluffy solid (0.312 g, 77%); m.p. 203.4–209.2 ºC; Rf (EtOAc:Hex, 
1:1) 0.41; 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J 
= 8.3 Hz, 1H, H3), 7.44 (d, J = 0.7 Hz, 1H, H1), 
7.29 (dd, J = 8.3, 1.0 Hz, 1H, H2), 3.18 (s, 3H, 
H4a), 3.13 (s, 3H, H4b), 2.55 (s, 3H, H5); 13C NMR 
(101 MHz, CDCl3) δ 153.55, 152.89, 151.38, 
139.61, 139.04, 127.47, 127.00, 121.01, 111.51, 
107.07, 37.51, 36.19, 22.06; LC-MS (APCI/ESI): Purity > 99%, tR = 4.43 
min, m/z [M+46]+ = 318.1. 
N-((dimethylcarbamoyl)oxy)-4-methylbenzo[d]oxazole-2-carbimidoyl cyanide, 47 
Yellow solid (0.233 g, 69%); m.p. 184.4–187.3 ºC; Rf (EtOAc:Hex, 1:1) 0.42; 
1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 7.7 Hz, 1H, 
H1), 7.44–7.38 (m, 1H, H2), 7.26 (dt, J = 7.2, 1.0 Hz, 
1H, H3), 3.19 (s, 3H, H4a), 3.14 (s, 3H, H4b), 2.70 (s, 
3H, H5); 13C NMR (101 MHz, CDCl3) δ 152.51, 
151.34, 150.86, 140.64, 132.68, 128.12, 127.05, 
126.23, 108.72, 107.08, 37.51, 36.19, 16.40; LC-
MS (APCI/ESI): Purity > 99%, tR = 4.39 min, m/z [M+46]+ = 318.1. 
N-((dimethylcarbamoyl)oxy)-5-methylbenzo[d]oxazole-2-carbimidoyl cyanide, 48 
Yellow solid (0.288 g, 71%); m.p. 193.1–198.9 ºC; Rf (EtOAc:Hex, 1:1) 0.41; 
1H NMR (400 MHz, CDCl3) δ 7.68 (dt, J = 1.6, 0.8 
Hz, 1H, H3), 7.53 (d, J = 8.5 Hz, 1H, H1), 7.35 
(ddd, J = 8.5, 1.7, 0.6 Hz, 1H, H2), 3.19 (s, 3H, 
H4a), 3.14 (s, 3H, H4b), 2.53 (s, 3H, H5); 13C NMR 
(101 MHz, CDCl3) δ 153.35, 151.29, 149.32, 
141.29, 136.10, 129.77, 126.97, 121.30, 110.94, 
107.05, 37.52, 36.19, 21.48; LC-MS (APCI/ESI): Purity > 99%, tR = 4.33 
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5-bromo-N-((dimethylcarbamoyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 49 
Yellow solid (0.105 g, 56%); m.p. 231.1–232.7 ºC; Rf (EtOAc:Hex, 1:1) 0.46; 
1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 2.0 Hz, 
1H, H3), 7.81 (d, J = 8.5 Hz, 1H, H1), 7.67 (dd, J = 
8.5, 2.1 Hz, 1H, H2), 3.13 (s, 3H, H4a), 3.09 (s, 
3H, H4b); 13C NMR (101 MHz, CDCl3) δ 157.21, 
152.77, 141.98, 130.12, 126.53, 122.86, 122.71, 
117.74, 112.87, 107.65, 37.41, 36.28; LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.45 min, m/z [M+46]+ = 382.0, 384.0 (1:1). 
6-bromo-N-((dimethylcarbamoyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 50 
Brown solid (0.187 g, 49%); m.p. 232.9–236.6 ºC; Rf (EtOAc:Hex, 1:1) 0.47; 
1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 1.9 Hz, 
1H, H1), 7.77 (d, J = 8.5, 1H, H3), 7.63 (dd, J = 
8.5, 1.9 Hz, 1H, H2), 3.19 (s, 3H, H4a), 3.14 (s, 
3H, H4b); 13C NMR (101 MHz, CDCl3) δ 153.75, 
151.33, 151.13, 140.15, 129.73, 126.54, 122.58, 
121.89, 115.15, 106.82, 37.57, 36.21; LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.46 min, m/z [M+46]+ = 382.0, 384.0 (1:1). 
Methyl 2-(cyano(((dimethylcarbamoyl)oxy)imino)methyl)benzo[d]oxazole-6-carboxylate, 51 
Off-white solid (0.282 g, 73%); m.p. 233.7–237.1 ºC; Rf (EtOAc:Hex, 1:1) 
0.38; 1H NMR (400 MHz, CDCl3) δ 8.33 (d, J = 
1.1 Hz, 1H, H1), 8.20 (dd, J = 8.5, 1.4 Hz, 1H, 
H2), 7.95 (d, J = 8.4 Hz, 1H, H3), 4.00 (s, 3H, 
H5), 3.20 (s, 3H, H4a), 3.15 (s, 3H, H4b); 13C 
NMR (101 MHz, CDCl3) δ 165.83, 155.52, 
151.05, 150.65, 144.32, 130.28, 127.39, 
126.56, 121.38, 113.24, 106.79, 52.66, 37.60, 36.23; LC-MS (APCI/ESI): 
Purity > 99%, tR = 4.19 min, m/z [M+46]+ = 362.1. 
N-((dimethylcarbamoyl)oxy)-6-(trifluoromethyl)benzo[d]oxazole-2-carbimidoyl cyanide, 52 
Off-white solid (0.105 g, 59%); m.p. 189.0–192.4 ºC; Rf (EtOAc:Hex, 1:1) 
0.48; 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.5, 1H, H3), 7.95 (d, J = 2.0, 
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1H, H1), 7.79 (dd, J = 8.5, 2.0 Hz, 1H, H2), 3.20 
(s, 3H, H4a), 3.15 (s, 3H, H4b); 13C NMR (101 
MHz, CDCl3) δ 155.48, 150.99, 150.36, 143.38, 
130.39 (q), 126.37, 124.89, 123.19, 122.31, 
109.49, 106.72, 37.61, 36.22; LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.51 min, m/z 
[M+46]+ = 372.1. 
6-chloro-N-((dimethylcarbamoyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 53 
Brown solid (0.160 g, 81%); m.p. 227.9–230.8 ºC; Rf (EtOAc:Hex, 1:1) 0.45; 
1H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 8.6, 0.5 
Hz, 1H, H3), 7.67 (dd, J = 1.9, 0.5 Hz, 1H, H1), 
7.47 (dd, J = 8.6, 1.9 Hz, 1H, H2), 3.19 (s, 3H, 
H4a), 3.14 (s, 3H, H4b); 13C NMR (101 MHz, CDCl3) 
δ 153.92, 151.11 (2C), 139.74, 134.43, 126.98, 
126.51, 122.20, 112.17, 106.81, 37.56, 36.20; 
LC-MS (APCI/ESI): Purity > 99%, tR = 4.38 min, m/z [M+46]+ = 338.1. 
5-chloro-N-((dimethylcarbamoyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 54 
Yellow solid (0.207 g, 72%); m.p. 191.0–193.1 ºC; Rf (EtOAc:Hex, 1:1) 0.44; 
1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 2.1, 0.5 
Hz, 1H, H3), 7.60 (dd, J = 8.8, 0.5 Hz, 1H, H1), 
7.52 (dd, J = 8.8, 2.0 Hz, 1H, H1), 3.19 (s, 3H, 
H4a), 3.14 (s, 3H, H4b); 13C NMR (101 MHz, CDCl3) 
δ 154.49, 151.08, 149.52, 141.95, 131.71, 
128.82, 126.51, 121.49, 112.41, 106.79, 37.57, 
36.21; LC-MS (APCI/ESI): Purity > 99%, tR = 4.38 min, m/z [M+46]+ = 338.1. 
N-((dimethylcarbamoyl)oxy)-6-fluorobenzo[d]oxazole-2-carbimidoyl cyanide, 55 
Brown solid (0.225 g, 67%); m.p. 202.5–205.9 ºC; 
Rf (EtOAc:Hex, 1:1) 0.39; 1H NMR (400 MHz, 
CDCl3) δ 7.87 (dd, J = 8.8, 5.0 Hz, 1H, H3), 7.83 
(dd, J = 8.5, 2.3 Hz, 1H, H1), 7.35 (ddd, J = 9.8, 
8.8, 2.3 Hz, 1H, H2), 3.19 (s, 3H, H4a), 3.14 (s, 3H, 
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H4b); 13C NMR (101 MHz, CDCl3) δ 163.77, 161.28, 153.97, 151.09, 137.47, 
126.50, 122.44, 114.77, 106.85, 99.70, 37.55, 36.19; LC-MS (APCI/ESI): 
Purity > 99%, tR = 4.07 min, m/z [M+46]+ = 322.1.  
N-((dimethylcarbamoyl)oxy)-5-fluorobenzo[d]oxazole-2-carbimidoyl cyanide, 56 
Yellow solid (0.167 g, 62%); m.p. 196.5–197.7 ºC; Rf (EtOAc:Hex, 1:1) 0.40; 
1H NMR (400 MHz, DMSO-d6) δ 7.83 (dd, J = 8.9, 
4.0 Hz, 1H, H1), 7.78 (dd, J = 8.5, 2.6 Hz, 1H, H3), 
7.40 (ddd, J = 9.6, 8.9, 2.7 Hz, 1H, H2), 3.20 (s, 
3H, H4a), 3.16 (s, 3H, H4b); 13C NMR (101 MHz, 
DMSO-d6) δ 164.08, 160.23, 155.98, 148.31, 
142.20, 126.57, 122.91, 114.57, 112.81, 107.49, 
37.53, 36.21; LC-MS (APCI/ESI): Purity > 99%, tR = 4.14 min, m/z [M+46]+ = 
322.1. 
N-((dimethylcarbamoyl)oxy)-6-nitrobenzo[d]oxazole-2-carbimidoyl cyanide, 57 
Brown solid (0.114 g, 55%); m.p. 210.4–212.8 ºC; Rf (EtOAc:Hex, 1:1) 0.36; 
1H NMR (400 MHz, DMSO-d6) δ 8.57 (d, J = 2.0 
Hz, 1H, H1), 8.45 (dd, J = 8.8, 2.0 Hz, 1H, H2), 
8.05 (d, J = 8.8 Hz, 1H, H3), 3.21 (s, 3H, H4a), 
3.16 (s, 3H, H4b); 13C NMR (101 MHz, DMSO-d6) 
δ 157.18, 150.82, 150.13, 147.29, 145.41, 
126.05, 121.96, 121.74, 108.31, 106.54, 37.66, 
36.25; LC-MS (APCI/ESI): Purity = 96%, tR = 4.37 min, m/z [M+46]+ = 349.1. 
6-acetamido-N-((dimethylcarbamoyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 58 
Yellow solid (0.071 g, 47%); m.p. 240.6–243.7 ºC; Rf (EtOAc:Hex, 1:1) 0.37; 
1H NMR (400 MHz, DMSO-d6) δ 10.41 (br s, 
1H, H5), 8.27 (d, J = 2.1 Hz, 1H, H1), 7.86 (d, 
J = 8.9 Hz, 1H, H3), 7.55 (dd, J = 8.9, 2.1 
Hz, 1H, H2), 3.09 (s, 3H, H4a), 3.05 (s, 3H, 
H4b), 2.12 (s, IH, H6); 13C NMR (101 MHz, 
DMSO-d6) δ 169.13, 153.97, 151.59, 
151.42, 140.03, 136.04, 127.62, 121.59, 118.41, 108.41, 101.59, 37.62, 
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36.03, 24.76; LC-MS (APCI/ESI): Purity > 99%, tR = 3.09 min, m/z [M+46]+ = 
361.1.  
General procedure 12: Synthesis of epoxide-based compounds 59 and 60 
To a stirred solution of 2.10b or 2.10i (1.0 Eq) in anhydrous acetonitrile, 
K2CO3 (3.0 Eq) was added, and the mixture was heated to reflux at 90 ºC for 
30 minutes under N2 atmosphere. Epichlorohydrin (5.0 Eq) was then added 
to this mixture and refluxed for 18 h. Upon removal of acetonitrile under 
reduced pressure, a black solid was obtained, which was then resuspended 
in water and extracted with DCM (×3). The combined organic extracts were 
then rinsed with brine, dried over anhydrous MgSO4, concentrated, and the 
residue was purified by column chromatography (SiO2, 100% DCM) to afford 
compound 59 or 60.  
6-methyl-N-(oxiran-2-ylmethoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 59 
Yellowish green solid (0.320 g, 45%); m.p. 116.0–118.9 ºC; Rf (EtOAc:Hex, 
1:1) 0.45; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J 
= 8.2 Hz, 1H, H3), 7.42 (dt, J = 1.5, 0.7 Hz, 1H, 
H1), 7.27 (dd, J = 8.2, 1.5 Hz, 1H, H2), 4.78 (dd, J 
= 12.3, 3.4 Hz, 1H, H4a), 4.54 (dd, J = 12.3, 6.1 
Hz, 1H, H4b), 3.42 (dddd, J = 6.0, 4.1, 3.4, 2.6 
Hz, 1H, H5), 2.96 (dd, J = 4.8, 4.2 Hz, 1H, H6a), 
2.79 (dd, J = 4.8, 2.6 Hz, 1H, H6b), 2.54 (s, 3H, H7); 13C NMR (101 MHz, 
CDCl3) δ 153.37, 151.12, 138.90, 138.70, 127.22, 123.41, 120.79, 111.17, 
107.25, 78.90, 49.13, 44.54, 22.00; LC-MS (APCI/ESI): Purity > 99%, tR = 
4.32 min, m/z [M+H]+ = 258.1. 
6-chloro-N-(oxiran-2-ylmethoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 60 
Yellow solid (3.15 g, 46%); m.p. 143.2–147.7 ºC; 
Rf (100% DCM) 0.42; 1H NMR (400 MHz, CDCl3) δ 
7.80 (d, J = 8.6 Hz, 1H, H3), 7.65 (d, J = 1.9 Hz, 
1H, H1), 7.45 (dd, J = 8.6, 1.9 Hz, 1H, H2), 4.81 
(dd, J = 12.3, 3.3 Hz, 1H, H4a), 4.55 (dd, J = 12.3, 
6.1 Hz, 1H, H4b), 3.43 (dddd, J = 5.9, 3.9, 3.3, 2.8 
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Hz, 1H, H5), 3.01–2.92 (m, 1H, H6a), 2.79 (dd, J = 4.8, 2.6 Hz, 1H, H6b); 13C 
NMR (101 MHz, CDCl3) δ 154.46, 150.90, 139.72, 133.64, 126.75, 123.03, 
121.99, 111.85, 107.02, 79.21, 49.09, 44.50; HRMS (EI) m/z, 276.9896 (M+ 
C12H8ClN3O3 requires 277.0254); LC-MS: Purity > 99%, tR = 4.54 min.  
General procedure 13: Synthesis of β-amino alcohol-based target compounds 61–69 
To a stirred solution of the epoxide-based 59 or 60 (1.0 Eq) and lithium 
perchlorate (2.0 Eq) in anhydrous acetonitrile, the appropriate alkyl amine 
(4.0 Eq) was added, and this mixture was stirred at 25 ºC for 2 to 24 h. After 
completion of the reaction, acetonitrile was removed in vacuo, and the 
resulting crude residue was treated with water and then extracted with DCM 
(×4). The organic extracts were combined, rinsed with brine, dried over 
anhydrous MgSO4, followed by removal of DCM. The residue was then 
purified by column chromatography (SiO2, MeOH-DCM) to furnish the 
desired target compound. 
N-(2-hydroxy-3-(isopropylamino)propoxy)-6-methylbenzo[d]oxazole-2-carbimidoyl cyanide, 61 
Off-white solid (0.231 g, 94%); m.p. 241.5–245.8 ºC; Rf (MeOH:DCM, 1:9) 
0.26; 1H NMR (400 MHz, Methanol-d4) δ 
7.72 (d, J = 8.3 Hz, 1H, H3), 7.52 (dt, J = 
1.9, 0.7 Hz, 1H, H1), 7.34 (dd, J = 8.2, 1.9 
Hz, 1H, H2), 4.63 (dd, J = 5.3, 2.8 Hz, 2H, 
H4), 4.33 (dtd, J = 10.5, 5.3, 3.2 Hz, 1H, 
H5), 3.46 (hept, J = 6.6 Hz, 1H, H9), 3.28 
(dd, J = 12.7, 3.1 Hz, 1H, H6a), 3.12 (dd, J = 12.7, 9.8 Hz, 1H, H6b), 2.54 (s, 
3H, H11), 1.38 (dd, J = 6.5, 2.7 Hz, 6H, H10); 13C NMR (101 MHz, Methanol-
d4) δ 153.88, 151.06, 138.94, 138.56, 126.98, 123.24, 119.97, 110.71, 
106.99, 79.53, 65.33, 50.67, 46.62, 20.47, 18.16, 17.60; LC-MS (APCI/ESI): 
Purity = 98%, tR = 3.36 min, m/z [M+H]+ = 317.1. 
6-chloro-N-(2-hydroxy-3-(isopropylamino)propoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 62 
Yellow solid (0.390 g, 92%); m.p. 218.5–223.9 ºC; Rf (MeOH:DCM, 1:9) 0.34; 
1H NMR (400 MHz, DMSO-d6) δ 8.30 (s, 1H, H8), 8.13 (d, J = 2.0 Hz, 1H, H1), 
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7.98 (d, J = 8.6 Hz, 1H, H3), 7.59 (dd, J = 
8.6, 2.0 Hz, 1H, H2), 5.94 (s, 1H, H7), 4.62 
(dd, J = 11.6, 4.5 Hz, 1H, H4a), 4.56 (dd, J = 
11.7, 6.3 Hz, 1H, H4b), 4.27–4.16 (m, 1H, 
H5), 3.39–3.32 (m, 1H, H9), 3.14 (dd, J = 
12.7, 3.0 Hz, 1H, H6a), 2.96 (dd, J = 12.7, 
9.6 Hz, 1H, H6b), 1.25 (dd, J = 6.5, 3.7 Hz, 
6H, H10); 13C NMR (101 MHz, DMSO-d6) δ 155.42, 150.86, 139.86, 132.55, 
126.98, 123.40, 122.47, 112.53, 108.30, 80.30, 65.64, 50.43, 46.37, 19.35, 
18.71; LC-MS (APCI/ESI): Purity = 96%, tR = 3.46 min, m/z [M+H]+ = 337.1. 
6-chloro-N-(2-hydroxy-3-morpholinopropoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 63 
Off-white solid (0.220 g, 56%); m.p. 102.4–108.3 ºC; Rf (MeOH:DCM, 5:95) 
0.36; 1H NMR (400 MHz, DMSO-d6) δ 8.12 
(d, J = 1.9 Hz, 1H, H1), 7.95 (d, J = 8.6 Hz, 
1H, H3), 7.57 (dd, J = 8.6, 2.0 Hz, 1H, H2), 
5.04 (d, J = 5.1 Hz, 1H, H7), 4.62 (dd, J = 
11.3, 3.7 Hz, 1H, H4a), 4.51 (dd, J = 11.3, 
6.7 Hz, 1H, H4b), 4.10–3.99 (m, 1H, H5), 
3.58 (t, J = 4.7 Hz, 4H, H9), 2.49–2.36 (m, 
6H, H6,8); 13C NMR (101 MHz, DMSO-d6) δ 155.61, 150.89, 139.91, 132.31, 
126.82, 122.59, 122.34, 112.56, 108.37, 82.29, 66.72 (2C), 66.60, 61.44, 
54.49 (2C); LC-MS (APCI/ESI): Purity > 99%, tR = 3.43 min, m/z [M+H]+ = 
365.1. 
6-chloro-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 64 
Light brown solid (0.178 g, 55%); m.p. 106.7–110.0 ºC; Rf (MeOH:DCM, 1:9) 
0.27; 1H NMR (400 MHz, DMSO-d6) δ 8.12 
(d, J = 1.9 Hz, 1H, H1), 7.95 (d, J = 8.6 Hz, 
1H, H3), 7.57 (dd, J = 8.6, 2.0 Hz, 1H, H2), 
4.96 (s, 1H, H7), 4.61 (dd, J = 11.3, 3.5 
Hz, 1H, H4a), 4.48 (dd, J = 11.3, 6.8 Hz, 
1H, H4b), 4.09–3.93 (m, 1H, H5), 2.48–2.29 
(m, 6H, H6,8), 1.57–1.43 (m, 4H, H9), 1.43–1.31 (m, 2H, H10); 13C NMR (101 
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MHz, DMSO-d6) δ 155.62, 150.89, 139.91, 132.30, 126.82, 122.53, 122.33, 
112.57, 108.37, 82.49, 66.74, 61.80, 55.27 (2C), 26.12 (2C), 24.40; LC-MS 
(APCI/ESI): Purity > 99%, tR = 3.37 min, m/z [M+H]+ = 363.1.  
6-chloro-N-(2-hydroxy-3-(piperazin-1-yl)propoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 65 
Yellow solid (0.118 g, 36%); m.p. 178.2–181.3 ºC; Rf (DCM:MeOH:7N NH3-
MeOH), 9:1:0.2) 0.11; 1H NMR (400 MHz, 
DMSO-d6) δ 8.40 (s, 1H, H10), 8.11 (d, J = 
2.0 Hz, 1H, H1), 7.96 (d, J = 8.6 Hz, 1H, 
H3), 7.58 (dd, J = 8.6, 2.0 Hz, 1H, H2), 
5.12 (d, J = 4.9 Hz, 1H, H7), 4.62 (dd, J = 
11.3, 3.9 Hz, 1H, H4a), 4.52 (dd, J = 11.3, 
6.5 Hz, 1H, H4b), 4.11–3.97 (m, 1H, H5), 3.16–3.03 (m, 4H, H8), 2.75–2.60 
(m, 4H, H9), 2.51–2.42 (m, 2H, H6); 13C NMR (101 MHz, DMSO-d6) δ 155.58, 
150.87, 139.90, 132.36, 126.88, 122.70, 122.37, 112.54, 108.38, 81.98, 
66.94, 60.31, 50.53 (2C), 43.64 (2C); LC-MS (APCI/ESI): Purity = 97%, tR = 
3.45 min, m/z [M+H]+ = 364.1. 
6-chloro-N-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 66 
Yellow solid (0.155 g, 41%); m.p. 154.4–161.4 ºC; Rf (DCM:MeOH:7N NH3-
MeOH), 9:1:0.2) 0.43; 1H NMR (400 
MHz, Methanol-d4) δ 7.85–7.80 (m, 2H, 
H1,3), 7.52 (dd, J = 8.5, 2.0 Hz, 1H, H2), 
4.69 (dd, J = 11.5, 4.0 Hz, 1H, H4a), 
4.61 (dd, J = 11.5, 6.2 Hz, 1H, H4b), 
4.29–4.16 (m, 1H, H5), 3.30–3.19 (m, 
4H, H8), 3.05–2.94 (m, 4H, H9), 2.88 (s, 3H, H10), 2.73–2.65 (m, 2H, H6); 13C 
NMR (101 MHz, Methanol-d4) δ 155.31, 150.95, 139.66, 133.02, 126.27, 
122.42, 121.39, 111.47, 106.96, 80.94, 66.72, 58.99, 53.51 (2C), 50.59 
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6-chloro-N-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 67 
Off-white solid (0.151 g, 48%); m.p. 165.7–167.5 ºC; Rf (MeOH:DCM, 1:9) 
0.24; 1H NMR (400 MHz, Methanol-d4) δ 
7.84 (d, J = 8.6 Hz, 1H, H3), 7.81 (d, J = 2.0 
Hz, 1H, H1), 7.52 (dd, J = 8.6, 2.0 Hz, 1H, 
H2), 4.65 (dd, J = 11.3, 4.3 Hz, 1H, H4a), 
4.61 (dd, J = 11.3, 5.1 Hz, 1H, H4b), 4.41 
(tdd, J = 7.0, 5.5, 4.8 Hz, 1H, H5), 3.57–3.42 
(m, 4H, H8), 3.40 (d, J = 7.0 Hz, 2H, H6), 2.21–2.07 (m, 4H, H9); 13C NMR 
(101 MHz, Methanol-d4) δ 155.14, 150.97, 139.64, 133.14, 126.32, 123.09, 
121.45, 111.49, 106.85, 79.79, 64.76, 56.50, 54.20 (2C), 22.52 (2C); LC-MS 
(APCI/ESI): Purity > 99%, tR = 3.28 min, m/z [M+H]+ = 349.1. 
6-chloro-N-(2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 68 
Yellow solid (0.209 g, 53%); m.p. 152.8–158.0 ºC; Rf (MeOH:DCM, 5:95) 0.59; 
1H NMR (400 MHz, CDCl3) δ 7.80 
(d, J = 8.6 Hz, 1H, H3), 7.65 (d, J = 
1.9 Hz, 1H, H1), 7.45 (dd, J = 8.6, 
1.9 Hz, 1H, H2), 7.30 (dd, J = 8.8, 
7.3 Hz, 2H, H11), 6.95 (dd, J = 8.8, 
1.0 Hz, 2H, H10), 6.94–6.88 (m, 1H, 
H12), 4.67 (d, J = 5.0 Hz, 2H, H4), 
4.38–3.29 (m, 1H, H5), 3.39–3.26 (m, 4H, H9), 3.04–2.94 (m, 2H, H6), 2.84–
2.68 (m, 4H, H8); 13C NMR (101 MHz, CDCl3) δ 154.53, 150.89, 150.81, 
139.73, 133.60, 129.22, 126.74, 125.81, 122.77, 121.95, 120.32, 120.24, 
116.39, 111.84, 107.16, 80.68, 65.01, 60.20, 53.41 (2C), 48.93 (2C); LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.38 min, m/z [M+H]+ = 440.1. 
6-chloro-N-(2-hydroxy-3-(4-(pyridin-2-yl)piperazin-1-yl)propoxy)benzo[d]oxazole-2-carbimidoyl cyanide, 69 
Light brown solid (0.364 g, 92%); m.p. 161.7–166.1 ºC; Rf (MeOH:DCM, 5:95) 
0.44; 1H NMR (400 MHz, CDCl3) δ 8.26–8.18 (m, 1H, H13), 7.80 (d, J = 8.6 
Hz, 1H, H3), 7.65 (d, J = 1.9 Hz, 1H, H1), 7.52 (ddd, J = 8.6, 7.3, 2.0 Hz, 1H, 
H11), 7.45 (dd, J = 8.6, 1.9 Hz, 1H, H2), 6.71–6.65 (m, 2H, H10,12), 4.66 (d, J 
= 5.0 Hz, 2H, H4), 4.39–4.28 (m, 1H, H5), 3.76–3.59 (m, 4H, H9), 3.02–2.85 
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(m, 2H, H6), 2.83–2.62 (m, 4H, H8); 13C NMR (101 MHz, CDCl3) δ 159.06, 
154.52, 150.89, 147.95, 139.72, 
137.66, 133.59, 126.73, 122.76, 
121.95, 113.82, 111.85, 107.23, 
107.15, 80.68, 65.02, 60.32, 53.18 
(2C), 44.93 (2C); LC-MS 
(APCI/ESI): Purity = 99%, tR = 4.09 
min, m/z [M+H]+ = 441.1.  
Synthesis of oxime ether-based target compounds 70–74 
General procedure 12 was adapted, wherein the appropriate halide (2.0 Eq) 
was used in place of epichlorohydrin and reacted with the free oxime 
intermediate 2.10a (1.0 Eq).  
N-(benzyloxy)benzo[d]oxazole-2-carbimidoyl cyanide, 70 
White solid (0.269 g, 71%); m.p. 130.9–135.1 ºC; Rf (EtOAc:Hex, 50:50) 0.52; 
1H NMR (400 MHz, CDCl3) δ 7.90–7.86 (m, 1H, 
H4), 7.66–7.62 (m, 1H, H1), 7.54–7.39 (m, 7H, 
H2,3,6,7,8), 5.60 (s, 2H, H5); 13C NMR (101 MHz, 
CDCl3) δ 154.12, 150.75, 141.01, 134.64, 
129.10, 128.81 (4C), 127.51, 125.70, 122.82, 
121.42, 111.17, 107.43, 80.70; LC-MS 
(APCI/ESI): Purity = 98%, tR = 4.96 min, m/z [M+H]+ = 278.1. 
N-((4-chlorobenzyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 71 
White solid (0.270 g, 66%); m.p. 120.7–123.5 ºC; Rf (EtOAc:Hex, 50:50) 0.59; 
1H NMR (400 MHz, CDCl3) δ 7.88 (ddd, J = 7.7, 
1.5, 0.7 Hz, 1H, H4), 7.65–7.62 (m, 1H, H1), 
7.53–7.48 (m, 1H, H2), 7.48–7.43 (m, 1H, H3), 
7.42 (s, 4H, H6,7), 5.56 (s, 2H, H5); 13C NMR 
(101 MHz, CDCl3) δ 153.95, 150.75, 140.98, 
135.20, 133.12, 130.19 (2C), 129.06 (2C), 
127.61, 125.75, 123.13, 121.46, 111.18, 107.33, 79.65; LC-MS (APCI/ESI): 
Purity = 97%, tR = 4.99 min, m/z [M+H]+ = 312.1. 
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N-((2,4-dichlorobenzyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 72 
Yellow solid (0.204 g, 74%); m.p. 115.9–118.3 ºC; Rf (EtOAc:Hex, 1:4) 0.40; 
1H NMR (400 MHz, CDCl3) δ 7.89 (ddd, J = 7.7, 
1.5, 0.7 Hz, 1H, H4), 7.64 (ddd, J = 8.2, 1.3, 
0.7 Hz, 1H, H1), 7.54–7.49 (m, 2H, H2,3), 7.49–
7.44 (m, 2H, H6,8), 7.34 (dd, J = 8.3, 2.1 Hz, 
1H, H7), 5.69 (s, 2H, H5); 13C NMR (101 MHz, 
CDCl3) δ 153.85, 150.77, 140.98, 135.71, 
134.69, 131.18, 131.12, 129.74, 127.69, 
127.49, 125.79, 123.41, 121.50, 111.20, 107.21, 76.85; LC-MS (APCI/ESI): 
Purity > 99%, tR = 5.11 min, m/z [M+H]+ = 346.0. 
N-((3-chlorobenzyl)oxy)benzo[d]oxazole-2-carbimidoyl cyanide, 73 
White solid (0.270 g, 81%); m.p. 138.0–141.2 ºC; Rf (EtOAc:Hex, 1:4) 0.31; 
1H NMR (400 MHz, CDCl3) δ 7.89 (ddd, J = 7.7, 
1.5, 0.7 Hz, 1H, H4), 7.64 (ddd, J = 8.2, 1.3, 0.7 
Hz, 1H, H1), 7.51 (ddd, J = 8.2, 7.4, 1.5 Hz, 1H, 
H2), 7.48–7.43 (m, 2H, H3,9), 7.41–7.36 (m, 3H, 
H6,7,8), 5.56 (s, 2H, H5); 13C NMR (101 MHz, 
CDCl3) δ 153.92, 150.76, 140.98, 136.60, 
134.74, 130.14, 129.27, 128.75, 127.64, 126.76, 
125.76, 123.25, 121.47, 111.20, 107.30, 79.56; LC-MS (APCI/ESI): Purity > 
99%, tR = 4.95 min, m/z [M+H]+ = 312.1. 
2-(((benzo[d]oxazol-2-yl(cyano)methylene)amino)oxy)acetic acid, 74 
Off-white solid (0.043 g, 19%); m.p. 228.9–233.4 
ºC; Rf (DCM:MeOH:7N NH3-MeOH) 0.27; 1H NMR 
(400 MHz, DMSO-d6) δ 7.91 (d, J = 7.8 Hz, 1H, 
H4), 7.83 (d, J = 8.2 Hz, 1H, H1), 7.56 (td, J = 7.8, 
1.4 Hz, 1H, H2), 7.50 (td, J = 7.7, 1.2 Hz, 1H, H3), 
4.72 (s, 2H, H5); LC-MS (APCI/ESI): Purity > 99%, 
tR = 2.98 min, m/z [M+H]+ = 246.0.  
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Synthesis of SAR 3 benzoxazole-based target compounds 75–82 
2-(benzo[d]oxazol-2-yl)-2-cyclohexylideneacetonitrile, 75 
To a solution of 2-(benzo[d]oxazol-2-yl)acetonitrile, 2.9a (0.200 g, 1.26 
mmol) in absolute ethanol (4 mL), ammonium acetate (0.77 g, 10 mmol) and 
cyclopentanone or cyclohexanone (10 mmol) were added. The reaction 
mixture was heated under reflux for 2 h and left to cool to room 
temperature. The separated crystalline product was filtered, dried and 
recrystallized from ethanol. White solid (0.276 g, 92%); m.p. 99.5–102.8 ºC; 
Rf (EtOAc:Hex, 1:1) 0.60; 1H NMR (400 MHz, CDCl3) δ 
7.79–7.76 (m, 1H, H4), 7.61–7.58 (m, 1H, H1), 7.43–
7.36 (m, 2H, H2,3), 3.23–3.15 (m, 2H, H5), 2.87–2.80 (m, 
2H, H9), 1.93–1.86 (m, 2H, H6), 1.85–1.80 (m, 2H, H8), 
1.78–1.71 (m, 2H, H7); 13C NMR (101 MHz, CDCl3) δ 
174.31, 157.50, 149.84, 141.29, 125.82, 124.91, 
120.28, 115.32, 110.81, 97.67, 36.63, 32.41, 28.52, 
28.08, 25.65; LC-MS (APCI/ESI): Purity > 99%, tR = 4.87 min, m/z [M+H]+ = 
239.1.  
N-phenylbenzo[d]oxazole-2-carbohydrazonoyl cyanide, 76
Orange solid (0.201 g, 61%); m.p. 192.8–197.7 ºC; Rf (EtOAc:Hex, 2:3) 0.55; 
1H NMR (400 MHz, CDCl3) δ 13.59 (s, 1H, H5), 7.84–
7.81 (m, 1H, H4), 7.70–7.66 (m, 1H, H1), 7.54–7.42 
(m, 6H, H2,6,7), 7.23 (tt, J = 7.4, 1.4 Hz, 1H, H8); 13C 
NMR (101 MHz, CDCl3) δ 155.72, 148.20, 141.42, 
140.16, 129.64 (2C), 127.07, 125.67, 125.53, 
119.85, 115.85 (2C), 114.94, 111.41, 101.44; LC-MS 
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White solid (0.220 g, 69%); m.p. 221.1–225.8 ºC; Rf (EtOAc:Hex, 1:1) 0.35; 
1H NMR (400 MHz, CDCl3) δ 8.56–8.52 (m, 1H, H4), 
7.65–7.61 (m, 1H, H1), 7.59–7.54 (m, 1H, H2), 7.54–
7.49 (m, 1H, H3), 6.30 (q, J = 0.9 Hz, 1H, H5), 2.52 (d, J 
= 1.0 Hz, 3H, H6); 13C NMR (101 MHz, CDCl3) δ 157.58, 
156.87, 151.59, 146.67, 127.58, 126.87, 125.96, 
117.10, 112.97, 111.50, 111.11, 73.68, 20.96; LC-MS 
(APCI/ESI): Purity > 99%, tR = 3.82 min, m/z [M+H]+ = 
225.1.  
2-(benzo[d]oxazol-2-ylmethylene)thiazolidin-4-one, 78 
Brown solid (0.099 g, 34%); m.p. 209.3–211.6 ºC; Rf (EtOAc:Hex, 1:1) 0.43; 
1H NMR (400 MHz, DMSO-d6) δ 11.59 (br s, 1H, H6), 
7.64–7.60 (m, 1H, H4), 7.60–7.57 (m, 1H, H1), 7.33–7.24 
(m, 2H, H2,3), 6.05 (s, 1H, H5), 3.94 (s, 2H, H7); 13C NMR 
(101 MHz, DMSO-d6) δ 174.18, 163.07, 153.32, 149.39, 
142.52, 124.76, 124.18, 118.69, 110.43, 85.49, 33.82; 
LC-MS (APCI/ESI): Purity = 84% (E/Z), 14% (E/Z), tR = 
3.87 (E/Z), 4.44 (E/Z) min, m/z [M+H]+ = 233.0. 
2-(benzo[d]oxazol-2-yl)-2-(5-oxo-3-phenylthiazolidin-2-ylidene)acetonitrile, 79 
Brown solid (0.280 g, 67%); m.p. 315.2–317.9 ºC; Rf (EtOAc:Hex, 1:1) 0.49; 
1H NMR (400 MHz, DMSO-d6) δ 7.76–7.72 (m, 1H, H4), 
7.72–7.69 (m, 1H, H1), 7.60–7.54 (m, 3H, H7,8), 7.53–
7.48 (m, 2H, H6), 7.42–7.34 (m, 2H, H2,3), 4.22 (s, 2H, 
H5); 13C NMR (101 MHz, DMSO-d6) δ 173.60, 167.59, 
160.17, 149.20, 141.53, 135.30, 131.09, 130.00 (2C), 
129.89 (2C), 125.44 (2C), 119.30, 112.20, 111.04, 
73.00, 33.50; LC-MS (APCI/ESI): Purity > 99%, tR = 
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Yellow solid (0.199 g, 54%); m.p. 203.2–206.6 ºC; Rf (EtOAc:Hex, 1:1) 0.61; 
1H NMR (300 MHz, DMSO-d6) δ 10.80 
(s, 1H, H5), 7.69–7.52 (m, 4H, H1,4,8), 
7.45–7.38 (m, 1H, H2), 7.36 (d, J = 8.0 
Hz, 2H, H7), 7.33–7.23 (m, 1H, H3), 
7.23–7.15 (m, 1H, H9); LC-MS 
(APCI/ESI): Purity = 95%, tR = 4.46 min, m/z [M+H]+ = 294.1. 
4-amino-5-(benzo[d]oxazol-2-yl)-3-phenylthiazole-2(3H)-thione, 81 
Yellowish green solid (0.110 g, 27%); m.p. 236.5–
239.5 ºC; Rf (EtOAc:Hex, 1:1) 0.47; 1H NMR (400 
MHz, CDCl3) δ 7.72–7.62 (m, 4H, H6,7), 7.53 (ddd, J 
= 7.7, 1.4, 0.6 Hz, 1H, H4), 7.44–7.40 (m, 2H, H1,8), 
7.37 (td, J = 7.6, 1.4 Hz, 1H, H2), 7.34–7.29 (m, 1H, 
H3), 6.36 (br s, 2H, H5); 13C NMR (101 MHz, CDCl3) 
δ 187.54, 157.01, 148.83, 148.48, 139.48, 134.52, 
131.02, 130.78 (2C), 128.64 (2C), 125.20, 124.34, 117.62, 110.34; LC-MS 
(APCI/ESI): Purity > 99%, tR = 4.98 min, m/z [M+H]+ = 326.0. 
2-(benzo[d]oxazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile, 82 
Yellow solid (0.321 g, 83%); m.p. 169.0–173.3 ºC; Rf (EtOAc:Hex, 1:1) 0.40; 
1H NMR (400 MHz, CDCl3) δ 8.26 (s, 1H, H5), 
7.90 (d, J = 2.2 Hz, 1H, H6), 7.82–7.78 (m, 1H, 
H4), 7.60–7.57 (m, 1H, H1), 7.53 (ddd, J = 8.4, 
2.2, 0.5 Hz, 1H, H7), 7.43–7.37 (m, 2H, H2,3), 
6.99 (d, J = 8.5 Hz, 1H, H8), 4.01 (s, 3H, H9), 
4.00 (s, 3H, H10); 13C NMR (101 MHz, CDCl3) δ 
159.51, 153.34, 150.69, 149.46, 148.81, 141.67, 127.14, 125.81, 125.36, 
125.14, 120.31, 115.68, 111.27, 111.12, 110.59, 95.95, 56.15, 56.11; LC-
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6.3 Biological Evaluation 
6.3.1 In vitro Antimycobacterial Assay 
Minimum inhibitory concentrations (MIC) were determined using the 
standard broth micro dilution method. In this case, a 12.8 mM stock 
solution of the test compound was prepared in DMSO, and then diluted 
using the appropriate growth medium (GAST-Fe or 7H9/ADC) to a 
concentration of 640 μM. 100 μL of this solution was added into wells in row 
1 in duplicate, while 50 μL of the appropriate growth medium was added 
into wells in rows 2–12. This was followed by a two-fold serial dilution, 
which was attained by transferring 50 μL of a solution from row 1 to a 
subsequent row until row 12 was reached, from which 50 μL was discarded 
so as to bring the final volume in all wells to 50 μL, and concentrations 
ranging from 320–0.3125 μM in rows 2–12, respectively. At the same time, a 
10 mL culture of Mtb (H37Rv) was grown until they reached an optical 
density of 0.6–0.7 at 600 nm (OD600). This culture was then diluted 1:100 
using the appropriate medium as the diluent. Thereafter, 50 μL of the 
diluted Mtb culture was added to all wells in rows 2-12. As such, cells were 
not added to wells in row 1 because they served as contamination controls. 
Other controls included the neat medium, 5% DMSO, rifampicin, and 
kanamycin. The microplate was then placed in a secondary container and 
incubated at 37 °C, in the presence of a humidifier to minimize liquid 
evaporation. Finally, the lowest concentration of the test compound that 
inhibited the growth of more than 99% of the Mtb population [Minimum 
Inhibitory Concentration (MIC99)] was scored visually at Day 7 and day 14 
post inoculation. MIC99 scoring was facilitated by the use of Alamar blue dye 
in a technique commonly referred to as Microplate Alamar Blue Assay 
(MABA), which is paramount in the visual, or fluorimetric cell-growth 
reading. In some instances, the green fluorescent protein (GFP)-tagged Mtb 
H37Rv (pMSP12::GFP) was used in the assays. In this case, the MICs were 
determined using a dose-response curve analysis of the relative fluorescence 
(excitation wavelength at 485 nm, and emission wavelength at 520 nm) 
measured on the FLUOstar OPTIMA microplate reader. Data was normalized 
to the minimum and maximum inhibition controls to generate a dose 
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response curve (% inhibition) using the Levenberg-Marquardt algorithm 
(damped least-squares) method, from which the MIC90 and MIC99 were 
calculated. 
6.3.2 In vitro Cytotoxicity Assay 
In vitro cytotoxicity of potent target compounds against the Chinese Hamster 
Ovarian (CHO) cells was performed using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT)-assay, which determines cellular 
growth and survival. For each test compound, a stock solution (2 mg/mL) 
was prepared in 10% DMSO, and then diluted with the assay medium to 
yield a starting concentration of a 100 μg/mL. This was then serially 10-fold 
diluted to give six assay concentrations ranging from 100–0.001 μg/mL. 
Emetine was subjected to similar dilutions and used as the positive assay 
control. In all cases, triplicate samples were prepared. Negative control was 
the highest concentration of DMSO used, which had to be demonstrated 
that it had no measurable effect on the viability and survival of CHO cells.  
A solution of MTT was then added after 44 hours of exposure of the cells to 
the test compound. This was followed by a further 4 hours of incubation at 
37 ºC, after which the supernatant was separated from the cells by suction. 
Crystals of the reduced dye were then dissolved by addition of DMSO to 
each well. The amount of formazan in each well was determined by 
measuring the absorbance at 540 nm, which was then used to prepare dose-
response curves. A non-linear dose-response curve analysis, using 
GraphPad Prism software, generated the 50% inhibitory concentration (IC50) 
values.  
6.4 Turbidimetric Solubility Assay 
Turbidimetric method described by Bevan and Lloyd was adapted to provide 
an estimate of aqueous solubility of each target compound at pH 7.4. A 10 
mM stock solution of the appropriate test and control compound [reserpine 
and hydrocortisone] was prepared in DMSO, and 50 μL was placed in 
triplicate in row H of a 96-well microtiter plate. An 8 mM (100 μL) solution 
in DMSO was prepared in row G and then serially diluted by transferring 50 
μL to the wells above it [containing 50 μL DMSO] up to row B. This yielded 
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eight pre-dilution solutions with concentrations of 0.00, 0.25, 0.50, 1.00, 
2.00, 4.00, 8.00, and 10.00 mM in rows A, B, C, D, E, F, G, and H 
respectively. Secondary dilutions, in triplicate, of the pre-dilution solutions 
were prepared in DMSO (wells in columns 1–6) and 0.01M pH 7.4 phosphate 
buffered saline (PBS) (wells in columns 7–12) in a second 96-well microtiter 
plate, which thus meant that only two test compounds could be 
accommodated per plate. This was accomplished by pipetting 4 μL of each 
pre-dilution solution to the corresponding well of the second plate 
containing 196 μL of the appropriate diluent (DMSO or PBS). Therefore, the 
final concentration of DMSO in the PBS preparations was 2% v/v. The final 
200 μL assay solutions had concentrations of 0.0, 5.0, 10.0, 20.0, 40.0, 
80.0, 160.0, and 200.0 μM.  
Subsequently, the plates were covered and left to equilibrate for 2 hours at 
ambient room temperature. This was followed by reading the UV-VIS 
absorbances at 620 nm using a SpectraMax 340PC384 microplate reader 
(Molecular Devices, Sunnydale, CA). For each compound, a line graph of 
corrected absorbance [that is; absorbance of PBS solution minus the 
absorbance of the corresponding DMSO solution] against concentration was 
plotted. Solubility of each test compound was then taken as that 
concentration at which the line graph raised from the zero absorbance 
(DMSO) line. For instance, compound 3 had an estimated solubility of 80 
μM as depicted in Figure 6.1 below. 
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6.5 Supramolecular Derivatization Studies 
6.5.1 Powder X-ray Diffraction (PXRD) 
Powder X-ray diffraction patterns were recorded on a BRUKER D8 Advance 
X-ray diffractometer using CuK1 radiation (λ = 1.5406 Å). Approximately 5 
mg of a manually ground test sample was placed on a zero background 
sample holder and scanned over a 2θ range of 4–40° at a rate of 0.03° per 
second. The X-ray generator was set at 30 kV and 40 mA. 
6.5.2 Elucidation of Crystal Structure 
Single crystal intensity data were collected on a Bruker KAPPA APEX II DUO 
X-ray diffractometer using graphite-monochromated MoK radiation (λ = 
0.71073 Å), which was generated by a Bruker K780 generator operating at 
50 kV and 30 mA. A Cryostream cooler (Oxford Cryostreams, UK), with N2 
gas flowing at 20 cm3 min-1, was used to facilitate low-temperature data 
collections. The Bruker SAINT Software10 was used for unit cell refinement 
and data reduction. All intensity data were corrected for Lorentz-polarisation 
effects and the multi-scan method (SADABS)11 was employed to correct data 
for absorption effects.  
The observed Laue symmetry of the diffraction pattern was used to establish 
the crystal system while the space group was determined by examining 
systematic absences and matching the observed conditions to a known 
space group. The input files for structure solution were prepared using the 
program XPREP.12 Programs SHELXS, SHELXL, and SHELXH were 
employed for structure solution and refinement.13,14 All these programs were 
operated within the X-SEED interface.15 Intramolecular and intermolecular 
geometrical parameters were calculated using the program PLATON.16,17 
POV-Ray15 was used to create crystal structure images whereas the program 
LAYER15 was used for the graphic display of intensity data.  
6.5.3 Hot-Stage Microscopy (HSM) 
Test samples were placed on a cover slip with silicone oil and placed on a 
Linkam TH MS600 hot stage coupled to a Linkam TP92 temperature control 
unit. The hot stage was fitted with a Nikon SMZ-10 stereoscopic microscope 
for sample monitoring and the images were captured using a real-time Sony 
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Digital Hyper HAD color video camera operating on Soft Imaging System 
[analySIS] software.   
6.5.4 Thermogravimetric Analysis (TGA) 
A TA-Q500 Thermogravimetric Analyzer (TA instruments) with Universal 
Analysis 2000 Software (v4.5A, TA Instruments-Waters LLC) was used. The 
instrument was operated with a dry nitrogen purge gas flowing at 60 cm3
min-1. All test samples (2–3 mg) were heated at a rate of 10 ºC min-1 in an 
open aluminium crucible. 
6.5.5 Differential Scanning Calorimetry (DSC) 
Data were recorded on a pre-calibrated TA DSC-25 (Discovery Series) 
Differential Scanning Calorimeter (TA instruments) operated with TRIOS 
Software v4.2.1. Sample masses, scanning rates, purge gas flow rates were 
in the same ranges as those employed in TGA. An aluminium standard mass 
was used as the reference.  
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Appendix A1: 1H NMR spectrum {in DMSO-d6 at 300 MHz}, TGA and PXRD 
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Appendix A3: 1H NMR spectrum {in DMSO-d6 at 300 MHz}, TGA and PXRD 
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Appendix A4: 1H NMR spectrum {in DMSO-d6 at 300 MHz}, TGA and PXRD 
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Appendix A5: Summary of HPLC solubility (PBS pH 7.4) determination. 
HPLC method = that described in the experimental section with a flow rate 
of 0.7 mL/min.    
 
 
